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Abstract  
 There is a continuing need to make new antitubercular drugs due to 
development of resistance towards present drugs. To do this, series of pyruvate 
hydrazones (PVAHs) and their respective Cu(II) complexes and Zn(II) complexes were 
synthesized and fully characterised. Variable temperature NMR studies of PVAHs 
indicate the presence of E and Z isomers in the solution. Determination of the obtained 
single crystal X-ray structures reveals that Cu(II) ion binds to PVAH ligand in 1:1 ratio 
resulting in square pyramidal geometry in most of the Cu(II) complexes, whereas Zn(II) 
ion binds to two PVAH ligands in 1:2 ratio giving rise to octahedral geometry. The 
electrochemical studies of Cu(II) complexes of PVAH performed using cyclic 
voltammogram indicate the presence of quasi-reversible behaviour assigned to a 
Cu2+/Cu1+ peak potential. This indicates structural reorganisation of Cu(II) square 
pyramidal geometry towards Cu(I) tetrahedral geometry. The tetrahedral geometry of a 
synthesized Cu(I) complex of PVAHs was confirmed by  X-ray crystal structure.  
The stability studies of selected PVAH ligands and their metal complex indicate 
that the investigated compounds were stable in extreme basic conditions, but they 
were unstable in extreme acidic conditions due hydrolysis of azomethine bond. 
However, stability of these compounds in physiological conditions, i.e. in PBS buffer, 
reveals that ligand hydrolyses slowly over a period of time, whereas the Cu(II) complex 
remains quite stable over a monitored period of 120 hours. Interestingly, dihydrazide 
analogue of PVAH was fairly stable in PBS buffer. EPR studies of investigated Cu(II) 
complexes in DMSO indicate that PVAHs remains strongly coordinated to Cu(II) centre. 
The evaluation of the antimycobacterial activity showed that the anionic PVAHs 
and Zn(II) complexes are essentially inactive. Some of the corresponding neutral Cu(II) 
complexes, however, exhibit promising antimycobacterial activities if tested under high 
iron (8 µg Fe per mL) conditions. As observed for the related antimycobacterial agent 
isoniazid, the activity of the complexes decreases if the M. tuberculosis cells are grown 
under low iron (0.02 µg Fe per mL) conditions. The Cu(II) complexes may thus have a 
similar mode of action and may require an iron-containing heme-dependent peroxidase 
for activation.  
A series hydrophobic cinnamaldehyde hydrazones (CAHs) and their Cu(II) 
complexes were also synthesized and tested for their antitubercular activity under 
similar conditions to that of PVAH series. But they failed to show any inhibitory activity 
due to their poor cellular uptake owing to their limited solubility in aqueous buffer. 
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1.0 Introduction 
1.1 Overview 
Tuberculosis (TB) is a globally significant disease that has led to billions of 
deaths worldwide. Although the current methods of treating TB are effective, the 
persistence of bacilli and the widespread emergence of resistance against current 
antibiotics is a significant cause of concern. The broad goal of this bio-inorganic 
project was to design an array of novel metal-based antitubercular agents using 
simple yet potent organic ligands, such as hydrazones.  
1.2 A brief introduction to tuberculosis 
Tuberculosis is one of the most serious infectious airborne diseases, 
affecting one third of the world’s population. Statistics from 2009 indicate that 
around 9.2 million people develop TB every year, while 2 million people succumb to 
the disease (WHO, 2009). As indicated in figure 1.1, TB has severely affected Asian 
and African countries1 and if the spread of the disease is not contained, it could 
pose a worldwide threat with an estimated 1 billion people affected by 2020.2  
 
Figure 1.1: Map indicating TB affected areas.1 
TB generally affects the respiratory system but may also spread to other 
parts of body such as the brain, spleen, bones and gastrointestinal tract. The 
symptoms of TB are a persistent dry cough for more than 3 weeks and in later 
stages coughing up of blood, loss of appetite, anaemia and diarrhoea. If not treated 
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in time TB can eventually lead to death in certain cases.3 TB is caused by a 
bacterial species known as Mycobacterium tuberculosis (Mtb), which is generally 
characterised as an aerobic, slow growing and non-motile species. The majority of 
mycobacterial species replicate freely in the natural ecosystem, but only a small 
number of them are able to successfully inhabit the intracellular environment of 
mononuclear phagocytes in higher vertebrates. These species include 
Mycobacterium leprae, Mycobacterium lepraemurium, Mycobacterium avium subsp. 
Paratuberculosis, and the members of the Mycobacterium tuberculosis complex.4  
The cell wall of Mtb consists of a lipid bilayer made up of peptidoglycans and 
complex lipids such as mycolic acid, as shown in figure 1.2. The extraordinary 
structure of the cell wall allows the bacteria to lie dormant in latent infections for 
many years.5  
 
Figure 1.2: Schematic representation of the mycobacterial cell wall5 
Due to the  lipophilic nature of the cell wall, hydrophilic molecules cannot 
cross the cell wall efficiently, which is a major concern as this can lead to drug 
resistance.6  Directly Observed Therapy-Short course (DOTS) therapy is used to 
treat TB, which is a combination of widely used first line drugs such as isoniazid, 
rifampin, ethambutol and pyrazinamide prescribed for 2 months, followed by 
isoniazid and pyrazinamide for the next 4-5 months.7 The mechanism of these four 
widely used drugs is discussed in detail in the following section. 
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1.3  Mechanism of action of few antitubercular drugs 
 The complex lipid bilayer of the cell wall, arising from the extensive long 
chain fatty acid framework, acts as a barrier against chemical damage. Most of the 
antitubercular drugs, which include isoniazid8, pyrazinamide9, ethionamide10 and 
thiacetazone11 (figure 1.3) act on the fatty acid biosynthesis mechanisms. The 
suggested mode of action for these antibiotics involves the inhibition of enzymes, 
such as InhA, FabH, MabA, Kas B involved in the fatty acid synthesis pathways.12-14 
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Figure 1.3: Structure of fatty acid pathway inhibitors a) isoniazid, b) pyrazinamide, c) 
ethionamide and d) thiacetazone 
 1.3.1 Isoniazid  
Isonicotinic acid hydrazide, commonly called isoniazid (INH), discovered in 
1952, was a major breakthrough in antitubercular drug design as it is a highly active 
and inexpensive that does not possess serious side effects. Since its discovery, 
isoniazid is the most commonly used drug worldwide for treating TB infections. This 
frontline anti-TB drug has a remarkably low minimum inhibitory concentration (MIC) 
of 0.1-0.7µM in the human body and is very specific to Mtb.15  This has encouraged 
several researchers to investigate the mechanism of action of INH. 
INH inhibits mycolic acid biosynthesis,8 however, it has been proposed that 
the molecule itself does not possess any inhibitory action15 but instead acts as a 
pro-drug, which was thoroughly investigated by Rozwarski et al.16 Once inside the 
bacterial cell, INH is converted into its activated form, the INH radical or anion with 
the help of Mtb catalase-peroxidase (KatG), as indicated in figure 1.4.  
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Figure 1.4: Formation of active species of INH via step a) INH radical and step b) 
INH anion16 
The resulting active species of INH form a covalent bond with nicotinamide 
adenine dinucleotide (NADH) to produce an isonicotinic acyl (INA)-NADH adduct, 
which then inhibits the InhA enzyme.15-17 InhA is an enoyl-acyl carrier protein (ACP) 
reductase that is known to catalyse the NADH dependent reduction of an alkene 
bond within a fatty acid chain. The resulting products of the InhA catalysis are used 
by Mtb to generate mycolic acids, which are long chain fatty acids, and are 
considered to be essential components of the bacterial cell wall. The INA-NADH 
adduct occupies the active site of the InhA enzyme, as indicated by crystal structure 
analysis (figure 1.5) and binds to the neighbouring amino acid side chains.16 
 
Figure 1.5: Crystal structure of active site of InhA with bound INA-NADH adduct16 
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The molecular representation of the active site of InhA with the bound INH-
NADH adduct is illustrated in figure 1.6. The INA moiety of the INA-NADH adduct is 
shown in red, whereas the NADH is shown in blue and the amino acid side chains 
are shown in green. Numbers indicated in black are in Å units and represents the 
atomic spacing between the selected atoms. The conformational difference between 
the active site of the native enzyme and that of bound INA-NADH adduct is the 
orientation of Phe149 amino acid side chain. In the native form of the enzyme, the 
side chain of Phe149 lies directly above the nicotinamide ring. In the bound INA-
NADH adduct, however, the side chain of Phe149  is rotated away from the 
nicotinamide ring, thus allowing space for INA group, as indicated in figure 1.6.16 
Upon blocking the active site of InhA the enzyme fails to produce the fatty acid 
chains, which form the integral part of the cell wall. This may eventually lead to 
bacterial cell death. Ser94 indicated in magenta (figure 1.6), is responsible for INH 
resistance which is converted into Ala in resistant strains. 
 
Figure 1.6: Molecular representation of active site of InhA with bound INA-
NADH adduct16 
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1.3.1.1 Pharmacokinetics of INH metabolism in the human body 
A detailed investigation of the pharmacokinetics of INH in the human body 
was performed by Ellard and Gammon.18 The analysis of blood and urine samples 
suggests that INH is eventually metabolised into a series of metabolites by the 
human body, as indicated in figure 1.7. Some of these metabolites may inactivate 
INH and hence prove an obstacle in the mechanism of its action on Mtb. Depending 
on the rate at which these metabolites are produced, they can be classified as slow 
and fast inactivators of INH. Hence, the therapeutic dose and length of the 
treatment may vary in different individuals. 
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Figure 1.7: Proposed metabolic pathway and metabolites of INH in the human 
body18 
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Ellard and Gammon proposed that INH can be converted directly into its acid 
form in human body as indicated in the figure 1.7. Although it was also hypothesized 
that isonicotinic acid can be formed via the intermediate acetyl isoniazid. This 
intermediate product is caused by the enzymes known as acetylators present in the 
human body. The acetylators which can be classified as fast and slow acetylators 
determine the rate of formation of acetyl isoniazid. The calculated values indicate 
that fast acetylators acetylate the INH three to four times faster than the slow 
acetylators. Furthermore, it was observed that in slow acetylators, the rate of 
formation of isonicotinic acid and isonicotinyl glycine was increased when compared 
to that of fast acetylators. Isonicotinyl glycine, another metabolite of INH, is a result 
of conjugation of amino acid glycine with isonicotinic acid.18  
Subsequently, hydrazine and its other analogues, which include mono-acetyl 
and di-acetyl hydrazine, are also produced as by-products of these metabolites. An 
enzyme that catalyses the hydrolysis of acetyl isoniazid to give isonicotinic acid and 
mono-acetyl hydrazine that undergoes further acetylation resulting in the formation 
of di-acetyl hydrazine, which is excreted from the body as evident from the urine 
samples of INH administered individuals. The amount of di-acetyl hydrazine 
excreted also depends on the rate of the acetylation process, which can be 
accredited to the fast and slow forms of these enzymes.  
INH is also known to form Schiff base conjugates with pyruvic acid and α-
ketoglutaric acid in the body to give the respective hydrazones, as shown in figure 
1.7.  This could prove to be a drawback as it could conjugate with carbonyl-
containing compounds that might be essential for normal metabolic processes. For 
example, INH is known to combine with vitamin B6 (figure 1.8) resulting in patients 
suffering from the effects of B6 deficiency.19 Hence, TB patients who are being INH 
are given additional supplements of vitamin B6. 
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Figure 1.8: Schiff base of conjugate of INH and vitamin B6 
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1.3.2 Pyrazinamide 
Pyrazinamide (PZA), which is one of the drugs used in DOTS therapy, has 
shortened the original treatment regime of TB from the original 9-12 months to the 
current 6 months course. The mechanism of action of PZA is not completely 
understood despite it being a structural analog of INH and also acting as a prodrug. 
It is found to inhibit fatty acid synthase-I, thereby disrupting the cell wall 
biosynthesis.9 In its active from, pyrazinoic acid (POA) is formed by the bacterial 
pyrazinamidase (PZase) enzyme in a lower pH cellular environment.20-21  
Interestingly, PZA is known to kill mycobacteria which lie in a semi-dormant 
state, residing in the acidic environment. However, other antitubercular drugs fail to 
eradicate these bacteria, which is one of the main reasons so as to why PZA helps 
in shortening the TB therapy. PZA is only active against mycobacteria in a low 
acidic environment, whereas other bacteria are insensitive to PZA. It was found that 
even though POA is produced in acidic environments, it fails to accumulate in 
certain strains of mycobacteria due to highly active POA efflux mechanisms. Those 
bacteria which were deficient in this efflux pump are highly susceptible to PZA, 
whereas those for example M. smegmatis are natural resistant of PZA due to 
extremely active POA efflux.20 Studies by Bamaga et al. have illustrated that 
mutations in the pncA gene encoding PZase have led to the development of PZA 
resistant bacteria.22 
1.3.3 Ethambutol 
 Ethambutol inhibits Mtb by targeting the arabinogalactam and 
peptidoglycan biosynthesis pathway of the bacterium.23 Other drugs that inhibit this 
pathway include cycloserin24 and amoxicillin25 (figure 1.9). Ethambutol is known to 
inhibit arabinofuranosyl transferase(s) of arabinogalactam.  Moreover, Häusler et al. 
have shown that even small changes in the parent pharmacophore decreased the 
antitubercular activity exhibited by ethambutol.26 
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Figure 1.9 : Arabinogalactam and peptidoglycan biosynthesis inhibitors a) 
Ethambutol b) Cycloserin c) amoxicillin 
1.3.4 Rifampin 
Rifampin as depicted in figure 1.10, binds to the β-subunit of the DNA-
dependent polymerase thereby inhibiting bacterial RNA synthesis.27-29 
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Figure 1.10: Rifampin 
1.3.4 Fluoroquinolone 
Fluoroquinolones, as depicted in figure 1.11, are the second line of 
antitubercular agents used in targeting resistant strains of mycobacteria. These 
compounds target the bacterial DNA gyrase enzymes, viz. topoisomerase II (topoII) 
and DNA topoisomerase IV (topoIV) in Gram-negative and Gram-positive bacteria. 
Fluoroquinolones block the ligation step of the cell cycle, producing single and 
double stranded breaks, which consequently leads to cell death.30-31 
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Figure 1.11: Fluoroquinolone antibiotics a) ciprofloxacin and b) levofloxacin 
1.4 Drawback of present antitubercular drugs 
The length of the DOTS therapy (6-12 months) has resulted in patient non-
compliance and eventually led to the emergence of multidrug resistant TB (MDR-
TB)  in some patients.32 The major drawback of the drugs presently used to treat TB 
infections is that they only typically target the actively growing bacteria, while there 
is a notable absence of drugs which can target latent infections.33 These latent 
infections could lead to the reactivation of the disease in patients with compromised 
immune systems. This is most notably seen in HIV patients, with TB being a major 
cause of death in AIDS patients7. Drug related adverse side effects can cause 
significant morbidity, arising from serious conditions such as drug-induced hepatitis 
and severe gastrointestinal distress. Most common side effects of TB drugs include 
fever and rashes.34  
As a consequence, there is an urgent need for the development of new 
antitubercular compounds to overcome these drawbacks. The new antitubercular 
agent must be effective against resistant and persistent strains of the bacteria, 
whilst keeping the side effects to a minimum. In order to design more efficient 
antitubercular drugs, it will be useful to understand the mechanism involved in 
resistance and persistence. 
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1.5 Cause for the resistant state of mycobacteria 
The increasing number of resistance cases is a major concern amongst the 
health organisation throughout the world. A survey done by the WHO in 2008 has 
found that around half a million people develop MDR-TB worldwide. In addition,  
10,000 new cases of extensive drug resistant TB (XDR-TB) emerged in 2008. XDR 
is a term used when a bacterial species is resistant against most, or all, antibiotics 
capable of threating such infections.35 
1.5.1 The lipophilic cell wall of mycobacteria 
One of the limitations for certain types of antimicrobial agents is the ability to 
cross the lipid membrane of the bacterial cell, failing to do so may result in the 
resistance of a drug. Rastogi et al. succeded in overcoming this mycobacterial 
resistance by synthesizing an amphipathic derivative of the drug isoniazid, as 
indicated in figure 1.12.36 These amphipathic analogs of INH exhibited promising 
activity against mycobacteria which were 100 % resistant to INH.  
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O
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Figure 1.12: Amphipathic derivatives of INH36 
It was porposed that the lipophilic part of the molecule acts as a carrier of 
the INH drug, which allows it to cross the lipid membrane of the bacterial cell wall. 
Once inside the cell, the INH part of the molecule is resposible for the inhibitory 
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action against mycobacteria. INH is a very hydrophilic and polar molecule, which 
prevents effective absorption by the cell but it is a very potent drug. Hence attempts 
could be made to modify the drug to overcome the resistance problem caused by its 
inability to cross the lipid barrier effectively.  
1.5.2 Mutation in the katG gene 
Resistance can also develop through mutations in the katG gene, which is 
responsible for converting INH into its active form. Bernadou et al.,37-39 have made 
synthetic analogs of truncated INH-NADH (minus the ADP moeity), where the the 
isonicotinic ring was substituted with a benzoyl ring (BH-NADH). These analogs can 
directly bind to the active site of InhA, inhibiting the enzyme, hence bypassing the 
KatG dependent step. However, these truncated adducts lead to very poor activity 
against InhA, due to the lack of an ADP moiety. To overcome this problem, they 
synthesised a bisubstrate analogue of BH-NADH adduct. A representative example 
from the series is shown in figure 1.13. 
 
N
HN
O
HO
 
 
Figure 1.13: Synthetic analogue of the BH-NADH adduct39 
This analogue is more likely to accurately mimic the bonding profile of the 
InhA substrate and would be recognised by the active site of InhA. This will provide 
more affinity and selectivity towards the catalytic site of InhA. Interestingly, some of 
these derivatives not only inhibit the InhA enzyme, but also exert promising MIC 
values against active strains bacteria of Mtb. However, the possibility that an 
additional hydrophobic moeity might be responsible for the increased uptake of the 
benzoyl hydrazone across the lipid cell membrane cannot be discounted. Morover, 
the compound depicted in figure 1.13 did not inhibit InhA but exhibited potential 
antimycobacterial activity. This suggests that some of the synthesized BH-NADH 
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derivatives may not inhibit InhA actively and act against Mtb through a different 
mechanism of action.  
While the compounds above may have future potential as antitubercular 
drugs, they could also prove active against the KatG mutant resistant strains. These 
studies also suggest that hydrazides other than INH can also act as potential 
inhibitors of InhA and thus could be a useful strategy in antitubercular drug design. 
Moreover, impairment of KatG may also result from a lack of redox active 
species in the environment, leading to INH resistance.40 KatG appears to utilize 
superoxide anions to activate INH, as the INH turnover by the purified enzyme is 
completely abolished in the presence of a catalytic quantity of superoxide dismutase 
(SOD).41   
1.5.3 Acetylation of the hydrazinic chain (-NH-NH2) 
INH can undergo acetylation in the body through the action of N-
acetyltransferase (NAT) enzymes. NAT enzymes have been able to acetylate 
various substrates including INH- and sulfonamide-based antibacterial drugs. 
Acetylation of the amine functionality of INH, as indicated in figure 1.14, may result 
in poor antimycobacterial activity. Different forms of NAT enzymes are not only 
present in the human body but also in Mtb. The effective therapeutic doses of INH 
have to be taken into account, depending on the effect of fast and slow 
acetylators.18,42 
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Figure 1.14: Acetylation of INH by NAT enzymes18 
In order to avoid the acetylation of potent hydrazine drugs, an effective 
strategy would be to block the amine group with an appropriate moiety, possibly a 
biologically active pharmacophore, which could enhance the activity. For example, 
as previously discussed, INH can be conjugated to hydrophobic molecules that 
would allow passive diffusion through the lipid cell wall of the mycobacteria. 
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1.6 Persistent/ latent bacteria 
 One of the major drawback of drugs presently used to treat Mtb is the failure 
to target the persisent/latent bacteria present in the host organism, hence TB cannot 
be completely eradicated. Various research groups are working in this field in order 
to understand the mechanisms responsible for the persistent state of bacteria. One 
of the well known processes is the glyoxylate shunt pathway (GSP).43-46 
1.6.1 Role of the glyoxylate shunt pathway in persistent bacteria 
The glyoxylate shunt pathway (GSP) has been determined to be important 
for bacterial survival in the activated macrophage and for persistent infections of 
Mtb in the host organism. The majority of the microorganisms growing on fatty acids 
for their carbon source utilise the glyoxylate bypass for the biosynthesis of cellular 
material. In Mtb, isocitrate lyase activity is increased when the bacilli are in an 
environment of low oxygen tension or in a transition from an actively replicating to a 
non-replicating state.  The GSP bypasses the loss of two carbon dioxide molecules 
from the tricarboxylic acid (TCA) cycle, thereby permitting the net incorporation of 
carbon into cellular structure, as illustrated in figure 1.15. The vital enzymes of the 
GSP are isocitrate lyase (ICL) and malate synthase. ICL converts isocitrate into 
succinate and glyoxylate as indicated in scheme 1.1, whereas malate synthase 
condenses glyoxylate with acetyl coenzyme A (acetyl-CoA) to give malate and 
coenzyme A (CoA) respectively.43-46  
O O
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O O
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Scheme 1.1: Conversion of isocitrate to glyoxylate and succinate36 
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Figure 1.15: Isocitrate lyase pathway46 
The GSP has been found in most prokaryotes, lower eukaryotes and plants, 
but there is no evidence thus far of this pathway being present higher vertebrates, 
hence its inhibition will not interfere with the human metabolic pathways, thus 
allowing specific targeting of the bacterial survival pathways.47 
1.6.1.1  ICL inhibitors 
A number of ICL inhibitors (figure 1.16) have been investigated to date, 
including 3-nitropropionate, 3-bromopyruvate, phosphoenolpyruvate, 3-
phosphoglycerate and itaconate.48-52 Since the most common structural motif 
observed in the known ICL inhibitors is the pyruvate moiety, as highlighted in figure 
1.16, incorporation of this moiety may provide an effective route for targeting the ICL 
enzyme, thereby inhibiting persistent bacteria. 
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Figure 1.16: Isocitrate lyase inhibitors (a-e) 
Sacchettini et al.53 investigated the mode of inhibition of 3-bromopyruvate 
and 3-nitropropionate. It was established that both inhibitors showed activity against 
bacteria grown on acetates but have no effect on bacteria grown on glucose. In 
order to gain further insight into the mechanism of action, the inhibitors were co-
crystallised with the ICL enzyme and orthorhombic shaped crystals were obtained. 
The binding of glyoxylate was examined at the active site of ICL which is located at 
the C-terminal ends of the β-strands, as shown in figure 1.17. It was determined that 
the carboxylate group or the nitro group of 3-nitropropionate hydrogen bonds with 
the side chains of residues Asn313, Glu285, Arg 228, His193, Ser317, Thr347  and Gly192 of 
the protein, as shown in figure 1.18. The glyoxylate binds by coordination to the 
active site Mg2+ (indicated as yellow sphere, figure 1.18) and forms hydrogen bonds 
with amino acid residues such as Ser910, Gly92, Trp93 and Arg228 of the protein. 
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Figure 1.17: Active site of the of the ICL C191S mutant with glyoxylate (GA) and 3-
nitropropionate bound.53 Generated using CCP4mg software (PDB code 1F8I) 
 
Figure 1.18: Schematic diagram of the interactions of ICL with glyoxylate and 
succinate53 
Moreover, similar co-crystallisation studies with 3-bromopyruvate reveal that 
it acts as an inhibitor of ICL by forming a covalent adduct with nucleophile Cys191 in 
the active site, achieved by dehalogenation of the inhibitor. As can be seen in figure 
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1.19 the pyruvyl moiety forms hydrogen bonds with the side chains of His193, Asn313, 
Ser315, Ser317, Thr347 and to a solvent molecule (water). 
 
 
Figure 1.19: Active site of ICL (pyruvyl moiety (purple) attached to the thiolate of 
Cys191).53 Generated using CCP4mg software (PDB code 1F8M) 
Kumar and Bhakuni54 investigated the role of metal salts in the ICL enzyme 
mechanism. Mg2+ is vital for the activity of the enzyme, exhibiting almost 100% 
activity whereas Mn2+ yielded around 45% activity. Cd2+ and Zn2+ inhibited the 
enzyme, as these metal ions led to the unfolding of the catalytic domain. However, 
Mg2+ and Mn2+ did not significantly affect the structure of the enzyme, as such the 
zinc and cadmium complexes could be explored for any effect the ions could have 
on the inhibitory action of ICL. 
ICL inhibitors containing non-pyruvyl moieties have also been explored. Shin 
et al. and his group isolated seven sesterterpene sulfates from the tropical sponge 
Dysidea sp. and evaluated their inhibitory activity against ICL from Candida 
albicans. Amongst them, the compound as shown in figure 1.20 was found to be 
most active having an IC50 value of 16.9 µM.55  
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Figure 1.20: Sesterterpene sulfate55 
5-hydroxy type alkaloids from the tropical marine sponge Hyrtios sp. were 
also investigated. The inhibitory properties of these compounds were investigated 
using ICL enzyme obtained from Candida albicans. The compound as shown in 
figure 1.21, was the most active of this type of compounds, having an IC50 of 89.0 
µM.56 
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Figure 1.21: Hyrtiosin B56 
Synthetically-derived inhibitors have also been investigated in inhibition 
studies of ICL. Shin et al. synthesized a new series of bromophenol derivatives, 
where the compound as shown in figure 1.22 exhibited the most potent inhibitory 
activity against ICL from Candida albicans.57  
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Figure 1.22: (3-Bromo-4,5-dihydroxyphenyl)-(2,3-dibromo-4,5-dihydroxy-phenyl)-
methanone57 
From these literature studies, it can be concluded that ICL is an attractive 
target to eradicate persistent bacterial strains. Pyruvate-containing molecules have 
shown to inhibit the ICL enzyme, however, non-pyruvate containing ICL inhibitors 
have also been explored. 
Furthermore, recent studies  by Shi et al.58 show that PZA is known to inhibit 
ribosomal protein S1 (RpsA), an important protein involved in trans-translation 
process. This process is essential in non-replicating or latent bacteria; therefore 
PZA may be useful in eradicating persistent mycobacteria. 
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1.7 Hydrazones and metal complexes as antitubercular agents 
Hydrazones and their metal complexes represent an important class of 
compounds, as they are not only good antitubercular agents59-60 but also have other 
biological applications, as indicated in figure 1.23. These include anticonvulsant61-62, 
analgesic62, anti-inflammatory63-64, anticancer65-66, antiviral67-68 antimalarial69, 
antigout70, antidiabetic71, antifungal72 antiplatelet73 and vasodilator74 applications.  
Antitubercular
Anti-gout
Antivirus Anticonvulsant
Anticancer
Antimalarial Anti-platelet
Analgesic
Hydrazones
Antidiabetic
Vasodilator
AntifungalAnti-inflammatory
 
Figure 1.23: Biological applications of hydrazones 
Owing to their various pharmacological applications, there has been a 
growing interest in hydrazones. Various reviews are available in the literature, which 
have covered various aspects of these compounds, including biological and non-
biological applications.75-77 
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1.7.1 Hydrazones as antitubercular agents 
 Pavan et al. synthesised 20 different substituted thiosemicarbazones (figure 
1.24), semicarbazones, dithiocarbazates  and hydrazide/hydrazones  that were then 
evaluated against Mtb. One interesting result arising from the study is that the 
compounds bearing more hydrophobic moieties (R groups) were shown to be more 
active than those containing hydrophilic groups. This could be attributed to the more 
facile diffusion of the hydrophobic molecules across the lipid-rich bilayer78.  
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Figure 1.24: a) Thiosemicarbazones (X=S)  b) Dithiocarbazates c) Semicarbazones                                            
   One other possible mechanism by which these type of ligands may act as 
antitubercular agents is due to the presence of N, O, S donor binding sites. It is well 
established that sequestering intracellular iron can cause bacteria to starve, as iron 
is essential for mycobacterial survival.79 Whilst donor atoms such as N, S, O have 
the ability to coordinate to metal ions in various combinations (such as NNO, ONO, 
ONS, NNS), the organic framework forms stable 5- or 6-membered chelate rings. 
Once iron is coordinated to the ligand, it is no longer available for use by the 
bacteria, thus leading to iron starvation.  
A similar observation was made by Vigorita et al.,80-81 through their 
investigation of isoniazid related hydrazones, hydrazides and cyanoboranes as 
shown in figure 1.25.  
  Chapter – 1   
23 
 
N
N
H
O
N
R'
R
 
                                                          (a) 
N
N
H
O
N
R'
R
BH2CN
 
(b) 
Figure 1.25: Isoniazid derivates a) hydrazone b) Cyanoborane adduct of hydrazone 
R = H, CH3; R’ = CF3, Ph 
Amongst these hydrazones, the ones bearing fluoro- and trifluoro-
substituents on the benzene ring were proven to be most active. The cyanoborane 
adducts, however proved to be more active than the corresponding hydrazones. 
They displayed EC99 (EC99 is the lowest concentration effecting 99% reduction in 
colony forming units) of 1.14 and 0.116 µg ml-1, respectively, against  Mtb Erdman 
growing within mouse bone marrow macrophages, which is between 10-100 times 
more when compared with the same strain in culture medium, (MIC= 12.5 µg ml-1). 
The increase in the activity was attributed to the increase in lipophilicity. It was also 
observed that the cyanoborane-containing phenyl group was more potent than the 
trifluoromethyl-group. Interestingly, the tested compounds were found to be active 
against ethambutol and rifampin resistant strains of Mtb. 
Further to this, Vavříková et al.82 synthesized, fluoro- and tri-fluoromethyl-
substituted hydrazones derived from second-line antitubercular drugs including 
para-amino salicylic acid (PAS), norfloxacin (Nrf) and ciprofloxacin (Cpf). These 
compounds exhibit greater activity on MDR-TB strains (resistant to at least INH and 
RIF), when compared to their parent compounds - PAS, Nrf and Cpf, however, did 
not show any improved activity over normal Mtb. These compounds were further 
tested for cellular cytotoxicity against human cell lines using the MTT assay. 
Interestingly, these compounds were relatively non-toxic to human hepatocellular 
carcinoma cells HepG2, PBMC (Peripheral Blood Mononuclear Cells) and human 
SH-SY5Y neuroblastoma cells within the MIC range of their antitubercular activity. 
Most of the tested compounds exhibited similar MIC values against MDR-TB cells, 
however, one of the para-substituted fluorohydrazone analogues of Cpf (4FH-Cpf) 
as indicated in figure 1.26, displayed the highest selectivity index (SI) of 1268.58 as 
compared to Cpf (110.37).  Values of selectivity index (SI) indicate rate between 
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IC50 (mmol L-1) of HepG2 cytotoxicity and MIC (µg mL-1). Higher values indicate a 
greater level of selectivity, which means they possess a higher level of toxicity 
towards mycobacteria while being less toxic to human cells.  
As 4FH-Cpf (figure 1.26), is highly selective towards TB cells, it was chosen 
for stability studies in rat plasma and in aqueous buffer at varying pH. The HPLC 
results obtained indicate that 4FH-Cpf undergoes decomposition at a faster rate in 
acidic buffer solutions. The half life was found to be 2.9 and 11.8 hours in pH 3 and 
5 buffer solutions, respectively. The compound is relatively stable at  pH 7.4, as no 
significant decomposition was observed when monitored over 48 hours. Similar 
results were obtained when the stability of 4FH-Cpf was investigated in rat plasma. 
Even after 96 hours, the compound appears to be stable, suggesting no enzymatic 
degradation of the compound in rat plasma. The rate of degradation was very slow 
and is similar to the decomposition rate when studied in pH 7.4 buffer.82 
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Figure 1.26: Cpf conjugate of fluoro-substituted hydrazone (4FH-Cpf)82 
 Hence, the above studies by Vavříková and Vigorita suggests that fluoro- 
and trifluoromethyl-substituted compounds could be useful in the design of  novel 
antitubercular agents. 
Interestingly, hydrazones have also been proven to inhibit ICL enzyme. 
Sriram et al.83 synthesized a combinatorial library of novel pthalazinyl hydrazones 
(figure 1.27) for use as ICL enzyme inhibitors. The compounds were evaluated in 
vitro and in vivo against 8 mycobacterial strains and Mtb ICL. The compound shown 
in figure 1.27 a) inhibited all 8 species of mycobacteria with MICs (minimum 
inhibitory concentrations) ranging from <0.09-12.25 µM. A structure activity 
relationship (SAR) analysis reveals that electron withdrawing groups, such as nitro- 
and halo-substituents, improved activity whereas electron donating groups, such as 
methoxy-, methyl-, hydroxyl- and dimethylamino- substituents reduced activity. The 
compounds that displayed high activity were further screened against Mtb cells that 
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had been grown for six weeks under carbon-deprived conditions. The compounds 
exhibited %-inhibition values in the range of 45.1-61.6% at 10 µM concentration and 
the inhibitor as shown in the figure 1.27 b displayed the highest inhibition of 61.6%. 
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Figure 1.27: Phthalazinyl hydrazone83 a) R-H, R1-4- NO2Ph 
b) R-H, R1-3- NO2Ph 
Recently, docking studies reported by Padhye’s et al.;84 illustrated that the 
hydrazones derived from pyruvic acid can bind to the active site of ICL. The 
hydrazones form hydrogen bonds with surrounding amino acid side chains and the 
binding energy lies between -7.51 and -8.89 kcal mol-1, where as the parent pyruvic 
acid shows a binding energy of -8.36 kcal mol-1. Ligand L4, as indicated in figure 
1.28, exhibited highest binding energy of -8.89 kcal mol-1, where the amide proton 
forms a hydrogen bond with the oxygen atom of amino acid Gly287. Moreover, it is 
also observed with other ligands that the oxygen atom of carboxylate and/or 
carbonyl functional groups also participates in hydrogen bonding with amino acids 
such as His, Ser, Asn, which are in close vicinity of the active site. 
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L1: Y=H, X1,X2 = C 
L2: Y=OH, X1,X2 = C 
L3: Y=H, X1= N, X2 = C 
L4: Y=H, X1=C, X2 = N 
 
L4 docked at active site of ICL enzyme 
Figure 1.28: Structures of pyruvic acid hydrazones (L1-L4) (left) investigated by 
docking studies involving ICL, L4 binding in the ICL active site84 
 Interestingly, these ligands and their respective Cu(II) complexes are also 
known to inhibit actively growing Mtb H37RV.  
 The literature studies performed on hydrazones conclude that this class of 
compounds can be considered as useful for the discovery of novel antitubercular 
agents. Moreover, a number of the mentioned hydrazones are also able to inhibit 
the ICL and can thus serve a dual purpose of eradicating actively growing and 
persistent bacteria. 
1.7.2 Metal complexes as antitubercular agents 
Metal complexes can offer certain advantages over organic ligands as they 
have been reported to possess excellent antimycobacterial activity and are also 
effective against resistant strains.85-87 Reactive oxygen radicals initiate the 
transcription of the katG gene resulting in the activation of INH drug, therefore, in 
order to overcome the problem of resistance, redox active species can be 
introduced along with INH. For example, redox active metal cations, such as Cu(II) 
or Fe(II) can be considered, as they can cause oxidative stress within the bacterial 
cell. Oxidative stress caused by metal ions may also be helpful, as it may exert 
damaging effects on bacterial cells, eventually leading to their death. This could 
happen due to the Fenton reaction occurring in the cells. Redox active metal ions, 
such as Fe(II), can react with endogenous hydrogen peroxide to give rise to 
hydroxyl radicals, as shown in equation 1.1. The resultant reactive oxygen species 
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can be lethal to the cell by damaging its DNA.88 To confirm this theory, Imlay et al.89 
investigated the action of hydrogen peroxide on Escherichia coli (E. coli). They 
found that micromolar concentrations of hydrogen peroxide inactivate the 
isopropylmalate isomerase (IPMI) enzyme, which belongs to the class of iron-sulfur 
cluster proteins. Inhibition of IPMI prevents the biosynthesis of the amino acid 
leucine.  
Fe(II) + H2O2 → HO· + OH- + Fe(III)    ------------ equation 1.1 
Cu(II), which can also undergo redox reactions, is also believed to generate 
hydroxyl radicals through similar Fenton-like reactions, thus eventually causing 
toxicity to cells. However, further work carried out by Imlay et al.90-91 illustrates that 
copper(II) does not cause DNA damage. It was suggested that intracellular 
glutathione may chelate free copper, hence it is unavailable to undergo redox 
reactions producing free radicals. Therefore, in order to investigate the mechanism 
underlying the Cu toxicity, Cu(I) was incubated with iron-cluster enzyme and it was 
found that copper displaces iron from the enzyme and binds to sulphur-containing 
ligands, subsequently leading to enzyme inhibition. 
Several researchers are working on metal-based antitubercular compounds, 
a selection of which is discussed in this section. In order to support the theory of 
activation of INH by metal ions, Basso et al.92-94 coordinated INH to redox active 
metal ions, including Fe(II) ([Fe(III)(CN)5(NH3)]2-) and Fe(III) ([Fe(II)(CN)5(NH3)]3-). 
The study suggests that the Fe ions bind to INH through the heterocyclic nitrogen 
atom as indicated in figure 1.29. It was proposed that the electron transfer involving 
the Fe-INH complex takes place via an inner sphere mechanism, resulting in an 
oxidised species of INH (INHox), ([Fe(III)(CN)5(INHox)]2-). INHox is the product of the 
oxidation process involving isonicotinic acid or isonicotinamide, as indicated in 
figure 1.30. These oxidative products or activated INH can give rise to the INH 
radical, which is known to bind the active site of Inh A, leading to inhibition of the 
enzyme as discussed previously on page 4 and 5.  
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Figure 1.29: Iron complex of INH, ([Fe(III/II)(CN)5(INHox)]2-/3-)92-93 
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Figure 1.30: Scheme illustrating the mode of action of self-activating antitubercular 
metallodrugs of INH, (X= OH, NH2) i) Failed activation of INH by mycobacteria due 
to KatG mutations, ii) Intramolecular electron transfer within the metal complex iii) 
electron transfer kinetics (KET) 92 
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The synthesised iron complex of INH proved to be active against INH-
resistant and INH-sensitive strains of bacteria. It was hypothesized that KatG is not 
required for INH activation if there is a redox active metal present in close vicinity of 
the drug. The electron transfer mechanism associated with Fe-INH complex can 
bypass the KatG activation step by self activating the INH drug. This strategy can be 
useful in designing novel antitubercular drugs, which can overcome  drug resistance 
caused by KatG mutations. Inhibition of Inh A proved to be unsuccessful with 
([Fe(III)(CN)6]). This proves that INH is an essential pharmacophore required to 
inhibit the InhA enzyme. 
Furthermore, other redox active metal ions, such as ruthenium(II) was also 
coordinated to INH in order to support their theory. However, [Ru(II)(CN)5(INH)]3- 
and [Ru(II)(NH3)5(INH)]2+ failed to show any inhibitory action against Inh A. The 
reason was attributed to the difference in their electrochemical potential. The 
oxidation potential of ([Fe(II)(CN)5(INH)]3- was found to be 305 mV vs. SCE, 
whereas Ru(II)(CN)5(INH)]3- exhibits a significantly low E1/2 value of 112 mV and 
[Ru(II)(NH3)5(INH)]2+ has  an extremely high oxidation potential (~750 mV). Hence, 
this suggests that intramolecular electron transfer reactions, which are associated 
with electrochemical behaviour of metal complexes, may play a vital role in the 
design of antitubercular metallodrugs. 
Similar studies carried out by Bodiguel et al.,95 suggest that addition of Mn2+ 
ions to a mixture of INH and KatG, increase the rate of formation of the active 
species isonicotinic acid as indicated by HPLC results. However, in order to achieve 
noticeable results a ratio of Mn2+: KatG enzyme of 20:1 had to be used. It was 
hypothesized that both the process of INH oxidation by enzymatic peroxidation and 
Mn2+ auto-oxidation may occur simultaneously. 
Likewise in human beings there are number of metal ion transport proteins 
present in bacteria in order to transport metal ions like Fe, Cu and Zn across the cell 
membrane. Depending upon the organism these types of proteins are either 
involved in uptake or efflux of certain metal ions. For example, ferric uptake 
regulator (Fur) imports the extracellular essential metal ions such as Fe inside the 
mycobacteria. Free Cu ion, which is toxic to certain bacterial species is exported out 
of the cells using copper transporting ATPases.96 It has been proposed that the Fur 
A protein which is a member of ferric uptake regulator family is co-expressed along 
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with KatG.97-98 The furA gene encoding Fur A protein is located upstream of the 
katG gene as indicated in figure 1.31.  
 
Figure 1.31: Schematic representation of the function of Mtb. FurA98 
Once inside the bacterial cell, Fe(III) gets reduced to Fe(II) by proteins 
belonging to iron reductase family. The reduced Fe is associated with the activation 
of fur A gene which inturn co-transcribes katG gene. The increased levels of KatG 
helps in boosting the activation of INH drug, hence helps in increasing its 
antitubercular activity. 
As FurA plays a vital role in controlling the activity of KatG, it has attracted 
considerable attention in the development of novel antitubercular drug design, which 
could potentially enhance KatG levels thus enhancing INH potency. 
[Ferric uptake] 
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Fe Fe 
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Extensive work is being carried out by Yangzhong Liu et al.99-101 on metal-
based inhibitors of the RecA intein enzyme, which is responsible for protein splicing 
in Mtb. The investigation of the inhibitory effect of some of the first row transition 
metal ions on RecA intein suggests that Cu2+ and Zn2+ have high affinity towards the 
enzyme, whereas Co2+, Ni2+, Mn2+ and Cd2+  show weak inhibition and Mg2+ and  Ca2+ 
ions fail to exert any inhibitory activity against recA. 
One of the mutants of the RecA enzyme of Mtb (∆I-SM) was isolated and co-
crystallised with Zn2+. The crystal structure in which zinc is binding to the active site 
of ∆I-SM is depicted in figure 1.32. Zinc (indicated in blue spheres) coordinates to 
four amino acid residues in a tetrahedral manner. The amino acids involved in the 
coordination are His349, His429, Asn440 and Glu424. These studies also suggest that 
the binding of zinc to ∆I-SM, results in conformational changes leading to the 
dimerisation of the protein. Additional NMR spectroscopic studies were carried out 
in order to confirm these results. Interestingly, the addition of the strong chelating 
agent EDTA reverses the inhibition of the enzyme by Zn2+, indicating that the 
binding affinity of zinc is stronger for EDTA than the protein active site.  
 
Figure 1.32: Crystal structure of ∆I-SM co-crystallised with Zn2+ (blue sphere)99 
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Continuing this work, they also examined the interaction of Cu(II) and Cu(I)  
with ∆I-SM. Although the crystal structure with copper bound to the enzyme could 
not be obtained, UV/Vis, atomic absorption spectroscopy (AAS), NMR spectroscopy 
and extended X-ray fine structure (EXFAS) techniques were used to investigate the 
mechanism. The studies revealed that Cu(II)  gets reduced to Cu(I) and in turn 
oxidises the thiol group of intein. Moreover, the copper binds to intein in a 1:1 ratio 
and it coordinates to cysteine and histidine side chains. The binding site of the two 
copper ions Cu(I) and Cu(II) varies as Cu(I) prefers tetrahedral coordination and 
Cu(II) prefers square planar geometry. Interestingly, it was observed that Cu(II)  
coordinates to the sulfur donor of cysteine, whereas this was not observed with 
Cu(I). This observation violates the HSAB principle, which suggests that Cu(I) 
favours sulfur coordination. 
Surprisingly, Liu et al. also found that the inhibition of RecA intein can be 
achieved using the well known anticancer drug cis-platin (figure 1.33). A range of 
platinum(II) compounds were tested and it was found that cis-platin exhibits the 
lowest IC50 of 2.5 µM, whereas the trans-isomer has a significantly high IC50 > 200 
µM. This is also true for anticancer activity, where trans-isomer is inactive against 
cancer cells. 
Pt
ClH2N
H2N Cl
 
Figure 1.33: Structure of cis-platin 
Vigorita et al.87 also studied the in vitro antimycobacterial activity of Co2+ and 
Cu2+ complexes of fluorinated INH-hydrazones, as can be seen in figure 1.34. It was 
observed that all metal complexes exhibit excellent activity and two of the lead 
compounds displayed EC99 values lower than that of the parent drug INH, whilst all 
of the tested metal chelates significantly inhibited the growth of single-drug-resistant 
Mtb strain. 
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Figure 1.34: Metal complex of fluorinated INH-hydrazones (M= Co2+, Cu2+)87 
Schiff bases and their copper complexes as antibacterial agents have also 
been explored by Padhye et al.85 Copper complexes of carboxiamidrazone, as 
shown in figure 1.35, exhibited a 32 to 64-fold activity enhancement when compared 
to their respective ligands and displayed MICs in the range 2-4 µM. As the metal 
conjugates are more lipophilic than their organic counter parts, it allows complexes 
to easily permeate through the mycobacterial cell wall. In addition, the intracellular 
reduction of Cu(II) to Cu(I), leads to the generation of reactive oxygen species which 
can be deleterious  to bacterial cells.102-104 
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Figure 1.35: Copper complex of carboxyamidrazone85 
Other first row transition metal complexes have also been investigated for 
their antitubercular activity, including vanadium, iron, cobalt, nickel and zinc 
complexes.86,105-110 
Additionally, metal complexes of second and third row transition metals, 
such as Pd, Pt, Ru, Ag, Au have been investigated.111-114  Palladium(II) and 
platinum(II) complexes of various fluoroquinolones (ciprofloxacin, levofloxacin, 
ofloxacin, sparfloxacin, and gatifloxacin) have been synthesisied by Fonts et 
al..Based on the results obtained, it was proposed that Pd binds to the ligands 
through the planar β-diketo system of the fluoroquinolone, as shown in figure 1.36. 
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The complexes display MIC values in the range of 0.31-1.25 µg/ml against Mtb 
strain H37Rv.115 
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Figure 1.36: Palladium complex of ciprofloxacin115 
1.8 Project Aims 
 In order to address the problem of persistence and resistance in Mtb, there 
is a need for the development of new novel antitubercular drugs. This can be 
achieved by either designing new chemical entities or modifying the existing TB 
drugs in order to overcome their inherent drawbacks. 
The aim of the project was to synthesise analogs of the currently available 
antitubercular drug isoniazid and the Cu(II) and Zn(II) complexes of the analogues 
obtained. In addition, the stability of the synthesised compounds was to be 
investigated, under near physiological conditions and in different pH environments. 
Furthermore, the redox behaviour of the Cu(II) complexes was to be studied using 
cyclic voltammetry. In order to investigate structural aspects of the compounds, 
especially the metal complexes, single crystal X-ray diffraction studies were carried 
out. The results obtained informed the structure activity relationship (SAR) analysis 
of the compounds with respect to their antitubercular activity. 
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2.0 Synthesis and Characterisation 
2.1 Introduction: 
Schiff base ligands have been extensively studied for their role in biological 
fields, as well as in coordination chemistry. Apart from their important role in 
studying the coordination chemistry of metal complexes, 116-120 Schiff base ligands 
have also played a major role in the development of bioinorganic chemistry for the 
past few years, 121-124. In addition to the growing interest in using Schiff base ligands 
for mimicking metalloenzymes, their metal complexes have also been investigated 
for their activity against various biological disorders including cancer, 125-126 
tuberculosis, 82,127-129 inflammation130-131 and diabetes132-133.  
Hydrazones (figure 2.1) are widely studied due to their chelating ability. 
Depending on the metal ion, hydrazones can exhibit bidentate, 134 tridentate135 
tetradentate136 or multidentate137-138 coordination modes depending on the 
geometric arrangement of the neutral and anionic donor atoms present. Hydrazones 
(figure 2.1) contain two nucleophilic nitrogen atoms; with the amino nitrogen being 
the more nucleophilic than the azomethine nitrogen. The C=N double bond, 
generally called azomethine bond, is conjugated with the lone pair of electrons on 
the terminal nitrogen atom77. The physical and chemical properties of hydrazones 
depend on these structural fragments. The carbon atom of the hydrazone group has 
both electrophilic and nucleophilic character which makes it useful in organic 
synthesis, especially in the synthesis of heterocyclic compounds139 
N
N
R2
R1R3
R4
Nu
E
E
E
 
Figure 2.1: Hydrazone, E = electrophile, Nu = nucleophile77 
The synthesis of hydrazones involves condensation of hydrazine or a 
hydrazide with an aldehyde or ketone, resulting in the elimination of a water 
molecule, as shown in scheme 2.1. These types of reactions are classified as 
reversible acid-catalysed reactions and proceed best at around pH 4.5.140  
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Scheme 2.1: Hydrazone formation140, hydrazine (R - H), hydrazide (R - O=C-R) 
  It is well established that hydrazones can form E/Z isomers141 and/or keto-
enol tautomers142 in solution. This allows hydrazones to be present as the different 
isomers (E or Z) as well as neutral, monoanionic, dianionic species depending on 
pH, medium, reaction conditions and the coordinating meta.l143-145 Derivatives of 
hydrazones such as thiosemicarbazone, dithiocarbazate and acyl hydrazones can  
provide both hard and soft donor atoms, such as oxygen (O), nitrogen (N) and 
sulphur (S). Various combinations of these donor atoms such as ONO, 146 ONS, 147 
NNS148 have been studied, especially with transition metal ions. Moreover, changing 
the donor atoms can help to tune the redox property of the metal ion.149  
Chapter-2 is divided in two sections; section A describes synthesis and 
characterisation of pyruvate hydrazones (PVAHs) and their respective metal 
complexes. Section B deals with synthesis and characterisation of cinnamaldehyde 
hydrazones (CAHs) and their respective Cu(II) complexes 
Section A: 
In section A, synthesis and characterisation of twenty pyruvate hydrazones 
(PVAHs) and their Cu(II) and Zn(II) complexes along with Cu(I) complexes of 
selected ligands is discussed. In addition, synthesis and characterisation of a di-
hydrazide analogue of a pyruvate hydrazone is also described. 
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2.2 Synthesis of pyruvate hydrazones (PVAHs) 
 The synthesis of a Schiff base through the reaction of sodium pyruvate with 
a hydrazide is a one step condensation reaction, as given in scheme 2.2. PVAH 
(pyruvate hydrazone) ligands NaHL1-NaHL20, were synthesized according to a 
reported procedure.135 Commercially available hydrazides were used in the 
syntheses, except for NaHL20. The starting hydrazide for NaHL20, pyrazinoyl 
hydrazide, was synthesized by condensing methyl pyrazine 2-carboxylate and 
hydrazine hydrate using standard literature procedures.150 The details of the 
preparation of pyrazinoyl hydrazide and PVAHs can be found in the experimental 
section (chapter -7).   
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Scheme 2.2: General synthetic scheme for the preparation of PVAHs a) MeOH:H2O 
(7:3), reflux, 2 hours, water 
The detailed mechanism for the formation of Schiff bases and hydrazones is 
given in Scheme 2.3. The carbonyl group and the amine group of two biologically 
active pharmacophores, sodium pyruvate and the respective hydrazide are 
combined and the azomethine bond is formed via the loss of a water molecule. The 
reaction begins with the nucleophilic attack of the lone pair on the amine nitrogen 
onto the electrophilic carbon centre which gives rise to a hemiaminal intermediate. 
The intermediate then reacts with a proton and the subsequent loss of a water 
molecule yields the PVAH. These reactions are known to proceed best around pH 4 
– 5, as strongly acidic conditions favour the formation of the protonated amine, 
which cannot behave as a nucleophile (step a). Strong basic conditions do not 
favour the protonation of the hemiaminal intermediate (step c), hence it cannot act 
as a good leaving group (step d). 140  
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Scheme 2.3: General mechanism for the formation of PVAHs140 
A range of hydrazides bearing different R-groups; such as electron-
withdrawing, electron-donating, hydrophilic, hydrophobic and heterocyclic groups 
containing nitrogen have been used to synthesize a series of structurally related 
PVAHs. Lists of R groups along with their compound codes are provided in table 
2.1. The rationale behind using the different substituents or the same substituent at 
different positions on the aromatic group is that it allows for an analysis of structure 
activity relationships (SARs) with regards to antitubercular activity. Schiff base 
compounds have always been a popular choice amongst medicinal chemists, as it 
is generally a one step reaction with high yields and also the starting materials are 
mostly inexpensive. Once the biologically active lead compounds are known they 
can be further modified to improve their efficacy. 
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Table 2.1: Library of PVAHs with their compound codes and yields 
                  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X1
X2
X3
N
H
N
O
CH3
O ONa
R
 
  R (X = C) Yield  
1 NaHL1 H 82 % 
2 NaHL2 o-OH 89 % 
3 NaHL3 m-OH 87 % 
4 NaHL4 p-OH 83 % 
5 NaHL5 o-Cl 83 % 
6 NaHL6 p-Cl 90 % 
7 NaHL7 m-CH3,  p-NO2 82 % 
8 NaHL8 p- NO2 95 % 
9 NaHL9 p-CH3 86 % 
10 NaHL10 m-Br 86 % 
11 NaHL11 p-Br 96 % 
12 NaHL12 m-OCH3 81 % 
13 NaHL13 p-OCH3 83 % 
14 NaHL14 p-CF3 89 % 
15 NaHL15 m-F 80 % 
16 NaHL16 p-(CH3)3C 96 % 
17 NaHL17 o-OH, p-OCH3 92 % 
 Heterocyclic compounds 
(R = H) 
 
18 NaHL18 X1 = N, X2, X3 
= C 
89 % 
19 NaHL19 X2 = N, X1, X3 
= C 
82 % 
20 NaHL20 X1 = C, X2, X3 
= N 
80 % 
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2.3 Synthesis of Cu(II) complexes of PVAHs 
The syntheses of the Cu(II) complexes of the PVAHs were performed in a 
1:1 metal-to-ligand ratio. The details of the synthetic procedures used can be found 
in the experimental section. The X-ray crystal structures (discussed in chapter 4) 
and elemental analysis data, which can be found in experimental section, indicate 
that most of the copper complexes are isolated as 1:1 complexes. Initially, the 
reaction was tried in methanol, according to a procedure reported in the literature 
that gave crystalline solids upon slow evaporation,151 but this resulted in overall low 
yields. The low yields isolated are likely due to the high solubility of the Cu(II)-PVAH 
complexes in methanol. In order in improve the overall yield, the reactions were 
attempted in water as reported by Turta et al152. The combination of the aqueous 
solutions of the reactants gave rise to green precipitates, which were isolated by 
filtration and washed with water in order to remove any salt impurities. A selection of 
reactions with different ligands was repeated in water and it was found that the yield 
increased 2-fold in most of the complexes. ESI-MS confirmed the formation of 1:1 
complex and purity was confirmed using elemental analysis.  
The ligands behave as tridentate, dianionic ligands and bind to the Cu-
centre as shown in Scheme 2.4. The remaining coordination sites on the Cu-centre 
can be occupied by anions or neutral solvent molecules, such as H2O or methanol. 
The negatively charged oxygen donors balance the charge of the positively charged 
Cu(II) centre, whereas the nitrogen atom donates its lone pair of electrons, allowing 
the formation of an overall neutral complex. 
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         X= H2O/CH3OH 
Scheme 2.4: Synthesis of Cu(II) complexes of PVAHs a) CuCl2.2H2O 
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As reported earlier, pyruvate hydrazones can either form square planar,152 
square pyramidal84 or octahedral complexes.153 In octahedral complexes, two 
ligands bind to a single copper centre. Both the octahedral and square pyramidal 
forms have been observed in the crystal structures of some of the Cu(II) complexes 
of pyruvate hydrazones but most complexes exist as square pyramidal complexes. 
One exception is the crystal structure of the octahedral Cu(II) complex of ligand 
NaHL7, although the elemental analysis supports the formation of a square 
pyramidal complex. More on the structural aspects of the copper complexes is 
discussed in chapter-3. 
2.3.1 ESI-MS of Cu(II) complexes   
According to elemental analysis data and single crystal X-ray structures, the 
expected molecular ion peak in the ESI-MS positive mode for copper complexes, 
should either correspond to the [[Cu(II)LX(H2O)2]+H]+ or [[Cu(II)LX(H2O)2]+Na]+ ions. 
For example, the sodiated molecular ion peak for [Cu(II)L9(H2O)2] is expected at 
m/z 340.0096 for [M+Na]+. However, this was not found, instead the mass spectrum 
of Cu(II)L9(H2O)2] exhibits a molecular ion peak one mass unit higher than 
expected. The ESI-mass spectrum of [Cu(II)L9(H2O)2] was recorded in acetonitrile 
and is shown in figure 2.2. The positive ion peak observed at m/z 341.0434 can be 
assigned to [M+H+Na]+ The additional large peak at m/z 363.0249 corresponds to 
[M+2Na]+, whereas the peak at 323.0349 corresponds to [M-H2O+H+Na]+.  
 
Figure 2.2: Positive high resolution ESI-mass spectrum of [Cu(II)L9(H2O)2] 
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Since the higher molecular ion peak has only one positive charge, it could be 
due to addition of one hydrogen atom or one proton, which is likely to be associated 
with the reduction of Cu(II) to Cu(I). The reduction of Cu(II), in the positive ion mode 
in the gas phase has been reported in the literature, where the reduction can be due 
to the transfer of an electron from a solvent molecule to Cu(II) centre in the gas 
phase.154-155 The reduction of a Cu(II) complex in presence of solvent molecule, 
especially a coordinated or non-coordinated water molecule, can be explained with 
the help of theory proposed by Frański. The water molecule undergoes an 
electrochemical oxidation, most likely at the ESI source, subsequently giving rise to 
electrons and protons as given in equation 2.1. These resulting electrons can 
reduce Cu(II) to Cu(I) as indicated in equation 2.2. Additionally, Frański observed 
that addition of water increased the formation of Cu(I) species over Cu(II) 
species.154  
2H2O → O2 + 4H+ + 4e- ………….equation 2.1154 
  Cu(II) + e- → Cu(I) ........................equation 2.2 
Oxidation of a water molecule in the gas phase can result in an addition of a 
proton as indicated in Scheme 2.5. This would then result in reduction of Cu(II) to 
Cu(I) and with an addition of Na ion it would give rise to [M+H+Na]+ molecular ion 
peak. 
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Scheme 2.5: Reduction of Cu(II) to Cu(I) complex with an addition of H+ and 
Na+ ESI-mass spectrometer 
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The molecular ion peak at 323.0349, corresponding to [M-H2O+H+Na]+, 
could be due to the loss of a weakly bound water molecule from the coordination 
sphere of Cu(II) complex. Longer distances of the apically bound water molecules, 
as expected according to the Jahn-Teller distortion, have been observed in the 
crystal structure of Cu(II) complexes of PVAHs (chapter - 3). Hence, the bond 
strength of the apical water molecule is weak as compared to those of the equatorial 
bonds which results in fragmentation of [Cu(II)L9(H2O)2] in the gas phase arising 
from the loss of a water molecule. Similar behaviour is observed in other Cu(II) 
complexes of PVAHs and the details can be found in the experimental section. 
However, [Cu(II)L7(H2O)2] does not seem to undergo this reduction in the ESI 
mode.  
The simulations for the corresponding peaks are given in figure 2.3. There is 
a relatively large difference observed between the calculated (341.0169) and 
experimental (341.0434) values. As the Cu(II) complex does not ionise very well in 
the ESI-MS, it gives only a low intensity peak and is thus difficult to measure 
accurate values at high resolution.  
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Figure 2.3: Measured (top) and simulated (middle, bottom) positive ion high 
resolution ESI-MS spectrum of [Cu(II)L9(H2O)2] 
 However, the observed and simulated isotopic pattern of the 
investigated copper complexes of PVAHs matches reasonably well as displayed in 
the  ESI-MS spectrum [Cu(II)L9(H2O)2]  displayed in figure 2.3. The ESI-MS spectra 
of [Cu(II)L7(H2O)2], [Cu(II)L8(H2O)2], [Cu(II)L9(H2O)2], [Cu(II)L14(H2O)2], 
[Cu(II)L15(H2O)2], [Cu(II)L16(H2O)2], [Cu(II)L20(H2O)2] can be found in  Appendix 1. 
2.4 Synthesis of Zn(II) complexes of PVAHs 
 Unlike Cu(II), Zn(II) forms 1:2 metal : ligand complexes with PVAHs, as 
shown in scheme 2.6. The composition of the complexes was confirmed by X-ray 
crystallography, elemental analysis and ESI-mass spectrometry. Most of the 
mixtures of PVAHs and ZnSO4 in aqueous solution yielded white precipitates. Good 
quality crystals suitable for X-ray diffraction were obtained from the NMR samples of 
[Zn(HL7)2], [Zn(HL8)2], [Zn(HL9)2], and [Zn(HL13)2] in d6-DMSO. The details of the 
synthetic and characterisation procedures can be found in experimental section, 
whereas the crystal structures can be found in chapter-3. The NMR-spectra of the 
zinc complexes are discussed in the following section. 
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Scheme 2.6: Synthesis of Zn(II) complexes of PVAHs a) ZnSO4.7H2O 
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2.5 Nuclear magnetic resonance (NMR) studies: 
All the NMR studies described in this chapter were done in d6- DMSO. 
A detailed analysis of a representative example of the ligand NaHL9 by 1H and 13C 
NMR spectroscopy is discussed in this chapter. Full characterisation data of ligands 
NaHL1 - NaHL20 is given in chapter-7. 
2.5.1  1H NMR spectroscopic analysis of NaHL9 
The 1H NMR spectrum of NaHL9 along with the structure and its atom 
numbering scheme is illustrated in figure 2.4. The spectrum shows two sets of 
signals suggesting two different types of species present in the solution. These 
major and the corresponding minor peaks observed in the spectra can be attributed 
to the isomers of NaHL9 present in the solution.  
 
Figure 2.4: 1H NMR spectrum of NaHL11 recorded in d6-DMSO 
Before investigating the structure of two isomers, assigning of the peaks will 
be done. Two sharp singlets of relative integration three are observed at 1.98 and 
2.36 ppm and can be assigned to the two CH3 groups. The peak at 2.36 can be 
attributed to the aromatic CH3 group as it is more deshielded than the methyl group 
C10. These assignments were further confirmed by a 2D COSY experiment. The 
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NH peak is observed 10.90 ppm and is deshielded if compared to the parent 
hydrazide (9.69 ppm) owing to the conjugation with the C=N bond. The equivalent 
peak for the major isomer appears at 16.2 ppm. The aromatic protons of the major 
isomer give rise to two doublets at 7.30 ppm and 7.70 ppm with a coupling constant 
of  JH-H = 8.0 Hz which is consistent with the para-substituted aromatic protons. The 
aromatic protons corresponding to the minor isomer appear at 7.34 ppm and 7.84 
ppm and the coupling constant (JH-H = 8.0 Hz) is the same as that of the major 
isomer. However, the JH-H for the resonance at 7.34 ppm cannot be calculated 
accurately as the resonances of two isomers merge. 
2.5.2 E/Z isomerisation of pyruvate hydrazone ligands: 
It is well established that hydrazones exhibit keto/enol tautomerism and/or 
E/Z isomerism in solution and that the ratio of the isomers depends upon the nature 
the compounds and the solvent used.141,156-157 The NMR spectra of PVAHs exhibited 
additional minor peaks in addition to the expected major peaks, suggesting two 
types of species present in the d6-DMSO solution. A representative example of 
NaHL9 showing its 1H NMR spectrum in the aromatic region 7.20 – 7.90 ppm is 
illustrated in figure 2.5.  
Ha or Hb
(major isomer)
Ha or Hb
(minor isomer)
 
N
H
O
N
O
CH3
ONaH3C
Hb
Ha
Ha
Hb
 
NaHL9 
Figure 2.5: 1H NMR spectrum (7.20 – 7.90 ppm) of a solution of NaHL9 in d6-DMSO 
showing major and minor peaks in the aromatic region 
In order to gain further insight, variable temperature (VT) 1H NMR studies 
were performed on NaHL9 and NaHL13. The stacked NMR spectra of NaHL9 
recorded at different temperatures are shown in figure 2.6. In the aromatic region 
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between 7.20 and 7.90 ppm, it is observed that the relative integration of the minor 
peak decreases with an increase in the temperature, whereas the integrals of the 
isomeric equivalents increase. Likewise, the resonances of the protons of both 
methyl-groups display a similar behaviour.  
The rate of isomerisation is slow at room temperature, due to high activation 
barrier of the rotation around the azomethine double bond and much slower than 
the NMR timescale. This gives rise to two distinct NMR resonances for the protons 
as indicated protons in figure 2.6. The major and minor peak can be assigned to E 
and Z isomers.141   
 
Figure 2.6: Stacked NMR spectra of NaHL9 in d6-DMSO recorded at the indicated 
temperatures 
 16  14  12  10  8  
a) 298 K 
b) 328 K 
c) 378 K 
d) 298 K 
0.95 
0.35 
0.84 
0.75 
0.97 
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2.0 
2.0 
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The rate of isomerisation can be increased by heating the solution of 
isomers to a higher temperature. Heating to high temperatures overcomes the 
activation energy required to convert the E form present in the solution to the Z 
form. As the Z form is more stable than the E form, the ligand remains in the Z form 
even after cooling the solution back to 298 K (figure 2.6 d). Similar VT results were 
obtained for ligand NaHL13 and can be found in the Appendix 2.   
The structures of the Z and E isomers of pyruvate hydrazones are illustrated 
in figures 2.7 a/b and 2.7 c, respectively. The reason for the prevalence of the Z 
isomer in solution could be attributed to the strong intramolecular hydrogen bond N-
H---O, as depicted in figure 2.7 a, which makes it a more stable species than the E 
isomer. The resonances at 16.2 and 10.9 ppm can be assigned to the N-H proton of 
Z and E isomer, respectively. Owing to the fact that the strong hydrogen bond 
deshields the amide proton, the (N-H) in the Z isomer resonates at higher frequency 
as compared to the E isomer.156-157 Extreme downfield shift of the proton at 16.2 
ppm can also be attributed to the O-H signal of the imine tautomer as indicated in 
figure 2.7 b.   
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Z isomer - imine form (b)                            
O
N
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R
Na
        
E isomer  (c) 
Figure 2.7: a) Z- amide form and b) Z- imine form and c) E isomers of 
PVAHs 
Extensive studies done by Landge et al.158 on hydrazones as depicted in 
figure 2.8, suggests that the Z → E isomerisation process takes places through 
rotation (around C=N bond) pathway rather than inversion pathway via the 
formation of polar transition state. Moreover, the energy of activation (Ea) and 
energy of enthalpy (∆H≠) lies in the range 6.7 – 11.2 kcal mol-1 and 6.1 – 10.6 kcal 
mol-1 respectively, depending on the substituent attached to aromatic ring and NMR 
solvents (d8-toluene, CD3CN) used for the study. These values can be related to 
breaking of O---H bond and/or rotation around C=N bond. Furthermore, the negative 
entropy (∆S≠ = -38.0 to -56.6 cal mol-1 K -1) values, suggests the formation of a 
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polarised transition state in Z → E isomerisation process leading to a rotation 
pathway. Inversion pathway for Z → E isomerisation involves non-polarised 
transition pathway.  
N
N
O
O
N
R
H
 
Figure 2.8: Structure of  investigated hydrazone/s (Z isomer shown in 
figure)for Z → E isomerisation process158 
2.5.3 Trends in the 1H NMR data 
Different substituents on the aromatic ring can influence the electronic 
properties of Schiff base ligands. The 1H NMR chemical shifts for the major Z 
isomers in ligands NaHL1-NaHL20 are listed in table 2.2. Generally, the aromatic 
protons in PVAHs are more deshielded where there is an electron withdrawing 
group (EWG) as compared to ligands with electron donating groups (EDG). The 
same effect is observed for the amide (N-H) proton; however, the aromatic 
substituents had no or little effect on the resonances of the CH3 protons. The amide 
proton resonance for PVAHs exhibits a large range of chemical shifts between 
15.48 and 16.77 ppm, which can be correlated with the properties of the different 
substituents on the aromatic ring. The trend observed in 1H NMR resonance of the 
amide protons is discussed in detail below. 
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Table 2.2: 1H NMR chemical shifts (in ppm) for the indicated PVAH protons, 
recorded in d6-DMSO (NaHL1-NaHL20) 
X1
X2
X3
O
N
H
N
CH3
R
Na OO
 
  R (X = C) Ar-H CH3 N-H Ar-R 
(CH3/ 
OCH3) 
 Sodium 
pyruvate 
 - 2.07 - - 
1 NaHL1 H 7.52, 7.82 2.01 16.17 - 
2 NaHL2 o-OH 6.87, 7.18, 7.38,  
7.69 
2.05 16.02 - 
3 NaHL3 m-OH 6.97,7.26 2.02 15.92 - 
4 NaHL4 p-OH 6.88, 7.68 2.01  15.75 - 
5 NaHL5 o-Cl 7.31-7.57 2.04 15.48 - 
6 NaHL6 p-Cl 7.58, 7.81 2.01 16.48 - 
7 NaHL7  m-CH3,  p-
NO2 
7.78, 7.87, 8.10 2.00 16.61 2.56 
8 NaHL8 p- NO2 8.02, 8.34 2.02 16.69 - 
9 NaHL9 p-CH3 7.70, 7.30 1.98 16.12 2.35 
10 NaHL10 m-Br 7.48, 7.78, 7.92 2.01 16.46 - 
11 NaHL11 p-Br 7.73 2.01 16.36 - 
12 NaHL12 m-OCH3 7.13, 7.39 2.00 16.21 3.80 
13 NaHL13 p-OCH3 7.03, 7.77 1.99 16.09 3.80 
14 NaHL14 p-CF3 7.89, 7.99 2.01 16.60 - 
15 NaHL15 m-F 7.51 2.01 16.41 - 
16 NaHL16 p-(CH3)3C 7.51,7.73 1.97 16.17 1.30 
17 NaHL17 o-OH, p-
OCH3 
6.47, 6.88, 7.62 2.05 15.81 3.76 
Heterocyclic compounds  (R = H)    
18 NaHL18 X1 = N, 
X2,X3 = C  
7.69, 8.75 2.03 16.46 - 
19 NaHL19 X2 = N, 
X1,X3 = C 
7.55, 8.14, 8.74, 
8.97 
2.02 16.46 - 
20 NaHL20 X1 = C,  
X2, X3 = N 
 
8.73, 8.86, 9.22 2.02 16.77 - 
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The data for the substituent-induced chemical shift (SCS) is given as a 
proton shift for N-H relative to those of the unsubstituted ligand L1. Positive and 
negative ∆ SCS values indicate shielding and deshielding, respectively and the data 
is provided in table 2.3.  
Table 2.3: 1H substituents-induced chemical shifts of N-H (indicated in red) of the Z 
isomer for ligands NaHL1 - NaHL20 
O
N
H
N
CH3
R
Na OO
 
 R H-N    (∆ 
SCS) 
 R H-N (∆ 
SCS) 
NaHL1 H 0 (16.17 ppm) NaHL12 m-OCH3 +0.04 
NaHL5 o-Cl -0.69 NaHL11 p-Br +0.19 
NaHL4 p-OH -0.42 NaHL15 m-F +0.24 
NaHL17 o-OH, p-
OCH3 
-0.36 NaHL10, 
NaHL18, 
NaHL19 
m-Br/ one 
heterocyclic N 
+0.29 
NaHL3 m-OH -0.25 NaHL6 p-Cl +0.31 
NaHL2 o-OH -0.15 NaHL14 p-CF3 +0.43 
NaHL13 p-OCH3 -0.08 NaHL7 m-CH3, p-NO2 +0.44 
NaHL9 p-CH3 -0.05 NaHL8 p-NO2 +0.52 
NaHL16 p-
(CH3)3C 
0.00 NaHL20 Two heterocyclic 
N 
+0.66 
In the proton NMR experiment, the NaHL1 N-H proton resonates at 16.17 
ppm and is used for comparison with other substituted PVAHs. PVAHs containing 
electron donating hydroxyl substituent viz NaHL2, NaHL3, NaHL4 and NaHL17 give 
negative ∆ SCS values as compared to NaHL1. This may be due to their shielding 
properties which in turn makes the amide proton electron rich. The hydroxyl group 
also known as strongly activating group gives rise to more negative values as 
compared to weakly activating groups, such as H (NaHL1), CH3 (NaHL9) and tert-
butyl (NaHL16). In addition, a negative value is also observed for NaHL13, 
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possessing an electron donating p-OCH3 group. m-OCH3, however, exhibits a 
slightly positive value. 
On the other hand, PVAHs possessing weakly deactivating groups, such as 
the halogens F (NaHL15), Cl (NaHL6) and Br (NaHL11) exhibit positive values. This 
indicates that a halogen group renders the amide proton electron deficient resulting 
in a deshielding of the N-H resonance. p-Cl (NaHL6) is the most deshielding as 
compared to p-Br (NaHL11), m-F (NaHL15) and m-Br (NaHL10).  
Moreover, within the series with the same substituent (hydroxyl, methoxy, 
and bromo), the N-H resonances in meta-substituted PVAHs are more deshielded 
as compared to the para substituted ones. Owing to the fact that the resonance 
effect of certain substituents is much more dominant in para position compared with 
meta position. Interestingly, N-H proton of o-Cl (15.48 ppm) substituted PVAH is far 
less deshielded than p-Cl (16.48 ppm) as can be seen from the table 2.2. This could 
be attributed to the intramolecular hydrogen bonding between the partially negative 
o-Cl- ion and the N-H proton. 
A strong electron withdrawing group or strongly deactivating group, such as 
NO2, has a very large deshielding effect which is reflected in its ∆ SCS value of 
+0.52 ppm in NaHL8. In comparison, electron donating groups, such as hydroxyl, 
methoxy and methyl groups have negative values. This is in good agreement with 
literature reports that describe the effect of electron withdrawing and electron 
donating groups on azomethine protons (N-H) within a series of para-substituted 
aroylhydrazone ligands159. However, in the di-substituted NaHL7 ligand, the electron 
donating CH3 group in meta-position in addition to the para-substituted NO2 group 
lowers the ∆ SCS positive value observed for the mono-substituted p-NO2 group in 
NaHL8. This shows the less electron deficient nature of N-H proton in NaHL7 over 
NaHL8. 
PVAHs containing a heterocyclic nitrogen atom show positive ∆ SCS values 
indicating their strong electron withdrawing nature which results in an electron poor 
amide proton. The deshielding effect increases with the number of heterocyclic 
nitrogen atoms. For example, NaHL20 with two heterocyclic nitrogen atoms has the 
highest ∆ SCS value of +0.66 ppm as compared to NaHL18 and NaHL19 
possessing, one heterocyclic nitrogen atom. NaHL18 (N at 4th position) and NaHL19 
(N at 3rd position) both exhibit a value of + 0.29 ppm, which implies that the position 
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of the heterocyclic nitrogen within the aromatic ring is less important with regards to 
the deshielding effect on the amide proton. 
Hammett plots were used in order to further investigate the trend observed 
for the chemical shift of the amide proton of PVAHs with respect to the substituent 
parameter or commonly called Hammett parameter. The influence of different para- 
and meta-aromatic substituents on the chemical shift of the N-H proton resonance 
can be correlated with the Hamett constant (σ). Hammett reported the quantitative 
relationship between the rate of a reaction and the substituents present in systems 
containing substituted benzene rings in 1937160. Since then ‘Hammett values’ are 
used as a practical method of measuring electron withdrawing/donating effects of 
substituents161-163. The Hammett parameter (σ) is obtained by comparing the 
hydrolysis of benzoic acid with the hydrolysis of the appropriate meta- or para-
substituted benzoic acid. Ortho-subsituted compounds are avoided, because the 
steric effects of such substituents prevents an accurate analysis of the reaction 
rates. The sign of the σ parameter indicates the electronic nature of the substituent, 
with a positive value for electron withdrawing substituents and negative value for 
electron donating substituents.  
For compounds NaHL1-NaHL20, a reasonable correlation of the chemical 
shifts of the N-H protons with the respective Hammett parameter is observed, as 
can be seen from figure 2.9. PVAHs containing heterocyclic nitrogen(s) or ortho and 
di-substituted aromatic rings are not included in the correlation, hence thirteen 
ligands were used for Hammett plot. The chemical shifts for the N-H resonances of 
the Z-isomer NaHL1-NaHL20 are listed in table 2.1.  
Electron withdrawing groups (EWGs) cause a downfield shift, indicating 
increased deshielding of the amide proton, which is also involved in strong 
intramolecular hydrogen bonding with the carboxylate group. Most of the values lie 
quite close to the linear fit and are consistent with trend expected for the obtained 
experimental values. However, the values for para- and meta- hydroxyl-substituted 
PVAHs do not correlate as well to the proposed line of best fit, which may be due to 
intermolecular hydrogen bonding effects.  
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Figure 2.9: Plot of the 1H NMR chemical shifts of the N-H proton of the Z isomer of 
thirteen indicated PVAHs in d6-DMSO vs σ (R2 = 0.77). 
A similar trend is observed in the Hammett plot, where strong electron 
withdrawing groups, for instance NO2, have a significant deshielding effect which is 
reflected in the chemical shift of the amide proton, whereas electron donating 
groups, such as CH3 and (CH3)3 are shielding.  
2.5.4 13C NMR spectra of PVAHs 
The 13C NMR spectrum of NaHL9 along with its structure and the atom 
numbering scheme is shown in figure 2.10. In the 13C NMR spectrum of sodium 
pyruvate the resonance observed at 205.4 ppm can be attributed to the carbonyl 
(Cii) carbon of the keto-group. Upon conjugation as in NaHL9, the resonance is 
shifted to 150.5 ppm (figure 2.10) and can be assigned to the azomethine carbon 
(C-2). The carbon atom is less electron-deficient in the azomethine than in the keto 
group, which can be attributed to the difference in the electronegativities of nitrogen 
and oxygen, respectively. A similar effect is observed for the resonance of the Ci 
carbon, where the azomethine bond formation causes a upfield shift of the 
carboxylate carbon (Ci → C1).  
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Figure 2.10: 13C NMR spectrum of NaHL9 in d6-DMSO 
The resonance observed at 166.3 ppm can be assigned to the carboxylate 
(C1) carbon, whereas the peak at 161.9 ppm is due to the carbonyl carbon (C3). 
The peaks observed at 127.0 and 129.3 ppm can be assigned to the aromatic 
carbons (5, 9/ 6, 8), whereas the peaks at 130.9 and 141.7 ppm can be assigned to 
either C7 or C4. The resonance at 141.7 ppm is likely to be due to the C4 carbon as 
it is close to the electronegative carbonyl group. The peaks at 21.06 and 21.02 ppm 
can be assigned to the protons of the CH3 (C10) or Ar-CH3 (C11) groups. The 
quaternary carbon atoms were detected using a 13C-DEPT experiment.  
The resonances at 13.9, 21.1, 128.3 and 128.9 ppm for the minor E isomer, 
disappeared when heated to higher temperatures, as observed in the 1H NMR 
spectra. When compared with the parent hydrazide, 4-methyl-benzoic acid 
hydrazide, and sodium pyruvate, the carbons which are in the close vicinity of the 
azomethine bond (C1,2,3,10) show a considerable upfield shift, whereas the 
carbons which belong to the hydrazide (C4,5,6,7,8,9,11) show only little downfield 
shift in the spectrum of NaHL9, except for C3.  
Additionally, in the 13C NMR spectrum, the resonances due to the methyl 
carbon (C10) of the major Z isomer and minor E isomer are observed at 21.0 and 
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13.9 ppm respectively. Turner et al observed 13C NMR chemical shifts for the CH3 
group of methyl pyruvate hydrazones at 13.0 and 20.1 ppm for the Z and E isomers, 
respectively.157 Hence, from the NMR studies, it can be confirmed that the observed 
major and minor resonances observed for NaHL9 correspond to its Z and E isomer, 
respectively. 
Previously, correlations between the 13C NMR chemical shifts of azomethine 
(C=N) carbons and Hammet parameters for Schiff bases have been studied in order 
to compare the electronic environment of imines and hydrazones.164  As indicated in 
figure 2.11, a linear correlation is observed in 13C NMR chemical shifts of the 
azomethine carbon against the Hammett parameter. It is observed that EWGs 
cause a downfield shift, whereas electron donating groups (EDGs) cause an upfield 
shift when compared with the ligand NaHL1, in which there are no substituents on 
the aromatic ring.  
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Figure 2.11: Plot of the 13C NMR chemical shift of the C=N carbon of indicated 
thirteen PVAHs in d6-DMSO versus σ (R2 = 0.92) 
EWGs increase the pi-electron density on azomethine carbon which in turn 
makes it electron deficient causing a downfield shift of carbon resonance. Hence, 
the PVAHs containing strong EWGs such as p-NO2, p-CF3 cause the carbon 
resonance of azomethine bond to shift downfield. Whereas, PVAH possessing 
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EDGs such as p-CH3, p-(CH3)3 have an inverse effect on the carbon shift, indicating 
their electron rich nature of the azomethine carbon which is in consistent with the 
literature.163,165 
2.5.5 NMR analysis of the Zn(II) complexes of PVAHs: 
As Zn(II) has d10 configuration and is diamagnetic, the Zn(II) complexes of 
PVAHs give rise to well-resolved proton NMR spectra with chemical shifts in the 
same frequency range as those of the free ligands. The NMR experiments were 
performed in the same solvent as used for the ligands (d6-DMSO) in order to be 
able to compare the results directly. The composition of the 1:2 (LX:Zn) zinc 
complexes is evident from the elemental analysis data and X-ray crystal structure. 
However, it cannot be derived conclusively from the NMR spectrum of [Zn(HL9)2] 
whether the species in solution is a 1:1 or 1:2 complex because the environment of 
the two coordinated PVAH ligands around the Zn(II) centre may be equivalent on 
the NMR timescale resulting in equivalent protons for both ligands. 
As representative example of the 1H NMR spectra obtained, the spectrum of 
[Zn(HL9)2] is shown in figure 2.12. The resonance observed at 2.38 ppm is due to 
both Ar-CH3 and CH3. The two doublets which are typical of a para-substituted 
aromatic ring appear at 7.35 and 7.90 ppm.  In comparison to free ligands, there is a 
very slight downfield shift observed for the resonances of the aromatic protons and 
Ar-CH3 whereas the CH3 proton resonance exhibits a downfield shift of 0.25 ppm. 
As a result of the coordination of the azomethine nitrogen to Zn(II), the adjacent 
amide proton observed at 12.69 in [Zn(HL9)2] shifts considerably downfield by 1.79 
ppm as compared to that of free ligand (10.90 ppm, E isomer). 
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Figure 2.12: 1H NMR spectrum of mer-[Zn(HL9)2] in d6 DMSO shown in the range 
from 2.0 to 13.0 ppm 
Some line broadening is observed in the spectra of the 1H NMR spectra of 
zinc complexes when compared to those of the free ligands. These line broadening 
in turn gives rise to inaccurate coupling constant values as similar to observed by 
Bell et al for zinc complexes of hydrazone ligand.166 It is evident that the two sets of 
signals observed in the case of the ligands are due to the presence of E/Z isomers, 
where the Z isomer is present as the major form. In the case of [Zn(HL9)2] the ligand 
exists in only one form, the E form which allows for tridentate metal coordination.  
The stacked NMR spectra of NaHL9 and [Zn(HL9)2] shown in figure 2.13 
indicate the presence of one form as the minor peaks observed in the aromatic 
region of the ligand are absent. In order to bind to Zn(II) in a tridentate manner 
NaHL9 adopts E configuration, as observed in the X-ray crystal structure of 
[Zn(HL9)2]. The resonance at 16.02 ppm assigned to the hydrogen bonded amide 
proton in the Z-conformer of the sodium salt of the HL9_ is absent in the Zn(II)-
complex; no resonance is observed in the region 14-18 ppm. There is, however, a 
significant peak at 12.69 ppm which can be attributed to the non-hydrogen-bonded 
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N-H proton. In case of NaHL9, the N-H proton of the E-isomer resonates at 10.90 
ppm.  
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Figure 2.13: Stacked NMR spectra of NaHL9 in d6 DMSO (top) and mer-[Zn(HL9)2] 
(bottom) in the region 7- 16.5 ppm 
The quaternary carbons were not observed in the 13C NMR spectrum of the 
Zn(II) complexes of PVAHs even after an increased number of scans and longer 
relaxation delay time (10 sec). Hence, only the secondary and tertiary carbons were 
used for analysis. The signals appearing at 13.5 ppm and 21.2 ppm can be 
assigned to the CH3 and Ar-CH3 carbons, respectively, whereas the aromatic 
carbons resonate at 128.8 ppm and 129.2 ppm. The fact that the CH3 carbon 
resonates at 13.5 ppm suggests that the ligand adopts E conformation in order to 
bind to Zn(II).157 For the ligand NaHL9, the resonance of the CH3 carbon of the E-
isomer appears at 13.9 ppm, whereas it is observed at 21.06 for the Z-isomer. 
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2.6 Infrared spectroscopic (IR) study of PVAHs and their Cu(II) and 
Zn(II) complexes: 
The solid state analyses of PVAHs and their metal complexes were 
performed using infrared (IR) spectroscopy. IR spectra were recorded from 4000 to 
400 cm-1 using KBr discs. As representative example NaHL9 and its respective 
Cu(II) and Zn(II) complexes are discussed in detail here. For comparison, the IR 
spectra of the starting materials 4-methyl benzoic acid hydrate and sodium pyruvate 
are also discussed. The IR data for the rest of the investigated PVAHs and their 
metal complexes can be found in experimental section (chapter-7).  
An overlay of the IR spectra of sodium pyruvate, 4-methyl benzoic acid 
hydrazide and NaHL9 along with their structures is illustrated in figure 2.14. The 
strong (s) band at 1708 cm-1 (figure 2.14, red IR spectrum) in the IR spectrum of 
sodium pyruvate can be assigned to the ketone (C=O) stretch vibration. This band 
is absent in the IR spectrum of NaHL9 indicating successful formation of the 
azomethine (C=N) bond, the stretch vibration of which appears as medium (m) 
intensity band at 1610 cm-1. A strong band due to the asymmetrical stretch vibration 
(νsym) and a weaker band due to the symmetrical stretch vibration (νasym) of the 
carboxylate group of sodium pyruvate is observed at 1634 cm-1 and 1405 cm-1, 
respectively167.  
The strong band observed at 1660 cm-1 in 4-methyl benzoic acid hydrazide 
(figure 2.14, blue IR spectrum) can be assigned to the carbonyl stretching frequency 
which shifts towards lower wavenumber 1649 cm-1 in NaHL9 (figure 2.14, magenta 
IR spectra). The shift towards a lower wavenumber can be accounted for by the 
resonance forms of the conjugated system, which increase the single bond 
character of the carbonyl group, as indicated in scheme 2.6.168 However, there is no 
significant difference in the carboxylate stretching frequencies of sodium pyruvate 
and the conjugated hydrazone. 
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Figure 2.14: Overlaid IR spectra of NaHL9 (magenta), sodium pyruvate (red) and 4-
methyl benzoic acid hydrazide (blue) in the region 1500-1750 cm-1 (bottom) and 
their corresponding structures (top) 
Electron withdrawing groups on the aromatic ring cause the ν(C=O) to shift 
towards higher frequencies, whereas electron donating groups have the opposite 
effect.168 This trend can be explained with the help of resonance forms. Electron 
donating groups in para-position of the aromatic ring stabilise the positive charge on 
the aromatic ring which in turn favours the formation of resonance form II (scheme 
2.7).169 Whilst the change in the azomethine stretching frequency of PVAHs is in the 
range 1580 - 1612 cm-1, the variation in the stretching frequency of the carbonyl 
group ranges from 1640 – 1690 cm-1. The values are consistent with literature 
values reported for aroyl-type hydrazones.170 
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Scheme 2.7: Resonance forms of PVAHs 
 The coordination of PVAHs to metal centres is also reflected in their IR 
stretching frequencies. The overlaid IR spectra of NaHL9 and its Cu(II) and Zn(II) 
complexes in the region 1000 – 1700 cm-1 and 1550 – 1670 cm-1  are shown in 
figures 2.15 and 2.16, respectively. The carboxylate asymmetrical stretching 
frequency of NaHL9 appears at 1632 cm-1. The band merges either with the 
carbonyl band in [Cu(II)L9(H2O)2] or the azomethine (C=N) band in [Zn(HL9)2], 
indicating the involvement of the carboxylate group in complexation. However, in 
other Cu(II) complexes of PVAHs, for example [Cu(II)L8(H2O)2], all three bands 
merge together resulting in a strong broad band at 1639 cm-1. 
In addition, the copper complexes lack the medium intensity broad band at 
3284 cm–1, assigned to the NH vibration and the band at 1649 cm–1 due to the C=O 
stretch vibration, an observation that is consistent with the deprotonation of the –NH 
group and subsequent coordination of the oxygen of the amide carbonyl to the 
metal ion via enolization.171 The C=O and C=N stretching frequencies are 
summarised in table 2.4.  
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wavenumber (cm-1)
 
Figure 2.15: Overlaid IR spectra of NaHL9 (blue), [Cu(II)L9(H2O)2] (green) and 
[ZnH(L9)2] (red) shown in the region 1000 – 1700 cm-1 
Moreover, the broad (br) bands of medium intensity located at around 3400 
cm–1 in the case of the copper complexes can be attributed to the presence of 
coordinated water molecules172. In case of the sodium salts of the ligands, this can 
be due to the hydrogen bonding of water to the sodium cation as observed in the 
crystal structures of PVAHs. The elemental analysis and single crystal X-ray 
structure of ligand confirms the presence of water molecules in the pyruvate 
hydrazones. 
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Figure 2.16: Overlaid IR spectra of ligand NaHL9 (blue), [Cu(II)L9(H2O)2] (green) 
and [Zn(HL9)2] (red) in the region 1550 – 1670 cm-1 
Table 2.4: Selected vibrational frequencies for NaHL9, [Cu(II)L9(H2O)2] and 
[Zn(HL9)2] 
Compound (ν) C=O1 (cm-1) 
(carbonyl) 
(ν) O-C=O2 
(cm-1) 
(carboxylate) 
(ν) C=N (cm-1) 
(azomethine) 
NaHL9 (blue 
spectrum) 
1649 1632 1610 
[Cu(II)L9(H2O)2] 
(green 
spectrum) 
1653 1637 1609 
[Zn(HL9)2]  (red 
spectrum)  
1649 1623 1611 
 Hence, the IR studies indicate the successful formation of PVAHs 
and its coordination to Cu(II) and Zn(II) centres is reflected in their stretching 
frequencies. 
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2.7 Synthesis of Cu(I) complexes 
In order to gain further insights into structural aspects of the Cu(I) centre, the 
Cu(I) complexes of NaHL8 and NaHL9 were synthesised. The synthesis was carried 
out using the Cu(I) precursor [Cu(I)(CH3CN)4]PF6, which was synthesised using a 
literature procedure173. The reaction was carried out under a nitrogen atmosphere 
using Schlenk techniques with dry solvents. Initially, the reaction mixture consisting 
of the precursor and the hydrazone ligand were stirred in methanol and then the 
product was precipitated using an excess of diethyl ether. The yellow solid that was 
formed was isolated by filtration and dried under vacuum. The NMR spectrum of the 
product confirmed the formation of a diamagnetic Cu(I) complex. However, the Cu(I) 
complex could not be crystallised as it was unstable when left in solution for a long 
time. Upon air exposure, the yellow colour of the Cu(I) complex turned green 
indicating the oxygen sensitivity of complex.  
To stabilise the soft Cu(I) centre it was necessary to introduce soft donor 
atoms, such as P or S. After stirring the reaction mixture consisting of 
[Cu(I)(CH3CN)4]PF6 (2 mmol) and hydrazone (1 mmol) ligand for 10 minutes, 
triphenylphosphine (PPh3) (5 mmol) was therefore added to the reaction mixture, 
yielding a clear solution. The product was precipitated using an excess of diethyl 
ether, which also helped in removing unreacted PPh3 due to its high solubility in 
diethyl ether. The PPh3 ligand not only provides the soft donor phosphorus atom, 
but also additional steric bulk that helps to stabilise the 4-coordinate tetrahedral 
environment around the Cu(I) centre. Interestingly, Samuelson et al illustrated that 
the stability of Cu(I) complexes when coordinated to a mixture of soft and hard 
donor atoms is greater than when binding to only soft donor atoms.174-175 The 
general scheme for the synthesis of the Cu(I) complexes is given in scheme 2.8. 
Details of the synthetic procedure can be found in chapter-7.  
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Scheme 2.8: Synthesis of Cu(I) complexes - [HLRCu(I)2(PPh3)5]PF6 
Single crystals for X-ray analysis were obtained from MeOH and diethyl 
ether. The X-ray crystal structure revealed the presence of two Cu(I) centres, within 
the Cu(I) complexes of NaHL8 and NaHL9, as indicated in final product shown in 
scheme 2.8. The Cu(I) crystals obtained from MeOH ([Cu(I)2HL8(PPh3)5]PF6, 
[Cu(I)2HL9(PPh3)5]PF6) indicate that NaHL8 and NaHL9, act as bidentate ligands, 
coordinating through oxygen and nitrogen atoms instead of ONO, due to the rigidity 
of the planar ligands. The bidentate coordination mode of PVAHs allow the Cu(I) 
centre to adopt the preferred tetrahedral geometry which is predicted for a Cu(I) 
complex. The remaining two tetrahedral coordination sites are occupied by two 
PPh3 groups, in a similar way to the structure observed in the case of a recently 
published Cu(I) hydrazone complex.176 As expected for Cu(I) complexes, 
NaHL8/NaHL9 and two PPh3 groups forms a tetrahedral coordination sphere 
around one the Cu(I) centre. The second Cu(I) centre also exhibits tetrahedral 
geometry, where the oxygen atom of the carboxylate group of NaHL8/ NaHL9 binds 
to the copper centre. The remaining three tetrahedral coordination sites are 
occupied by PPh3 groups. The overall positive charge on the overall complex is 
balanced by a hexafluorophosphate anion. 
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Interestingly, crystals obtained from diethyl ether for the Cu(I) complex of 
NaHL9, [Cu(I)2HL9(PPh3)4]PF6], show coordination of two PPh3 groups, instead of 
three around the second Cu(I) centre. This allows the copper centre to adopt a 3-
coordinate geometry. On the other hand, tetrahedral coordination site of the other 
Cu(I) centre remains the same. The crystal structures are discussed in detail in 
chapter-3. 
2.7.1 1H NMR analysis of the Cu(I) complexes 
Figure 2.17 shows the proton NMR spectrum of [Cu(I)2HL9(PPh3)5]PF6 and 
its chemical structure is provided in figure 2.18 b (right). Two singlets of relative 
integration three are observed at 1.89 and 2.43 ppm and correspond to the two CH3 
groups. The resonance at 2.42 ppm is attributed to the Ar-CH3 group as it is more 
deshielded than the methyl group which is next to the azomethine bond. The 
aromatic protons give rise to two doublets at 7.35 and 7.72 ppm as indicated in 
figure 2.18 a (left). These assignments were made by comparison with the ligand 
NaHL9. There is no significant shift in these resonances of the Cu(I) complexes as 
compared to the free ligand.  Multiplets in the aromatic region 7.22 - 7.30 ppm and 
7.38 – 7.45 ppm can be assigned to the five PPh3 groups on the two different Cu(I) 
centres.  
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Figure 2.17: 1H NMR spectrum of [Cu(I)2HL9(PPh3)5]PF6 in d4-MeOH in the range 
1.5 – 8.0 ppm. 
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Figure 2.18: a) 1H NMR spectrum of [Cu(I)2HL9(PPh3)5]PF6 in d4-MeOH in the range 
7.1 – 7.8 ppm (left) b) Structure of [Cu(I)2HL9(PPh3)5]PF6 (right). 
The peaks appearing at 3.30 ppm (d4-MeOH), 3.35 ppm (MeOH) 4.89 ppm 
(water), are due to the solvent peaks. The presence of the solvent molecule, MeOH, 
in the compound is also evidenced from the elemental analysis data and the single 
crystal X-ray structure. 
2.7.2 31P {1H}   NMR analysis of [Cu(I)2HL9(PPh3)5]PF6 
In order to gain more insight into the behaviour of the investigated Cu(I) 
complexes in solution, detailed 31P {1H} NMR experiments were carried out on 
[Cu(I)2HL9(PPh3)5]PF6. All the 31P spectra referred to in this chapter are proton-
decoupled. The 31P NMR spectrum of PPh3 recorded in d4-MeOD exhibits a sharp 
singlet at -5.0 ppm, whereas the spectrum of the [Cu(I)2HL9(PPh3)5]PF6 complex 
displays a broad resonance at 0 ppm at room temperature, as indicated in figure 
2.18 a. The 31P chemical shift of PPh3 in [Cu(I)2HL9(PPh3)5]PF6 appears downfield 
compared to free PPh3 (figure 2.19 c), which is likely due to the decrease in 
shielding caused by metal centre and is generally known to occur in σ-donor 
ligands like phosphine.177 When the solution is cooled down to 200 K, the broad 
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peak resolves into two peaks as indicated in figure 2.19 b.178 The two peaks can be 
attributed to the PPh3 ligands bound to the two different Cu(I) centres in the dimeric 
complex.  
 
Figure 2.19: Stacked 31P {1H} NMR spectra of a) [Cu(I)2HL9(PPh3)5]PF6 at 298 K b) 
[Cu(I)2HL9(PPh3)5]PF6 at 200 K c) free PPh3 at 298 K in d4-MeOH 
The broad nature of the resonance indicates the fluxional nature of the 
complex in solution, which is likely due to ligand exchange processes.177,179 In order 
to gain more insight into possible ligand exchange processes, free PPh3 was added 
to the solution of the Cu(I) complex. In the resulting spectrum, the resonance 
broadens further with increasing amounts of free PPh3, as indicated in figure 2.20 a-
c. This observation confirms that ligand exchange processes are occurring. 
Moreover, even with seven equivalents of PPh3 added (figure 2.20 c) there is no 
separate resonance observed that corresponds to free PPh3 (figure 2.20 d) 
indicating the fast exchange of the ligands on the NMR timescale.  
a 
b 
c 
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Figure 2.20: Stacked 31P {1H} NMR spectra of a) [Cu(I)2HL9(PPh3)5]PF6 b) 
[Cu(I)2HL9(PPh3)5]PF6 with added four equivalents PPh3  c) [Cu(I)2HL9(PPh3)5]PF6 
with added seven equivalents of PPh3 d) free PPh3 in d4-MeOH 
Hence, from above 31P {1H} NMR experiments it can be concluded that, 
there is a ligand exchange process occurring either at the Cu(I) centres which is 
evident from the broad 31P NMR peak of PPh3.  
The 13C NMR spectra showed no quaternary peaks and the primary and 
secondary peaks were not very distinctive even in spectra with higher scan rates, as 
observed for the Zn(II) complexes of PVAHs. Hence the carbon NMR spectra were 
not used in the analysis. 
b 
a 
c 
d 
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2.7.3 Infrared analysis of the Cu(I) complexes 
In order to gain further insight into the solid state structure of the Cu(I) 
complexes, IR spectra were recorded using KBr discs. The stretching frequencies of 
the carbonyl and azomethine groups in the Cu(I) complexes tend to merge giving 
rise to a single broad band, indicating their involvement in complexation. 
[Cu(I)2HL8(PPh3)5]PF6 bearing the EWG nitro-group exhibits a band at 1632 cm-1, 
whereas the corresponding band for [Cu(I)2HL9(PPh3)5]PF6  with the EDG methyl-
group
 
appears at a lower wavenumber of 1617 cm1. Similar behaviour for 
EWG/EDG groups is observed and discussed in the previous section for PVAHs. In 
addition, the C=C ring stretching vibrations at 1475 cm-1 observed in free PPh3 
indicate a shift towards higher frequency in both the Cu(I) complexes. 
Hence the IR analysis of investigated Cu(I) complexes of PVAHs confirms 
the coordination of the ligand to the Cu(I) centre. 
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2.8 Synthesis of a di-hydrazide analogue of PVA 
As discussed earlier, the Schiff base condensation reaction is a reversible 
process and the products obtained can undergo hydrolysis. The stability of these 
types of compounds under different conditions have been explored in the past by 
several researchers.180-181 It is evident that the azomethine bond undergoes rapid 
hydrolysis under extreme acidic and basic conditions, and hydrolysis at a reduced 
rate at neutral pH. Kalia and Raines have proposed the detailed mechanism for its 
hydrolysis under acidic conditions as shown in scheme 2.9. The  azomethine bond 
hydrolyses, when it comes in contact with water, as the resultant protonated species 
is highly susceptible to attack due to the enhanced electrophilicity of the carbon 
atom.182 The base hydrolysis may result from the attack of OH- on electrophilic 
azomethine carbon followed by generation of negative charge on nitrogen. The 
nucleophilic nitrogen then deprotonates a water molecule resulting into the cleavage 
of C=N bond via hemiaminal intermediate.  
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X = O       oxime
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Scheme 2.9: Suggested mechanism for the acid hydrolysis of hydrazones and 
oximes182 
Hence, in order to increase the stability of PVAHs, reduction of the C=N 
bond to form a secondary amine was attempted in order to gain more stability. The 
resultant C-N bond would then be less susceptible to nucleophilic attack by H2O. 
2.8.1 Attempted reduction of a PVAH 
Initially, the reduction was attempted using sodium borohydride (NaBH4) with 
NaHL9 according to literature procedures.183  Subsequently, a palladium catalyst 
was used under an atmosphere of hydrogen.184 Both reactions failed to give the 
reduced product indicated in scheme 2.10. The reactions were monitored using TLC 
and the identity of the isolated product was confirmed by ESI-MS. The molecular ion 
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peak remained unchanged from the starting compound NaHL9. The expected 
product would result in an increased mass due to the addition of two hydrogens 
across the C=N bond.  
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Scheme 2.10: Attempted reduction of the azomethine (C=N) bond of NaHL9 a) 
NaBH4, refluxing under water for 24 hr, MeOH or H2, Pd/C (10%), 24 hr, MeOH 
NaBH4 is a mild reducing agent, however, the reducing power of NaBH4 can 
be improved by adding reagents such as NiCl2, TiCl3, TiCl4, CoCl2, I2, ZrCl4.185-186  
As previously described in chapter-1, 3-bromopyruvate is known to inhibit  
M. tuberculosis ICL, an enzyme found to implicated in the persistent state of the 
bacteria. This was illustrated with the help of co-crystallisation studies, which 
revealed that 3-bromopyruvate forms a covalent adduct with the active site of ICL 
achieved by dehalogenation of the inhibitor.53 In an attempt to target the ICL, the 
Schiff base condensation of 3-bromopyruvate with a hydrazide was performed. 
However, the resultant product (step a) of the reaction was found to have 
undergone an alkylation reaction (step b) to form the di-hydrazide analogue 
NaH3D1, as shown in scheme 2.11. 
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Scheme 2.11: General synthetic scheme for NaH3D1 a) NaHCO3, reflux in methanol 
for 4 hours 
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 The di-hydrazide analogue possesses a C-N single bond on one 
side of the molecule which may provide the hydrolytic stability of the molecule. This 
type of ligand may thus help to overcome the issues of both hydrophilicity and 
hydrolysis. Hence, further attempts to reduce the azomethine bond of PVAHs to 
make them hydrolytically stable were discontinued. 
2.8.2 Synthesis and characterisation of NaH3D1 
The proposed mechanism for the formation of NaH3D1 is given in scheme 
2.12.  In the first step (i), single molecule of hydrazide attacks the carbonyl carbon 
to give the bromopyruvate hydrazone, this Schiff base mechanism is similar to 
discussed in detail for PVAHs in previous section (page 38). This is followed by 
attack of second molecule (ii) of hydrazide at the adjacent carbon of bromine to 
undergo alkylation. The intermediate formed undergoes deprotonation of amine 
proton giving rise to final product (iii).   Attack of two molecules of hydrazides on 3-
bromopyruvate could also be simultaneous giving rise to the final product or it could 
be other way round, where alkylation first takes places followed by hydrazone 
formation.  
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Scheme 2.12: Proposed mechanism for the formation of the di-hydrazide analogue; 
NaH3D1 
  Chapter-2                 
 75
 Successful formation of the dianalogue NaH3D1 is evident from 
ESI-MS and is further confirmed by NMR analysis. The positive and negative mass 
spectrum of NaH3D1 shows a peak at m/z 369.1543 corresponding to [M-Na+2H]+,  
and 367.1409 corresponding to [M-Na]- respectively. NaH3D1 also exhibits isomers 
in solution, most likely due to E/Z isomerisation, as observed for PVAH (NaHL9). 
This is evident from the  1H NMR spectrum recorded in d6-DMSO and the two 
isomers are roughly in the ratio 3:2, as calculated from the integration values. Figure 
2.21 displays the full 1H NMR spectrum in the region 2.0 to 17.0 ppm. 
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Figure 2.21: 1H NMR spectrum of NaH3D1 in the region 1-18 ppm in d6-DMSO 
Figure 2.22, shows three singlets in the region 2.30 – 2.40 ppm (right 
spectrum) due to the two Ar-CH3 groups labelled a and j in the two isomers. There 
are actually 4 singlets, the peak at 2.37 ppm is a result two peaks merging, giving 
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rise to a broad singlet. The protons of two aromatic rings resonate in the region 7.2 
– 7.8 ppm (figure 2.22, left). 
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Figure 2.22: 1H NMR spectrum of NaH3D1 in the region 2.20 – 2.40 ppm (right) and 
7.20 – 7.80 ppm (left) in d6-DMSO 
The proton resonances of the methyl and aromatic protons do not provide 
conclusive information on the isomerisation of NaH3D1, however the NMR 
resonances of the NH and CH2 protons can help to gain more insight. For instance, 
the carboxylate oxygen atom can hydrogen bond with the amide proton, as shown 
in figure 2.23 a (Z isomer, left), whereas in the other isomer the same oxygen atom 
can form a hydrogen bond with the amine proton, as shown in figure 2.23 b (E 
isomer, right). In the Z isomer, the NH proton of the amine group labelled as e1 
resonates at 5.70 ppm with a relative integration of one showing an apparent 
quartet (ideally should be dt) arising from coupling to adjacent the CH2 protons (f1) 
and the amide proton (d1) as indicated in figure 2.24. The 1H-1H COSY spectrum of 
NaH3D1 displayed in figure 2.25 confirms the coupling of the amine proton to the 
CH2 and amide protons. The doublet at 3.68 is due to the CH2 protons and the 
amide proton also appears as doublet at 10.11 ppm with coupling constants of 6.8 
Hz and 6.4 Hz, respectively, in line with the proton splitting pattern of the amine 
proton. 
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                          E isomer                      (b) 
Figure 2.23: a) Structure of NaH3D1 showing Z isomer (left) and E isomer (right) 
with respect to azomethine bond (C=N) indicated in red  
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Figure 2.24: 1H NMR spectrum of NaH3D1 in the region 3.60 – 5.80 ppm in d6-
DMSO 
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Figure 2.25: 1H-1H COSY spectrum of NaH3D1 in the selected region in d6-DMSO 
showing coupling of N-H (e1) with CH2 (f1) and N-H (d1) 
However, in the E form, when the amine proton (e2) forms a hydrogen bond 
with the oxygen atom, it shifts considerably downfield to either 16.38/ 16.43 ppm 
and appears as a singlet (figure 2.26, right). Whereas the CH2 (f2) and amide proton 
(d2) also appears as a singlet at 3.88 (figure 2.24) and 16.38/ 16.43 ppm (figure 
2.26, right) respectively. Due to rapid exchange of the amine proton (e2) with the 
carboxylate oxygen atom, the spin-spin coupling constant with adjacent methyl and 
amide proton is difficult to observe. The other amide proton (g2) appears as singlet 
at 9.83 ppm, while in Z form (g1) it exhibits significant downfield shift at 16.38/ 16.43 
ppm as indicated in figure 2.26. 
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Figure 2.26: 1H NMR spectrum of NaH3D1 in the region 9.70 – 10.20 ppm (left) and 
16.30 – 16.40 ppm (right) of selected region in d6-DMSO 
Hence, it can be concluded from this section that, the attempted reduction of 
azomethine bond of NaHL9 was unsuccessful. The formation of a di-hydrazide 
analogue of PVAH, NaH3D1, was achieved using 3-bromopyruvate and 4-methyl 
benzoyl hydrazide in an attempt to make bromopyruvate hydrazones. Due to the C-
N single bond character of NaH3D1, it can overcome some of the issues of 
hydrolysis, thus further attempts to reduce azomethine bond were discontinued.  As 
for the NMR spectrum of NaHL9, the 1H NMR spectrum of NaH3D1 also indicates 
the presence of E/Z isomers in d6-DMSO solution. Full characterisation data can be 
found in the experimental section. In order to explore the stability of NaH3D1 
towards hydrolysis, its absorption spectrum was monitored under physiological 
conditions; these studies can be found in chapter-5.  
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Section B: 
Section B mainly focuses on synthesis and characterization of fourteen 
cinnamaldehyde hydrazone ligands and their respective Cu(II) complexes. Single 
crystal X-ray structures, stability studies and biological studies will be discussed in 
subsequent chapters. 
 Cinnamaldehyde and their derivatives have been extensively studies for 
their antitubercular properties.187-190 It has been proven that cinnamaldehyde is 
known to inhibit the bacterial cell division protein FtsZ.191 Several studies have 
proven that lipophilic molecules are advantageous over hydrophilic molecules as 
they can effectively diffuse through the mycobacterial cell wall.189 In order to explore 
a lipophilic library of antitubercular compounds, a series of compounds was 
synthesized by Schiff base condensation of cinnamaldehyde and a selection of 
substituted hydrazides. In addition to the free ligands, their Cu(II) complexes were 
also synthesised. 
2.9 Synthesis of cinnamaldehyde hydrazones (CAHs)  
The synthesis of the cinnamaldehyde hydrazones  HCA1-HCA14 was 
carried out according to literature procedures.135 The detailed synthetic procedure 
can be found in the experimental section and the general synthetic scheme is given 
in scheme 2.13. CAHs were obtained in good yields and are indicated in table 2.5, 
along with their compounds codes and substituents.  
X1
X2
N
H
O
NH2
R
O X1
X2
N
H
O
R
N
i
Hydrazide Cinnamaldehyde
HCA1 - HCA14
 
Scheme 2.13: Synthesis of cinnamaldehyde hydrazones i)  EtOH, 4h heated under 
reflux 
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Table 2.5: Compound codes of CAHs along with their respective substituents and 
yields 
X1
X2
N
H
O
R
N
 
Compound R (X=C) Yield 
HCA1 H 70% 
HCA2 p-Cl 77% 
HCA3 p-CH3 79% 
HCA4 p-OCH3 71% 
HCA5 p-NO2 84% 
HCA6 p-CF3 83% 
HCA7 p-(CH3)3C 79% 
HCA8 p-OH 72% 
HCA9 m-F 79% 
HCA10 m-OH 80% 
HCA11 o-OH 71% 
HCA12 m-CH3, p-NO2 81% 
Heterocyclic Compounds  (R=H)  
HCA13 X1=N, X2=C 73% 
HCA14 X1=C, X2=C 69% 
 The formation of the ligands was confirmed using HR-ESI MS, 1H and 13C 
NMR spectroscopy and the purity of a few hydrazones was confirmed using 
elemental analysis. The details of the full characterisation can be found in chapter-7. 
2.10 NMR analysis of CAHs 
 
1H NMR spectra of CAHs were recorded in d6-DMSO. As a representative 
example, the 1H NMR spectrum of HCA3 is given in figure 2.27. The proton 
resonance observed at 2.37 ppm can be attributed to the protons of the aromatic 
methyl substituent. The most deshielded signal observed at 11.67 ppm can be 
assigned to a N-H proton. As indicated in the inset of figure 2.27, the signals 
observed in the region 7.0 – 8.3 ppm are part of either the aromatic or the 
conjugated system (except N-H), where the most downfield proton signal can be 
attributed to the azomethine proton (H9) 
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Figure 2.27: 1H NMR spectrum of HCA3 in d6-DMSO 
The 13C NMR spectrum of HCA4Me exhibits a downfield signal at 162.7 ppm 
which can be assigned to the carbonyl carbon (C10), whereas the azomethine 
carbon (C9) is observed at 149.3 ppm. Other carbon signals fall in the range 125.0 
– 142.0 ppm, except the aromatic methyl (C17) which appears at 21.5 ppm. The 
quaternary carbons C6/11/14 were assigned with the help of a DEPT 1350 scan 
which was also performed on all CAHs along with 13C NMR.  
Unlike PVAHs, only a few CAHs, HCA13, HCA14 and HCA5, exhibit distinct 
major and minor peaks in the NMR spectra, which could possibly due to E/Z 
isomers. 
Hammett plots for the amide proton (N-H) and the azomethine proton 
(HC=N) vs substituent parameter (σ) are indicated in figure 2.28 and 2.29, 
respectively. For compounds HCA1-HCA14, a reasonable correlation is observed 
between the amide proton and σ, as can be seen from figure 2.28. CAHs containing 
heterocyclic nitrogen, ortho and di-substituted are not included in the correlation.  
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Figure 2.28: Hammett plot of the 1H NMR chemical shifts of the amide (N-H) proton 
of ten indicated CAHs in d6 DMSO vs σ (R2 = 0.90). 
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Figure 2.29: Hammett plot of the 1H NMR chemical shifts of the azomethine proton 
(HC=N) proton of ten indicated CAHs in d6 DMSO vs σ (R2 = 0.55). 
It is observed that EWGs cause a downfield shift of the amide proton, 
whereas EDG groups cause an upfeild shift when compared with the ligand HCA1, 
  Chapter-2                 
 84
where there are no substituents on the aromatic ring. A similar Hammett plot is 
obtained from the 1H NMR chemical shifts for the N-H proton for the PVAHs ligands 
in d6 DMSO versus σ. 
However, the azomethine proton shows very little or no shift, as can be seen 
from figure 2.29. This signifies that the EWG/EDG do not have a significant effect on 
the azomethine proton. The reason for this might be the larger distance from the R 
group. Similarly observed for PVAHs, where there is no considerable shift observed 
for methyl protons.  
2.11 Synthesis of Cu(II) complexes of CAHs 
Cu(II) complexes of CAHs were synthesized using copper(II) acetate and the 
respective CAH in a 1:2 (M:L) ratio, as indicated in scheme 2.14. 
X1
X2
N
O
R
N
X1
X2
N
O
R
N
Cu
X1
X2
N
H
O
R
N
HCA1 - HCA14

 
Proposed structure of Cu(II) 
complexes of HCA1 – HC14 
Scheme 2.14: Synthesis of Cu(II) complexes of CAHs i) copper acetate dehydrate, 
MeOH, 2h 
The binding of CAHs to the Cu(II) centre in a 2:1 ratio was confirmed using 
ESI MS and elemental analysis data. Unfortunately, single crystal X-ray structures 
of the copper complexes could not be obtained. Owing to the fact that CAHs have 
two donor atoms, N and O, it is most likely to prefer bidentate mode of binding. 
Hence, a square planar geometry as expected for four coordinate Cu(II) 
complexes.192 This will allow it to maintain an overall neutral charge by binding to 
two anionic oxygen atoms from two ligands, as indicated in scheme 2.14. Cu(II) 
complexes of cinnamaldehyde hydrazones are not reported elsewhere. The Ni(II) 
complex of cinnamaldehyde salicylhydrazone shows a bidentate mode of binding. 
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The nickel complex achieves octahedral geometry by coordinating to two 
cinnamaldehyde hydrazones in the equatorial plane, whilst the apical sites are 
occupied by two solvent molecules.193  
Interestingly, the positive ESI-MS spectra of Cu(II) complexes of CAHs 
exhibit peaks at [M+2H]+, suggesting the reduction of Cu(II) to Cu(I), as observed for 
the Cu(II)-complexes of PVAHs. Details of the characterisation of the Cu(II) 
complexes of CAHs can be found in chapter-7. 
2.11 Infrared (IR) analysis of CAHs and their Cu(II) complexes 
In order to gain more insight into the solid state structures of CAHs and their 
respective Cu(II) complexes, IR spectra were recorded using KBr disc. 
A representative example of overlaid IR spectra in the region 1400 – 1700 
cm-1 is displayed in figure 2.30. The intense band at 1636 cm-1 in HCA3 (blue 
spectrum) can be assigned to the carbonyl (C=O) bond and the band at 1623 cm-1 
can be attributed to the azomethine (C=N) bond.  
C=O stretch
C=N stretch
 
Figure 2.30: Overlaid IR spectra of ligand, HCA3 (blue) and its Cu(II) complex 
[Cu(II)(CA3)2] (magenta) in the region 1100 – 1700 cm-1 
  Chapter-2                 
 86
The carbonyl and the azomethine stretching frequencies shifts to lower 
frequencies. 1611 cm-1 and 1587 cm-1 respectively, in [Cu(II)(CA3)2] indicating the 
coordination of donor atoms O and N. This is similar to what is observed in PVAH 
compounds. The lowering of the frequency can be attributed to a lengthening of the 
bond which is due to the shift of the double bond nature of the carbonyl towards 
single bond character indicating enolisation of C=O bond.171 
As expected, CAHs bearing electron withdrawing groups on the aromatic 
ring have higher frequencies for the ν(C=O) band, while those containing electron 
donating groups have decreased frequencies.  The coordination of Cu(II) to HCA3 is 
also evidenced from the fact that the N-H stretching frequency observed around 
3200 cm-1 in CAH ligands disappears in copper complexes. Although the crystal 
structures of Cu(II) complexes of CAHs are not available, similar examples of metal 
complexes indicate the formation of monoanionic ligands through the loss of amide 
proton (N-H).  
2.12  Reduction of azomethine (C=N) bond 
Attempts at reducing the azomethine (C=N) bond of HCA1 failed, as 
observed for PVAHs. The reduction was first attempted using the reducing agent 
NaBH4 but the reaction failed, hence a palladium catalyst under an atmosphere of 
hydrogen was used. The reduction was confirmed using TLC and ESI-MS 
(consistent with addition of two hydrogen atoms). However, instead of the 
azomethine bond getting reduced (product B, scheme 2.15), the olefin bond was 
reduced to give product C, RHCA1 as indicated in scheme 2.15.  
N
H
O
N N
H
O
H
N
N
H
O
N
i
A
B
C
a
b
 
Scheme 2.15: Reduction of C=C bond i) H2, Pd/C (10%), 18 hours 
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The reduction of the C=C bond was confirmed through 1H, 13C, DEPT and 
2D NMR experiments. The proton resonances of the reduced olefin bond labeled as 
b and a, appear at 2.59 ppm and 2.83 ppm, respectively, each with a relative 
integration of two. Their corresponding carbon atom peaks appear at 32.5 ppm and 
34.3 ppm, respectively. The stability of the reduced compound, RHCA1 is studied 
for comparison with HCA1, which will be further discussed in chapter-6                                                                                                                                                                                       
2.13 Summary of Chapter – 2 
A series of sodium pyruvate hydrazones with aromatic substituents, ranging 
from electron withdrawing to electron donating groups were synthesised and 
characterised by 1H NMR spectroscopy, 13C NMR spectroscopy, high resolution ESI 
mass spectrometry, infrared spectroscopy, elemental analysis and melting point 
analysis. Variable temperature 1H NMR studies indicate that PVAHs exist as a 
mixture of E and Z isomers in solution, with the Z form predominating owing to the 
strong hydrogen bond formed between amide N-H and carboxylate oxygen atom 
Furthermore, the Cu(II) and Zn(II) complexes of the PVAHs and Cu(I) 
complexes of NaHL8 and NaHL9 were synthesised and characterised using the 
above mentioned techniques, except for the NMR characterisation of the Cu(II) 
complexes due to their paramagnetic nature. Elemental analysis indicates the 
formation of 1:1 and 1:2, M:L complexes for Cu(II) and Zn(II) which is further 
confirmed by the single crystal X-ray structures. The 1H NMR spectra of the Cu(I) 
complexes indicate their diamagnetic nature, whereas 31P NMR spectra indicate 
ligand exchange processes in solution. 
Attempts to reduce the azomethine bond using sodium borohydride and 
palladium catalysts were unsuccessful. The synthesis of a di-hydrazide analogue of 
pyruvate with 4-methyl benzoyl hydrazide was achieved using bromopyruvate and 
the product was fully characterised using the above mentioned techniques.  
Fourteen cinnamaldehyde hydrazones (HCA1-HCA2) and their respective 
Cu(II) complexes were synthesised and characterised. Studies indicate a Cu(II):L 
ratio of 1:2 with possible bidentate mode of binding allowing for a square planar 
geometry. Reduction of the azomethine bond of HCA1 was unsuccessful, instead 
the olefinic bond was reduced, as indicated by ESI-MS and NMR analysis. 
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3.0 Structural investigation in the solid state by single crystal X-ray 
crystallography 
3.1  Introduction 
As discussed in chapter - 2, hydrazones can exist in different forms in solution 
for example neutral, anionic and dianionic, which allows them to bind to different metal 
ions, resulting in various geometries around the metal centre.194-195 Due to their 
versatile nature, they have been considered as important ligands in the field of 
coordination chemistry.196 The geometry adopted by a metal complex of a hydrazone 
depends on the type of metal and its oxidation state. For example, various geometries 
of Cu(II) complexes of hydrazones ranging from 6-coordinate octahedral, 5- coordinate 
square pyramidal and trigonal bipyramidal and 4-coordinate square planar geometry 
have been reported in the literature,134,143,197-198 depending on the ligand donor system. 
It is well known that, Jahn-Teller distortion is observed for Cu(II) d9 systems, resulting 
in distorted octahedral and 5-coordinate geometries.199 Whereas the ligand mostly 
binds to Cu(I), d10 , in a tetrahedral manner, 176 Zn(II) d10 complexes are known to exist 
in trigonal pyramidal, square pyramidal and octahedral geometry.200-202 Apart from 
mononuclear metal complexes, di-, tri- and polynuclear metal complexes of Schiff 
bases have also been reported as hydrazone/s are also present as a part of a 
polydentate ligand system.196,200,203-205  
Ketcham et al., investigated the binding of 2-pyridineformamide 3-piperidyl 
thiosemicarbazone (HAmpip) (Figure 3.1) to first row transition metal ions, such as 
Cu(II), Fe(III) and Zn(II). The crystal structures of the metal complexes reveal that 
HAmpip acts as a tridentate ligand and binds through the thione sulphur, imine nitrogen 
and pyridyl nitrogen atoms. The compound depicted in figure 3.1 is a good example, as 
it shows how the same ligand can be part of different geometries when coordinated to 
different metal ions.  
N
N
N
NH2
N
S
H
 
Figure 3.1: Structure of 2-pyridineformamide 3-piperidyl thiosemicarbazone 
(HAmpip)206 
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The Cu(II) and Zn(II) complexes, as shown in figure 3.2 a and 3.2 b 
respectively, exhibit square pyramidal geometry but the Zn(II) complex shows 
considerable distortion towards trigonal geometry. However, in the case of the Fe(III) 
complex, as indicated in figure 3.2 c, an octahedral geometry is obtained through 
coordination to two ligands206.    
 
N
N
N
H2N
N
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Cl
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a 
N
N
N
H2N
N
S
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Br
Br
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N
N
N
H2N
N
S
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N
N
N
NH2
N
S
c 
Figure 3.2: Structure of a) [Cu(HAmpip)Cl2], b) [Zn(HAmpip)Br2], c) [Fe(Ampip)2]206 
Since, Cu(II) and Zn(II) ion binds to HAmpip with 1:1 and Fe(III) in 1:2 
stoichiometry, this coordination behaviour can be used as a useful tool in bioinorganic 
drug design. This, then would allow the metal ion, to facilitate the transport of two 
biologically active pharmacophores across the cell membrane. 
3.1.1 Geometries of copper and zinc centres present in biological 
systems 
 
 The biological function of several metalloenzymes is closely related to the 
geometric and electronic properties of the metal sites, influenced by the coordination 
environment of the enzyme.207 Various coordination geometries of copper and zinc 
metalloenzymes are present in biological systems. Most of the copper-containing 
metalloenzymes have a  4-coordinate geometry around the copper centre, for e.g. type 
I blue copper proteins such as azurin, plastocyanin possess distorted tetrahedral 
geometry208 and type II copper proteins such as superoxide dismutase have a square 
planar geometry.209 These Cu centres are surrounded by N, O and S donor atoms 
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provided by amino acid side chains, such as histidine (N), cysteine (S), methionine (S), 
aspartate (O) and glutamate (O). The donor atoms from these amino acids are also 
known to form Zn(II) tetrahedral sites in proteins, such as superoxide dismutase, 
carbonic anhydrase, ß-lactamase, metallothionein and zinc fingers. Superoxide 
dismutase (CuZnSOD), shown in figure 3.3, possesses two metal centres; the Cu(II) 
ion is coordinated to histidine molecules via nitrogen atoms whereas Zn(II) binds to 
three histidine residues and one aspartate residue. Cu(II) adopts square planar 
geometry with tetrahedral distortion, whereas Zn(II) has a distorted tetrahedron 
geometry. 
 
Figure 3.3:  Schematic representation of superoxide dismutase209 
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3.2  Structural aspects of pyruvate hydrazone ligands 
 As discussed in Chapter-2, the investigated pyruvate hydrazone ligands 
(PVAHs) are present in the general molecular formula of NaHLx, predominantly 
existing in the Z form in solution. In order to establish the molecular structure of the 
ligand in the solid state, crystals of selected ligands were isolated from concentrated 
solutions of the ligands in ethanol. Crystal data and their refinement data of single 
crystal X-ray structures described in this chapter can be found in chapter-7 and all 
other related crystallographic data can be found in Appendices 3-22. Detailed 
discussions of the crystal structures of ligands NaHL9, NaHL11 and H2L20 will be given 
in the following section. 
3.2.1 NaHL9.2H2O 
NaHL9.2H2O crystallises in a rhombohedral R-3 space group and the 
corresponding ORTEP plot is shown in figure 3.4.  Unless otherwise mentioned, 
ORTEP plots of the crystal structures described in this chapter have 50 % ellipsoid 
probability. The ligand is essentially planar with Z (syn) conformation with respect to 
the imine C=N bond. This is revealed by the torsional angle (C(1)-C(2)-N(1)-N(2)) of 
2.06(2)°.210 The molecule is nearly planar with the exception of the Na+-counterion, 
which lies in a different plane with a interplanar angle of 48.09°. Since the hydrazones 
possess hydrogen bond acceptors as well as donors, the ligand has the opportunity to 
form hydrogen bonds in the crystal lattice.  
 
Figure 3.4: ORTEP plot (50% probability ellipsoids) of the molecular structure of 
NaHL9.2H2O 
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Intramolecular hydrogen bonds observed involve N(2)-H bonding to the O(1) of 
the carboxylate group with  a distance of 2.5772(14) Å  and an angle of 141.7(16)°. 
Also, O(1) is ionically bonded to Na+ with a distance of 2.3427(15) Å. Moreover, N(1) 
forms a hydrogen bond with one of the water molecules (O(5)) bonded to sodium. It is 
also interesting to note that the carbonyl (C(3)-O(3)) oxygen atom is ionically bonded to 
Na with a distance of 2.3482(10). The C=O bond length is 1.234(2) Å which strongly 
suggests that ligand exist predominantly in the keto form in the solid state.  
3.2.2 NaHL11.2H2O 
NaHL11.2H2O crystallises in trigonal R-3 space group, as indicated in the figure 
3.5. Ligand NaHL11.2H2O  show similar characteristics to that of NaHL9.2H2O. As 
expected, the ligand NaHL11 is nearly planar except for the Na+ ion and exhibits Z-
conformation with respect to the imine (C(2)-N)(1)) bond with a torsional angle (C(1)-
C(2)-N(1)-N(2)) of 2.58( 3).  
 
Figure 3.5: ORTEP plot (50% probability ellipsoids) of the molecular structure of 
NaHL11.2H2O 
3.2.3 Packing diagram of NaHL9.2H2O and NaHL11.2H2O 
The packing diagram showing the Na+ coordination environment and the 
separation between two planes for NaHL9.2H2O and NaHL11.2H2O are shown in 
Figures 3.6 a, 3.6 b, 3.7 a and 3.7 b, respectively. Mercury software version 2.4 is used 
in this chapter, to show the packing diagrams and the planes passing through the 
atoms. 
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                                                                    a 
 
                                                      b 
Figure 3.6: a) Crystal structure packing. b) planes showing separation between two 
crystallographically equivalent ligands NaHL9.2H2O. Colours of the atom: purple - Na, 
grey - C, brown - Br, blue - N, red - O 
 
                                                                            
a                   
 
b
Figure 3.7: a) Crystal structure packing. b) planes showing separation between two 
crystallographically equivalent ligands NaHL11.2H2O. Colours of the atom: purple - Na, 
grey - C, blue - N, red - O 
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3.2.4 Interaction of NaH9.2H2O and NaHL11. 2H2O with sodium 
In the solid state structures of both, NaHL9.2H2O and NaHL11.2H2O, the 
sodium counter ion interacts with the hydrazinic carbonyl oxygen O(3) and the 
carboxylate donor atom O(1) of an adjacent ligand. The two adjacent ligands are 
crystallographically equivalent and lie in different planes separated by 3.539 and 3.537 
Å for NaHL9.2H2O and NaHL11.2H2O, respectively. The Na centre completes its 
octahedral coordination sphere by binding to four water molecules, with the oxygen 
atoms bridging between two sodium cations. Three water molecules and carbonyl 
oxygen lie in one plane, whereas the carboxylate and water molecule occupy the apical 
positions. General schematic representation showing the Na+ coordination sphere is 
depicted in figure 3.8. The bond lengths and bond angles of NaHL9.2H2O and 
NaHL11.2H2O involving the Na atom are given in table 3.1.  
Na
H2
O
O
H2
Na
O(3)=C
O(1)-C
O
H2
H2
O
O(3)=C
O(1)-C
H2
O
O
H2
f
d
c
e
b
a
NaNa
g
 
Figure 3.8: Schematic representation of the Na+ octahedral complex 
Table 3.1: Comparison of selected bond lengths (Å) and bond angles (°) for the 
octahedral Na+ environment in NaHL9.02H2O and NaHL11.2H2O  
Bonds NaHL9 NaHL11 
a 2.3482(10) 2.3427(15) 
b 2.4222(11) 2.4214(15) 
c 2.3162(11) 2.3207(16) 
d 2.3952(11) 2.3915(17) 
e 2.4232(11) 2.4193(17) 
f 2.3459(11) 2.3516(16) 
g 3.3864(6) 3.3896(8) 
d-Na-c 90.86(4) 90.68(5) 
e-Na-f 89.40(4) 89.33(6) 
a-Na-b 88.03(3) 87.94(6) 
a-Na-f 160.98(4) 159.81(6) 
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As seen from table 3.1, both structures exhibit similar bond lengths and bond 
angles and are in good agreement with literature values211. The Na-O bond distances 
fall in the range 2.31 - 2.43 Å and two of the neighbouring sodium ions (Na---Na) 
distance measures 3.38 Å. The bond angles, especially a-Na-f, indicate a slight 
distortion from a perfect octahedral geometry. Furthermore, one of the water molecules 
participates in hydrogen bonding with N(1), with an O(4)-H(4A)----N(1) bond distance of 
3.1579(16) Å and bond angle of 162(2)°.  
3.2.5 H2L20.H2O 
H2L20.H2O (figure 3.9) crystallises in the triclinic space group P-1. The ligand 
crystallised out of a methanolic solution of the corresponding zinc complex, suggesting 
that the ligand is labile. H2L20.H2O adopts   E (anti) conformation with respect to the 
imine bond similar to the reported crystal structures of pyruvic acid hydrazones.212-213 
This is further confirmed by the torsional angle (C(6)-C(7)-N(4)-N(3)) of 179.65(11)º 
which is typical for the E isomer of hydrazones.145 The dissimilarity of geometric 
isomers, E and Z present in the ligands may be due to the presence of sodium ion in 
the crystal lattice and intramolecular hydrogen bonding, which stabilises the Z 
conformation in sodium pyruvate hydrazone.  
 
Figure 3.9: ORTEP plot (50% probability ellipsoids) of the molecular structure of 
H2L20.H2O 
Moreover, H2L20.H2O is essentially planar with the mean plane of deviation of 
1.73° as compared to the sodium salts of the deprotonated ligands (5.84 and 7.25°). 
This can be attributed to the Na+ cation, which results in the distortion of the molecule. 
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Due to the presence of a water molecule in the crystal lattice, the hydrogen bonding 
interactions differ from those observed for NaHL9.2H2O and NaHL11.2H2O.  
Although, no intramolecular hydrogen bonding interactions were observed, the 
nitrogen atom of the imine forms an intermolecular hydrogen bond with water with a 
bond distance (N(4)- H(4a)-O4) of 3.1579(16) Å. The intermolecular H-bond distance is 
slightly longer than the intramolecular H-bond distance observed for NaHL9.2H2O and 
NaHL11.2H2O with 2.5772(14) and 2.933(3) Å, respectively. On a similar note, the 
same water molecule is involved in hydrogen bonding with pyridyl nitrogen N(1), 
carboxylate oxygen O(3) and carbonyl oxygen O(1) with bond distances of 2.8656(17), 
3.082(2) and 2.9683(16) Å, respectively. These hydrogen bonds are absent in 
NaHL9.2H2O and NaHL11.2H2O as the respective oxygen atoms are ionically bonded 
to Na+ as described earlier. The crystal packing of H2L20.H2O illustrating hydrogen 
bonds is shown in figure 3.10.  
 
Figure 3.10: Crystal packing diagram of H2L20.H2O showing intermolecular hydrogen 
bonding interactions (indicated with dotted lines). Colours of the atom: grey - C, blue - 
N, red - O, white – H. 
3.2.6 Comparing PVAHs with the  literature data 
The selected bond lengths and bond angles of NaHL9.2H2O, NaHL11.2H2O  
and H2L20.H2O  and their comparison with literature data are given in table 3.2. A 
general schematic representation of PVAH with atom numbering scheme is given in 
figure 3.11. To our best knowledge, crystal structures of sodiated pyruvate hydrazones 
do not exist in the literature, hence the ligands are compared to the pyruvic acid 
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hydrazones. In order to make a direct comparison of equivalent bonds, the numbering 
system in the schematic representation is not in accordance with the ORTEP plots. The 
ORTEP plot indicates that the oxygen atom of the hydrazinic carbonyl (C(3)-O(3)) in 
sodiated ligands (NaHL9.2H2O  and NaHL11.2H2O) are ionically bonded to the Na+ 
cation. This makes the carbonyl bond length slightly longer than the corresponding 
bond in H2L20 and similar bonds reported in the literature. This might be due to the 
involvement of lone pairs on oxygen in interactions with the sodium cation. Similarly, 
the bond lengths observed for C(1)-O(2) of the carboxylate moiety for sodiated ligands 
were slightly longer than the non-sodiated counterpart.  
X
X
N
N CH3
O
H
O O1
224 3
1
1 2
3
5
6
7
8
9 10
R
Y
 
                  R                  X                Y 
NaHL9.2H2O       p – Me          C                 Na 
NaHL11.2H2O     p – Br           C                 Na 
H2L20.H2O         H                  N                 H 
Lit ref212      p – Me          C                 H 
Lit ref213      p – Cl            C                 H 
 
Figure 3.11: General structure of pyruvate hydrazones with atom numbering scheme 
Table 3.2: Selected bond lengths (Å) for NaHL9.2H2O, NaHL20.2H2O, H2L20.H2O  and 
two examples from the literature 
 
Bonds  NaHL9.2H2O NaHL11.2H2O H2L20.H2O Lit ref212 Lit ref213  
C(1)-O(2) 1.2380 (16) 1.234(2) 1.2151 (17) 1.213 (3) 1.219 (2) 
C(1)-O(1) 1.2743 (16) 1.278(2) 1.3163 (17) 1.312 (3) 1.3161 (19) 
C(2)-N(1) 1.2897 (17) 1.290(3) 1.2831(18) 1.277 (3) 1.281 (2) 
C(3)-O(3) 1.2330 (15) 1.234(2) 1.2209 (17) 1.222 (2) 1.220 (2) 
C(3)-N(2) 1.3522 (16) 1.348(3) 1.3616(18) 1.369 (3) 1.379 (2) 
N(1)-N(2) 1.3835 (15) 1.383(2) 1.3745 (16) 1.377 (2) 1.360 (2) 
N(2)-H 0.916(18) 0.827() 0.83(3) 0.87 (2) 0.878 (9) 
O(1)-H - - 0.93(2) 0.83 (2) 0.829 (10) 
O-Na 2.4223(11) 2.3427(15) - - - 
 
In contrast to H2L20.H2O  and compounds listed from references, the bond 
distances for C(1)-O(1) observed for NaHL9.2H2O and NaHL11.2H2O were significantly 
shorter than for the other ligands. Comparing with  typical bond lengths  of C-O (1.42 
Å) and C=O (1.23 Å), this indicates that the electron density is delocalised in case of 
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the carboxylate group (O(1)-C(1)-O(2)) in order to make it resonance stabilised. The 
fact that in NaHL9 and NaHL11  the C(1)-O(1) bond is slightly longer than the C(1)-
O(2) bond reflects the interaction of O(1) with the sodium counter ion. The imine bond 
remains unaffected and is very similar in the protonated and deprotonated ligands. This 
is seen from the (C(2)-N(1)) bond length, which has a double bond character,  typical of 
Schiff base ligands.210 
Selected bond angles are given in table 3.3. Owing to the fact that oxygen 
donor atoms of NaHL9.2H2O and NaHL11.2H2O, which include O(3) and O(1), are 
associated with Na+, the N(2)-C(3)-O(3) bond angles were slightly larger than in H2L20 
and literature ligands. Likewise, the N(1)-C(2)-C(1) bond angle observed for sodiated 
ligands were 126.4 o and for non-sodiated ligands it ranges from 114.0 – 116.0 o.  
Table 3.3: Selected bond angles (°) of NaHL9, NaHL11, H2L20 and two examples from 
the literature 
 
X
X
N
N CH3
O
H
O O1
224 3
1
1 2
3
5
6
7
8
9 10
R
Y
 
                               R                  X                Y 
NaHL9.2H2O       p – Me          C                Na 
NaHL11.2H2O     p – Br           C                 Na 
H2L20.H2O          H                  N                 H 
Lit ref212              p – Me          C                 H 
Lit ref213              p – Cl            C                 H 
Bonds  NaHL9.2H2O NaHL11.2H2O H2L20.H2O Lit ref212 Lit ref213  
N2-C3-O3 123.37(12) 123.39(17) 121.55(13) 121.82 (19) 121.63 (16) 
N2-C3-C4 115.55(11) 115.79(16) 115.10(12) 117.06 (17) 116.93 (13) 
C3-N2-N1 119.46(11) 119.59(16) 117.71(12) 116.00 (17) 116.41 (12) 
N1-C2-C1 126.45(11) 126.48(16) 115.74(12) 113.55(17) 114.38(13) 
C2-C1-O1 118.72(11) 118.46(16) 113.30(12) 118.40(18) 121.04(14) 
C(1)-C(2)-
N(1)-N(2) 
(torsional 
angle) 
2.06(2) 2.58(3) 179.65(11) 176.43(17) 177.31(11) 
The other bond angles are more or less similar and the small differences can be 
attributed  to crystal packing effects and hydrogen bonding. It is also noted that the R 
group on the aromatic ring does not have a significant effect on the bond lengths or 
bond angles of the PVAHs. 
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3.3 Structural aspects of cinnamaldehyde hydrazone ligands 
The crystals of cinnamaldehyde hydrazone ligands (CAHs), which will be  
discussed further in this section were obtained from ethanolic solutions of the ligands. 
HCA2 and HCA5 crystallise in the triclinic space group P-1 and the monoclinic space 
group P21/c, respectively. The ORTEP plots for the corresponding crystal structures 
are displayed in figures 4.12 a and 4.12 b. The crystal structures indicate that both 
ligands are protonated at N1, indicating the presence of predominantly the keto from in 
the solid state, as observed for pyruvate hydrazone ligands. 
 a 
       b 
Figure 3.12: ORTEP plot (50% probability ellipsoids) of the molecular structure of a) 
HCA2 and b) HCA5 
The ligands adopt Z conformation with respect to imine (C(8)-N(2)) bond , with 
the two aromatic rings lying in two different planes, which allows them to remain in the 
lower energy conformation by experiencing less steric hindrance. The torsional angle 
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(C(9)-C(8)-N(2)-N(1)) of 177.16(12) and 177.09(14) for HCA2 and HCA5 further 
confirms the Z form. Unlike PVAHs, CAHs crystal structures, are non-planar with a 
interplanar angle of 57.64 (HCA2) and 53.83 (HCA5), as can be seen from figure 3.13 
a and 4.13 b respectively. The interplanar angle is measured by passing the planes 
through the two aromatic rings. The small difference in the interplanar angle of HCA2 
and HCA5 may be attributed to their packing effect of the crystal in the unit cell. 
          
                                                            a 
 
 
 
b 
Figure 3.13: Asymmetric unit cell of a) HCA2 and b) HCA5 showing the two planes 
passing through the aromatic rings 
Although, no intramolecular hydrogen bonding was observed for HCA2 and 
HCA5, the ligands exhibit some interesting intermolecular hydrogen bonding  and pi-
interactions, as displayed in figures 3.14 a and 3.15 a, respectively. The imine proton 
on N(2)-H forms intermolecular hydrogen bonds with symmetry generated carbonyl 
O(1) oxygen lone pairs which is indicated in figures 3.14 b and 3.15 b. In addition, C-H-
--pi interactions are also observed, which allow the molecule to pack in a bilayer array. 
The proton on the aromatic ring interacts with the pi electron density of another phenyl 
ring of adjacent symmetry generated molecule and vice versa. The C-H---pi interactions 
for HCA4Me and HCA5 are illustrated in figures 3.14 c and 3.15 c, respectively. The C-
H----pi interactions for both the ligands range from 2.7 to 2.9 Å214. These C-H----pi 
interactions are not observed in the solid state structures of PVAHs, which could be 
due to presence of only one aromatic ring. 
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Figure 3.14 a:  Crystal structure packing diagram showing interactions for CA4Cl 
(indicated with dotted lines). Colours of the atom: grey - C, blue - N, red - O, white - H, 
green-Cl 
b          c 
Figure 3.14: b) Intramolecular hydrogen bonding interactions c) C-H---pi interactions for 
HCA2 (indicated with dotted lines).Colours of the atom: grey - C, blue - N, red - O, 
white - H, green-Cl 
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Figure 3.15:  a) Crystal structure packing diagram showing interactions for CA4NO2 
(indicated with dotted lines). Colours of the atom: grey - C, blue - N, red - O, white - H 
 
 
Figure 3.15: b) Intramolecular hydrogen bonding interactions c) C-H---pi interactions for 
HCA5 (indicated with dotted lines). Colours of the atom: grey - C, blue - N, red - O, 
white – H. 
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Additionally, weak pi-pi interactions are also observed for the ligands leading to 
the formation of pi stacks of the molecules. In HCA5, the molecules are also interlinked 
amongst themselves via C-H---Onitro interactions between aromatic proton on the para-
position of C(14) carbon with two oxygen atoms of nitro group on two different 
molecules. Whereas in CA4Cl, chlorine does not take part in any kind of interactions, 
but delocalised pi-electrons on C(10) – C(11) C-H---pi interactions with one of the proton 
on aromatic ring. Selected bond lengths and bond angles for HCA2 and HCA5 can be 
found in table 3.4. 
N
N
O
H
R
1 1
3
2 4
5
6
7
8
9
10
11
12
13
14
15
16
2
1
 
   R = p-Cl (HCA2), R = p-NO2 (HCA5) 
Figure 3.16: General structure of CAH with atom numbering scheme 
Table 3.4: Selected bond lengths (Å) and bond angles (°) for HCA2 and HCA5 
Bonds  HCA2 HCA5 
C(4)-C(7) 1.4974(19) 1.499(2) 
C(7)-O(1) 1.2259(18) 1.228(2) 
C(9)-C(8) 1.442(2) 1.436(2 
C(7)-N(1) 1.3548(19) 1.353(2) 
C(8)-N(2) 1.288(2) 1.286(2) 
N(1)-N(2) 1.3838(17) 1.382(2) 
N(2)-H 0.88(2) 0.86(2) 
O(1)-C(7)-N(1) 123.97(13) 124.07(16) 
C(7)-N(1)-N(2) 119.96(12) 120.67(15) 
N(2)-C(8)-C(9) 119.50(14) 120.63(16) 
C(9)-C(10)-C(11) 126.97(16) 126.25(14) 
C(1)-C(2)-N(1)-N(2) 
(torsional angle) 
177.16(12) 177.09(14) 
As expected, both ligands show similar bond lengths and bond angles for 
equivalent bonds suggesting that the R group on the aromatic ring has little or no 
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influence on the bond distances, as observed for PVAHs. The keto form of ligand is 
present in the solid state which is confirmed by the presence of the double bond 
character of the carbonyl C(7)-O(1) moiety, with bond lengths of 1.2259(18) and 
1.228(2) Å for HCA2 and HCA5, respectively. The imine, C(8)-N(2) bond lengths 
observed for ligands HCA2 (1.288(2)) and HCA5 (1.286(2)) is indicative of a double 
bond  and is characteristic of aroyl hydrazones.215 Similar lengths for equivalent bonds 
were observed for both the series of compounds. 
3.4 Significance of hydrogen bonding in medicinal chemistry 
From the X-ray crystal structures, it is evident that PVAHs and CAHs participate 
in intra and/or intermolecular hydrogen bonding. Hydrogen bonding interactions play a 
crucial role in medicinal chemistry, as they can affect drug uptake, distribution, 
metabolism and excretion (ADME). The importance of the hydrogen bond acceptor and 
donor properties of a drug is reflected by the Lipinski’s rule of five.216  One of the rules 
states that there should be a considerable number of hydrogen bond donor and 
acceptor atoms, but no more than five H-bond donors (including OHs, NHs and SHs) 
and no more than ten H-bond acceptors. This is because a large number of hydrogen 
bond donor atoms can affect the drug permeability through cell membrane.  
The LogP value gives an indirect measure of hydrogen bond donor/acceptor 
properties of a molecule, and it should be below five, in line with the Lipinski’s rule of 
five. A LogP value greater than five could lead to poor drug absorption and can be 
calculated theoretically and determined experimentally. The ClogP for PVAHs and 
CAHs were calculated theoretically using OSIRIS Property Explorer.217 The ClogP 
values lie between -1.03 to 2.74 and 2.58 to 5.18 for PVAHs and CAHs respectively 
depending on the R group attached to the aromatic group, whereas for the well known 
antitubercular drug isoniazid the calculated value is -0.78. It is evident from the crystal 
structures that the PVAHs form a greater number of hydrogen-bonding interactions 
than the CAHs investigated. Hence, the ClogP values are larger for the CAH series as 
compared to the PVAH series, which implies that CA hydrazones have a  more 
lipophilic character. However, greater ClogP values of active pharmacophores can be 
useful in antitubercular drug design, since increased lipophilicity would facilitate the 
passage of the molecule through the lipid bilayer of the waxy mycobacterial cell 
wall.189,218 
Hydrogen bonding interactions are not only vital for the drug delivery 
mechanism, but also known to determine interactions with the active site of enzymes, 
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thereby affecting the activities of certain enzymes. For example, the pyruvate moiety 
which is a resultant of dehalogenation of 3-bromopyruvate is known to form hydrogen 
bonds with amino acids of the active site of isocitrate lyase (ICL) thus blocking the 
enzymatic activity. ICL is found in Mycobacterium tuberculosis and allows the bacteria 
to remain in the latent state.53 Furthermore, it has been shown that hydrogen bonding 
with the active site of catalase peroxidase helps to stabilise the active pharmacophore 
of isoniazid219. 
3.5  Structural investigation of Cu(II) complexes of PVAHs 
3.5.1 Monomeric square pyramidal Cu(II) complexes 
3.5.1.1 [Cu(II)(L9)(H2O)2] 
 Most of the Cu(II) complexes of PVAHs described in this chapter were obtained 
from slow evaporation of methanolic solutions. [Cu(II)(L9)(H2O)2] crystallizes in the 
triclinic space group P-1  and the ORTEP plot is shown in figure 3.17. Interestingly, the 
crystal structure of [Cu(II)(L9)(H2O)2] possesses two crystallographically independent 
molecules in the same unit cell.  
 
 
Figure 3.17: ORTEP plot (50% probability ellipsoids) of the molecular structure of 
[Cu(II)(L9)(H2O)2]. Hydrogen atoms apart from water molecules, H9 and H20 are 
omitted for clarity 
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The Cu(II) centre is penta-coordinated with three coordination sites occupied by 
the tridentate ligand L9, which forms two stable 5-membered chelate rings. The other 
two sites of coordination are occupied by neutral aqua ligands. While the equatorial 
positions of the Cu(II) centre are occupied by the hydrazinic carbonyl oxygen (O3), the 
imine nitrogen (N2) atom, one carboxyl oxygen (O3) , and one water oxygen (O4), the 
apical position is taken by oxygen atom (O5) of another  water molecule, which is 
typical of Cu(II) tridentate hydrazone complexes.135 Loss of the N(2)-H proton imparts a 
negative charge on the O(3) atom resulting in a dianionic ligand, which helps stabilise 
the two positive charges on the Cu(II) centre. The ligand, L92- remains nearly planar 
when coordinated to the Cu(II) centre. 
It is known that 5-coordinate metal complexes exhibit an extensive range of 
geometries ranging from regular trigonal bipyramidal to square pyramidal, with most of 
displaying structures that are intermediate between the two ideal geometries. Hence,  
the angular structural parameter τ, which was first defined by Addison et al. can be 
applied to describe these kind of geometries. τ is calculated according to equation, τ =  
(β-α)/60 and angles are as indicated in figure 3.18. For a perfect square pyramidal 
geometry τ = 0 and for a trigonal bipyramidal geometry τ = 1.220 
                                                                                                                                                                                                                                                                                                                                                                                                                 
 
 
 
Figure 3.18: Addison’s model to calculate τ values220 
 
The two crystallographically independent complexes present in the unit cell of 
[Cu(II)(L9)(H2O)2] exhibit different τ values. For complex 1, the basal angles N(4)–Cu–
O(1) and N(1)–Cu–Cl(1) are 157.41° and 166.42°, resp ectively, giving a  τ value of 
0.04, whereas for complex  2, this value  is 0.2. Hence, the geometry around the Cu(II) 
centres of both the complexes of [Cu(II)(L9)(H2O)2] can be best described as slightly 
distorted square pyramidal. Other examples of two crystallographically independent  
Cu(II) complexes within the same unit cell exhibiting different τ values are known to 
exist in the literature.184 
MO
L
O
N Lα 
ß 
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As discussed in section 3.2, the corresponding ligand NaHL9 adopts Z 
conformation with a torsional angle of 2.06(2)° involving the imine bond (C(1)-C(2)-
N(1)-N(2)). However, in order to bind to the Cu(II) centre  in a tridentate manner, the 
ligand changes confirmation from Z to E, which is indicated from the torsional angles of 
177.69(19) and 177.85(19)145 for the two complexes, respectively. It can be noted that 
the torsional angles are similar to that of the protonated ligand H2L20. Moreover, the 
two chelating rings consisting of O(1)-C(1)-C(2)-N(1)-Cu and N(1)-N(2)-C(3)-O(3)-Cu 
are nearly coplanar with a interplanar angle of 3.48 and 3.77° for the two complex, 
respectively. 
3.5.1.2 [Cu(II)(L11)(H2O)2].H2O 
 
Similar characteristic features were observed for [Cu(II)(L11)(H2O)2].H2O as can 
be seen from the ORTEP plot (figure 3.19). The complex also crystallises in the  
triclinic space group P-1.   
 
Figure 3.19: ORTEP plot (50% probability ellipsoids) of the molecular structure of 
[Cu(II)(L11)(H2O)2] .H2O. Hydrogen atoms apart from water molecules and H5 are 
omitted for clarity 
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3.5.1.3 Comparing [Cu(II)(L9)(H2O)2] and [Cu(II)(L11)(H2O)2].H2O 
Although no intramolecular hydrogen bonding was observed for 
[Cu(II)(L9)(H2O)2] and [Cu(II)(L11)(H2O)2].H2O, the coordinated  aqua ligands were 
involved in intermolecular hydrogen bonding. In [Cu(II)(L11)(H2O)2].H2O the water 
molecule in the equatorial position in complex 1, forms a hydrogen bond with carbonyl 
oxygen (O(5)-H----O(8))  with a bond distance of 2.805(3) Å. The apical water molecule 
is involved in hydrogen bonding with O(2) of the carboxylate group of the symmetry 
generated molecule.  
Whilst the free ligand NaHL11 adopts a  Z conformation with a torsional angle 
of 2.58(3)°, the coordinated ligand has an E conformation which is revealed from the 
torsional angles of 179.3(2) and 179.6(2)145 for the two complexes, respectively. In 
addition, the two chelating rings in the corresponding complexes, consisting of O(1)-
C(1)-C(2)-N(1)-N(2)-C(3)-O(3)-Cu are nearly planar with a interplanar angle of 4.51 
and 2.61°. Selected bond lengths and bond angles for complex 1 and 2 of 
[Cu(II)(L9)(H2O)2]  and [Cu(II)(L11)(H2O)2].H2O are tabulated in table 3.5. The general 
schematic representation of Cu(II) square pyramidal complexes with atom numbering 
scheme displayed in figure 3.20. will be used throughout this chapter to represent 
square pyramidal Cu(II) complexes. In order to directly compare the bond lengths and 
bond angles of different copper complexes, the numbering system may not match with 
the atom numbers in the ORTEP plots.  
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Figure 3.20: Schematic representation of square pyramidal Cu(II) complexes, showing 
the atom numbering scheme used in this chapter. 
Table 3.5: Selected bond lengths (Å) of [Cu(II)(L9)(H2O)2] and [Cu(II)(L11)(H2O)2].H2O 
Bonds [Cu(II)(L9)(H2O)2] [Cu(II)(L11)(H2O)2].H2O 
 Complex-1 Complex-2 Complex-1 Complex-2 
C(1)-O(1) 1.291(3) 1.282(3) 1.297(3) 1.294(3) 
C(1)-O(2) 1.226(3) 1.244(3) 1.2393(3) 1.248(3) 
C(3)-O(3) 1.301(3) 1.295(3) 1.295(3) 1.302(3) 
C(3)-N(2) 1.326(3) 1.328(3) 1.321(3) 1.332(3) 
N(1)-N(2) 1.372(2) 1.371(2) 1.372(3) 1.375(3) 
C(2)-N(1) 1.286(3) 1.289(3) 1.289(3) 1.290(3) 
Cu-O(1) 1.9877(16) 1.9940(16) 2.0056(17) 2.0075(18) 
Cu-O(3) 1.9873(16) 1.9939(16) 1.9941(18) 1.9945(17) 
Cu-O(4) 1.958(2) 1.971(2) 2.001(2) 1.9379(18) 
Cu-O(5) 2.218(2) 2.152(2) 2.147(2) 2.289(2) 
Cu-N(1) 1.8988(19) 1.9065(19) 1.905(2) 1.902(3) 
 
The bond lengths for crystallographically independent molecules are almost 
identical, except for the Cu-OH2 distances. The equatorial bond distances involving the 
Cu(II) centre (Cu-O/N) are very similar; however the apical bond distances are 
significantly longer which is due to Jahn-Teller distortion, as expected for Cu(II) 
complexes.199,221 It is noteworthy that the C(3)-O(3) carbonyl bond distances for 
[Cu(II)(L9)(H2O)2]  and [Cu(II)(L11)(H2O)2].H2O  range from 1.29-1.30 Å , whereas in 
the respective ligands the bond distances range from 1.20-1.23 Å. The expected 
lengthening of carbonyl bond distance in copper complexes indicates that the C(3)-
O(3) bond changes from a double bond to a bond with more  single bond character due 
to deprotonation at N(2). This clearly indicates that the ligand undergoes keto-enol 
tautomerisation in order to allow it to attain its dianionic form,  making the overall 
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complex neutral. Selected bond angles, distortion angle and τ values are given in table 
3.6.  
Table 3.6: Selected bond angles (°) and τ values for complexes 1 and 2 of 
[Cu(II)(L9)(H2O)2]  and [Cu(II)(L11)(H2O)2].H2O 
O
N
N O
O
CH3
R
Cu
1
2
34 1
13
2 2
H2O OH2
45
 
Bonds [Cu(II)(L9)(H2O)2] [Cu(II)(L11)(H2O)2].H2O 
 Complex-1 Complex-2 Complex-1 Complex-2 
O(1)-Cu-O(3) 161.11(7) 160.22(7) 160.38(7) 160.65(7) 
N(1)-Cu-O(4) 156.67(9) 152.75(9) 147.52(9) 163.62(9) 
O(4)-Cu-O(5) 93.73(9) 95.72(9) 96.26(10) 89.98(8) 
N(2)-C(3)-O(3) 124.6(2) 124.1(2) 124.8(2) 124.4(2) 
C(2)-C(1)-O(1) 114.82(19) 116.03(19) 115.7(2) 116.0(2) 
N(2)-C(3)-C(4) 115.9(2) 116.4(2) 115.2(2) 116.1(2) 
C(3)-N(2)-N(1) 107.91(18) 107.53(18) 108.12(19) 107.85(19) 
N(1)-C(2)-C(1) 111.9(2) 111.5(2) 111.8(2) 111.4(2) 
C(1)-C(2)-N(1)-N(2) 
(torsional angle) 
177.69(19) 177.85(19) 179.3(2) 179.6(2) 
τ 0.075 0.125 0.214 0.050 
The dianionic nature of the ligand is also reflected in the carbonyl C(3)-O(3) and the 
carboxylate C(1)-O(1) bond lengths, as they have nearly similar bond distances in case 
of copper complexes. A similar effect was observed for the bond distance C(3)-N(2), 
where the bond length is shortened (1.32-1.33 Å) as compared to that of the free 
ligands (1.34-1.36 Å), indicating the delocalisation of pi- electrons over the N(2)-C(3)-
O(3) bonds. Additionally, the N(1)-N(2) bond lengths are also slightly shortened, 
whereas the imine bond C(2)-N(1) remains relatively unaffected. The τ value is 
calculated using the basal plane angles O1-Cu-O3 and N1-Cu-O4. Amongst the listed 
values, the ligand based bond angles are more or less similar for equivalent bonds of 
[Cu(II)(L9)(H2O)2]  and [Cu(II)(L11)(H2O)2]. The basal angles, N(1)-Cu-O(1) are 
different for the complexes, hence resulting in dissimilar τ values. Moreover, a 
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distortion of the square pyramidal geometry is indicated by the O4-Cu-O5 bond angle 
as for perfect square pyramidal geometry it should be 90°. The larger the τ value, the 
greater is the deviation from 90°.  
The bond angles O1-C1-C2 and N2-C3-O3 suggest that the two 5-membered 
rings are not identical. It is interesting to note that in CuL9, the two crystallographically 
independent complexes lie nearly in the same plane as shown figure 3.21 a, whereas 
the two complexes in CuL11 lie in two different planes as shown in figure 3.21 b, with a 
distance of 4.875 Å between two Cu centres.  
 
a   b   
 
Figure 3.21: Planes passing through the copper complexes of two crystallographically 
independent molecules a) [Cu(II)(L9)(H2O)2], b) [Cu(II)(L11)(H2O)2].H2O 
3.5.1.4 Comparing [Cu(II)(L8)(MeOH)2], [Cu(II)(L13)(H2O)(MeOH)], 
[Cu(II)(L17)(H2O)2] and [Cu(II)(L7)(MeOH)2] 
The Cu(II) complexes of other ligands, including L82-, L132-, L172- and L72- also 
crystallised with similar square pyramidal geometries, with the apical/equatorial 
positions occupied by H2O and/or  MeOH.  The Cu(II) complex of L82- crystallises in the 
monoclinic space group P2(1)/n with a molecular structure [Cu(II)(L8)(MeOH)2], as 
indicated in the ORTEP plot (figure 3.22). The Cu(II) ion is coordinated in the plane by 
the tridentate ligand and a coordinated methanol molecule instead of water, as 
observed for [Cu(II)(L9)(H2O)2]  and [Cu(II)(L11)(H2O)2]. A weakly bound methanol 
completes the coordination sphere in the axial position, indicating appreciable Jahn-
Teller distortion. The τ value of 0.05 indicates a slight distortion from the ideal square-
pyramidal geometry.  
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Figure 3.22: ORTEP plot (50% probability ellipsoids) of the molecular structure of 
[Cu(II)(L8)(MeOH)2] 
The coordinated methanol molecules in [Cu(II)(L8)(MeOH)2] are involved in 
intermolecular hydrogen bonding with adjacent symmetry-generated molecules, with 
the mercury plot of the crystal lattice showcasing hydrogen bonds shown in figure 3.23.  
 
 
 
Figure 3.23: Crystal packing of [Cu(II)(L8)(MeOH)2] showing intermolecular hydrogen 
bonds with the symmetry generated molecules. Colours of the atom: grey - C, blue - N, 
red - O, white - H, brown - Cu 
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The equatorial methanol molecule forms hydrogen bond with one of the 
symmetry generated carboxyl O(1) atom (O(5)-H---O(1)) with a bond distance of 
2.7072(15) Å. The apical methanol is involved in hydrogen bonding with O(1) atom 
(O(4)-H---O(2)) of another symmetry generated molecule with a bond distance of 
2.7085(15) Å. 
The Cu(II) complex of L72- crystallises in the monoclinic space group P21/n with 
a molecular structure of [Cu(II)(L7)(MeOH)2]. The ORTEP plot of the corresponding 
complex is shown figure 3.24. The copper complex shows similar characteristics to 
[Cu(II)(L8)(MeOH)2].  
 
 
Figure 3.24: ORTEP plot (50% probability ellipsoids) of the molecular structure of 
[Cu(II)(L7)(MeOH)2] 
 
The Cu(II) complexes of L132- and L172- crystallise in the triclinic space group 
P-1 and the monoclinic space group P21/n with the molecular structures 
[Cu(II)(L13)(H2O)(MeOH)] and [Cu(II)(L17)(H2O)2], respectively. The ORTEP plots of 
the corresponding Cu(II) complexes are shown in figures 3.25 and 3.26. The methoxy 
group in [Cu(II)(L13)(H2O)(MeOH)]  is disordered over two positions. 
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Figure 3.25: ORTEP plot (50% probability ellipsoids) of the molecular structure of 
[Cu(II)(L17)(H2O)2] 
 
 
Figure 3.26: ORTEP plot (50% probability ellipsoids) of the molecular structure of 
[Cu(II)(L13)(H2O)(MeOH)] 
It is interesting to note that the  methoxy group on the aromatic ring takes part 
in C-H---pi interactions and are displayed in figures 3.27 and 3.28 for 
[Cu(II)(L13)(H2O)(MeOH)] and [Cu(II)(L17)(H2O)2], respectively. For both the methoxy 
containing complexes, the proton on OC(11)H3 and the  delocalised pi electrons of the 
neighbouring aromatic ring  give rise to C-H---pi interactions with distance ranging from 
2.60-2.90 Å. The adjacent symmetry generated molecules stack almost coplanar to 
each other with an average distance of 3.67 Å and 3.91 Å for [Cu(II)(L13)(H2O)(MeOH)] 
and [Cu(II)(L17)(H2O)2], consistent with C-H---pi interactions. The distance is measured 
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between the two oxygens (O(4)) of methoxy group for [Cu(II)(L17)(H2O)2], whereas for 
[Cu(II)(L13)(H2O)2] it is measured between between oxygen (O(4)) of methoxy and 
C(3) of carbonyl carbon.  
 
Figure 3.27: Crystal packing of [Cu(II)(L17)(H2O)2] showing C-H---pi and intramolecular 
hydrogen bonding interactions (indicated with dotted lines). grey - C, blue - N, red - O, 
white - H, brown - Cu 
 
 
Figure 3.28: Crystal packing of [Cu(II)(L13)(H2O)(MeOH)] showing C-H---pi and 
intramolecular hydrogen bonding interactions (indicated with dotted lines). grey - C, 
blue - N, red - O, white - H, brown - Cu 
  Furthermore, intermolecular hydrogen bonding is observed for the coordinated 
solvent molecules in both complexes. Due to the presence of the OH group in ortho 
position, [Cu(II)(L17)(H2O)2]  exhibits intramolecular hydrogen bonding between N-H 
and the OH group present in ortho-position. The N-H----O bond distance is 2.576(2) Å. 
Selected bond lengths and bond angles for the copper complexes [Cu(II)(L8)(MeOH)2], 
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[Cu(II)(L13)(H2O)(MeOH)], [Cu(II)(L17)(H2O)2] and [Cu(II)(L7)(MeOH)2] are given in 
figure 3.7 and 3.8, respectively.  The torsional angle including the imine bond, (C(1)-
C(2)-N(1)-N(2)) as well as the τ value are provided in the same table. 
The listed bond lengths of all four copper complexes of equivalent bonds are 
similar to the monomeric copper complexes, [Cu(L9)(H2O)2] and [Cu(L11)(H2O)2].H2O. 
This implies that the electron-withdrawing or electron-donating group on the aromatic 
ring has little or no effect on the listed bond lengths. As expected the equatorial 
coordinate bonds (Cu-N(1)/O(1)/O(3)/O(4)) are similar, whereas Jahn – Teller distortion 
affects the apical bond distance (Cu-O(5)), making it longer than the equatorial bonds. 
A change of the coordinating solvent molecule from aqua to methanol does not 
significantly affect the bond distances. This shows that the Cu(II) centre plays an 
important role in controlling the immediate bond lengths surrounding it. 
Table 3.7: Selected bond lengths (Å) for [Cu(II)(L8)(MeOH)2], 
[Cu(II)(L13)(H2O)(MeOH)], [Cu(II)(L17)(H2O)2] and [Cu(II)(L7)(MeOH)2] 
O
N
N O
O
CH3
R
Cu
1
2
34 1
13
2 2
H2O OH2
45
 
                         R 
[Cu(L8)(MeOH)2]                p-NO2 
[Cu(L7)(H2O)(MeOH)]      m-Me, p-NO2 
[Cu(L13)(H2O)(MeOH)]      p-OMe 
[Cu(L17)(H2O)2]                 o-OH, p-OMe 
Bonds [Cu(L8) 
(MeOH)2] 
[Cu(L7)(H2O) 
(MeOH)] 
[Cu(L13)(H2O) 
(MeOH)] 
[Cu(L17) 
(H2O)2] 
C(1)-O(1) 1.2970(17) 1.3008(17) 1.300(4) 1.289(2) 
C(1)-O(2) 1.2322(17) 1.2296(18) 1.230(4) 1.242(2) 
C(3)-O(3) 1.2862(17) 1.2896(18) 1.277(4) 1.299(2) 
C(3)-N(2) 1.3355(18) 1.3305(19) 1.343(4) 1.341(2) 
N(1)-N(2) 1.3724(16) 1.3791(16) 1.381(3) 1.371(2) 
C(2)-N(1) 1.2852(18) 1.2829(19) 1.278(4) 1.286(2) 
Cu-O(1) 2.0033(10) 1.9988(12) 1.989(2) 2.0061(12) 
Cu-O(3) 1.9688(11) 1.9725(11) 1.973(2) 1.9755(12) 
Cu-O(4) 1.9285(11) 1.9506(11) 1.933(2) 1.9357(13) 
Cu-O(5) 2.2824(11) 2.2138(14) 2.284(2) 2.2227(14) 
Cu-N(1) 1.9128(12) 1.9130(13) 1.910(3) 1.9129(14) 
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  Similarly, the bond angles of equivalent bonds are little affected by the R 
group on the aromatic ring. The τ values indicate a slight distortion from the perfect 
square pyramidal geometry. Although the differences in the values of the  basal angle 
O(1)-Cu-O(3), are insignificant, the differences in the basal angle N(1)-Cu-O(4), 
contribute to the small differences in the τ value. The dissimilarity of the bond angles, 
comprising of two chelate rings, especially O(3)-Cu-N(1) and O(1)-Cu-N(1) signifies 
that the two 5-membered ring are not exactly the same. The distortion angle reveals 
that the ligand binds to the Cu(II) centre in a E confirmation with respect to the imine 
(C=N) bond, and are in agreement with the Cu(II) complexes of PVAHs described 
before. 
Table 3.8: Selected bond angles (°) for [Cu(II)(L8)(MeOH)2], [Cu(II)(L13)(H2O)(MeOH)], 
[Cu(II)(L17)(H2O)2] and [Cu(II)(L7)(MeOH)2] 
O
N
N O
O
CH3
R
Cu
1
2
34 1
13
2 2
H2O OH2
45
 
         R 
[Cu(L8)(MeOH)2]              p -NO2 
[Cu(L7)(H2O)(MeOH)       m -Me, p -NO2 
[Cu(L13)(H2O)(MeOH)      p -OMe 
[Cu(L17)(H2O)2]                o -OH, p -OMe 
Bonds [Cu(L8) 
(MeOH)2] 
[Cu(L7)(H2O) 
(MeOH)] 
[Cu(L13)(H2O) 
(MeOH)] 
[Cu(L17) 
(H2O)2] 
O(1)-Cu-O(3) 161.64(4) 160.24(5) 161.10(9) 161.06(5) 
N(1)-Cu-O(4) 164.51(5) 171.44(5) 166.59(11) 166.52(6) 
O(4)-Cu-O(5) 96.62(5) 90.04(5) 98.63(10) 93.16(6) 
O(3)-Cu-N(1) 80.06(5) 79.88(5) 79.58(10) 79.99(5) 
O(1)-Cu-N(1) 81.87(5) 82.12(5) 82.12(9) 81.35(6) 
N(2)-C(3)-O(3) 125.75(13) 125.69(13) 124.1(3) 122.78(15) 
C(2)-C(1)-O(1) 116.51(12) 116.24(12) 116.0(3) 116.34(14) 
C(3)-N(2)-N(1) 106.74(11) 106.71(12) 107.4(2) 109.02(14) 
N(1)-C(2)-C(1) 111.65(12) 111.74(13) 111.6(3) 111.23(14) 
C(1)-C(2)-N(1)-N(2) 
(torsional angle) 
179.43(12) 177.71(12) 179.6(2) 179.36(14) 
τ 0.05 0.18 0.09 0.09 
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3.5.2 The dimeric Cu(II) square pyramidal complex [Cu(II)2(HL9)2Cl2] 
Interestingly, the Cu(II) complex of ligand L9 also crystallises as a dimer with 
molecular structure [Cu(II)2(HL9)2Cl2] in monoclinic space group P2(1)/n. The ORTEP 
plot is shown in figure 3.28. The asymmetric unit contains one half of the dimeric 
molecule and the other half of the complex if generated by a centre of inversion. The 
ligand binds to the Cu centre in a tridentate manner as described for the monomeric 
[Cu(II)L9(H2O)2]  complex, whereas the other two coordination sites of the square 
pyramidal complex are occupied by bridging chloride ions. The τ value of 0.18 indicates 
distortion from the perfect square pyramidal geometry.  However, the ligand 
coordinates in its monoanionic form, contrary to the dianionic coordination mode 
observed in the monomeric square pyramidal Cu(II)complexes. This is evident from the 
fact that N(2) remains protonated allowing the overall copper complex to remain 
neutral.  
Moreover, the carbonyl C(3)-O(3) has more of a double bond character as the 
bond distance is 1.254(2) Å as compared to the [Cu(II)L9(H2O)2] complex (1.301(3) Å), 
which suggest that O(3) is neutral when coordinated to the Cu centre. Due to Jahn-
Teller distortion, the apical Cu-Cl bond distance is larger than the basal Cu-Cl distance. 
The intramolecular Cu-Cu bond distance is 3.332 Å, typical of chloride-bridged dimeric 
copper complexes, but reported values vary slightly depending on the ligand 
system.222-223 
 
a 
b 
 
Figure 3.29: a) ORTEP plot and  b) crystal packing diagram of [Cu(II)2(HL9)2Cl2] 
 
Furthermore, the crystal lattice of the complex displays a two dimensional array 
of a ladder-like zig-zag structure, as shown in figure 3.15 b, where the Cu2Cl2 core is 
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planar. In addition, Cu2Cl2 is almost perpendicular to the two basal 5-membered ring 
with a interplanar angle of 88.40°. Each unit of the complex forms an intermolecular 
hydrogen bond involving the proton on N2, and O(2) of the other symmetry-generated 
copper complex unit. The distance observed for N(2)-H---O(2) is 2.819(2) Å. Selected 
bond lengths and bond angles are given in Table 3.9 and are in agreement with the 
literature values.223-224 The τ value calculated using basal angles O(1)-Cu-O(3) and 
N(1)-Cu-Cl(1) is equal to 0.18 and indicates distortion of square pyramidal geometry, 
similarly observed for the monomeric Cu(II) square pyramidal complexes of PVAHs.  
 
Table 3.9: Selected bond lengths (Å) and bond angles (°) of [Cu(II)2(HL9)2Cl2]  
 
Bonds Å Bond angles ° 
C(1)-O(1) 1.274(2) O(1)-Cu-O(3) 159.50(6) 
C(1)-O(2) 1.239(2) N(1)-Cu- Cl(1) 170.55(5) 
C(3)-O(3) 1.254(2) Cl(1)-Cu- Cl(1)#1 94.718(18) 
C(3)-N(2) 1.368(2) N(2)-C(3)-O(3) 119.53(17) 
N(1)-N(2) 1.377(2) C(2)-C(1)-O(1) 116.78(16) 
C(2)-N(1) 1.281(2) N(2)-C(3)-C(4) 121.31(16) 
Cu(1)-O(1) 1.9562(14) C(3)-N(2)-N(1) 111.96(15) 
Cu(1)-O(3) 1.9967(13) N(1)-C(2)-C(1) 110.17(16) 
Cu(1)-Cl(1) 2.2198(5) O(1)-C(1)-C(2) 116.78(16) 
Cu(1)-Cl(1)#1 2.6737(6) Cu(1)-Cl(1)-Cu(1) #1 85.282(18) 
Cu(1)-N(1) 1.9545(16) C(1)-C(2)-N(1)-N(2) 179.42(17) 
N(2)-H 0.87(2) τ 0.18 
 Symmetry transformations used to generate equivalent atoms: #1 -x+2,-y+1,-z+1 
The apical bond distance, Cu(1)-Cl(1)#1 (2.6737(6) Å) is quite long as 
compared to other Cu(II) complexes of square pyramidal complexes of PVAH. The 
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bond length is too long to be considered as a true coordinate bond.  Hence, the 
monomeric unit containing one Cu(II) centre of [Cu2(HL9)2Cl2]  (structure shown in table 
3.9) can be best described as pseudo square pyramidal complex or can be 
alternatively designated as square planar complex, if the apical coordinate bond is not 
taken into consideration. 
3.5.3 Cu(II) octahedral complex of PVAH 
 Interestingly, the Cu(II) complexes of L152- crystallise with octahedral geometry, 
having the molecular formulae [Cu(HL15)2] and Na[Cu(HL15)(L15)]. The copper 
complexes crystallise in the triclinic space group P-1 with two crystallographically 
independent molecules present in the unit cell. As indicated in the ORTEP plot (figure 
3.30), each ligand is coordinated as a tridentate ONO ligand around the Cu(II) centre, 
giving rise to octahedral geometry. The ligands coordinate meridonially because of the 
planarity of the conjugated hydrazone ligand system.225-226  
 
Figure 3.30: Ortep plot of the molecular structure [Cu(HL15)2] 
Na[Cu(HL15)(L15)] 
The two crystallographically independent molecules differ due to their charge on 
the overall complex. One of the copper complexes is neutral, whereas the other 
       Chapter – 3                      
    
 
 
121 
complex carries one negative charge overall, making it anionic. This is evident due to 
the fact that in one of the ligands the proton on N-H is lost upon coordination, making it 
dianionic, whereas the other ligands attain monoanionic nature by retaining the N-H 
proton. Hence, in order to balance the negative charge, a Na+ cation is present in the 
crystal lattice.  
The sodium counterion exhibits octahedral geometry, as observed for NaHL9 
and NaHL11, although the coordination around the Na ion is slightly different for [Cu 
(HL15)2] Na[Cu(HL15)(L15)] as can be seen in figure 3.31. In the dimeric complex, the 
two sodium cations are bridged by two water molecules, whereas the rest of the 
coordinating sites are occupied  by two more water molecules, neutral methanol and 
O(2) of the neutral  [Cu(HL15)2] complex. The other sodium cation is associated with 
the symmetry-generated neutral complex in a similar fashion. While Na+ is directly 
bonded to O(2), the coordinated water molecules on the Na+ atom are involved in 
hydrogen bonding with the carboxylate O(1) atom. At the same time, intermolecular 
hydrogen bonding is also observed between N-H of one complex and carbonyl O(3) 
atom of other crystallographically independent molecule. The N(2)-H-----O(3) bond 
distance is 2.884(3) A. One of the phenyl rings is disordered over two positions and 
also the  F atom is disordered over two meta-positions. 
.  
Figure 3.31: Mercury plot of [Cu(HL15)2] Na[Cu(HL15)(L15)] showing the 
coordination around the sodium cation and intermolecular hydrogen bonding 
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The coordination plane around the Cu(II)-centre which includes Cu-C(1)-C(2)-
O(1)-N(1)-N(2)-C(3)-O(3) is essentially planar. On the other hand, the deviation of the 
mean plane of the 5-membered ring and the aromatic ring is considerably larger. The 
deviations for the anionic complex are 8.93º and 20.77º for each ligand, whereas for 
the neutral complex the deviation is 11.73º and 27.68º Å. The loss of planarity of the 
ligand may be due to the steric repulsion caused by two ligands when coordinating to 
the copper centre, since in the square pyramidal complex the ligand remains almost 
planar. The distortion angle suggests E conformation for both ligands with respect to 
the imine bond and the values fall in the range 176.0 – 180.0° and are similar to the 
square pyramidal complexes. The bond angles of 173° consisting of the basal angle, 
N(1)-Cu-N(3) for both the complexes suggests a distortion from idealised octahedral 
geometry as perfect octahedral geometry requires this angle to be 180°.227-228  
In order to evaluate the differences in the geometric parameters of the two 
complexes, selected bond lengths and bond angles are given in table 3.10. 
Subsequently, these were then compared to a similar Cu(II) complex of 2-[2-(2-
hydroxybenzoyl)hydrazone]propanoic acid synthesized by Feng Liu and group as 
shown in figure 3.32.229  
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Figure 3.32: Numbering scheme for [Cu(HL15)2] showing immediate bonds surrounding 
the Cu(II) centre, R= Ar-3-F, Feng Liu’s copper complex R= Ar-2-OH229 
Table 3.10: Selected bond lengths (Å) and bond angles (°) of neutral [Cu(HL15)2] and 
anionic Na[Cu(HL15)(L15)]  in comparison with an example described in the 
literature229 
Bonds Complex 1 (neutral) Complex 2 (anionic) Lit ref229 
 (HL1)- (HL2)- (HL1)- (L)2- (HL1)- (HL2)- 
Cu-O(1) 2.1956(18) 2.0008(18) 2.2574 
(18) 
2.0059 
(18) 
2.047(2) 2.092(3) 
Cu-O(3) 2.2820(19) 2.0277(18) 2.3696 
(19) 
2.0397 
(18) 
2.208(3) 2.281(3) 
Cu-N(1) 2.013(2) 1.949(2) 2.015(2) 1.911(2) 1.942(3) 1.982(3) 
C(3)-O(3) 1.232(3) 1.251(3) 1.227(3) 1.301(3) 1.246(4) 1.228(4) 
C(1)-O(2) 1.225(3) 1.228(3) 1.225(3) 1.233(3) 1.279(4) 1.264(4) 
C(3)-N(2) 1.372(3) 1.361(3) 1.371(3) 1.324(3) 1.352(4) 1.358 
(14) 
C(1)-O(1) 1.276(3) 1.284(3) 1.270(3) 1.290(3) 1.279(4) 1.264(4) 
C(2)-N(1) 1.283(3) 1.278(3) 1.281(3) 1.281(3) 1.281(3) 1.282(4) 
O(1)-Cu-N(1) 76.98(8) 80.65(8) 75.29(7) 81.83(8) 78.90 
(11) 
75.37 
(10) 
O(3)-Cu-N(1) 73.98(8) 79.17(8) 73.22(7) 78.87(8) 77.76 
(11) 
74.94 
(10) 
O(1)-Cu-(O3) 150.34(7) 147.99(6) 156.66(10) 
N(1) (L1)-Cu-
N(1) (L2) 
173.68(9) 173.59(9) 175.97(12) 
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The coordination characteristics of Feng Liu’s copper complex are identical to 
the neutral complex of [Cu (HL15)2Cu(HL15)(L15)]. 
The comparison of bond lengths is done in three ways, which are as follows 
i. Comparison between the ligands on the same Cu(II) centre 
The coordinate bonds especially Cu-O(1) and  Cu-O(3) are significantly 
and Cu-N(2) moderately longer in one of the ligands, this may be 
accounted to the steric repulsion caused by two ligands in order to form 
octahedral environment around the metal centre. As a consequence, 
C(1)-O(1) and C(3)-O(3) show similar trend, although the differences are 
small. This may also be accounted to Jahn-Teller distortion of the axial 
ligands. Feng Liu’s copper complex show similar behaviour, however 
the differences are not large. The reverse trend was noticed for the bond 
angles, O(1)-Cu-N(1) and O(3)-Cu-N(1), which signifies that ligand 
having greater coordinate bond lengths have shorter chelate bond 
angles comprising of the Cu(II) centre. 
ii. Comparison between neutral and anionic complex 
As a result of deprotonation of N(2) proton of one of the ligand, the C(3)-
O(3) ((1.301(3) bond distance  is significantly greater than other ligand 
(1.227(3) Å)Å), similarly observed for monomeric square pyramidal 
complex of pyruvate hydrazones. The bond distance has partial single 
bond character making it negatively charged, hence dianionic in nature. 
iii. Comparison with the Feng Liu’s Cu(II) complex. 
Although most of the bond lengths and bond angles of equivalent bonds 
don’t show significant differences, it is observed that the Cu-O(1), Cu-
N(1) bond distances are slightly longer as compared to Feng Liu’s 
complex. The complex also indicates that C(1)-O(2) has more single 
bond character when compared with the copper complexes of PVAHs.  
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3.6 Structural investigation of Cu(I) complexes of PVAHs 
Cu(I) complexes of NaHL8 and NaHL9 were synthesized in order to investigate 
the coordination behaviour of PVAHs around the Cu(I) centre. As discussed in chapter-
2, PPh3 were introduced in order to stabilise the soft Cu(I) centre. As expected for Cu(I) 
complexes  both the ligands form a tetrahedral environment around the copper 
centre.230  
3.6.1 Structural aspects of [HL9(PPh3)5]PF6 and [Cu(I)2HL8(PPh3)5]PF6 
Both the Cu(I) complexes crystallise as dimeric structures and the two crystal 
structures show a similar kind of environment around the Cu(I) centre. [Cu(I)2HL9 
(PPh3)5]PF6] crystallises in a monoclinic space group P21/n, and the ORTEP plot is 
displayed in figure 3.33. Due to the rigidity of the PVAHs, HL8- and HL9- can only act 
as bidentate ligands, coordinating through O and N donor atoms to form a tetrahedral 
arrangement around the Cu(I) centre. The remaining two coordination sites are 
occupied by two PPh3 ligands, similar to the structure observed for a related Cu(I) 
hydrazone complex synthesized by Krishnamoorthy and group176. The O atom of the 
carboxylate group of the ligand binds to the other Cu(I) centre and the other three 
tetrahedral coordination sites are occupied by PPh3 ligands. The overall positive charge 
of the complex is balanced by a PF6- anion.  
 
Figure 3.33: ORTEP plot (50% probability ellipsoids) of the molecular structure of 
[Cu(I)2HL9(PPh3)5]PF6 
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As seen from the ORTEP plot, the hydrazide part of the pyruvate hydrazone 
binds to one of the Cu(I) centre, whereas the pyruvate moiety acts a bridge, connecting 
the other copper centre. Similar bridging by dicarboxylates between two Cu(I) centres 
has been investigated by Lang and group.179 The complex [Cu(I)2HL8(PPh3)5]PF6 
crystallises in the monoclinic space group P21/n with two crystallographically 
independent molecules in the same unit cell. The ORTEP plot of the corresponding 
complexes is shown in figure 3.34. It is important to note that the ligand prefers to 
remain in the Z confirmation, when coordinating to the Cu(I) centre which is revealed 
from the torsional angle (C(1)-C(2)-N(1)-N(2)). The torsional angles values are 
provided in table 3.11 and are similar to the sodiated PVAHs. 
 
Figure 3.34: ORTEP plot (50% probability ellipsoids) of the molecular structure of 
[Cu(I)2HL8(PPh3)5]PF6 
3.6.3 Structural aspects of [Cu(I)2HL9(PPh3)4]PF6.2Et2O.H2O 
Interestingly, the Cu(I) complex of HL9-, which crystallised out of Et2O has three 
coordinate geometry around the Cu(1) centre with one less PPh3 group. It is surprising 
to notice that, changing the solvent system from polar MeOH to non-polar Et2O can 
change the geometry around the copper centre. However, the coordination behaviour 
around the Cu(2) centre remains the same as can be seen from the ORTEP plot as 
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indicated in figure 3.35. The crystal structure crystallises in the triclinic space group P-
1. Eventhough three-coordinate copper complexes are rare, a few examples of three-
coordinate Cu(I) and Cu(II) complexes are known to exist in the literature.177,231-232 
There is an increasing interest, towards making of low coordinate copper complexes, 
as they are known to exist in the biological systems.233-234 Moreover, the crystal 
structure of a linear, two- coordinate Cu(I) complex, is also reported in the literature235.  
 
Figure 3.35: ORTEP plot (50% probability ellipsoids) of the molecular structure of 
[Cu(I)2HL9(PPh3)4]PF6.2Et2O.H2O 
The details of the bond lengths and angles of [Cu(I)2HL8(PPh3)5]PF6, 
[Cu(I)2HL9(PPh3)5]PF6 and [Cu(I)2HL9(PPh3)4]PF6.2Et2O.H2O are provided in tables 
3.11 and 3.12, respectively and are consistent with the literature. The proton on the N 
atom of  the hydrazide is not lost during coordination, which is also reflected in the 
bond length of the (C(3)-O(3) carbonyl group. In case of the Cu(I) complex, the 
carbonyl C(3)-O(3) bond length is more towards a double bond (1.23 - 1.24 Å), 
whereas in case of the monomeric square pyramidal Cu(II) complex, the same bond 
length is more towards a single bond (1.3 Å).229 
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3.6.3 Comparison of [Cu(I)2HL9(PPh3)5]PF6, [Cu(I)2HL9(PPh3)4]PF6.2Et2O.H2O and 
[Cu(I)2HL8(PPh3)5]PF6 
N
O
N
CH3
O
O
Cu Cu
Ph3P
PPh3
PPh3
Ph3P
PPh3
R
2 1 1
11
2
3
3
3
1
2
2
2
5
4
H
 
Figure 3.36: General structure of the Cu(I) complex showing the atom numbering 
scheme, R = 4-Me for [Cu(I)2HL9(PPh3)5]PF6, R= 4NO2 for [Cu(I)2HL8(PPh3)5]PF6 
Table 3.11: Selected bond lengths (Å) [Cu(I)2HL9(PPh3)5]PF6, [Cu(I)2HL9(PPh3)4]PF6. 
2Et2O.H2O, [Cu(I)2HL8(PPh3)5]PF6 
 [Cu(I)2HL9(PPh
3)5]PF6 
[Cu(I)2HL9(PPh
3)4]PF6. 
2Et2O.H2O 
[Cu(I)2HL8(PPh3)5]PF6 
   Complex 1 Complex 2 
C(1)-O(1) 1.256(4) 1.256(4) 1.252(4) 1.256(4) 
C(1)-O(2) 1.250(4) 1.251(4) 1.257(4) 1.247(4) 
C(3)-O(3) 1.238(4) 1.241(4) 1.238(5) 1.236(4) 
C(3)-N(2) 1.339(4) 1.353(4) 1.341(5) 1.336(4) 
N(1)-N(2) 1.385(3) 1.384(3) 1.377(4) 1.377(4) 
C(2)-N(1) 1.293(4) 1.288(4) 1.295(5) 1.298(4) 
N(2)-H(1) 0.83(4) 0.88(3) 0.87(4) 0.90(5) 
Cu(2)-N(1) 2.052(3) 2.081(3) 2.092(3) 2.072(3) 
Cu(2)-O(3) 2.175(2) 2.162(2) 2.142(3) 2.205(2) 
Cu(1)-O(1) 2.024(2) 2.024(2) 2.131(2) 2.108(2) 
Cu(1)-O(2) 3.530(2) 2.756(2) 3.424(2) 3.434(2) 
Cu(2)-P(4) 2.2253(8) 2.2176(12) 2.2127(12) 2.2242(10) 
Cu(2)-P(5) 2.2602(9) 2.2676(12) 2.2656(12) 2.2614(11) 
Cu(1)-P(1) 2.2981(8) 2.2289(11) 2.3056(9) 2.3292(9) 
Cu(1)-P(2) 2.3013(9) 2.2417(11) 2.3446(10) 2.3596(9) 
Cu(1)-P(3) 2.3299(8) - 2.3288(9) 2.3285(9) 
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The electron donating methyl group and the electron withdrawing nitro group fail 
to have any significant effect on the Cu(I) centre, similar to the observation made for 
the Cu(II) complexes. The small differences in bond lengths and bond angles may be 
due  to packing effects in the crystal lattice. This is evident from the fact that,small 
differences are observed for the two crystallographically independent molecules of 
[Cu(I)2HL8(PPh3)5]PF6 which crystallise in the same unit cell.  
Within the Cu(I) complex, the Cu(1)-O(1) bond distance is slightly shorter than 
Cu(2)-O(3). Furthermore, the Cu-P bond distances on the Cu(2) centre are shorter than 
those coordinated to the Cu(1) centre except for [Cu(I)2HL9(PPh3)4]PF6. 2Et2O.H2O. 
This may be attributed to the steric repulsion caused due to three PPh3 ligands on the 
Cu(1) centre, hence longer bond lengths. It is interesting to note that in case of the 
three-coordinate complex of [L9Cu2(PPh3)4]PF6. 2Et2O.H2O the Cu(1)-O(2) non 
bonding distance is significantly smaller than in the other Cu(I) complexes, which are 
provided in table 3.3. The bond distances taken from the mercury software indicate that 
there might be considerable interaction of O(2) with the Cu(I) centre. Therefore the 
Cu(I) centre in the corresponding complex can be described as pseudo tetrahedral 
complex as indicated figure 3.37.  
 
Figure 3.37: Mercury plot of [Cu(I)2HL9(PPh3)5]PF6 illustrating the strongly asymmetric 
didentate carboxylate coordination to Cu(1) and intramolecular hydrogen bonding 
(indicated with dotted line). Colour of the atom: grey - C, white – H, red – O, blue – N,  
brown – Cu, yellow – P, green – F. 
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As the Cu(I) centre is coordinatively unsaturated, with one missing PPh3 
molecule with respect to other Cu(I) complexes, the other Cu-P coordinating bond 
distances are affected accordingly. This is reflected by the Cu(1)-P(2) and Cu(1)-P(2) 
bond distances, which  have shorter bond lengths as compared to other Cu(I) 
complexes and also Cu(2)-P distances within the same molecule. Fujisawa and group 
observed a similar behaviour when they isolated a three-coordinate Cu(I) crystal 
structure bearing one PPh3 along with other ligand containing pyrazole rings as shown 
in figure 3.38. In fact, the isolated Cu(I) complex exhibited  an even shorter  Cu-P  bond 
distance of 2.1726 Å. This is due to the fact that it has only PPh3 molecule, which 
results in less sterical hindrance and hence, a shorter bond length. 
N
N
N
N
Cu
PPh3
 
Figure 3.38 : Fujisawa three-coordinate Cu(I) complex177 
All the Cu(I) complexes of PVAHs described in this chapter participate in 
intramolecular hydrogen bonding which involve the N(2)-H and carboxylate O(2) atoms 
as can be seen from figure 3.37. The selected bond angles of all the three Cu(I) 
complexes are provided in table 3.12. The ligand-based angles of equivalent bonds 
remains unaffected, which signifies that the bond angles are not affected by electron 
withdrawing and donating groups or the Cu(I) coordination geometry. Although the 
crystal packing of the molecule might have little influence on values of ligand based 
bond angles, but it considerably affects the angles comprising of Cu(I) centre. Hence, 
two crystallographically independent molecules for [Cu(I)2HL8(PPh3)5]PF6 are 
observed, where the bond angles, especially N(1)-Cu(2)-P(5) show significant 
differences in complex 1 and 2, respectively, as can be seen from the values in table 
3.12.  
In addition, there is considerable deviation from regular tetrahedral angle 109°, 
which is reflected from the bond angles of O-Cu-P of both Cu(I) centres within the 
molecule236, hence the obtained Cu(I) complexes can be described as distorted 
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tetrahedral geometry. It can be noted that in the three-coordinate Cu(I) complex, 
[L9Cu2(PPh3)4]PF6.2Et2O.H2O, the Cu(1)-O(1)-C(1) bond angles is substantially smaller 
than other Cu(I) complexes. This can be explained on the basis that, the carboxylate 
O(2) donor atom is inclined  towards Cu(1) atom in order to form pseudo tetrahedral 
geometry around the Cu(1) centre which makes the bond angle shorter.  
Table 3.12: Selected bond angles (°) for [Cu(I)2HL9(PPh3)5]PF6, [Cu(I)2HL9(PPh3)4]PF6. 
2Et2O.H2O and [Cu(I)2HL8(PPh3)5]PF6 
N
O
N
CH3
O
O
Cu Cu
Ph3P
PPh3
PPh3
Ph3P
PPh3
R
2 1 1
11
2
3
3
3
1
2
2
2
5
4
H
 
 [Cu(I)2HL9 
(PPh3)5]PF6 
[Cu(I)2HL9(PPh3)
4]PF6.2Et2O.H2O 
[Cu(I)2HL9(PPh3)5]PF6 
   Complex  1 Complex 2 
Cu(1)-O(1)-C(1) 133.7(2) 107.9(2) 129.4(2) 131.1(2) 
O(1)-C(1)-O(2) 127.8(3) 125.1(3) 126.4(3) 126.3(3) 
C(1)-C(2)-N(1) 124.3(3) 124.5(3) 124.4(4) 124.7(3) 
C(2)-N(1)-N(2) 116.3(3) 118.4(3) 116.6(3) 117.1(3) 
N(1)-N(2)-C(3) 118.3(3) 118.0(3) 118.2(3) 118.4(3) 
N(2)-C(3)O(3) 122.2(3) 121.6(3) 122.6(4) 122.5(3) 
C(3)-O(3)-Cu(2) 110.39(19) 110.9(2) 109.8(3) 109.7(2) 
O(3)-Cu(2)-N(1) 78.00(9) 77.61(9) 77.97(12) 76.94(10) 
N(1)-Cu(2)-P(4) 104.65(7) 102.48(8) 100.41(10) 105.05(8) 
N(1)-Cu(2)-P(5) 116.19(7) 121.88(8) 129.51(10) 119.38(8) 
O3-Cu(2)-P(4) 109.98(6) 97.51(7) 100.14(10) 95.30(7) 
O3-Cu(2)-P(5) 102.59(6) 117.63(7) 115.87(3) 112.97(7) 
P(4)-Cu(2)-P(5) 131.65(3) 127.12(4) 122.11(5) 131.06(4) 
O(1)-Cu(1)-P(1) 92.90(6) 118.68(8) 92.36(8) 87.77(7) 
O(1)-Cu(1)-P(2) 100.77(7) 111.46(8) 104.80(7) 100.44(7) 
O(1)-Cu(1)-P(3) 110.47(6) - 113.83(7) 117.41(7) 
C(1)-C(2)-N(1)-
N(2) (torsional 
angle) 
5.6(4) 2.3(5) 0.2(5) 1.6(5) 
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3.7 Structural diversity observed in copper complexes pyruvate 
hydrazones 
 As discussed in the introduction (section 3.1), copper complexes of hydrazones 
adopt a wide variety of structures. This is also observed in the crystal structures of 
Cu(II) and Cu(I) complexes of the PVAHs. However, Cu(II) complexes mostly adopt a 
mononuclear square pyramidal geometry in the solid state, but dinuclear square 
pyramidal complexes and complexes with octahedral geometry were also isolated. The 
reduction of Cu(II) to Cu(I), changes the coordination geometry to distorted tetrahedral 
around the Cu(I) centre, whereas three-coordinate Cu(I) complexes are also isolated. 
In order to compare the different types of copper complexes obtained from 
ligand L9, selected bond length and bond angles of each representative geometry are 
tabulated in figure 3.13. The copper complexes include [Cu(II)(L9)(H2O)2] (monomeric 
square pyramidal), [Cu2(HL9)2Cl2] (dimeric square pyramidal), [Cu(II)(HL15)2] 
(octahedral) and [Cu(I)2HL9(PPh3)5]PF6 (tetrahedral). Although, all the copper 
complexes used for comparison are of same ligand except [Cu(II)(HL15)2], as it is the 
only complex which crystallises out as an octahedral complex. Also, it is observed that 
the R-group does not have much influence on the bond lengths and bond angles in 
direct vicinity of the Cu centre, hence [Cu(II)(HL15)2] can be used to compare the 
octahedral complex with the other copper geometries 
As discussed in section 3.2, NaHL9 binds to two Na+ ions in a monodentate 
manner as shown 3.39 a and same ligand binds to Cu(II) in a tridentate fashion (3.39 
b) 
N
O
O
M
M
1
3
1
 
                          a                   
N
O
O
M
1
1
3
 
                           b  
N
O
O
M
1
1
3
N
O
O
1
1
3
 
                                   c 
N
O
O
M
1
1
3
M
 
                    d 
Figure 3.39: Schematic representation of different coordination modes of PVAH 
hydrazones 
Furthermore, two ligands can bind to Cu(II) centre in a similar binding mode 
resulting in octahedral geometry (figure 3.39 c). However, in the Cu(I) complex the 
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binds to two different Cu(I) centres in a bidentate and monodentate manner, 
respectively (figure 3.39 d). Furthermore, the Cu(II) complex is stable with the O and N 
donor atoms, whereas the Cu(I) complex prefers soft P donors. 
In square pyramidal complexes, the ligand can acts as a dianionic donor, which 
involves deprotonation of N(2)-H in order to make the overall complex neutral. In the 
case of the dimeric square pyramidal copper complex, where the Cu(II) is coordinated 
to chloride ion, N(2)-H remains protonated which allows the ligand to remain in its 
monoanionic form. Similarly, the ligand remains in monoanionic form in the case of the 
neutral octahedral complex, [Cu(II)(HL15)2]. In addition, the ligand behaves as a single 
negatively charged molecule when coordinated to Cu(I). This eventually affects the 
C(3)-O(3) bond length as indicated in table 3.13. In the ligand, dimeric, octahedral and 
tetrahedral complexes, this bond length ranges from 1.23 to 1.25 Å, which signifies 
more of a double bond character. Whereas in the case of the mononuclear square 
pyramidal complex, the bond length (1.295 (3)) indicates partial single bond character. 
As indicated in table 3.13, the coordinate bond lengths around the Cu(I) centre 
(M-N, M-O) are significantly longer than those observed in the Cu(II) complexes. This 
may be attributed to the filled d shell of Cu(I) centre, resulting in  weaker interactions 
than in d9 Cu(II) complex.  As the electron density is contributed from donor atoms of 
both ligands, the coordinate bonds are not significantly longer in case of octahedral 
complex. C(1)-O(1) and C(1)-O(2) bond distances are similar in the Cu(I) complex as 
compared to the ligand and Cu(II) complexes, indicating the delocalisation of pi - 
electrons over O(1)-C(1)-O(2) bond. Although, the metal centre does not have much 
appreciable contribution towards imine C(2)-N(1) bond distance. 
The O(3)-Cu-N(1) bond angle which is  part of one of the five-membered rings 
ranges from 78.0 – 81.6 °, indicating the rigidity of the ring. On the other hand, the 
X(1)-Cu-X(2) bond distances vary considerably and it defines the geometry of the 
copper complexes. The highest value observed is 159.64(7) for the octahedral 
complex, whereas the lowest observed is for the square pyramidal complex. 
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                                          X1       X2          X3 
 
[Cu(II)(L9)(H2O)2]             OH2      OH2        - 
[Cu2(HL9)2Cl2]                  Cl         Cl            -   
[Cu(II)(HL15)2]                 O(L2)     N(L2)     O(L2)    
[Cu(I)2HL9(PPh3)5]PF6            PPh3        PPh3        - 
(Cu-O(1) absent)         
Figure 3.40: General structure showing numbering scheme for copper complex of 
PVAHs, dashed line indicates the presence or absence of bond depending on 
geometry 
Table 3.13: Selected bond lengths (Å) and bong angles (°) of NaHL9, 
[Cu(II)(L9)(H2O)2], Cu(II)(HL9)2Cl2, Cu(II)(HL15)2, [Cu(I)2HL9(PPh3)5]PF6 
 
Cu(II)(HL15)2 
(Octahedral) 
Bonds NaHL9 
(ligand) 
Cu(II)L9(H2
O)2 
(Monomeric 
Square 
pyramidal) 
Cu(II)(HL9)2Cl2 
(Dimeric 
Pseudo-Square 
pyramidal) L91 L92 
[Cu(I)2HL9 
(PPh3)5]PF6 
(Tetrahedral) 
C(1)-O(1) 1.2743 
(16) 
1.282(3) 1.274(2) 1.276(3) 1.284(3) 1.256(4) 
C(1)-O(2) 1.2380 
(16) 
1.244(3) 1.239(2) 1.225(3) 1.228(3) 1.250(4) 
C(3)-O(3) 1.2330 
(15) 
1.295(3) 1.254(2) 1.232(3) 1.251(3) 1.238(4) 
C(3)-N(2) 1.3522 
(16) 
1.328(3) 1.368(2) 1.372(3) 1.361(3) 1.339(4) 
C(2)-N(1) 1.2897 
(17) 
1.289(3) 1.281(2) 1.283(3) 1.278(3) 1.293(4) 
Cu-O(1) - 1.9940(16) 1.9562(14) 2.1956(18) - 2.024(2) 
Cu-O(3) - 1.9939(16) 1.9967(13) 2.2820(19) - 2.175(2) 
(Cu(2)) 
Cu-X(1) - 1.971(2) 2.2198(5) - 2.0008(18) 2.2253(8) 
Cu-X(2) - 2.152(2) 2.6737(6) - 2.0277(18) 2.2602(9) 
Cu-N(1)  1.9065(19) 1.9545(16) 2.013(2) 1.949(2) 2.052(3) 
O(3)-Cu-
N(1) 
- 81.66(7) 78.81(6) 73.98(8) 79.17(8) 78.00(9) 
X(1)-Cu-
X(2) 
- 95.72(9) 94.718(18) 159.64(7) 131.65(3) 
C(1)-
C(2)-
N(1)-N(2) 
(torsional 
angle) 
2.06 
(2) 
177.69(19) 179.42(17) 176.6(2) 178.4(2) 5.6(4) 
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The torsional angle (C(1)-C(2)-N(1)-N(2)) for the Cu(II) complexes lie in the 
range 176.0 – 180.0°, revealing E conformation with respect to the imine (C=N) bond, 
irrespective of different geometries. In contrast, the Cu(I) complex 
[Cu(I)2HL9(PPh3)5]PF6 exhibits a torsional angle of 5.6(4) °, which is similar to the 
sodiated ligand NaHL9 (2.06(2) °) indicating Z-conformation. 
3.8 Structural investigation of Zinc(II) complexes of PVAHs 
The crystals of Zn(II) complexes of PVAHs suitable for X-ray crystallography 
were successfully isolated from the NMR solvent, DMSO-d6. Unlike Cu(II) complexes of 
PVAHs, Zn(II) complexes failed to produce diffraction quality crystals from the reaction 
solvent MeOH, indicating the instability of the Zn(II) complex in the solution as 
compared to the Cu(II) complexes. This may be attributed to the acidic environment 
due to MeOH as compared to DMSO. Ligand binds to Zn(II) in 2:1 manner forming an 
octahedral complex, with the coordination around the zinc centre being similar to Cu(II) 
octahedral complex of HL15-.  
3.8.1 Structural aspects of [Zn(II)(HL7)2] ].H2O.DMSO, [Zn(II)(HL8)2] and 
[Zn(II)(HL9)2].H2O.CH3OH 
Zn(II) complexes of HL7-, HL8- and HL9- crystallise in the triclinic space group 
P-1. The ORTEP plots for [Zn(II)(HL7)2].H2O.DMSO, [Zn(II)(HL8)2].H2O and  
[Zn(II)(HL9)2].H2O.CH3OH are shown in figure 3.41a, 3.42 and 3.43, respectively. As 
indicated from the ORTEP plots of the corresponding Zn(II) complexes, N(2)-H remains 
protonated on both ligands. This allows the ligand to attain monoanionic form, hence 
forming an overall neutral Zn(II) complex. As expected, the two ligands are coordinated 
meridonially to the Zn(II)-centre.225-226 The crystal structures of the Zn(II) complexes of 
PVAHs mentioned in this chapter have meridonial arrangement, unless otherwise 
mentioned. The structure of a representative example, [Zn(II)(HL7)2] ] .H2O.DMSO, is 
displayed in figure 3.41 b. Two perpendicular planes are pass through the chelate rings 
of the two ligands coordinated to the same Zn(II) centre. The interplanar angle of the 
two planes measures 81.45°.  
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                   a 
 
                                                             b 
Figure 3.41: a)  ORTEP plot (50% probability ellipsoids) of the molecular structure of 
mer-[Zn(II)(HL7)2].H2O.DMSO b) planes showing the meridonial arrangement of the 
ligands around the Zn(II) centre 
 
Figure 3.42: ORTEP plot (50% probability ellipsoids) of the molecular structure of mer- 
[Zn(II)(HL8)2].H2O 
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Figure 3.43: ORTEP plot (50% probability ellipsoids) of the molecular structure mer- 
[Zn(II)(HL9)2].H2O.CH3OH 
 As indicated in the ORTEP plots, the zinc complexes crystallise with solvent 
molecules, such as H2O, MeOH, and DMSO in the case of [Zn(II)(HL7)2].H2O.DMSO. 
Hydrogen bonding between the solvent molecules and the coordinated ligand atoms 
helps in stabilising the crystal lattice. In addition to the intermolecular hydrogen-
bonding network, weak pi interactions also occur in the crystal lattice with adjacent 
symmetry generated molecules. The Mercury plot of a representative example, 
[Zn(II)(HL7)2].H2O.DMSO is shown in figure 3.44. The pi-pi aromatic interactions, 
which are in the range of 3.31-3.5 Å allow the molecules to stack coplanar to each 
other. Similarly, weak electrostatic interactions between the electronegative chloride 
ion and electron deficient carbon atoms (C-Cl---C) C(1) (3.41 Å) and C(2) (3.37 Å) are 
also seen. 
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Figure 3.44: Mercury plot of mer- [Zn(II)(HL7)2].H2O.DMSO showing pi interactions 
3.8.2 Comparison of [Zn(II)(HL7)2].H2O.DMSO, [Zn(II)(HL8)2].H2O and 
[Zn(II)(HL9)2].H2O.CH3OH 
Selected bond lengths and bond angles of [Zn(II)(HL7)2].H2O.DMSO,  
[Zn(II)(HL8)2].H2O and [Zn(II)(HL9)2].H2O.CH3OH are given in table 3.14. The bond 
lengths and bond angles are in agreement with the literature values.237  The tridentate 
ligand binds to the zinc centre resulting in a distorted octahedral geometry which is 
indicated by the equatorial bond angles. As indicated in the table, the equatorial angles 
for N1(HL1)-Zn-N1(HL2) are not exactly 180° but lie in the range 168-170°, hence 
indicating distortion from perfect octahedral geometry.238 A general schematic 
representation of Zn(II) octahedral complex coordinating to the same ligands HL1 and 
HL2 along with the numbering scheme is shown in figure 3.45. In order to make the 
comparison easier, the numbering scheme may not be in accordance with the ORTEP 
plot numbering system. 
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                                              R 
mer-[Zn(II)(HL7)2].H2O.DMSO                 Ar-p-Cl 
mer-[Zn(II)(HL8)2].H2O                         Ar-p-NO2 
mer-[Zn(II)(HL9)2].H2O.CH3OH          Ar-p-CH3 
Figure 3.45: Numbering scheme for zinc complexes showing immediate bonds around 
the Zn(II) centre, mer- [Zn(II)(HL7)2].H2O.DMSO, mer- [Zn(II)(HL8)2].H2O, mer- 
[Zn(II)(HL9)2].H2O.CH3OH  
Table 3.14: Selected bond lengths (Å) and bond angles (°) of selected Zn(II) complexes 
of PVAHs 
Bonds mer-[Zn(II)(HL7)2] 
.H2O.DMSO 
mer-[Zn(II)(HL8)2]. 
H2O 
mer-[Zn(II)(HL9)2] 
.H2O.CH3OH  
 (HL1)- (HL2)- (HL1)- (HL2)- (HL1)- (HL2)- 
Zn-O(1) 2.1965 
(14) 
2.1588 
(14) 
2.0596 
(12) 
2.0502 
(12) 
2.091(2) 2.039(2) 
Zn-O(3) 2.0238 
(14) 
2.1014 
(14) 
2.1919 
(12) 
2.2975 
(12) 
2.169(2) 2.138(2) 
Zn-N(1) 2.0667(1
6) 
2.0728 
(16) 
2.0635 
(13) 
2.0673 
(13) 
2.048(2) 2.079(3) 
C(3)-O(3) 1.239(2) 1.227(2) 1.235(2) 1.232(2) 1.240(3) 1.242(3) 
C(1)-O(2) 1.236(2) 1.238(2) 1.230(2) 1.238(2) 1.221(4) 1.249(4) 
C(3)-N(2) 1.369(2) 1.371(3) 1.358(2) 1.359(2) 1.370(4) 1.372(4) 
C(1)-O(1) 1.272(2) 1.280(2) 1.278(2) 1.269(2) 1.290(4) 1.264(3) 
C(2)-N(1) 1.280(2) 1.279(2) 1.278(2) 1.282(2) 1.274(4) 1.273(4) 
O(1)-Zn-N(1) 73.07(6) 74.04(6) 77.30(5) 77.68(5) 77.24(9) 77.60(8) 
O(3)-Zn-N(1) 78.17(6) 76.59(6) 74.02(5) 72.56(5) 74.62(8) 73.70(9) 
O(1)-Zn-(O3) 150.37 
(5) 
150.54 (5) 151.13(5) 150.05(5
) 
151.83 
(8) 
150.05() 
C(1)-C(2)-
N(1)-N(2) 
(torsional angle)      
179.5(2) 179.8(2) 177.49 
(13) 
174.74 
(13) 
177.49 174.74 
N(1) (L1)-Zn-
N(1) (L2) 
168.87(6) 165.03(5) 169.75(9) 
O(1) (L1)-Zn-
O(1) (L2) 
90.67(6) 95.75(5) 98.21(8) 
O(3)(L1)-Zn-
O(3) (L2) 
92.40(6) 87.53(5) 91.38(8) 
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The R group on the aromatic ring does not have a significant effect on bond 
distances and bond angles in  direct vicinity of Zn(II) centre. The ligand based bond 
lengths are more or less similar for corresponding bonds of [Zn(II)(HL7)2].H2O.DMSO, 
[Zn(II)(HL8)2].H2O, [Zn(II)(HL9)2].H2O.CH3OH. On comparison of the coordinate bond 
Zn-O(3) bond distances are appreciably longer than Zn-O(1) and Zn-N(1) bonds. The 
Zn-O and Zn-N bond distances are consistent with literature values. Although, some of 
the literature values slightly differ, depending on the surrounding ligand system.239-241 
While it was observed in Cu(II) octahedral complex that coordinate bonds (M-O/N) 
show significant difference between the two ligands binding to same Cu(II) centre,  in 
the case of Zn(II) complexes the difference between the two ligands is quite small. 
Also, the equivalent bonds of the M-O/N distances in d10 Cu(I) and Zn(II) are slightly 
longer than in d9 Cu(II) complex. In [Zn(II)(HL7)2].H2O.DMSO, carboxylate O(2) atom 
of  HL1 forms intermolecular hydrogen bond with water. Whereas in [Zn(II)(HL8)2].H2O 
and [Zn(II)(HL9)2].H2O.CH3OH the N-H proton (N(5), N(2)) hydrogen bonds with non 
coordinating water.  
Each ligand bound to the Zn(II) centre looses its planarity in order to form  
stable zinc complexes, similar to observations made for octahedral complex of Cu(II) 
complex. The interplanar angle for each ligand in [Zn(II)(HL8)2].H2O is 5.07 and 10.29°, 
whereas for [Zn(II)(HL9)2].H2O.CH3OH this deviations are 3.38 and 17.33°, 
respectively. The values are obtained by measuring the angles between two planes, 
passing through the aromatic ring, and the two pentacoordinate rings surrounding the 
metal centre. Furthermore, [Zn(II)(HL8)2].H2O exhibits the greatest mean plane of 
deviation with 40.34 and 56.12°, which is likely due to the bulkier NO2 group. The 
torsional angle (C(1)-C(2)-N(1)-N(2)) indicates that both the ligands bind to the Zn(II) 
centre in E conformation, as observed for Cu(II) complexes and the values are not 
significantly different within the molecule. 
3.8.3 Structural aspects of [ Zn(II)(HL13)2] 
 The crystal structure of Zn(II)(HL13)2 was also obtained. The zinc complex 
crystallises in the terragonal space group P43212 with two crystallographically 
independent molecules in the unit cell. The ORTEP plot for corresponding molecule is 
given in figure 3.46. The molecules differ slightly in their bond lengths and bond angles, 
which may arise from the crystal packing effect. The mean plane of deviation of each 
ligand is 5.64 and 8.47° for complex 1 and is similar to complex 2 (5.07, 8.53°).  The 
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bond lengths and bond angles listed in table 3.15 are similar to the other zinc 
complexes.  
 
Figure 3.46: ORTEP plot (50% probability ellipsoids) of the molecular structure of mer-
Zn(II)(HL13)2 
Table 3.15: Selected bond lengths (Å) and bond angles (°) of mer-Zn(II)(HL13)2 
 
Bonds Complex-1 Complex-2 
 (HL1)- (HL2)- (HL1)- (HL2)- 
Zn-O(1) 2.101(3) 2.109(3) 2.111(3) 2.104(3) 
Zn-O(3) 2.096(3) 2.117(3) 2.111(4) 2.102(3) 
Zn-N(1) 2.080(4) 2.076(3) 2.081(4) 2.084(3) 
O(1)-Zn-N(1) 76.23 (14) 75.99(12) 76.28(14) 75.94(12) 
O(3)-Zn-N(1) 75.01(14) 74.57(12) 74.42(14) 74.87(12) 
O(1)-Zn-(O3) 149.86(13) 149.09(12) 149.10(13) 149.47(12) 
N(1) (L1)-Zn-
N(1) (L2) 
168.81(14) 167.64(14) 
C(1)-C(2)-
N(1)-N(2) 
178.5(4) 176.9(4) 176.5(4) 178.4(4) 
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3.9 Summary of Chapter - 3 
 PVAHs and CAHs crystallise predominantly in the keto form. The PVA ligands 
are essentially planar, although the two phenyl rings in CA hydrazones lie in a different 
plane with the an angle ranging from 53.0 – 58.0°. Under the synthetic conditions 
chosen, ligands NaHL9 and NaHL11, HCA5, HCA2 coordinate in their monoprotonated 
form. In the sodium salts NaHL9 and NaHL11, the negative charge on the carboxylate 
group present in the pyruvate hydrazones is balanced by the Na+ counter ion. On the 
other hand, H2L20 was crystallised in its di-protonated form. The sodium cation in 
NaHL9 and NaHL11 is surrounded by six ligands completing the octahedral geometry. 
Ligands HL9- and HL11- acts as monodentate ligand towards the Na ion and the rest of 
the octahedral coordination site is completed by water molecules. PVAHs show 
extensive intra and intermolecular hydrogen bonding, in contrast to cinnamaldehyde 
hydrazones. Hence, calculated CLogP values are greater for CAHs, whereas some of 
the PVAHs have even negative values.  The greater CLogP values may lead to poor 
oral drug absorption but may prove to be advantageous in promoting permeation 
through the lipid bilayer of the mycobacterial cell wall. 
 The torsional angles suggest that the sodiated ligands adopt Z confirmation, 
whereas the non-sodiated PVAH crystallises in E conformation. All the isolated crystals 
of Cu(II) and Zn(II) complexes of PVAHs exhibit E confirmation, whereas Cu(I) 
complexes prefer to remain in Z confirmation in the solid state. Pyruvate binds to Cu(II) 
and Zn(II) in a tridentate fashion, forming two stable five membered rings around the 
metal centre. Cu(II) complexes of PVAHs mostly adopt monomeric square pyramidal 
geometry, although a dimeric complex of similar geometry is also observed for L9. In 
the case of monomeric complexes, one ligand is bound to the Cu(II) with ONO donor 
atoms, whereas solvent (water/methanol) molecules occupy the remaining coordination 
sites. In the dimeric copper complex, the two Cu(II) centres are bridged by two chloride 
ions. The apical bond distances are significantly longer than the equatorial bond 
distances, indicating an appreciable Jahn - Teller distortion. In the monomeric square 
pyramidal complexes, the ligand is dianionic giving rise to an overall neutral complex .  
In the case of [Cu(II)(L9)(H2O)2]  and [Cu(II)(L11)(H2O)2].H2O, the complexes 
crystallise as two crystallographically independent molecules in one unit cell, which is 
relflected in their different τ values. The τ value indicates slight distortion from a perfect 
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square pyramidal geometry. The other copper complexes of L8-, L13-, L17- and L7- 
exhibit similar structural characteristics. Bond lengths and bond angles are comparable 
with literature values and the R group on the aromatic rings have little or no influence 
on the bond distances in the direct vicinity of metal centre. The ligand remains 
essentially planar when bound to Cu(II) centre.  
 In the dimeric complex, the ligand is coordinated in its monoanionic form 
with the positive charge of Cu(II) centre balanced by an additional chloride ion. 
Similarly, the ligand remains with a single positive charge in case of octahedral Cu(II) 
and Zn(II) complex. Two ligands bind to the metal centre making the overall complex 
neutral. The two ligands are organised in a meridonially around the metal centre due to 
the rigidity of the planar ligand. However, the copper complex of HL15 crystallises as 
two crystallographically independent molecules, one neutral and one anionic. In the 
latter, one of the ligands bound to the Cu(II) centre is dianionic, making the overall 
copper complex negatively charged which is balanced by a sodium counter ion. In the 
case of octahedral complexes, the coordinating ligand loses its planarity in order to 
reduce the steric repulsion caused by two ligands bound to the same metal centre. This 
is evident from the mean plane of deviation, which varies from 5.0 to 56.1° . It is also 
found that  the deviation for one ligand is smaller than for the other ligand bound to the 
same metal centre. Greater values are obtained for the [Zn(II)(HL8)2].H2O, as it bears a 
bulkier NO2 at para-position on the aromatic ring The distorted octahedral geometry is 
indicated by the bond angles. 
The PVAH ligand binds to one of the Cu(I) centre partially in a bidentate 
manner, thus allowing the Cu(I) complex to adopt a tetrahedral geometry. Whereas, the 
other part of the PVAH coordinates in a monodentate manner to the second Cu(I) 
centre. PPh3 occupies the rest of the tetrahedral sites. The overall copper complex is 
positively charged, hence PF6- is also present in the crystal lattice in order to balance 
the charge. Soft P donors provided by PPh3 stabilise the crystal structures of the Cu(I) 
complexes. The bond angles indicate distortion from perfect tetrahedral geometry. A 
three-coordinate Cu(I) complex is also isolated along with the dimeric complex of 
[Cu(I)2HL9(PPh3)4]. 2Et2O.H2O. 
 
 
 
 
 
 
 
Chapter-4 
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4.0    Electrochemistry and Electron paramagnetic resonance studies  
4.1 Introduction 
 Electrochemistry (Echem) is a useful technique, as it allows studying the 
redox processes of molecules. It has various applications, such as 
electrosynthesis242-243, evaluation of redox potential of metal complexes and 
enzymes containing redox active metal centres.244-246 Furthermore, in bioinorganic 
chemistry, the model complexes mimicking metalloenzymes have also been 
explored with the help of electrochemistry. This allows the study of electron / proton 
transfer processes associated with the metal centre, hence can be useful in 
elucidating mechanistic aspects of catalytic activities of certain enzymes.247 
Moreover, the redox potentials of metal complexes can be tuned by employing 
appropriate ligand systems which can be useful in effective drug design.248  
The electrochemistry of transition metal complexes has been extensively 
studied in the last two decades owing to their various redox states.249 Out of the 
various metal ions present in biological systems, copper, iron and molybdenum are 
preferred for redox processes.250  Copper is known to exist in oxidation states Cu(0), 
Cu(I), Cu(II) and Cu(III) depending on the conditions.251-253 Since the redox potential 
for Cu3+/Cu2+ is normally very high, the Cu(III) oxidation state is generally not found 
in biological systems.251 Applying an electric potential to copper complexes in 
solution allows the copper centre to be present in different oxidation states at certain 
electric potentials, ranging from 0 to 3.  These can be monitored using different 
electrochemical techniques, but linear-sweep cyclic voltammetry (LSCV or CV) is 
most commonly used to study transition metal complexes. 
As discussed in chapter - 3, the Cu-centre reorganises its coordination 
sphere while changing from one oxidation state to another. Whereas Cu(II) mainly 
prefers a 5-coordinate square pyramidal geometry, Cu(I) adopts a 4-coordinate 
tetrahedral geometry. This type of structural reorganisation is known to be hindered 
in copper-containing metalloproteins. In order to lower the activation energy during 
electron transfer processes, the coordination geometry in blue copper proteins is a 
compromise between Cu(I) and Cu(II) (entatic state), which can be considered as 
opposing Jahn-Teller distortion.254-255  
Solomon et al. have performed extensive studies on the blue copper protein 
plastocyanin which displays such a compromised geometry, as explained in figure 
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4.1. As indicated in figure 4.1a, a normal Cu(II) complex exhibits strong σ-bonding 
and weak pi-interactions as a lobe of the  dx2-y2 orbital is oriented along the metal-
ligand bond which give rise to a high energy σ charge transfer transitions . However, 
in case of plastocyanin (fig 4.1b) the dx2-y2 lobes are rotated by 45° which results in 
weak σ and strong pi interactions. Thus, the unusual geometry prevents the protein 
to undergo drastic geometric change upon oxidation, hence allowing rapid electron 
transfer. 
  
a)  (Normal Copper(II)) 
 
b) (Plastocyanin) 
Figure 4.1: a) Normal Cu-S (cysteine) bonding interactions b )Cu-S (cysteine) 
bonding interaction in plastocyanin.255 
Hence, most of the redox processes in biological systems are reversible, 
whereas in synthetic coordination chemistry, especially in copper complexes of 
Schiff bases, redox processes tend to exhibit either quasi-reversible or irreversible 
behaviour.256-257 This can be due to the major change of the geometry upon 
reduction of Cu(II) to Cu(I). As a result, the dissociation of partially or fully 
coordinated rigid molecules in order to attain the desired coordination geometry 
around the metal centre is often observed. However, McMaster and group, 
successfully synthesized Cu(I) and Cu(II) complexes of di-imidazole containing 
ligands (shown in figure 4.2) which are similar in structure.  
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Figure 4.2: Bis(1-methyl-4,5-diphenylimidazol-2-yl) ketone258 
Both complexes adopt a geometry that lies in between tetrahedral and 
square planar, as confirmed by X-ray crystallography.The redox behaviour of the 
Cu(II) complex is completely reversible which implies that there is no significant 
structural change at the copper centre upon reduction to Cu(I).258 
As discussed earlier, electrochemical properties of metalloenzymes or their 
model complexes have been helpful in elucidating the mechanistic aspects of 
catalytic properties of the metal centres. Furthermore, Echem in combination with 
other techniques, such as electron paramagnetic (EPR) spectroscopy, NMR and X-
ray crystallography can be useful in investigating the electronic and structural 
properties of metalloenzymes.246,259-260 Moreover, Echem and EPR can be 
employed to investigate the behaviour of metal complexes in solution containing 
paramagnetic centres. Nonetheless, EPR has been widely used by several 
researchers in the past to predict the potential geometries and nature of Cu(II) 
centres in solution.261-262  
For example, Solomon and group also explored the Cu(II)-containing blue 
copper protein plastocyanin with the help of EPR. Figure 4.3 indicates the EPR 
spectra of the protein (top) and normal copper (bottom). From the EPR studies, 
especially, the 2-fold reduction in A║ values of plastocyanin indicates a distortion 
from tetrahedral geometry.255 
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Figure 4.3: X-band EPR spectrum of plastocyanin (top) and D4h CuCl42- (bottom)255 
In this chapter, CV is used to explore the redox behaviour of the Cu(II) and 
Cu(I) complexes of selected pyruvate hydrazones. The investigated copper 
complexes have different substituents on the aromatic ring, ranging from electron 
withdrawing NO2 to electron donating CH3. This allowed the examination of the 
influence of different substituent on the redox properties of the copper complexes. 
Furthermore, to elucidate the behaviour of Cu(II) complexes of PVAHs in the 
electrochemical solvent (DMSO), selected copper complexes were also examined 
using EPR spectroscopy.  
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4.2  Redox properties of pyruvate hydrazones and their copper 
complexes 
Cyclic voltammetry (CV), was employed to investigate the redox properties 
of the sodium salts of the ligands, NaHL3, NaHL8, NaHL9, NaHL12, the Cu(II) 
complexes [Cu(II)L1(H2O)2], [Cu(II)L3(H2O)2], [Cu(II)L8(H2O)2], [Cu(II)L9(H2O)2], 
[Cu(II)L10(H2O)2], [Cu(II)L12(H2O)2], [Cu(II)L21(H2O)2] and the Cu(I) complexes 
[Cu(I)2HL8(PPh3)5)] and [Cu(I)2HL9(PPh3)5)].  
The CV studies were carried out at room temperature using a standard three 
electrode configuration, consisting of a platinum working electrode, platinum wire as 
auxiliary electrode and a Ag/AgCl reference electrode. The supporting electrolyte 
used was 0.1 M tetra-butyl ammonium hexafluorophosphate in DMSO. The solution 
was purged with N2 gas prior to use. The details of the procedure can be found in 
the chapter-7. The concentrations of the ligands and complexes were approximately 
1 mM and the cyclic voltammograms were scanned within the potential range of 
+1.0 to –1.0 V. DMSO decomposes beyond the potentials +1.0 and –1.0 V, hence 
only processes observed within these two limits were assigned in the present study.  
The redox potential (E1/2) of the ferrocene/ ferrocenium (Fe2+/Fe3+) couple in 
DMSO was observed at 0.45 ± 0.2 V versus standard calomel electrode (SCE), 
consistent with literature values within the error limits.263 In order to compare with 
literature values, potentials monitored with respect to the Ag/AgCl reference 
electrode were converted into SCE as per equation A.249 
Evs SCE = Evs Ag/AgCl – 0.0450 V ----------equation A249 
In case of the pyruvate hydrazone (PVAH) ligands and their Cu(II) 
complexes the potential is recorded from  voltage E1 at +1.0 V to voltage E2 (-1.0) 
and then back to E1. This scan direction will subsequently be called forward scan. 
For Cu(I) complexes, a reverse scan was employed due to the different oxidation 
state. 
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4.2.1  Electrochemical investigation of PVAHs 
As discussed in chapter-2, Cu(II) complexes of PVAHs were synthesized 
using one equivalent of NaHLx and CuCl2 as shown in Scheme 4.1  
O
N
N O
O
CH3
R
Cu
H2O OH2
O
N
H
N O
O
CH3
R
Na
CuCl2
 
Scheme 4.1: Synthesis of Cu(II) complex of PVAHs 
In order to examine the redox behaviour of starting material, before 
investigating the Cu(II) complexes, selected PVAH ligands and CuCl2 were also 
studied using CV. A representative example, NaHL3, is shown in figure 4.4. The CV 
indicates that the ligand does not show any redox activity. 
 
Figure 4.4: CV of NaHL3 in DMSO over the potential range from +1.0 to -1.0 in the 
forward sweep at the scan rate of 100 mV s-1 (the arrow represents the direction of 
the potential sweep) 
Other ligands, including NaHL9, NaHL12, NaHL15 exhibited similar 
characteristics and no redox peaks were observed. However, the ligand bearing an 
NO2 substituent on the aromatic ring (NaHL8) shows redox activity in the region -
0.06 to -0.1 V. This can be attributed to the redox activity of NO2 and will be 
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discussed further in detail when comparing with its respective Cu(I) and Cu(II) 
complexes. 
4.2.2 Electrochemical investigation of copper complexes 
In order to understand the behaviour of the Cu(II) complexes in 
electrochemical DMSO and in particular to investigate potential ligand exchange 
reactions in this co-ordinating solvent, the CV of free Cu(II) was recorded. CuCl2 
was used as source of Cu(II) as it was used as the starting material in the synthesis 
of the  Cu(II) complexes of PVAHs. If there is complete dissociation of the ligand, 
then it is likely that the copper complexes would exhibit similar behaviour to CuCl2 in 
DMSO (Cu-DMSO complex). It can be observed from figure 4.5, that CuCl2 in 
DMSO gives well defined symmetrical waves Epc (A) and Epa (B), which can be 
attributed to the Cu2+/ Cu1+ redox couple. The potentials for Epc and Epa are 0.22 V 
and 0.53 V at 100 mV s-1, respectively. 
A
B
 
Figure 4.5: CV of scan rate dependence for CuCl2 in DMSO over the potential range 
from +1.0 to -0.5 in the forward sweep at the scan rate of 100, 200, 300, 400 mV s-1 
(inner-outer) (blue arrows represents the direction of the potential varied) 
 Ukpong and coworkers, studied the electrode potential of CuCl2 in different 
solvents against a Pt working electrode and SCE as reference electrode. The 
observed Epc and Epa values in DMSO at 0.25 mV s-1 are 0.20 V and 0.40 V 
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respectively. Furthermore, it was also observed that the  electrode potential shifts 
towards more positive potential while going from DMSO < DMF < Acetonitrile (AN) 
This is likely due to the fact that, DMSO stabilises the Cu(II) species in solution.264  
Similar behaviour was observed for ferrocene in different solvents by Tsierkezos, 
although the shift is not as significant as observed for CuCl2. 265    
4.2.2.1 Electrochemical investigation of Cu(II) complexes of 
PVAHs                                                                                                                                              
[Cu(II)L9(H2O)2] 
The CV of [Cu(II)L9(H2O)2] (figure 4.6) exhibits cathodic waves at 0.26 V (A) 
and -0.64 V (B), whereas anodic waves are observed at 0.18 V (C) and 0.56 (D) at 
a scan rate of 10 mV s-1. This potential was monitored in a forward scan ranging 
from +1.0 to -1.0 V. The cathodic waves (A and B) and the corresponding anodic 
waves (C and D) can be assigned to metal-based redox processes. The peak A 
may be assigned to the reduction of Cu2+ to Cu1+ (equation 4.1), whereas the peak 
D may be attributed to the oxidation of Cu1+ to Cu2+ (equation 4.2). Moreover, the 
cathodic peak B can be assigned to the formation of Cu0 (equation 4.3), where the 
metallic copper starts depositing on the electrode. And the anodic peak C might be 
due to the redissolution of Cu0 (equation 4.4)  
start point
A
B
D C
 
Figure 4.6: CV of [Cu(II)L9(H2O)2] in DMSO over the potential range from +1.0 to -
1.0 in the forward sweep at the scan rate of 10 mV s-1 (the arrow represents the 
direction of the potential sweep) 
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Cu2+ + e-    → Cu1+ ………………. (4.1) Reduction process (A) 
Cu1+  → Cu2+ + e-  ……………….. (4.2) Oxidation process (D) 
Cu1+ + e-   → Cu0   …………………(4.3) Reduction process (B) 
Cu0  → Cu1+ + e-    …………………(4.4) Oxidation process (C) 
Going towards higher scan rates also leads to broadening and shifting of the 
peak D towards more positive potentials resulting in the merging of C and D peaks. 
The broadening of peaks can also be due to the presence of intermediates at higher 
scan rate. The intensity of peaks increases as scan rate increases, which can be 
observed from the scan rate dependence spectra as shown in figure 4.7. It is 
observed that the peak D increases in greater intensity as compared to peak A after 
repeated scanning. The greater intensities of anodic peaks might be due to the 
redissolution of elemental copper (Cu0) (equation 4.4). 
 
Figure 4.7: CV for [Cu(II)L9(H2O)2] recorded at different scan rates in DMSO over 
the potential range from +1.0 to -0.5 V in the forward sweep at scan rates of 10 - 
300 mV s-1 (blue arrows represent the direction of the potential sweep). 
These assignments were made according to similar work reported by 
Darchen et al for [Cu(NH3)4]2+. They observed a redox couple due to Cu2+/Cu1+, 
whereas the cathodic and anodic peak potential observed due to Cu1+/Cu0 occurs at 
a slower rate, due to the redissolution of copper electrodeposited which leads to the 
higher value of the peak current. [Cu(NH3)4]2+ exhibits similar CV spectra to that of 
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[Cu(II)L9(H2O)2] and the electrode potential for the equivalent peaks were observed 
at -0.22 V (A), -0.84 V (B), -0.32 V (C), -0.15 V (D) in aqueous solution at a vitreous 
carbon electrode with respect to SCE. 266 The difference in the potentials observed 
may be attributed to 1) different ligand system, 2) electrochemical solvent and the 3) 
working electrode.      
When [Cu(II)L9(H2O)2] was scanned in the limited potential range between 
+1.0 and -0.5 V, peaks B and C disappeared, giving more well defined A and D 
peaks. The CV was recorded at different scan rates (from inner to outer) of 10, 30, 
50, 70, 90, 100, 150, 200, 250, 300 mV s-1 as indicated in figure 4.8. The peak 
separation (∆E) of A and D peaks along with ferrocene redox peaks are provided in 
table 4.1. 
A
D
start
point
 
Figure 4.8: Scan rate dependence for [Cu(II)L9(H2O)2] in DMSO over the potential 
range from +1.0 to -0.5 V in the forward sweep at the scan rate of 10 – 300 (inner- 
outer) mV s-1 (blue arrows represents the direction of the potential varied). 
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With the increase of the sweep rate the value of ∆E (Eox – Ered) also 
increases, as evident from table 4.1, which is indicative of quasi-reversible 
behaviour. The ∆E observed for one electron reversible process for ferrocene at 10 
mVs-1 is 0.08 V. While, 0.18 V for [Cu(II)L9(H2O)2] at the same scan rate associates 
with  slow electron transfer kinetics which indicates quasi-reversibility. For an ideal 
one electron reversible process (fast electron transfer) it is 0.06 V and independent 
of the scan rate.267 
Table 4.1: ∆E values of [Cu(II)L9(H2O)2] and ferrocene at different scan rate 
 
 
 
 
 
 
 
 
 
ν (mVs-1) ∆E (V) 
[Cu(II)L9(H2O)2] 
∆E (V) 
ferrocene 
10 0.18 0.08 
30 0.20 0.08 
50 0.24 0.08 
70 0.26 0.09 
90 0.27 0.09 
100 0.27 0.09 
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[Cu(II)L8(H2O)2] 
NaHL8 studied under similar conditions exhibited reversible peak potential, 
which is indicated in figure 4.9.  
start point
 
Figure 4.9: CV of NaHL8 in DMSO over the potential range from +1.0 to -1.0 in the 
forward sweep at the scan rate of 10 mV s-1 (the arrows represents the direction of 
the potential sweep). 
 
The CV wave corresponds to the redox process of NO2 is given by equation 
4.5.268 The cathodic peak at -0.86 V corresponds to the reduction of the NO2 
subsituent to NO2- , whereas the anodic peak at -0.76 V can be attributed to the re-
oxidation of NO2- with a  E1/2 value of -0.81 V. The peak separation (∆E) is 0.089 V 
at 10 mV s-1 and is independent of increased scan rates, which is indicative of 
reversibility. 
R-NO2 R-NO2-
+ e-
- e-
(4.5)
 
The copper complex of NaHL8 displays a rather complicated CV as 
indicated in figure 4.10. The copper complex [Cu(II)L8(H2O)2] with R = NO2 exhibits 
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cathodic peaks at +0.27 V (A), -0.56 V (B) and -0.84 V (C) at a scan rate of 10 mV 
s-1. In addition, the anodic peaks are observed at -0.76 V (D), -0.16 V (E), +0.07 V 
(F), +0.06 V (G), +0.35 V (H). C and D can be attributed to the redox processes 
occurring due to NO2. Whereas, the rest of the peaks can be attributed to the metal 
based redox peaks and can be related to Cu2+/Cu1+  and Cu1+/Cu0 (equation 4.1-4.4, 
page-168) as assigned for [Cu(II)L9(H2O)2].  
A
C
H D
B
G F E
start point
 
Figure 4.10: CV of [Cu(II)L8(H2O)2]  in DMSO over the potential range from +1.0 to -
1.0 V in the forward sweep at the scan rate of 10 mV s-1 (the arrow represents the 
direction of the potential sweep) 
 The additional anodic and cathodic peaks observed for 
[Cu(II)L8(H2O)2] might be due to the presence of more than one species of copper 
complex in the DMSO solution. This may due to structural reorganisation of the 
coordination sphere taking place while going from one oxidation to different 
oxidation state.  
  [Cu(II)L8(H2O)2] was also scanned for different scan rates, similar to that of 
[Cu(II)L9(H2O)2]. As observed for later complex, the former complex displays similar 
behaviour, where the peaks tend to broaden which result in merging of bands as 
indicated in figure 4.11. Interestingly, certain species exists only at lower scan rate, 
which results in complete disappearance of peak E at higher scan rates 
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Figure 4.11: CV of scan rate dependence for [Cu(II)L9(H2O)2]  in DMSO over the 
potential range from +1.0 to -1.0 V in the forward sweep at the scan rate of 10- 300 
(inner-outer) mV s-1 (the arrows represent the direction of the potential varied) 
 Moreover, when [Cu(II)L8(H2O)2] was scanned in the limited range from +1.0 
to -0.5 V better defined A and H peaks were observed as indicated in figure 4.12. 
These peaks may be assigned as shown in equations 4.1 and 4.4, similarly 
observed for [Cu(II)L9(H2O)2] 
Cu2+ + e-    → Cu1+ ……………….. (4.1) Reduction reaction (A) 
Cu1+  → Cu2+ + e-…………………(4.4) Oxidation reaction (H) 
It can be noted that, when both the complexes are scanned in the potential 
range from +1.0 to -0.5 V, the cathodic and anodic peaks exhibit nearly symmetric 
peak heights as compared to the spectra ranging from +1.0 to -1.0 V. This can be 
due to fact that, as there is no process occurring due to Cu1+/Cu0 hence no Cu(0) 
deposition takes place which allows Cu2+/Cu1+ to take place at similar rate. However, 
the large ∆E (V) which rises with increase in the scan rate indicates quasi-reversible 
behaviour. 
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Figure 4.12: CV of scan rate dependence for [Cu(II)L8(H2O)2]  in DMSO over the 
potential range from +1.0 to -0.5 V in the forward sweep at the scan rate of 10 - 300 
(inner-outer) mV s-1 (arrows represent the direction of the potential varied) 
 The quasi-reversible behaviour of copper complexes observed for Cu2+/Cu1+ 
is likely to be due to the change in the coordination environment of the Cu(I) centre. 
In case of PVAH copper complexes, Cu(II) adopts either square pyramidal or 
octahedral geometry whereas Cu(I) prefers tetrahedral geometry269. Upon reduction 
to Cu(I), the rigid ligand either partially dissociates to form a Cu(I) complex as 
shown in Figure 4.13 or fully dissociates to form a Cu(I)-DMSO complex. 
Cu
O
N
O
NO
2+ Cu
OH
N
O
NO
1+
RR
+ e-
 
Figure 4.13: Structural reorganisation from Cu(II) → Cu(I)  complex of 
PVAHs. 
It has been confirmed by X-ray crystal crystallography, as described in 
chapter-3, that Cu(I) complexes of PVAHs adopt tetrahedral geometry and are more 
stable in presence of soft donor atoms like P, whereas Cu(II) complexes mainly 
adopt square pyramidal geometry and are stable with O,N donor atoms. The 
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structural reorganisation of the coordination sphere can account for the quasi-
reversible behaviour of the investigated Cu(II) complexes of PVAHs.  
In order to compare the electrochemical behaviour of Cu(I) complexes, 
[HL8Cu2(I)(PPh3)5]PF6 and [HL9Cu2(I)(PPh3)5]PF6 were also investigated under 
similar conditions. 
4.2.2.2 Electrochemical investigation of Cu(I) complexes of PVAHs  
 Synthetic scheme for Cu(I) complexes of PVAHs which is discussed in detail 
in chapter-2 is shown in scheme 4.2. 
 
Scheme 4.2: Synthesis of Cu(I) complex of PVAHs 
 
Likewise, PVAHs ligands were investigated for their redox behaviour, PPh3 is 
also examined using CV, as it is also part of the coordination sphere of Cu(I) 
complex. The cathodic and anodic peak potentials of PPh3 are observed at -0.45 V 
and -0.37 V respectively as indicated in figure 4.14. The peaks can be assigned to 
the redox potential of the PPh3 group as indicated in equation 4.6. The ∆E value is 
N
H
N
O
CH3
O ONa
R
[Cu(I)(CH3CN)4]PF6 PPh3 , MeOH 
N
O
N
CH3
O
O
Cu Cu
Ph3P
PPh3
PPh3
Ph3P
PPh3
R
PF6 
 
 R 
L8   =  p-NO2 
L9   =  p-CH3 
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88 mV at 50 mV s-1 but increases slightly with the rise in the scan rate which is 
indicative of quasi-reversibility.  
PPh3
+ e-
- e-
(4.6)PPh3
 
start point
 
Figure 4.14: CV of PPh3 in DMSO over the potential range from +0.5 to -0.5 V in the 
forward sweep at the scan rate of 30 mV s-1 (the arrows represents the direction of 
the potential sweep) 
The CV for [Cu(I)2HL9(PPh3)5]PF6 recorded at a scan rate of 10 mV s-1 is 
shown in figure 4.15. The reverse scan direction is followed for Cu(I) complexes, 
hence the start and end potential (E1) is -1.0 V and the turning potential E2 is +1.0 V. 
The CV of the copper complex [HL9Cu2(I)(PPh3)5]PF6 exhibits two cathodic peaks at 
+0.24 V (A) and -0.67 V (B), whereas the anodic peak is observed at +0.52 V (C), 
when scanned in the range from –1.0 to +1.0 V. 
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Figure 4.15: CV of [Cu(I)2HL9(PPh3)5]PF6 in DMSO over the potential range from -
1.0 to +1.0 V in the forward sweep at the scan rate of 10 mV s-1 (arrows represent 
the direction of the potential sweep) 
Peaks A and C can be assigned to the metal centred redox process of the 
complex. The peak A may be assigned to the reduction of Cu(II)  to Cu(I) (equation 
4.1), whereas the peak C may be attributed to the oxidation Cu(I) to Cu(II) (equation 
4.2). The irreversible cathodic peak B can be assigned to the formation of Cu(0) 
(equation 4.3). 
Cu(II) + e-    → Cu(I) ……………….. (4.1) Reduction reaction (A) 
Cu(I) → Cu(II) + e- ………………….. (4.2) Oxidation reaction (C) 
Cu(I) + e-   → Cu(0)…………………..(4.3) Reduction reaction (B) 
Similar results were obtained for the Cu(I) precursor complex, 
[Cu(I)(CH3CN)4]PF6 and the Cu(I) complex synthesized by Ouali and group.270 The 
Cu(I) complex shown in figure 4.16 displayed a quasi-reversible behaviour for 
Cu1+/Cu2+  and the cathodic peak corresponding to the oxidation of  Cu1+→ Cu2+ (C)  
was observed at 0.44 V, whereas the irreversible reduction process for Cu1+→ Cu0  
occurs at -1.35 V (B). Furthermore, Ouali and group also observed that 
corresponding processes for the precursor complex, [Cu(I)(CH3CN)4]PF6  was 
observed towards more positive potential, at +1.10 V (C) and -0.80 V (B), 
respectively, versus SCE in acetonitrile.270  
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Figure 4.16: Ouali’s Cu(I) complex270 
The intensity of the peaks of [HL9Cu2(I)(PPh3)5]PF6 increases as the scan 
rate increases, which can be observed from the scan rate dependence plots, as 
shown in figure 4.17. Going towards higher scan rates leads to shifting of the peak 
C towards more positive potentials and also leads to the broadening of the peaks, 
similarly observed for Cu(II) complexes. This might also be due the presence of 
intermediate at higher scan rates resulting from the structural reorganisation taking 
place while going from Cu1+→ Cu2+. 
 
Figure 4.17: CV of scan rate dependence for [HL9Cu2(I)(PPh3)5]PF6 in DMSO over 
the potential range from +1.0 to -1.0 in the forward sweep at the scan rate of 10- 
300 mV s-1 (arrow represents the direction of the potential varied) 
Figure 4.18 shows a comparison between the CVs of the Cu(I) complex 
[HL9Cu2(I)(PPh3)5]PF6 (blue spectrum, peaks with suffix a) and Cu(II) (red spectrum, 
peaks with suffix b) complex [Cu(II)L9(H2O)2]. As the ∆E in these complexes are 
quite high (0.22 V), the electron transfer processes in these complexes are  quasi-
reversible. Figure 4.18 also indicates that the metal based peaks corresponding to 
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Aa/Ab, Ba/Bb and Ca/Cb, of Cu(I) and Cu(II) complexes occur at nearly similar 
potentials. The peak potentials for [Cu(I)2HL9(PPh3)5]PF6 and [Cu(II)L9(H2O)2] 
reported versus SCE are listed in table 4.2. 
start point for
blue spectra
start point for
red spectra
Aa Ab
Bb
Cb
Ba
Ca
Db
 
 
Figure 4.18: Comparison of the CVs of [Cu(II)L9(H2O)2] (-) and 
[Cu(I)2HL9(PPh3)5]PF6 (-) in DMSO over the potential range from +1.0 V to -1.0 V at 
the scan rate of 10 mV s-1 (the arrows represent the direction of the potential varied) 
Table 4.2: Electrode peak potentials [Cu(I)2HL9(PPh3)5]PF6 and [Cu(II)L9(H2O)2] 
reported versus SCE, (a measured versus Ag/AgCl) 
 Peaks [Cu(I)2HL9(PPh3)5]
PF6  (V)  
Peaks Cu(II)L9(H2O)2 
(V) 
Aa +0.24 (0.29a) Ab +0.26 (0.31a) Cathodic peaks in 
mV Ba -0.67 (-0.62a) Bb -0.64 (-0.59a) 
Ca +0.52 (0.56a) Ca +0.56 (0.61a) Anodic peaks in 
mV 
  Da +0.18 (0.22a) 
Electrochemical studies were also performed on the Cu(I) and Cu(II) 
complexes of NaHL8 under similar conditions. The overlaid CV spectra of 
[HL8Cu2(I)(PPh3)5]PF6 (red spectrum with suffix a) and [Cu(II)L8(H2O)2]  (blue 
spectrum with suffix b) are shown in figure 4.19 and the peak potentials are listed in 
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table 4.3. The metal based peaks can be assigned to the oxidation and reduction of 
the Cu centre as described earlier. There are additional peaks as compared to the 
copper complexes of NaHL9. The peaks Ca/Cb and Da/Db in case of Cu(I)/Cu(II) 
complex can be assigned to the ligand based NO2 redox peaks. Electrode peak 
potentials of [HL8Cu2(I)(PPh3)5]PF6 and Cu(II)L8(H2O)2 reported versus SCE are 
listed in table 4.3. 
start point of 
blue spectrum
start point of 
red spectrum
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Ea Gb
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Bb
Ab
Fb
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Ba Ca
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Figure 4.19: Overlaid CV of Cu(II)L8(H2O)2 (-) and [Cu(I) 2HL8(PPh3)5]PF6 (-) in 
DMSO over the potential range from +1.0 V to -1.0 V at the scan rate of 10 mV s-1  
(blue/red arrow represents the direction of the potential varied) 
Table 4.3: Electrode peak potentials [Cu(I)2HL8(PPh3)5]PF6and Cu(II)L8(H2O)2 
reported versus SCE, (a measured versus Ag/AgCl) 
 Peaks [Cu(I)2HL8(PPh3)5]
PF6PF6 (V) 
Peaks Cu(II)L8(H2O)2 
(V) 
Aa +0.26 (0.31a) Ab +0.27 (0.32a) 
Ba -0.47 (-0.43a) Bb -0.56 (-0.52a) 
Cathodic peaks in 
mV 
Ca -0.91 (-0.86a) Cb -0.84 (-0.79a) 
Da -0.83 (-0.79a) Db -0.76 (-0.71a) 
Ea +0.45 (0.50a) Eb +0.35 (0.40a) 
  Fb +0.07 (0.18a) 
Anodic peaks in 
mV 
  Gb -0.16 (-0.18a) 
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When the voltammogram was scanned in the limited potential range 
between –1.0 and +0.5 V, it gave more well defined Aa/Ca and Aa/Ea peaks for 
[Cu(I)2HL9(PPh3)5]PF6 and [Cu(I)2HL8(PPh3)5]PF6, respectively, similarly observed 
for their respective Cu(II) complexes. As expected, with the increase in the scan 
rate, the value of ∆E also increases significantly, strongly suggesting quasi-
reversibility. The values are given in table 4.4. 
Table 4.4: ∆E values for [Cu2(I)HL9(PPh3)5]PF6and [[Cu2(I)HL8(PPh3)5]PF6reported 
versus SCE, (a measured versus Ag/AgCl) 
 Scan rate 
ν (mVs-1) 
∆E (V) 
[Cu(I)2HL9(PPh3)5]PF6 
∆E (V) 
[Cu(I)2HL8(PPh3)5]PF6 
1 10 0.224 0.220 
2 30 0.275 0.292 
3 50 0.279 0.308 
4 70 0.309 0.330 
5 90 0.317 0.335 
6 100 0.334 0.335 
 
The overlaid spectra of [Cu(I)2HL8(PPh3)5]PF6 (red spectrum), 
[Cu(II)L8(H2O)2] (blue spectrum) and NaHL8 (purple spectrum) in the region -0.2 V 
and -1.0 V are shown in figure 4.20. All the spectra were scanned in the forward 
sweep in order to compare the NO2 reduction potential and the redox peak 
potentials for NO2–subsituent are listed in table 4.5. 
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Figure 4.20: Overlaid CVs of [Cu(I)2HL8(PPh3)5]PF6 (-), [Cu(II)L8(H2O)2]  (-) and 
NaHL8 (-) in DMSO over the potential range from -0.2 V to -1.0 V at the scan rate of 
10 mV s-1 (arrow represents the direction of the potential varied) 
Table 4.5: Redox peak potentials of NO2 reported versus SCE, (a measured versus 
Ag/AgCl) 
 NO2 in 
[Cu(I)2HL8(PPh3)5]PF6 
(V)
   
 
NO2 in 
Cu(II)L8(H2O)2 
(V) 
NO2 in NaHL8 
(V) 
Ferrocene (V)  
Ec  - 0.91 (-0.86a) - 0.84 (-0.79a) - 0.91 (-0.86a) + 0.47 (0.51a) 
Ea  - 0.83 (-0.79a) - 0.76 (-0.71a) - 0.82 (-0.77a) + 0.39 (0.43a) 
∆E  0.071 0.078 0.089  0.079 
E1/2  - 0.87 (-0.04a) - 0.80 (-0.75a) - 0.87 (-0.76a) + 0.43 (0.47a) 
 
The ∆E value suggests that the aromatic NO2–substituent undergoes a one 
electron reduction process to give NO2- 271. In Cu(I) complex, the E1/2  for NO2 is 
similar to that of NaHL8. Whereas, in case of Cu(II) complex they are shifted 
towards positive potentials, implying that the NO2 is more easily reduced in the 
Cu(II) complex than in the Cu(I) complex.  
It is noteworthy, that the two Cu(I) centres in the dimeric copper complex 
appear to exhibit identical redox properties, as no distinguishable redox processes 
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could be observed. The higher ∆E value for Cu(I) complex of NaHL9 (0.22 V) and 
Cu(I) complex of NaHL8 (0.22 V) can be due to the quasi-reversible behaviour 
and/or presence of more than one Cu(I) centres. Furthermore, when compared with 
investigated Cu(II) and Cu(I) complexes, it is observed that the CVs of the Cu(I) 
complexes have fewer redox waves than the corresponding Cu(II) complexes. This 
may indicate that the Cu(I) complexes are less flexible in adopting intermediate 
geometries in the solution as compared to the Cu(II) complexes. This is perhaps 
likely due to bulkier PPh3 groups surrounding Cu(I) centre, making it difficult to 
change geometry drastically during structural reorganisation of the copper centre. 
Hence, the metal based redox waves observed in Cu(I) complexes are more well 
defined as compared to the  broad peaks of Cu(II) complexes. 
Both the Cu(I) complexes of NaHL8 and NaHL9 show similar behaviour as 
can be seen from figure 4.21, when scanned in the limited potential range of +1.0 
and 0.5 V. The voltammogram in red corresponds to free PPh3 and the peaks can 
be assigned to the processes related to PPh3 cation (equation 4.6).272-273 The 
cathodic and anodic peak potentials of PPh3, observed at -0.45 V and -0.37 V, 
respectively, are absent when the phosphine is coordinated to the Cu(I) centre.  
 
 
Figure 4.21: Overlaid CV of [Cu(I)2HL8(PPh3)5]PF6 (-), [Cu(I)2HL9(PPh3)5]PF6 (-) and 
TPP (-) in the DMSO over the potential range from +1.0 V to -0.6 V at the scan rate 
of 50 mV s-1 
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4.2.2.3 Comparing electrode potentials of Cu(II) complexes of PVAHs 
The Cu(II) complexes of the other ligands NaHL1, NaHL3, NaHL10, 
NaHL12, NaHL16, NaHL21 displayed electrochemical behaviour similar to 
[Cu(II)L8(H2O)2] and [Cu(II)L9(H2O)2].  
Anodic and cathodic peak potentials of selected Cu(II) complexes of PVAHs 
along with CuCl2 are listed in table 4.6. The anodic peak potential and the cathodic 
potential for the pyruvate hydrazone copper complexes are observed in the range of 
0.23 V-0.25 V and 0.41-0.52 V at a scan rate of 100 mV (table 4.6). However, in 
case of CuCl2, the potentials are observed at 0.22 V and 0.53 V, respectively. The 
larger range for cathodic peak potentials (0.41-0.52 V) is due to the broadness of 
the peak associated with Cu2+→ Cu1+. The anodic peak potential assigned to Cu1+→ 
Cu2+ for CuCl2 in DMSO falls below 0.20 V when compared with pyruvate hydrazone 
copper complex. Hence, it is quite evident that the ligand environment around the 
Cu(II) centres in free Cu ion (CuCl2) and the Cu(II) complexes of PVAHs is not 
same.                                                                                                                                                                                                                            
 Most of the studied copper complexes give similar Epa values at a particular 
scan rate and these differ significantly from that of CuCl2. Hence, the redox 
potentials of the Cu(II) complexes of investigated PVAHs are similarly affected by 
their surrounding ligand system and the different substituents on the aromatic ring of 
the PVAHs does not have significant influence on the electrode potentials. Similar 
observations were reported by Tas and group, where the E1/2 values of copper 
Schiff base complexes were independent of substituents on the aromatic ring, falling 
in the range 0.86 - 0.88 V vs SCE in DMSO.274  
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Table 4.6: Epa and Epc values for copper complexes at a scan rate of 100 mV s-1 
reported versus SCE 
Molecular 
formula 
R Epa (V) Epc (V) 
Cu(II)Cl2.2H2O  0.18 0.49 
[Cu(II)L1(H2O)2] H 0.23 0.39 
[Cu(II)L3(H2O)2] m-OH 0.23 0.41 
[Cu(II)L10(H2O)2] m-Br 0.23 0.41 
[Cu(II)L12(H2O)2] m-OCH3 0.23 0.44 
[Cu(II)L21(H2O)2] Heterocyclic N at 2,5 0.23 0.39 
[Cu(II)L8(H2O)2] p-NO2 0.23 0.42 
[Cu(II)L9(H2O)2] p-CH3 0.25 0.52 
On the other hand, Chen and group found that the electron withdrawing nitro 
group and the electron donating methyl group significantly affects the copper centre 
electrode potentials. The electrochemical properties of square pyramidal Cu(II) 
Schiff base complexes containing 2-aminopyridine-2-aminobiphenyl (N3O-mpy) 
ligand (figure 4.22)  were investigated against in acetonitrile Ag/AgCl electrode. The 
E1/2 values for the quasi-reversible peak potentials for the Cu2+/ Cu1+ wave for 
complex-1 (with CH3)  0.24 V, whereas for complex -2 (NO2) it is 0.54 V against 
SCE .275 While, the E1/2 values for Cu(II) complexes of PVAHs are 0. 32 V (CH3) and 
0.38 (NO2). The smaller change observed in case of Cu(II) complexes of PVAHs as 
compared to Cu(II) complexes of N3O-mpy can be attributed to ligand system or 
electrochemical solvent used. 
N
N
H
N
X
OH
 
X= CH3, NO2 
Figure 4.22: Structure of 2-aminopyridine-2-aminobiphenyl (N3O-mpy) 275 
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Due to the similarity of the Cu-centred redox processes in the complexes 
under investigation, further studies were required to ascertain the identity and 
confirm the stability of the complexes in DMSO solution. Hence, electron 
paramagnetic resonance (EPR) studies were carried out on selected Cu(II) 
complexes of PVAHs which will be discussed further in the following section. 
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4.3 Electron Paramagnetic Resonance (EPR) studies: 
Cu(II) contains one unpaired electron in the 3d shell, with S = ½, hence it is 
suitable for EPR spectroscopy.  The spectra discussed below were recorded in 
frozen DMSO at 77K and were referenced against the standard 
diphenylpicrylhydrazyl (DPPH) radical at a concentration of 1 mM. The EPR data of 
frozen solutions of selected complexes, [Cu(II)L8(H2O)2], [Cu(II)L13(H2O)2], 
[Cu(II)L16(H2O)2], [Cu(II)L14(H2O)2] were compared with the spectra of CuCl2 and 
CuSO4  recorded under the same conditions. 
4.3.1 EPR spectra of CuSO4 and [Cu(II)L14(H2O)2] 
63,65Cu(II), has nuclear spin quantum number (I) of  3/2, hence it should give 
rise to 4 hyperfine splittings, as given by 2nI+1.276 This is true for Cu(II) complexes 
when there are no interactions with the neighbouring atoms and is observed for 
CuSO4 and CuCl2. The EPR spectrum of CuSO4 is given in Figure 4.23. Whereas, 
in case of the studied Cu(II) complexes of PVAHs the spectra only show three lines. 
The EPR spectrum of [Cu(II)L14(H2O)2] is shown as a representative example in 
figure 4.24. The spectrum indicates coordination of the Cu(II) centre to the donor 
atoms of PVAHs. 
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Figure 4.23: X-band EPR spectrum of a frozen solution of CuSO4 in DMSO 
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Figure 4.24: X-band EPR spectrum of a frozen solution of [Cu(II)L14(H2O)2] in 
DMSO 
4.3.2 Comparison of EPR spectra of investigated Cu(II) complexes of PVAHs 
The overlaid spectra of Cu(II) complexes of ligands NaHL8, NaHL13, 
NaHL14 and NaHL16 are shown in figure 4.25. It is evident that electron donating or 
electron withdrawing substituents do not have a significant effect on the Cu(II) 
centre, resulting in similar EPR spectra. [Cu(II)L16(H2O)2] gives a less intense 
spectrum as compared to other three complexes. This can be due to the 
precipitation of the complex in the polar aprotic DMSO solution as it possesses 
hydrophobic tertiary group on the aromatic ring. 
The EPR parameters g║ and g⊥ can be calculated using the equation, g = 
hν/ (ßH), where h is the Planck constant, ν is the microwave frequency at which the 
EPR machine operates , H is the resonance magnetic field (G) and ß is the Bohr 
magneton. A║ is the distance between two parallel peaks as shown in figure 4.24, 
whereas A⊥ cannot be determined as the peaks were not very well resolved for 
perpendicular lines.   
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Figure 4.25: Overlaid X-band EPR spectra of [Cu(II)L8(H2O)2], [Cu(II)L13(H2O)2], 
[Cu(II)L16(H2O)2], [Cu(II)L14(H2O)2] 
The EPR parameters (A║, g║ and g⊥ value) are listed in table 4.7. It can be 
seen that both CuSO4 and CuCl2 have a value of g║ ≥ 2.3, whereas for the 
complexes under study the value g║ < 2.3. Kivelson and co-workers have reported 
that the compounds having g║ ≥ 2.3 are ionic in nature, while those with g║ < 2.3 
have covalent character277. In addition the EPR parameters for CuSO4 and CuCl2 
are very similar, which might be due to formation of CuXDMSO (X=Cl/ SO4) 
solvated species in DMSO278.  
It is established that, the hydrazones hydrolyse under extreme acidic 
conditions, which may lead to decomplexation of the copper. This was also reflected 
in the EPR spectra of [CuL13(H2O)2] at acidic pH < 1.5. In acidic pH, the spectra 
started to shift towards free Cu (CuSO4) as indicated in figure 4.26. Furthermore, 
the g and A values are similar to those of CuCl2 and CuSO4, which indicates that the 
DMSO coordinates to the free Cu(II) ion once its released from the ligand. In order 
to throw more light on the stability of the copper complexes, detailed investigation of 
selected PVAHs and their copper complexes at different pH conditions is discussed 
in chapter-5. 
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Figure 4.26: Overlaid X-band EPR spectra of CuSO4 (red), [Cu(II)L13(H2O)2] 
(green), and [Cu(II)L13(H2O)2] at pH < 1.5 (black) 
 
The EPR parameters of Cu(II) complexes listed in table 4.7 are in consistent 
with the reported literature values for Cu(II) Schiff base complexes.279-280 The 
expected g value for a free unpaired electron is 2.0023. Deviation of g value from 
2.0023 in metal complexes indicates the coupling of metal orbital’s containing 
unpaired electron with either filled or empty ligand orbitals involved in molecular 
orbitals. 
                                                                                                        Chapter – 4  
 
 
175 
Table 4.7: EPR data for selected for selected Cu(II) complexes of PVAHs 
Complex R g⊥ g║ A║ x 10-4 
cm-1 
f(α) 
cm 
[CuL8(H2O)2] p-NO2 2.062 2.273 159 143 
[CuL16(H2O)2] p-tert-
butyl 
2.077 2.293 161 142 
[CuL14(H2O)2] p-CF3 2.068 2.275 159 143 
[CuL13(H2O)2] p-OCH3 2.064 2.279 160 142 
[CuL13(H2O)2] at 
pH >1.5 
p-NO2 2.083 2.360 132 179 
CuSO4 - 2.083 2.400 129 186 
CuCl2 - 2.090 2.400 127 189 
Furthermore, g║ > g⊥ > 2 indicates a tetragonally elongated Cu(II) complex 
which is expected due to Jahn-Teller distortion along the z axis.281 X-ray crystal 
structures of square pyramidal Cu(II) complexes discussed in chapter-3 gives a 
evidence in the solid state structure, where the apical coordinate bond distance is 
considerably longer than the basal Cu-O/N bond distances. In addition, g and A can 
also be useful in elucidating the degree of tetrahedral distortion of square planar 
complexes in solution. The degree of distortion is given by the equation 4.7. 
f(α) = (g║/ A║)……..(4.7) 
For ideal square planar complexes the values lies in the range 110-120 cm, 
while 130-150 cm indicates slight to moderate distortion and 180-250 cm signifies 
large distortion. The values for Cu(II) complexes PVAHs is around 150, which 
indicates that, there is a moderate distortion from the planar complex due to rigidity 
of the tridentate hydrazone ligand. However, for copper salts (CuSO4 and CuCl2) it 
is ∼ 200 cm-1 which implies that the copper salts show considerable distortion which 
may be accounted to the flexibility of monodentate ions (Cl-, SO42-, solvent).282  
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4.4 Summary of Chapter 4 
The investigated PVAH ligands are redox inactive except for NaHL8, which 
exhibits reversible redox peaks corresponding to the -NO2 subsituent. The 
electrochemical studies indicate that there are copper centred redox processes 
corresponding to the conversion of Cu(II) to Cu(I) and vice-versa. Peaks 
corresponding to Cu1+/Cu0 have also been observed, where the investigated Cu(II) 
complexes are reduced to Cu(0), through the Cu(I) intermediate. The redissolution 
of Cu(0) deposited on the electrode surface leads to higher anodic peak current as 
compared to its corresponding cathodic peak current. The corresponding peaks are 
observed in both the Cu(I) and Cu(II) complexes, but they are more well defined in 
case of the Cu(I) complexes.  
The ∆E value of Cu(I) and Cu(II) complexes corresponding to Cu2+/Cu1+ 
indicates quasi-reversible behaviour and also the additional multiple peaks 
observed may be accounted to the presence of more than one species present in 
solution. This is likely due to structural reorganisation taking place within the 
coordination sphere whilst changing from a Cu(II) square-pyramidal to a tetrahedral 
Cu(I) complex geometry. The Epa values of Cu(II) complexes indicate that the PVAH 
ligand affects the metal-based redox peaks, irrespective of subsituent on the 
aromatic ring. 
Similarly, the EPR parameters, A║, g║ and g⊥ are similar for studied Cu(II) 
complexes of PVAHs, but distinct from ‘free’ Cu(II) ions (CuCl2, CuSO4). Hence, it 
can be concluded from the EPR studies that the ligands remain bound to the Cu(II) 
centre, even though there is large excess of DMSO present in solution.  
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5.0 Stability studies and Antitubercular activity 
5.1 Introduction 
 Pyruvate hydrazones (PVAHs) and their metal complexes have been 
extensively studied in the past for their coordination properties,227,229,283-285 however, 
little is known about their antitubercular activity. Recent computational studies have 
illustrated that pyruvate hydrazones may inhibit the active site of isocitrate lyase of 
M. tuberculosis (Mtb).84 As discussed in chapter-1, several hydrazones derived from 
other aldehydes/ketones and their respective metal complexes have previously 
been investigated for their potential activity against Mtb.78,80-81,85-87  
The presence of O, N and S donor sites in these hydrazone ligands allows 
the chelation to essential metal ions thereby disrupting physiological processes 
relying on these essential metal ions in bacteria. For example sequestration of 
Fe(III) or Fe(II) can lead to iron starvation in bacteria.79 Metal-containing 
antitubercular agents have been reported to possess excellent antimycobacterial 
activity, with some complexes even retaining activity against resistant strains.286 
Since certain bacterial resistance mechanisms are modulated by intracellular 
oxidative stress,41 the redox activity of the metal centres of metallodrugs is 
significant. 
This chapter describes the testing of pyruvate hydrazones (PVAHs) and their 
Cu(II) and Zn(II) complexes against Mtb. grown in Middlebrook 7H9 medium. All the 
antitubercular studies discussed in this chapter were done by Dr. Manjula 
Sritharan’s research group at the Department of Animal Sciences, University of 
Hyderabad, India. Furthermore, the compounds exhibiting promising antitubercular 
activities in terms of low minimum inhibitory concentration (MIC) values were further 
screened under high iron (8 µg Fe(II)/mL) and low iron (0.02 µg Fe(II)/mL) 
conditions.  
As discussed in chapter-2, the azomethine bond in hydrazones is more 
prone to hydrolysis under extreme acidic and basic conditions. In acidic conditions, 
the nitrogen of the azomethine bond becomes protonated, which makes the carbon 
more susceptible to the attack by a water molecule and in turn cleaves the C=N 
bond. In basic conditions, the electrophilic azomethine carbon can be attacked by a 
nucleophile (OH-) which makes it prone to hydrolysis. In order to gain insight into the 
stabilities of the compounds in aqueous solution, their UV-visible spectra were 
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recorded at a range of pH values. Moreover, the stability of the compounds was 
also examined in PBS (phosphate buffered saline) whilst maintaining the solution at 
37 ° C and at the biological pH of 7.4, which could po ssibly allow a comparison with 
physiological conditions in human plasma. 287 
5.2 Stability studies of PVAHs and CAHs and their metal complexes 
at different pH 
A drug can be administered into the body using different routes, including 
oral, injection, epithelial and inhalation. The preferred method is usually oral 
administration of a drug, which involves passing the drug through the 
gastrointestinal tract (GIT) consisting of mouth, throat, stomach and intestines. The 
pH varies at different parts of the body, for example in the mouth the pH of saliva is 
slightly acidic to neutral (pH 6.5 to pH 7.5). In the lower stomach it is extremely 
acidic (pH 1.5), whereas in the intestines the pH ranges from pH 5 – 7. Oral 
bioavailability then refers to the fraction of the orally taken drug reaching the blood 
(pH 7.4). Bioavailability is the term used in drug pharmacokinetics, which implies the 
concentration of a drug reaching the blood supply after absorption, distribution, 
metabolism and excretion, collectively abbreviated as ADME.288 Hence, the stability 
of a compound at different pH plays an important role in drug discovery.  An orally 
effective drug should be stable at the extremely low pH of the stomach; hence the 
stability of a compound under different pH conditions plays a vital role in deciding 
the mode of administration of a drug.  
Hydrazones of biological relevance have been investigated before in order to 
determine their pKa values and stability towards hydrolysis in basic and acidic 
conditions. UV-Vis studies conducted by Richardson et al. indicate that the rate of 
hydrolysis of pyridoxal isonicotinic hydrazone (PIH) and pyridoxal benzoyl 
hydrazone (PBH) occurs at a faster rate in extreme acidic and basic conditions, 
whereas it is very slow in neutral pH.289 Potentiometric titrations revealed that the 
pKa of the amide proton of these hydrazones varies from 9.94 to 11.40, depending 
on the R group present in the respective hydrazone.290 These type of ligands can 
strongly bind to Cu(II), for example the formation constant (Kc) of the Cu(II)-
salicaldehyde acetylhydrazone complex is reported to be 16.2, as expected for a 
Cu(II) complex of a tridentate ligand.291    
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PVAHs, CAHs and their metal complexes are designed for their 
antitubercular potential, hence it is essential to investigate the stability of these 
compounds. Therefore, the behaviour of selected compounds from the PVAH, CAH 
series, mainly those which exhibited potential antitubercular activity, were 
investigated at different pH. The change was monitored using UV-visible absorption 
spectroscopy. As discussed above, hydrazones hydrolyse at a faster rate at 
extremely low and high pH, hence two sets of titrations were performed. The 
compounds under investigation (0.05 mM for PVAHs and 0.02 for CAHs) were 
dissolved in water and were titrated with 0.01 M HCl (acid titration) and 0.01 M 
NaOH (base titration) and the spectral changes were recorded manually using a 
UV-vis spectrophotometer at regular intervals. Experimental details of the UV-vis 
studies can be found in chapter-7. However, for those compounds which exhibited 
limited solubility in water, a mixture of solvents (DMSO/MeOH: H2O) were used. 
5.2.1 Stability studies of NaHL20 and its Cu(II) and Zn(II) complexes 
NaHL20 and its respective Cu(II) and Zn(II) complexes were investigated for 
their stability in water at pH values ranging from 1 to 12. Overlaid UV spectra of 
NaHL20 and its respective Cu(II) and Zn(II) complexes along with the starting 
material, pyrazinoic acid hydrazide, are depicted in figure 5.2, whereas the 
corresponding structures are provided in figure 5.1. The spectra were recorded in 
HEPES buffer at pH 7.4 with concentration of 0.05 mM. 
N
N
N
H
O
NH2
 
a) Starting hydrazide 
N
N
N
H
O
N
OONa
 
b) Hydrazone (NaHL20) 
 
N
N
O
N
N O
O
Cu
H2O OH2
 
c) [Cu(II)L20(H2O)2] 
N
N
O
N
H
N O
O
Zn
N
N
O
N
H
N
O
O
 
d) [Zn(HL20)2] 
Figure 5.1: Structures of a) the starting hydrazide b) the hydrazone NaHL20 c) the 
Cu(II) complex and d) the Zn(II) complex of NaHL20 
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Both the hydrazone (NaHL20) and its starting hydrazide (pyrazinoic acid 
hydrazide) exhibit two distinct bands at 212 nm and 270 nm. The absorption 
maxima (λmax) for the electronic transitions observed at 212 nm for NaHL20 (ε= 19.5 
x 103 dm3 mol-1 cm-1) and pyrazinoic acid hydrazide (ε= 11.2 x 103 dm3 mol-1 cm-1) 
can be assigned to pi-pi* transitions. The higher absorption coefficient of NaHL20 
may result from the greater pi-conjugation of the hydrazone due to the additional 
azomethine bond (C=N) compared to the hydrazide. Furthermore, the band at 270 
nm can be attributed to pi-pi* transitions of the C=O bond in the hydrazide (ε= 9.98 x 
103 dm3 mol-1 cm-1). The resultant broad band at 270 nm in NaHL20 can be 
assigned to overlapped C=N and C=O pi-pi* transitions (ε= 15.7 x 103 dm3 mol-1 cm-
1).  
 
Figure 5.2: Electronic absorption spectra recorded for hydrazide (black spectrum), 
NaHL20 (red spectrum) and its Cu(II) (green spectrum) and Zn(II) complex (red 
spectrum) in HEPES buffer at pH 7.4 and a concentration of 0.05 mM 
In the spectrum of the Zn(II) complex, [Zn(II)(HL20)2)] (blue spectrum, figure 
5.2), two absorption bands attributed to pi-pi* transitions were observed at 268 nm 
(ε= 7.45 x 103 dm3 mol-1 cm-1) and 324 nm (ε= 13.5 x 103 dm3 mol-1 cm-1). Although, 
the pi-pi* transitions at 268 nm exhibits a slight blue shift as compared to NaHL20 
(270 nm), the pi-pi* transitions show a small red shift and appear at 215 nm (ε= 13.5 
x 103 dm3 mol-1 cm-1).6 In the Cu(II) complex, [Cu(II)L20(H2O)2] (green spectrum, 
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figure 5.2), an additional moderately intense band is observed at 346 nm (ε= 5.01 x 
103  dm3 mol-1 cm-1), which might be due to ligand to metal charge transfer (LMCT) 
transitions and can be assigned to O→Cu(II), which is usually observed in copper 
Schiff base complexes.7, 8 Moreover, Cu(II)L20(H2O)2 exhibits similar pi-pi* transitions 
at 270 nm (ε= 13.3 x 103  dm3 mol-1 cm-1) to that of NaHL20.  
5.2.2.1 Stability studies of NaHL20 at different pH 
NaHL20 (0.05 mM) dissolved in water, exhibits the absorption maximum 
(λmax) at   270 nm (ε= 11.46 x 103 dm3 mol-1 cm-1) as depicted in figure 5.3. The 
absorbance at 270 nm was monitored in order to investigate the stability of NaHL20 
in solution as this electronic absorption band is associated with pi-pi* of azomethine 
bond as discussed above. A change of pH from 4.34 to 1.48 does not seem to have 
a significant effect on the position of the ligand absorption band, as seen in figure 
5.3. As the absorption maximum of the pi-pi* transitions band for the parent 
hydrazide and its respective hydrazone are similar, it cannot be accurately 
determined from the band position when hydrolysis occurs. Additionally, the 
hydrolysis may also occur when dissolved in water, as water triggers the hydrolysis 
reaction. 
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Figure 5.3: Electronic absorption spectra recorded for NaHL20 during acid titration 
using 0.01 M HCl in the pH range 1.4-4.4 
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However, as can be seen from figure 5.3, there is a decrease in the intensity 
of the band at 270 nm as the pH is lowered (pH 1.48, figure 5.3). In addition, the 
broad band tends to get narrower going towards extreme acidic conditions 
comparable to parent hydrazide. This indicates hydrolysis at low pH. The compound 
remains hydrolysed even after back titrating to extreme basic pH 10.58 (dashed 
spectrum 10.58B, figure 5.3) indicating an irreversible process. To gain more insight 
into hydrolysis of NaHL20, a plot of absorbance at 300 nm is illustrated in figure 5.4. 
The decrease in the absorbance values at 300 nm towards acidic pH values (pH 
4.33 → pH 1.98) indicates hydrolysis of NaHL20 to the starting hydrazide. 
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Figure 5.4: Titration curve obtained for NaHL20 at 300 nm during acid titration in the 
pH range 1.4-4.4 
NaHL20 was also investigated under basic conditions. The spectra recorded 
with increasing pH (basic) are shown in figure 5.5, which indicates that there is not a 
significant change in the overall shape of the UV spectra up to a pH of 
approximately 10. 
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Figure 5.5: Electronic absorption spectra recorded for NaHL20 during base titration 
using 0.01 NaOH in the pH range 4.3-11.6 
The absorbance at 310 nm tends to increase with increase in pH above pH 
10, as indicated in figure 5.6. However, the original spectra is regained when the 
solution is back titrated to 5.73 (dashed spectrum 5.73B, figure 5.5). This indicates 
that the chemical process is reversible and may be associated with the 
deprotonation of the hydrazone. The pKa of  the amide proton (N-H) is around 11 
and is consistent with the literature. 290 
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Figure 5.6: Titration curve obtained for NaHL20 at 310 nm during base titration 
using 0.01 NaOH in the pH range 4.3-11.6 
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It can be concluded that NaHL20 undergoes irreversible hydrolysis in 
aqueous solution below pH 4, whereas it remains stable under basic conditions. 
These observations confirm earlier reports on hydrolysis under acidic conditions.289 
Moreover, hydrazones with N as heteroatom and also those with electron-
withdrawing groups on the aromatic ring undergo hydrolysis at a faster rate than 
other hydrazones possessing electron donating group. This was illustrated by Buss 
and Ponka180, where they studied the stability of acyl hydrazones in PBS buffer at 
pH 7.4 and 37 °C. Hydrazones possessing an isonicotinic ring (PIH) exhibit rate of 
hydrolysis at 8.2 x 103 min-1. While the hydrazone possessing benzoyl hydrazone 
ring (PBH) have a rate constant of 2.1 x 103 min-1. This is due to the electron 
withdrawing effect of the pyridine ring, which is expected to decrease electron 
density on the imine carbon atom through the highly conjugated system.  
The hydrolysis occurs at C=N imine bond, as confirmed by Raines and his 
group.182 Raines et al. also observed that the rate of hydrolysis is very slow at pH 7. 
The mechanism of hydrolysis of PVAHs is given in scheme 5.1. The reaction is 
initiated by the addition of a proton to the azomethine nitrogen, followed by an 
attack of a water molecule on the electrophilic azomethine carbon. The reaction 
gives rise to the starting materials sodium pyruvate and hydrazide via the formation 
of a hemiaminal intermediate and can be classified as a reversible mechanism. 
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Scheme 5.1: Mechanism for hydrolysis of PVAHs182 
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5.2.1.2 Stability of the [Cu(II)L20(H2O)2] at different pH 
The stability of the Cu(II) complex of NaHL20, [Cu(II)L20(H2O)2], was also 
investigated at a range of different pH values. The band with absorption maximum 
(λmax) at 346 nm at pH 5.80, decreases in intensity whilst titrating from pH 5.8 to 
pH 2.46, as shown in figure 5.7. This decrease might be due to the dissociation of 
the copper complex.  
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Figure 5.7: Electronic absorption spectra recorded for [Cu(II)L20(H2O)2] during acid 
using 0.01 HCl titration in the pH range 5.7 –2.4 
 A back titration from pH 2.46 to pH 5.78 (dashed spectrum 5.78B, figure 
5.7) was performed. The spectra taken at 5.78 resembles to that of obtained  at pH 
2.46 which confirms that the copper complex remains dissociated once acidified. 
This can be accounted to the hydrolysis of the ligands followed by decomplexation 
of copper complex. As the ligand hydrolysis is irreversible, as can be gathered from 
the NaHL20 pH studies, the dissociation of [Cu(II)L20(H2O)2], which may be 
associated with the hydrolysis of the ligand can also be classified as an irreversible 
process. 
Whilst titrating towards basic pH the overall shape of the UV spectra 
changes only little, as can be seen from figure 5.8. This indicates that the complex 
seems to be fairly stable even in extreme basic conditions. 
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Figure 5.8: Electronic absorption spectra recorded for [Cu(II)L20(H2O)2] during 
titration with using 0.01 M NaOH base in the pH range 5.9 –12.2 
Hence, it can be concluded that [Cu(II)L20(H2O)2] is unstable in acidic 
media, whereas it remains stable in basic conditions as indicated by the titration 
curve (figure 5.9) plotted for the absorbances in the pH range 2.4 – 12.3 at 346 nm. 
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Figure 5.9: Titration curve obtained for [Cu(II)L20(H2O)2]  at 346 nm in the pH range 
2.4-12.3 
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5.2.1.3 Stability studies of [Zn(HL20)2] at different pH 
A similar trend is observed for the Zn(II) complex of NaHL20. [Zn(II)(HL20)2)] 
dissociates under acidic conditions, but is stable in basic conditions. As indicated in 
figure 5.10, the spectrum recorded at pH 1.14, closely resembles that of the starting 
hydrazide. This is consistent with the behaviour observed for [Cu(II)L20(H2O)2] and 
can be accounted for the hydrolysis of NaHL20 followed by decomplexation of the 
zinc complex. 
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Figure 5.10: Electronic absorption spectra recorded for [Zn(II)(HL20)2)] in the pH 
range 1.4-11.9 
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5.2.2 Stability studies of NaHL9 
The stability of NaHL20 cannot be clearly determined from pH studies due to 
the similarity of the λmax values of the ligand and the starting hydrazide. Therefore, 
in order to get more insight into the stability of PVAHs, acid and base titrations were 
performed with NaHL9 instead. The titrations were also performed in water at a 
concentration of 0.05 mM. The λmax for the electronic absorption band of NaHL9 is 
observed at 269 nm as indicated in figure 5.11 (ε= 15.7 x 103 dm3 mol-1 cm-1) and 
may be attributed to overlapping C=N and C=O, pi-pi* transitions. The band 
decreases in intensity with the emergence of a new band at 243 nm upon titration 
from pH 5.7 to 3.5. The spectrum recorded at pH 3.5 closely resembles the 
spectrum of the starting hydrazide, which suggests the hydrolysis of NaHL9 to the 
starting hydrazide. This was confirmed by performing a back titration to pH 5.6, 
(dashed spectrum 5.60R, figure 5.11) which resulted in the same band remaining, 
proving the instability of the ligand under acidic conditions.  
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Figure 5.11: Electronic absorption spectra recorded for NaHL9 during acid titration 
using 0.01 M HCl in the pH range 3.5-5.6 
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In order to investigate the stability of NaHL9 in basic conditions, titrations 
were performed under similar conditions as use for the acid titrations. The same 
stock solution was used for basic titration which was used for the acid titration. The 
spectrum obtained at pH 5.80, figure 5.12, shows two bands at 269 nm and 243 nm, 
respectively. As discussed earlier, the band at 243 nm is characteristic for the 
starting hydrazide. This may be due to slow hydrolysis of NaHL9, since the base 
titrations were performed 2 hours after the acid titrations. From the figure 5.12, it 
can be noticed that the λmax at 270 nm does not shift significantly even going up to 
pH 11.6 indicating stability of the compound in basic conditions. Although, for the 
ligand NaHL9 hydrolysis occurs at a faster rate in acidic conditions, it remains fairly 
stable in basic pH. However, there is a slight decrease in the intensity of the bands 
with an increase in the intensity at 310 nm with an increase in pH, which may be 
associated with the pKa of the ligand. As can be seen from the figure 5.12, the 
isosbestic point for this change is observed at 290 nm. The titration curve obtained 
for NaHL9 at 270 nm in the pH range 3.5 – 12.0 is shown in figure 5.13. 
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Figure 5.12: Electronic absorption spectra recorded for NaHL9 during base titration 
using 0.01 M NaOH in the pH range 5.8-11.6 
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A similar observation is discussed above for NaHL20. Back titrating to pH 
2.90 (spectrum 2.90R, figure 5.12) results in the decrease of band at 310 nm and 
leads to hydrolysis of the ligand as the band at 264 nm, corresponding to the 
starting hydrazide, becomes more prominent. It can be concluded that NaHL9 
undergoes hydrolysis in acidic conditions, which is confirmed by back titrating to pH 
11.60 (spectrum 11.60R, figure 5.12), as it remains hydrolysed at pH below 4.  
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Figure 5.13: Titration curve obtained for NaHL9 at 270 nm in the pH range 3.5-11.6 
Hence, from the pH studies described above it can be concluded that PVAH 
ligands and their Cu(II) and Zn(II) complexes are fairly stable in basic conditions, but 
undergo hydrolysis under acidic conditions. 
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5.3 Stability studies of  CAHs at different pH 
5.3.1 Stability of HCA1  
Due to the limited solubility of CAHs in aqueous solution, a 0.02 mM solution 
of HCA1 in a mixture of methanol: water (4:1) was titrated between pH 1.8 - 11.2. 
However, using a mixture of solvents does not provide a pH value that is directly 
comparable with a pH value measured in aqueous solution, but the results of the 
study in the mixed solvent system can provide a rough estimate of the stability of 
the compounds. The UV-vis spectra from these titrations are shown in figure 5.14. 
The λmax is observed at 323 nm and can be attributed to overlapping pi-pi and pi-pi* 
transitions of the C=O and C=N bonds292. The starting reactants of HCA1, 
cinnamaldehyde and hydrazide gave a λmax values at 287 and 264 nm, respectively.  
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Figure 5.14: Electronic absorption spectra recorded for HCA1 in the pH range of 1-
12 
With increasing pH, there is a decrease in the intensity of the maximum 
absorption band observed at 323 nm. Above pH 11, there is a significant decrease 
of the band at 323 nm with an additional band appearing at 360 nm, which goes 
  Chapter – 5   
 193 
back to the original spectra when back titrated to pH 6.50 (spectrum 6.50B, figure 
5.14). The plot of absorbances at 360 nm with varying pH (1.5 – 12.0) is indicated in 
figure 5.15. This reversible process can be associated with the deprotonation of the 
amide proton (N-H) of HCA1, similarly discussed previously for PVAHs. Unlike 
PVAHs, no permanent new bands corresponding to the starting material appear 
with the change in pH, indicating that HCA1 is stable under acidic and basic 
conditions.  
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Figure 5.15: Titration curve obtained for HCA1 at 360 nm in the pH range 1.5-12.0 
The reason why HCA1 appears to be more stable in acidic conditions than 
the investigated PVAHs, may be due to the increased conjugation present in HCA1. 
This extra conjugation reduces the electrophilicity on the azomethine carbon, hence 
making it less favourable for the attack of water which in turn prevents hydrolysis. 
Kali and Raines illustrated that hydrazones exhibit greater hydrolytic stability than 
imines due to their ability to delocalise electron density through multiple resonance 
forms.182 
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5.3.2  Stability studies of HCA5 
Similarly, HCA5 was found to be stable in both acidic and basic conditions. 
In order to investigate the longer-term stability of HCA5 at pH 1.78, the UV-visible 
spectrum was recorded after 5 hours. There is a significant reduction in the intensity 
at the λmax of 329 nm (ε= 20.87 x 103 dm3 mol-1 cm-1) as indicated in figure 5.16. 
With a further increase in time, there is progressive reduction in intensity of the 
corresponding band and a new broad band appear ats 289 nm (ε= 14.40 x 103  dm3 
mol-1 cm-1) (spectrum pH 1.78, 48 hours, figure 5.16). The new band is very similar 
to that of cinnamaldehyde (287 nm). This indicates that HCA5 is prone to hydrolysis 
under acidic conditions at pH 1.78 over the time monitored and converts back to the 
starting materials used in its synthesis, cinnamaldehyde and hydrazide. 
Cinnamaldehyde was shown to have a higher molar absorption coefficient than the 
starting hydrazide. Hence, the λmax of the hydrazide is likely to be masked by that of 
cinnamaldehyde.   
260 280 300 320 340 360 380 400
0.0
0.1
0.2
0.3
0.4
0.5
Ab
so
rb
a
n
ce
Wavelength (nm)
 pH 7.15
 pH 6.40
 pH 4.60
 pH 3.98
 pH 3.34
 pH 2.85
 pH 2.14
 pH 1.78
 pH 1.78, 
          5 hours
 pH 1.78, 
         48 hours
 
Figure 5.16: Electronic absorption spectra recorded for HCA5 during acid titration 
using 0.01 M HCl in the pH range of 7.1-1.7 
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The hydrolysis of HCA5 in acidic pH over time led to the further investigation 
of the behaviour of an acidic solution of HCA1 over time. The UV-visible spectrum of 
a solution HCA1 at a pH of 1.5 was recorded at regular intervals for a period of 48 
hours. However, there was no significant change in the spectra over this time 
period. This indicates that HCA1 is even more hydrolytically stable than HCA5 
under acidic conditions. The instability of HCA5 can be due to the electron 
withdrawing effect of the NO2 substituent on the aromatic ring. This makes the 
azomethine carbon more electrophilic and susceptible to attack by H2O. HCA1 does 
not possess an EWG on the aromatic ring and is thus more stable. This is in line 
with the observation made by Buss and Ponka in that the hydrazones possessing 
EWGs accelerates the rate of hydrolysis when compared to those having EDGs.180  
The reduced form of HCA1 (HCA1R) indicated in scheme 5.2, in which the 
olefin bond was reduced as discussed in chapter-3, was also tested for its stability 
at acidic pH under similar conditions. A solution of HCA1R was titrated to pH 1.5 
with  using 0.01 M HCl and its UV-visible spectrum was monitored over time. 
Although HCA1 was stable over a period of 48 hours, its reduced form HCAR1 had 
hydrolysed after 4 hours. The instability of HCAR1 may be due to loss of 
conjugation within the molecule resulting in restricted delocalisation of electrons 
across the reduced species. 
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Scheme 5.2: Reduction of HCA1 at olefin bond resulting in HCA1R 
The base titrations of HCA5 indicate that there is an additional band at 390 
nm, the intensity of which increases whilst the intensity at 330 nm decreases, as 
indicated in figure 5.17. Moreover, back titration to pH 7.14 (spectrum 7.14 B, figure 
5.17) leads to complete disappearance of the band at 390 nm and the band at 330 
nm (ε= 17.42 x 103 dm3 mol-1 cm-1) is restored, similar to the observations made for 
HCA1. The titration curve obtained for HCA5 at 390 nm is depicted in figure 5.18. 
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 Figure 5.17: Electronic absorption spectra recorded for HCA5 during base titration 
using 0.01 M NaOH in the pH range of 7.1-12.31 
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Figure 5.18: Titration curve obtained for HCA5 at 310 nm in the pH range 2.1 – 12.3 
 As discussed previously for HCA1, this reversible process can be attributed 
to the deprotonation of amide proton of HCA5 with a rough estimation of a pKa of 11 
as expected for acyl hydrazones.290 It can also be noted that deprotonation of the 
amide proton in HCA1 starts above pH 11, whereas for HCA5 it begins around 10. 
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This can be attributed to the strong electron withdrawing nature of the nitro 
substituent in HCA5 as compared to the phenyl ring of HCA1. The nitro group 
withdraws electron density making the amide proton more susceptible to 
deprotonation by stabilising the resulting negative charge. 
5.3.3 Stability of Cu(II) complexes of CAHs 
The Cu(II) complexes of CAHs also showed poor water solubility, hence 
their stability was investigated in a 4:1 (DMSO:H2O) mixture. Initially, a solution 
containing 0.02 mM of [Cu(CA1)2] was titrated towards acidic pH, from pH 7.95 to 
pH 2.40. The UV-visible spectra as displayed in figure 5.19 show a broad absorption 
band between 300 – 410 nm with a λmax at 365 nm and another prominent 
absorption at 382 nm. These absorptions can either be attributed to the ligand-
based pi-pi* transitions, which undergo a red shift upon complexation as  compared 
to the free ligand HCA1 (330 nm) or can be assigned to a LMCT band of the Cu(II) 
complex.   
As soon as acid is added to the solution, the two absorption bands at 365 
nm and 382 nm decrease in intensity, whilst a new band at 330 nm emerges. With 
further lowering of the pH, the band at 330 nm increases in intensity, whilst there is 
a decrease in absorbance for the bands at 382 nm and 365 nm. This process can 
be associated with the dissociation of [Cu(CA1)2]. Below pH 4 the absorption bands 
assigned to the copper complex have nearly disappeared, indicating that both 
ligands have been released from the Cu(II) centre. A back titration was performed to 
basic pH 10.24 (spectrum pH 10.24 back, figure 5.19) during which the bands at 
382 nm (ε= 15.3 x 103 dm3 mol-1 cm-1) and 365 nm (ε= 16.0 x 103  dm3 mol-1 cm-1) 
reappeared. On the other hand, the absorbance at 330 nm decreased in intensity 
suggesting re-formation of the [Cu(CA1)2].  
In contrast, the Cu(II) complex is stable in solution under basic conditions 
(figure 5.20) as no change in the overall shape of the UV-visible spectra is evident, 
similarly observed for Cu(II) complex of PVAH ([Cu(II)L20(H2O)2]). The plot of 
absorbances at 382 nm with varying pH (2.4 – 11.8) for ([Cu(II)L20(H2O)2]) is 
indicated in the figure 5.21. 
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Figure 5.19: Electronic absorption spectra recorded for [Cu(CA1)2] during acid 
titration using 0.01 M HCl in the pH range of 7.9-2.4 
280 300 320 340 360 380 400 420 440
0.0
0.1
0.2
0.3
0.4
0.5
0.6
Ab
so
rb
an
ce
Wavelength (nm)
 pH 8.7
 pH 9.6
 pH 10.1
 pH 10.4
 pH 10.6
 pH 11.0
 pH 11.3
 pH 11.8
 
Figure 5.20: Electronic absorption spectra recorded for [Cu(CA1)2] during base 
titration using 0.01 M NaOH  in the pH range of 8.7-14.0 
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Figure 5.21: Titration curve obtained for [Cu(CA1)2]  at 382 nm in the pH range 2.4 – 
11.8 
The re-formation of the [Cu(CA1)2] complex at basic pH indicates that the 
complex formation is a reversible process, unlike the behaviour observed for the 
Cu(II) complexes of PVAHs. This can be accounted for the hydrolysis of the PVAH 
ligands in acidic solution, whereas CAHs tends to remain stable under acidic 
conditions. The mechanism of decomplexation for the copper complex is thought to 
proceed either via protonation of the amide nitrogen or anionic O atom, hence 
making the ligand neutral which is turn dissociates from the Cu(II) centre as 
indicated in scheme 5.3. The Cu-O bond cannot be maintained and the ligand 
dissociates from the copper complex. 
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Scheme 5.3: Decomplexation of CAH from a Cu(II) complex 
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 Hence, the pH studies of the CAHs investigated and the [Cu(CA1)2] complex 
suggest that the ligand is fairly stable in both acidic and basic conditions for a 
reasonable period of time. CAHs possessing EWG start to undergo hydrolysis at 
acidic pH values below 1.78 during prolonged period of time. The ligand dissociates 
from the Cu(II) centre in acidic conditions, however, reformation of the copper 
complex takes place when titrated back to basic pH 10.28 and the ligand remains 
coordinated even in extreme basic conditions (pH 11.8). 
5.4 Stability studies in PBS buffer 
5.4.1 Stability studies of PVAHs in PBS buffer 
In order to gain further insight into the rates of the hydrolysis of PVAHs and 
their corresponding metal complexes, a selection of compounds was investigated in 
PBS (phosphate buffer saline) buffer over a period of time. PBS is isotonic with 
human plasma and buffer to pH 7.4, hence mimicking the physiological conditions of 
human plasma. These properties make PBS a suitable medium for preliminary 
stability studies of a drug and PBS has been used before to explore the stability of 
related hydrazones.180 Dulbecco’s PBS buffer, purchased from Sigma, was used to 
study the hydrolysis of PVAHs and their metal complexes (0.05 mM) at 37 0C and 
pH 7.4. Stock solutions were made in DMSO and then diluted with PBS buffer 
maintaining a final ratio of 9:1 PBS: DMSO for investigated PVAH compounds. 
However, for compounds of the CAH series, the ratio had to be 5:5 due to their 
limited solubility in PBS buffer. The final 10 ml of solution was incubated in a sample 
tube immersed in a water bath, which was maintained at 37 0C.  The sample tube 
was closed to limit the evaporation of solvent and to provide accurate results.  
Spectral changes of the solution were recorded manually at regular intervals using a 
UV-vis spectrophotometer, as discussed in the following section. Experimental 
details can be found in chapter-7. 
The absorbance at λmax for NaHL11 (p-Br) was monitored at 270 nm (ε= 18.2 
x 103 dm3 mol-1 cm-1), as illustrated in figure 5.22. The associated band may be 
attributed to overlapping C=N and C=O pi-pi* transitions.292 When ligand NaHL11, 
was incubated with PBS buffer at 37 0C over a period of 6 days, a new band at 240 
nm emerged with a simultaneous decrease in the intensity of the band at 270 nm. 
The plot of decay of NaHL9 is indicated in figure 5.23 and the t1/2 is 38 hours. The 
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band at 240 nm is due to pi → pi* transitions of the aromatic ring of the starting 
hydrazide (dashed spectrum, figure 5.22). 
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Figure 5.22: Electronic absorption spectra recorded for NaHL11 in PBS buffer – Day 
1-6 
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Figure 5.23: Exponential decay obtained for NaHL11 at 270 nm over the period of 6 
days in terms of hours with a t1/2 of 38 hours 
NaHL14 (p-CF3) and NaHL16 (p-(CH3)3) were studied under similar 
conditions and showed comparable results to that of NaHL11 (p-Br). The plot 
illustrated in figure 5.24 indicates gradual hydrolysis of NaHL14, which is evident by 
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a decrease in the intensity of the band at 270 nm. In addition, this absorption band  
broadens with time while the final spectrum being almost comparable to the 
spectrum of the parent hydrazide shown as dotted line. The plot of decay of 
NaHL14 is indicated in figure 5.25 and the t1/2 is 54 hours, while for NaHL16 t1/2 is 
57 hours. 
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Figure 5.24: Electronic absorption spectra recorded for NaHL14 in PBS buffer (0 – 
120 hrs) 
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 Figure 5.25: Exponential decay obtained for NaHL14 at 270 nm over the 
period of 6 days in terms of hours with a t1/2 of 54 hours 
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Along with the decrease in the intensity of the band at 270 nm there is a small 
increase in the absorbance at around 330 nm. This may be due to formation of 
additional chemical species in solution, which can be attributed to either degradation 
or oxidation processes associated with hydrolysis of NaHL14. NaHL16 studied 
under similar conditions exhibit similar behaviour and the UV spectra of PBS studies 
can be found in Appendix 23. 
5.4.2 Stability studies of Cu(II) complexes of PVAHs in PBS buffer 
 Although the investigated PVAHs hydrolyse over longer periods of time, 
the copper complexes appear to be stable in PBS buffer. The absorption maxima 
(λmax) of [Cu(II)L11(H2O)2]  (figure 5.26) are observed at 277 nm (ε= 19.0 x 103 dm3 
mol-1 cm-1) and 320 nm (ε= 11.6 x 103 dm3 mol-1 cm-1) and can be assigned to pi → 
pi* transitions of the aromatic ring and overlapping of C=N and C=O pi-pi* transitions, 
respectively.292
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 Figure 5.26: Electronic absorption spectra recorded for [Cu(II)L20(H2O)2] 
in PBS buffer - Day 1-6 
 As evident from figure 5.26, there is no shift in the maximum of the band 
over 6 days. However, there is a slight decrease in the intensity of the band which 
can be accounted for the slow precipitation of the Cu(II) complex from PBS buffer 
due to the limited solubility of the complex in water. This leads to the conclusion that 
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copper coordination helps to stabilise the ligand. Hence, the copper complex can 
act as a potential drug candidate as the copper coordination may help to facilitate 
entry of the active drug into the bacterial cell without it being hydrolysed.  
 The Cu(II) complexes of NaHL14 and NaHL16 exhibit similar behaviour 
to that of [Cu(II)L11(H2O)2] as they remain stable over a period of 49 hours. As 
indicated in the plot for [Cu(II)L14(H2O)2] (figure 5.27) there is only little change in 
the overall shape of the UV-vis spectra over time. It can be noticed there is also a 
slight decrease in the intensity of the band at 320 nm which can be due to 
precipitation of the compounds with time.  
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Figure 5.27: Electronic absorption spectra recorded for [Cu(II)L14(H2O)2] in PBS 
buffer (0-49  hours) 
 [Cu(II)L14(H2O)2] studied under similar conditions exhibits similar 
behaviour and the UV spectra of the PBS studies can be found in  Appendix 23. 
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5.4.3 Stability studies of [Zn(HL11)2] in PBS buffer 
In contrast to the Cu(II) complexes of PVAHs, the Zn(II) complex of NaHL11 
is unstable in PBS buffer over time. [Zn(HL11)2] displayed similar behaviour to that 
of the PVAHs with the complex hydrolysing to the starting hydrazide (figure 5.28). 
The intensity of the band assigned to the pi-pi* transition of L11 in the zinc complex, 
observed at 312 nm (ε= 16.9 x 103  dm3 mol-1 cm-1), decreases and gives rise to a 
new band corresponding to the starting hydrazide. The exponential decay of 
[Zn(HL11)2]  is depicted in figure 5.29 with a t1/2 of 32 hours.  
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Figure 5.28: Electronic absorption spectra recorded for [Zn(HL11)2]  in PBS buffer - 
Day 1-6 
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Figure 5.29: Exponential decay of the absorption of [Zn(HL11)2]  at 270 nm over the 
period of 6 days(117 hours) with a t1/2 of 32 hours 
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The instability of [Zn(HL11)2]  can be attributed to the lability of the Zn(II) 
complex in the solution. This indicates that the Zn(II) ion is not coordinated strongly 
to PVAH ligand unlike Cu(II). Hence, when the zinc complex is dissolved in PBS 
decomplexation occurs followed by hydrolysis of the NaHL11 giving rise starting 
hydrazide. 
5.4.4 Stability studies of the di-hydrazide analogue NaH3D1 
As discussed in chapter-2, the di-hydrazide analogue of PVAH, NaH3D1, is 
expected to be more hydrolytically stable than PVAHs owing to its C-N single bond. 
To gain insight into the stability of NaH3D1, its behaviour was investigated in PBS 
buffer. The absorption coefficient at the λmax of NaH3D1 was determined at 275 nm 
(ε= 21.5 x 103 dm3 mol-1 cm-1) as shown figure 5.30. The associated band may be 
attributed to overlapping C=N and C=O, pi-pi* transitions.292  The intensity of the 
band decreases over a period of 98 hours. However, the decrease in the intensity is 
not as significant as observed for NaHL11, NaHL14 and NaHL16. Moreover, there 
is very little or no shift in the λmax value for the band observed at 275 nm. The slight 
decrease in the intensity can be attributed to the precipitation of the compound in 
the aqueous media and/or may be due to slow hydrolysis of the NaH3D1.  
 
Figure 5.30: Electronic absorption spectra recorded for NaH3D1 in PBS buffer (0 - 
98 hr) 
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Hence, it can be concluded that the dianalogue NaH3D1 is fairly stable over 
the investigated time period. This suggests that PVAH analogues with C-N single 
bonds are more stable than those with C=N double bonds. The stability could also 
due to an additional aromatic ring. This is indicated from the pH studies, as CAHs 
which are highly conjugated appear to be more stable than PVAHs. The stability of 
a compound over a long period of time can prove to be useful, since it may aid in a 
higher cellular uptake of the drug in bacteria.  
5.4.5 Stability studies of CAHs in PBS buffer 
Due to the poor solubility of CAHs and their copper complexes in PBS a 
mixture of PBS and DMSO (1:1 v/v) was used to investigate the stability of HCA1 
and its respective Cu(II) complex [Cu(CA1)2] (figure 5.31). The UV-visible spectra of 
the corresponding solutions were monitored over a period of 50 hours. For HCA1, 
there is no change observed in the overall shape of the UV spectra over the time 
period of 50 hours indicating its stability in PBS.  
The initial UV-visible spectrum of [Cu(CA1)2] in PBS recorded at 0 hours, as 
shown in figure 5.31, shows an absorption band at around 350 – 450 nm suggesting 
the presence of the copper complex. An intense band observed at 329 nm 
corresponds to the free ligand, HCA1. As can be seen from figure 5.31, the band 
observed in the region 350 – 450 nm disappears after one hour, and a prominent 
band at 329 nm develops. These spectral changes indicate that the complex rapidly 
dissociates to give free ligand and solvated Cu(II). The uncoordinated ligand HCA1 
remains stable for the period of 50 hours as there is no further shift observed in the 
λmax.  
The poor stability of the copper complexes in PBS buffer is likely to be 
associated with the additional DMSO used in the PBS study in order to make the 
copper complexes soluble in solution. DMSO is known to be a more coordinating 
solvent than water293 and it can replace weakly coordinated ligands in complexes294. 
Therefore, the complex could have been more stable in 100% PBS buffer solution.  
However, the solubility issues could not be solved as the copper complexes of 
CAHs were only soluble in DMSO and DMF. However, it is reported in the literature 
that complexes are less stable in DMF than DMSO264, hence replacing DMSO 
solvent with DMF may not have proven to be useful. 
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Figure 5.31: Electronic absorption spectra recorded for HCA1 in PBS buffer solution 
over a period of 50 hours then acidified to pH 1.5 with HCl 
Furthermore, the band at 329 nm shifts to 290 nm with lowering to pH 1 and 
appears at similar wavelength after 1 hour. The band at 290 nm closely resembles 
that of the starting material cinnamaldehyde (289 nm) suggesting the hydrolysis of 
HCA1 at pH 1. However, this contradicts results obtained in the pH studies of 
HCA1, where the ligand appears to be stable at pH 1.5. This suggests that PBS 
buffer accelerates the hydrolysis of the hydrazone at acidic pH. 
Buss and Ponka, showed that similar hydrazones dissociate at a slower rate 
in PBS buffer.180 However, when these compounds were further investigated by 
Kovaříková and group for their stability in animal plasma, they found that these 
compounds undergo rapid degradation in the plasma as compared to PBS 
solution181. 
Hence, PBS studies of CAH indicate that the ligand HCA1 appears to be 
stable in the buffer over the monitored time of 50 hours. However, copper complex, 
[Cu(HCA1)2] rapidly dissociates within an hour. 
From the combined stability studies it can be concluded that the investigated 
ligands and metal complexes remain stable under basic pH conditions, however, 
they undergo fast dissociation in acidic pH. This may considered as a drawback for 
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the oral administration of the compounds as the pH of stomach is below 2, hence it 
is likely the the drugs hydrolyse.   
5.5 Comparing CLogP values of PVAHs and CAHs 
It is well known that the CLogP plays an important role in drug design.216 As 
previously discussed in chapter-3, the theoretical CLogP values for PVAHs and 
CAHs lie between -1.03 to 2.74 and 2.58 to 5.18 respectively, depending on the 
substituent on the aromatic ring. It is obvious that the greater CLogP values for 
CAHs are due an additional aromatic ring as compared to PVAHs. Moreover, the 
lower CLogP values for PVAHs signify greater number of hydrogen-bonding 
interactions than the CAHs which is evident from the obtained X-ray crystal 
structures. The CLogP value for di-hydrazide analogue (NaH3D1) is 1.35, whereas 
its equivalent monoanalogue (NaHL9) is 1.34. As NaHL3D1 has two aromatic rings 
as compared to NaHL9 it should give higher CLogP values but gives similar values 
as indicated in table 5.1. The reduced CLogP value is more likely due to the 
presence of a greater number of hydrogen bond donor/acceptor atoms on NaH3L1. 
This is confirmed by comparing with the equivalent ligand (p-CH3 substituted 
hydrazone) of CAH series HCA9, which has a CLogP of 3.98. Hence, the greater 
CLogP of HCA9 can be accounted to a greater number or aromatic rings and a 
decrease in the number of hydrogen bond donor/ acceptor atoms over NaHL9 and 
NaH3D1. 
Table 5.1: Selected compounds with their structure and CLogP values 
Compound Structure CLogP 
NaH3D1 (Di- 
hydrazide analogue 
of a PVAH) 
N
H
N
O
O ONa
N
H
NH
OH3C
CH3
 
1.35 
NaHL9 
(Monoanalogue of a 
PVAH) 
N
H
O
N
O
CH3
OH3C Na  
1.34 
HCA9 (CAH) N
H
O
N
H3C
 
3.98 
As the lipophilicity of a drug increases with the increase in the ClogP values, 
CAHs can prove to be more useful in antitubercular drug design than PVAH ligands. 
This is because an increased lipophilicity would facilitate the passage of the 
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molecule through the lipid bilayer of the waxy mycobacterial cell wall.189,218 However, 
the hydrophobic nature of a drug can pose a serious issue of solubility in aqueous 
media, which may result in reduced uptake of a drug in the body resulting in low 
bioavailability of active pharmacophore.  
5.6 Antitubercular activity 
5.6.1 Antitubercular activity of PVAHs and their metal complexes  
As mentioned earlier, the antitubercular studies which will be discussed in 
this chapter, were done by our collaborators. All the synthesized PVAHs and their 
respective Cu(II) and Zn(II) complexes compounds were screened initially for anti-
tubercular activity against Mycobacterium tuberculosis H37Rv at a concentration of 
256 µg /mL. The tested compounds that exhibited an inhibitory effect were further 
examined to determine their minimum inhibitory concentrations (MIC). Although, 
PVAHs and their parent hydrazides exhibit inhibitory action, their MIC values were 
significantly higher than that of isoniazid, which is a well known antitubercular drug. 
However, when PVAHs were complexed to Cu(II), the activity increases 
tremendously.  
Cu(II) complexes exhibiting similar MIC value to that of isoniazid were 
screened along with their parent hydrazones and hydrazides under both high iron (8 
µg Fe(II)/mL) and low iron (0.02 µg Fe(II)/mL) conditions. MIC values of hydrazides 
and their respective PVAHs and Cu(II) complexes in different conditions are 
provided in tables 5.2, 5.3 and 5.4, respectively. The experimental details of the 
antitubercular assay are provided in chapter-7. 
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Table 5.2: MIC values of selected hydrazides along with INH under different 
conditions  
N
H
O
NH2X3
X1
X2
R
 
Compo
und 
R MIC value in 
7H9 
conditions 
(µg/mL) 
MIC value in 
high iron 
conditions 
(µg/mL) 
MIC value in 
low iron 
conditions 
(µg/mL) 
Fold difference 
between high 
and low iron 
MIC values 
INH X1 = N 0.25 0.125 32 256 
H9 p - CH3 256 32 256 8 
H8 p -NO2 128 16 256 16 
H16 p -(CH3)3 128 32 >256 <8 
H7 p -NO2 , m -
Me 
128 32 >256 <8 
H14 p -CF3 64 32 256 8 
H15 m -F 128 64 256 4 
H3 m -OH 128 32 >256 <8 
H20 X2, X3= N 64 32 256 8 
Isoniazid (INH) is a widely used antitubercular drug, whilst other hydrazides 
have proven to be less efficient than INH itself. However, hydrazones derived from 
INH and related hydrazides have been known to have improved activities if 
compared with their parent hydrazides.78,81 In addition, coordinating hydrazones to 
metal ions, such as Cu(II) and Co(II) has been reported to enhance their activity 
significantly.87 Metal complexation of such conjugates has been found to enhance 
their antibacterial properties due to enhanced lipophilicities facilitating passage 
through the lipophilic mycobacterial cell wall. The enhanced lipophilicities can be 
accounted to the binding of the anionic donor atoms to the copper centre, which is 
evident from the single crystal X-ray structures of Cu(II) complexes of PVAHs 
discussed in chapter-4. This renders the overall complex neutral. In addition, some 
metal complexes found in the literature are also found to inhibit resistant strains of 
bacteria.85-86,286  
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Table 5.3: MIC values of selected PVAHs under different conditions 
N
H
O
N
O
CH3
ONa
X3
X1
X2
R
 
 
Monoanalogue PVAHs (NaHLX) 
N
H
N
O
O ONa
N
H
NH
OH3C
CH
 
 
Dianalogue PVAH (NaH3D1) 
compound R MIC value in 
7H9 
conditions 
(µg/mL) 
MIC value 
in high 
iron 
conditions 
(µg/mL) 
MIC value in low 
iron conditions 
(µg/mL) 
Fold difference 
between high and 
low iron MIC 
values 
NaHL9 p- CH3 32 16 256 16 
NaHL8 p -NO2 32 8 256 32 
NaHL16 p -
(CH3)3 
32 16 256 16 
NaHL7 p -NO2 
, m-Me 
64 8 128 16 
NaHL14 p -CF3 16 16 256 16 
NaHL15 m -F 32 16 256 16 
NaHL3 m -OH 32 32 256 8 
NaHL20 X2, X3= 
N 
64 8 256 32 
NaH3D1 p -Me 32 16 256 16 
As previously discussed in the stability studies sections, the Cu(II) ion does 
not only provide stability towards hydrolysis, it also makes the overall molecule 
neutral which may facilitate the cellular uptake of their components. Poor activity of 
PVAHs may not necessarily indicate a lower intracellular potency but can be due to 
reduced cellular uptake. This can be attributed to many factors such as a) 
hydrophilicity b) unstability towards hydrolysis c) anionic nature at physiological pH. 
However, the synthesised di-hydrazide analogue, NaH3D1, proven to be nearly 
stable at physiological conditions as evident from PBS studies was proven to be 
inefficient and the MIC value is similar to the monoanalogue NaHL9. Thus, the 
restricted uptake of the monoanalogue and dianalogue PVAHs is likely to be due to 
the anionic nature of the PVAHs. 
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Table 5.4: MIC values of selected Cu(II) complexes of PVAHs obtained under the 
indicated conditions 
X1
X2
X3
O
N
N O
O
CH3
R
Cu
H2O OH2
 
Compound R MIC value 
in 7H9 
conditions 
(µg/mL) 
MIC value in 
high iron 
conditions 
(µg/mL) 
MIC value in 
low iron 
conditions 
(µg/mL) 
Fold 
difference 
between high 
and low iron 
MIC values 
[Cu(II)L9 
(H2O)2] 
p - CH3 8 <0.5 128 >256 
[Cu(II)L8 
(H2O)2] 
p -NO2 1 2 256 128 
[Cu(II)L16(
H2O)2] 
p -(CH3)3 16 1 64 64 
[Cu(II)L7 
(H2O)2] 
p -NO2 , m 
-Me 
4 <0.5 128 >256 
[Cu(II)L14(
H2O)2] 
p -CF3 8 <0.5 128 >256 
[Cu(II)L15(
H2O)2] 
m-F 8 0.5 64 128 
[Cu(II)L3 
(H2O)2] 
m -OH 8 1 32 32 
[Cu(II)L20(
H2O)2] 
X2, X3= N 16 <0.5 256 >512 
The stable Cu(II) complexes of PVAHs may be able to passively diffuse 
through the cell membrane owing to their neutral form. Our hypothesis supports the 
sequestering of the copper ions from the copper complex by mycobacterial 
metallothionein295, which in turn releases the hydrazone. Subsequent hydrolysis of 
the released hydrazone yields the hydrazide and pyruvate moiety. The inhibitory 
action may be attributed to the combination of the activity of released hydrazide and 
redox active Cu(II) ions. It can be seen from the MIC values that isoniazid and 
PVAHs and their copper complexes were less potent in limiting iron conditions. 
However, their potency increases with high iron levels, suggesting similar mode of 
inhibitory action towards mycobacteria to that of isoniazid. A schematic 
representation of our proposed mechanism of action is shown in figure 5.32.  
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Bacterial cell membrane
 
Figure 5.32.Suggested mechanism of action of Cu(II) complexes of PVAHs (active 
site of ICL enzyme53) 
Linking the hydrazinic chain (R-NH-NH2) of hydrazides with either aldehydes 
or ketones, such as pyruvate moiety, could possibly block the acetylation of these 
hydrazinic drugs.  The serum concentration of the hydrazide has been shown to be 
affected by N-acetyltransferase (NAT)-mediated acetylation of the amine centre, 
leading to either reduced or no antitubercular activity. Thus, the blocking of 
hydrazide acetylation would lead to an increase or the maintenance of their 
inhibitory activity against mycobacteria. NAT enzymes are not only present in 
humans but also known to exist in Mycobacterium smegmatis and Mycobacterium 
tuberculosis. It has been reported that the different forms of NAT enzymes have 
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been able to acetylate various substrates including INH and sullfonamide based 
antibacterial drugs under in vitro conditions. NAT enzymes can be classified into 
fast and slow acetylators and variable effective therapeutic doses of INH could 
possibly depend on different enzyme profiles.18,42  
One of the drawbacks of INH is that it causes vitamin B6 deficiency. This is 
due to the fact that the amine group of INH forms Schiff base conjugate with the 
carbonyl group of vitamin B6.296 Conjugating the amine group of hydrazide with 
appropriate aldehyde/ketone could possibly overcome the issue of vitamin B6 
deficiency. 
In addition, the pyruvate moiety provides an extra anionic donor oxygen 
atom which balances the positive charge of the bound Cu(II) centre making the 
overall complex neutral. Pyruvate analogs such as nitropropionate and 
bromopyruvate have shown to inhibit the active site of isocitrate lyase (ICL).48,53 The 
ICL enzyme is known to play a vital role in the persistence of mycobacteria, hence it 
is considered as an attractive target for discovering new antitubercular drugs 
especially for persistent strains.  
Recent computational studies done by Padhye and group illustrated that 
pyruvate hydrazones can potentially bind and inhibit the active site of ICL.84 
Moreover, the hydrazide/ hydrazone (NaHL20) derived from pyrazinoic acid is of 
particular interest, since this hydrolysis product of another well known antitubercular 
drug pyrazinamide is able to target persisting Mtb. Very recent studies in the 
literature illustrate that it is found to inhibit trans-translation, a vital process found to 
occur in stress survival and recovery from nutrient starvation.58 
As already discussed in chapter-1, isoniazid acts on mycolic acid 
biosynthesis8. The compound is believed to be a pro-drug, requiring activation by 
Mtb catalase-peroxidase (KatG)297  to generate a range of reactive oxygen species 
(ROS) and reactive organic radicals, which then damage multiple regions in the 
tubercle bacillus. INH can be activated in vitro by KatG with Mn2+ whereupon it loses 
its -NH-NH2 side chain to form an isonicotinic acyl radical as indicated in figure 5.33 
(step a).15  This active pharmacophore then reacts with NAD to form an INH-NAD 
adduct as shown in figure 5.33 (step b). This adduct formed within the active site of 
InhA enzyme in turn inhibits the InhA enzyme16-17,298. 
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Figure 5.33: a) Formation of active pharmacaphore, isonicotinic acyl radical (top 
right) from isonicotinic acid hydrazide (INH) (top left) b) formation of INH-NAD 
adduct15 
In addition, the redox activity of metal ions is significant since bacterial 
resistance is known to be modulated by intracellular oxidative stress.41 It is known 
that an excess of free Cu(II) or Fe(II), causes oxidative stress, which in turn initiates 
the transcription of the catalyse-peroxidase (KatG) gene. Consequently, more KatG, 
which activates the hydrazide is produced, eventually leading to destruction of the 
bacterial cell.299 Resistance to isoniazid can occur in strains with impaired KatG 
proteins and lack of redox activity is associated with resistance to INH.40 KatG 
appears to utilize superoxide anions to activate INH, as the INH turnover by the 
purified enzyme is completely abolished in the presence of a catalytic quantity of 
superoxide dismutase (SOD).41   
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Hence, Cu(II) complexes of pyruvate hydrazone can serve multiple purposes 
in  antitubercular drug design which are as follows:  
1) Eradicating the actively growing bacteria, this is proven from the present 
antitubercular studies and has been recently published by us.300  
2) Mycobacteria which are resistant to present antibacterial drugs may be 
targeted with the Cu(II) complex of PVAHs since metal complexes, 
especially copper complexes, are known to inhibit the bacterial resistant 
strains.85,286 
3) Inhibition of persistent bacteria, which could possibly be achieved by 
pyruvate moiety, if it is capable of blocking the active site of ICL similar to 
other pyruvate analogs.48-50,53,301  In addition, hydrazone analogues derived 
from the pyrazinamide-containing pharmacophore may prove to be useful in 
inhibiting trans-translation process which are required to maintain the 
persistent state of bacteria.58 
The failure of Zn(II) complexes of PVAHs to exhibit low MIC values can be 
attributed to the labile nature of the zinc complexes, which may eventually form 
Zn(II)-OH2 species in aqueous solution. This is evident from the PBS study of the 
investigated Zn(II) complex, where [Zn(II)(HL20)2] dissociates and releases its 
ligand, which then undergoes hydrolysis back to its parent hydrazide. Even though 
the overall Zn(II) complex is neutral, as evident from the single crystal X-ray 
structure, it fails to cross the bacterial cell membrane due to dissociation of PVAHs 
from the Zn(II) centre. The reason for the lower uptake of Zn(II) complexes can also 
be due to their limited solubility in aqueous media.  
The other possible reason for high MIC values of Zn(II) complexes of PVAHs 
may be due to the redox inactive nature of the Zn(II) ion. If this is true then it 
supports the theory that oxidative stress is essential for the inhibitory activity of 
hydrazide type molecules. This is also reflected in the present antitubercular studies 
on PVAHs, where it is proven that the inhibitory action is greatly improved under 
high Fe conditions. 
It should also be considered that the MIC values obtained are given in 
µg/mL, whereas the compounds have different molecular weights. Therefore, in 
order for a direct comparison of hydrazides with their respective hydrazones and 
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Cu(II) complexes the MIC values obtained in µg/mL under high iron concentration 
were converted into picomolar concentrations (pM = 10-12 M). The values are 
provided in Table 5.5 and the graphical representation of these MICs values are 
shown in figure 5.34. The number given on the X-axis corresponds to the number of 
the compound provided in Table 5.5. 
Table 5.5: MIC values of selected hydrazides, PVAHs and their respective Cu(II) 
complexes in pM concentration under high iron conditions  
N
o 
Compo
und/R 
Hydrazides 
(pM) 
Hydrazones 
(pM) 
Cu(II) complex 
(pM) 
  
N
H
O
NH2X3
X1
X2
R
 
N
H
O
N
O
CH3
ONa
X3
X1
X2
R
 
X1
X2
X3
O
N
N O
O
CH3
R
Cu
H2O OH2
 
 INH 0.9 - - 
1 p -Me 213 66 <1.5 
2 p -NO2 88 29 5.7 
3 
p -
(CH3)3 
167 56 2.8 
4 
p -NO2 , 
m -Me 
164 27 <1.4 
5 p -CF3 157 54 <1.3 
6 m-F 415 65 1.5 
7 m -OH 210 130 3.1 
8 
X2, X3= 
N 
232 34 <1.6 
 NaH3D1 213 43 - 
As can be gathered from Table 5.5, the MIC values of the Cu(II) complexes 
of PVAHs determined under high Fe conditions have comparable values to that of 
the frontline antitubercular drug INH (0.9 pM) ranging from <1.5 - 5.7 pM. While, the 
MIC values of hydrazides and hydrazones obtained under similar conditions falls in 
the range 88-415 pM and 27-130 pM respectively. Even though there is no 
improvement in terms of MIC values of the Cu(II) complexes with respect to INH,  
the copper complexes may be useful in targeting the bacterial strains which are 
proving resistant to INH.302 Although, the MIC value in µg/mL for the di-hydrazide 
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analogue (NaH3D1) and its equivalent monoanalogue PVAH (NaHL9) is 16 µg/mL, 
but in pM concentration it is 43 and 66 pM, respectively. The slightly lower MIC 
value of NaH3D1 is likely due to its increased cellular uptake, which may perhaps be 
due to its stability towards hydrolysis as evident from the PBS studies. 
 
Figure 5.34: Graphical representation of MICs of listed compounds in table 5.5 in 
pM concentration 
  Surprisingly, another front-line antitubercular drug, pyrazinamide (prodrug 
for pyrazinoic acid (PZA)) is known to possess a MIC value as high as 200 µg/mL 
under certain conditions.303 In spite of its high MIC value, it is used in the treatment 
of tuberculosis and is one of the most widely used drugs in modern chemotherapy in 
addition to isoniazid, rifampicin and ethambutol. Interestingly, pyrazinoic acid 
hydrazide, a congener of pyrazinamide, exhibits a MIC value of 232 pM, whereas its 
hydrazone and Cu(II) complex have a MIC of 34 and <1.6 pM as listed in Table 5.5. 
Hence, active Cu(II) complexes of PVAHs may prove useful as potential prodrugs 
and may provide an excellent alternative to current drugs to which resistance in 
emerging. 
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5.6.2 Structure activity relationship (SAR) of active compounds (Cu(II) 
complexes) of the PVAHs series 
1) Cu(II) complexes of PVAHs bearing electron donating groups such as p-
CH3 ([Cu(II)L9(H2O)2]) and p-(CH3)3 ([Cu(II)L16(H2O)2]), exhibit promising 
antitubercular activity which can be attributed to the enhanced 
liposolubilty due to the hydrophobic R groups on aromatic ring .78 
2) Those bearing fluoro [Cu(II)L15(H2O)2] (m-F)  and trifluoro 
[Cu(II)L14(H2O)2] (p-CF3) groups also exhibit low MIC values. Vigorita 
and coworker have extensively studied fluoro containing hydrazones and 
found that it enhances the antitubercular activities.80  
3) Complexes bearing electron withdrawing groups, such as nitro 
[Cu(II)L7(H2O)2] (m-CH3, p-NO2) and [Cu(II)L8(H2O)2]  (p-NO2)  are 
potent against mycobacteria. Density functional theory (DFT) 
calculations done by Tawari et.al. on a series of antitubercular 
compounds illustrated that the negative potential resulting from the NO2 
group makes them more active than other compounds which do not 
possess a nitro substituent.304  
4) [Cu(II)L20(H2O)2] containing two heterocyclic nitrogen atoms within the 
aromatic ring, which represents a pyrazinamide analogue of PVAH, 
possesses excellent activity. In contrast, the copper complexes of 
PVAHs bearing one heterocyclic nitrogen atom including the INH 
analogues of PVAH ([Cu(II)L18(H2O)2] and [Cu(II)L19(H2O)2]) failed to 
show any activity due to their insoluble nature, hence little or no cellular 
uptake is observed for these compounds. 
5) [Cu(II)L3(H2O)2]  bearing a OH group in meta position proved to be 
active, however [Cu(II)L2(H2O)2]  and [Cu(II)L4(H2O)2]  bearing OH 
groups in ortho and para position, respectively were inactive. 
6) Copper complexes bearing OCH3 groups, [Cu(II)L12(H2O)2]  (m-OCH3), 
[Cu(II)L13(H2O)2] (p-OCH3), [Cu(II)L17(H2O)2]  (o-OH, p-OCH3) Br group, 
[Cu(II)L10(H2O)2]  (m-Br), [Cu(II)L11(H2O)2]  (p-Br) and Cl group, 
[Cu(II)L6(H2O)2]  exhibited very high MIC values. 
Hence, from the SAR analysis it can be concluded that the Cu(II) complexes 
containing a pyrazine ring in addition to methyl, tert-butyl, fluoro and nitro 
substituents on the aromatic ring proved to be active. In contrast, the copper 
complexes containing Br, Cl, OCH3 substituents exhibited very high MIC values.  
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5.6.3 Antitubercular studies involving the CAH series 
Due to low solubility of the CAH ligands and their corresponding Cu(II) 
complexes in aqueous solution, the compounds precipitated from the buffer solution 
that was used for the antitubercular testing. Hence, the activity studies could not be 
performed on the CAH series using the technique employed for the PVAHs series. 
However, this does not rule out the possibility that CAHs may exhibit in vivo 
inhibitory activity. In order to overcome this problem, testing could also be done 
using the disc diffusion method. In this assay, a compound is dissolved in an 
appropriate solvent (in which they are soluble) and the disc impregnated with the 
inhibitor solution is placed on the agar (media used to grow bacteria) plate with the 
bacterial culture. The zone of inhibition observed directly relates to the antibacterial 
activity of the tested compound.305 This would limit the requirement of an aqueous 
solution and allow hydrophobic molecules like CAHs to be put in direct contact with 
the bacterial cells, hence would increase their cellular uptake. Once the in vitro 
studies of compounds prove to be successful, the lead compound/s can be further 
modified to improve its bioavailability. The solubility issues may potentially be solved 
by encapsulating the hydrophobic drug in a cyclodextrin, which has been 
successfully achieved in related studies.305 Due to time constraints, however, the 
CAHs could not yet be tested using such methods, but these can serve as a future 
goal. 
Hence, overall conclusions from the antitubercular studies that can be drawn 
are that the Cu(II) complexes of PVAHs are highly potent if compared with the 
hydrazone ligands and Zn(II) complexes. The low activity of PVAHs can be 
attributed to their anionic nature, whereas the neutrality of the Cu(II) complex of 
certain PVAHs facilitates the crossing of the bacterial cell membrane thereby 
inhibiting bacterial growth. The lower activity of neutral Zn(II) complexes may be 
related to the redox inactive nature of Zn(II) and/or their low uptake into bacterial 
cells due to their decreased stability and limited solubility in aqueous media. Similar 
solubility issues were encountered with the CAH series, as these compounds 
precipitated out in the buffer solution used. Hence, other methods like disc diffusion 
assays might be more suitable for such hydrophobic molecules.  
Therefore, for a drug to be orally active there should be a balance between 
its hydrophilic and lipophilic character. Thus, Cu(II) complexation of PVAHs may 
represent an promising strategy in antitubercular drug design, because the ligand 
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part (PVAH) is water soluble and the Cu(II) ion renders it less polar and neutral by 
binding to its anionic donor atoms. This in turn facilitates the passive diffusion of the 
copper complex through the lipophilic cell membrane. In addition, the redox nature 
of Cu(II) centre may aid the antitubercular activity of metal complexes. 
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5.7 Summary of Chapter- 5 
The pH-dependent stability studies of selected PVAHs indicate the hydrolysis 
of this type of ligands under acidic conditions, whereas the ligands are reasonably 
stable at basic pH. Similarly, the Cu(II) and Zn(II) complexes of NaHL20 are stable 
in basic pH. However [Cu(II)L20(H2O)2)]  undergo irreversible dissociation in acidic 
pH below 2 which can be attributed to the simultaneous dissociation and hydrolysis 
of the coordinated PVAH. Whereas [Zn(II)(HL11)2)] undergoes ligand dissociation 
below pH 5 followed by hydrolysis of the ligand below pH 2. 
On the other hand, HCA1 and HCA5 from the CAH series remain almost stable 
under both basic and acidic conditions over a certain period of time. HCA5, which 
possesses an electron withdrawing group, undergoes hydrolysis as indicated from 
the spectrum recorded after 5 hours, no change was observed for HCA1. In 
addition, the corresponding Cu(II) complex [Cu(CA1)2]  undergoes dissociation in 
acidic pH, however it re-forms and remains stable at basic pH. 
Stability studies in PBS buffer at pH 7.4 studies indicate that NaHL11, NaHL14 
and NaHL16 undergo slow hydrolysis with a t1/2 ranging from 36 – 57 hours. 
Similarly, [Zn(HL11)2)] proved to be unstable in PBS solution with a t1/2 32 hours. 
However, their respective Cu(II) complexes are stable over a monitored period of up 
to 6 days. Hence, the coordination of Cu(II) to PVAHs, helps to stabilise the ligands 
by preventing them from undergoing hydrolysis. Although, HCA1 appears to be 
stable in PBS buffer over the monitored period of time, its respective Cu(II) complex 
rapidly dissociates in the buffer solution. This indicates that the bidentate mode of 
binding of CAH is not as strong as the tridentate mode of binding of the PVAH 
ligands. 
The di-hydrazide analogue of PVAH (NaH3D1) proves to be fairly stable in PBS 
solution, which can attributed to the C-N single bond character of the molecule. This 
suggests that the reduction of azomethine bond can provide hydrolytic stability to a 
hydrazone ligand.   
The antitubercular activity tests revealed that hydrazone formation increases 
the inhibitory activity of the corresponding hydrazides by almost 3-7 fold when 
tested under high iron conditions. In addition, coordinating the hydrazones to Cu(II), 
increases the activity further to up to 270 fold in certain complexes. The activities. of 
some of the Cu(II) complexes of PVAHs are similar to that of the present 
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antitubercular drug isoniazid and may potentially prove useful in resistant bacterial 
strains. In addition, the redox active nature of Cu(II) may add to the activity of the 
compounds and, the coordination of Cu(II) to di-anionic PVAHs provided stability 
and lipophilicity to the resulting copper complexes. This cannot be achieved in Zn(II) 
complexes of PVAHs, which fail to show any promising activity.  
The clogP values indicate greater lipophilicity of CAHs over PVAHs, which can 
prove to be useful as it can facilitate the higher uptake of hydrophobic molecules 
across the lipophilic cell membrane of bacteria. Unfortunately, CAHs could not be 
tested for their antimycobacterial activity using the assay used for PVAH series due 
to their limited solubility in aqueous buffer solution. 
Hence, Cu(II) complexes of PVAHs can be considered as potential prodrug 
candidates for the treatment of TB and a further investigation of these complexes on 
MDR strains of mycobacteria would be very informative. 
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6.0 Conclusions and Future work 
 
6.1 Overall Conclusions 
A series of sodium pyruvate-based hydrazones (PVAHs); NaHL1-NaHL20, with 
a selection of aromatic substituents, ranging from electron withdrawing to electron 
donating groups, were synthesised and characterised by 1H NMR spectroscopy, 13C 
NMR spectroscopy, high resolution ESI mass spectrometry, infrared spectroscopy, 
elemental analysis and melting point analysis. Variable temperature 1H NMR studies 
indicate that PVAHs exist as a mixture of E and Z isomers in solution, with the Z form 
predominating owing to the strong hydrogen bond formed between amide N-H and 
carboxylate oxygen atom. This assignment was further confirmed by the torsional angle 
obtained from the single crystal X-ray structure data of NaHL9 and NaHL11, which 
confirm that the sodium salts of the ligands adopt the Z conformation. In contrast, 
NaHL20, which was crystallised in its protonated form (H2L20) adopts the E 
conformation in the solid state. 
Furthermore, the Cu(II) and Zn(II) complexes of the PVAHs were synthesised 
and characterised by using the above mentioned techniques, as appropriate. Single 
crystal X-ray diffraction data indicates that the Cu(II) complexes mainly exibit square 
pyramidal geometry, whereas Zn(II) coordinates two ligands to obtain octahedral 
geometry. The two ligands are coordinated meridonially due to the rigidity of the two 
ligands. The PVAH ligands bind to both Cu(II) and Zn(II) centres in a tridentate manner 
through the ONO donor system, forming two stable five membered chelate rings 
around the metal centre. In order to bind to the metal centre in a tridentate fashion the 
ligand has to change to E conformation, as was confirmed by the torsional angle 
determined for selected Cu(II) and Zn(II) complexes by X-ray crystallography.  
In the square pyramidal Cu(II) complexes the PVAH ligand binds in a dianionic 
manner (L2-), whereas in the octahedral Zn(II) complexes two PVAH ligands bind to 
Zn(II) centre in a monoanionic fashion (HL-), giving rise to overall neutral metal 
complexes in both cases. The remaining two coordination sites of the square pyramidal 
complexes are occupied by chloride or neutral solvent molecules such as water and 
methanol. The τ value of obtained for the square pyramidal Cu(II) complexes of 
PVAHs, indicates a slight distortion from perfect square pyramidal geometry. The 
apical bond distances are significantly longer than the equatorial bond distances, 
indicating an appreciable Jahn - Teller distortion, as expected for Cu(II) complexes due 
to the d9 electron count. The aromatic substituents have little or no influence on the 
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bond lengths and bond angles in the direct vicinity of metal centre. The ligands remain 
essentially planar when bound to Cu(II) in the square pyramidal complexes, however 
the ligands lose their planarity when bound in a octahedral geometry in order to reduce 
the steric repulsion between the two ligands bound to the same metal centre.  
Infrared studies indicate that electron withdrawing groups on the aromatic ring 
shift the stretching frequencies of carbonyl functional group towards higher 
frequencies, whereas electron donating groups have the opposite effect. A similar 
effect is observed in NMR spectroscopy, where the resonances assigned to the amide 
proton and azomethine carbon of PVAHs possessing electron withdrawing groups 
exhibit downfield shifts in comparison to those containing non-substituted and/or 
electron withdrawing groups. As a general trend, metal complex formation leads to the 
shifting and consequently merging of stretching frequencies assigned to the carbonyl, 
carboxylate and azomethine groups. 
The investigated PVAH ligands are redox inactive except for NaHL8, which 
exhibits reversible redox behaviour due to the -NO2 subsituent. The cyclic voltammetric 
studies indicate that the Cu(II) is reduced to Cu(I) when a negative potential starting 
from - 1000 mV with respect to Ag/AgCl is applied . The redox peak associated with the 
Cu2+/Cu1+ couple is classified as a quasi-reversible process, as the ∆E value increases 
with an increase in scan rate and ∆E >> 59 mV. The quasi-reversible behaviour is likely 
to be due to structural reorganisation taking place within the coordination sphere, whilst 
changing from a square-pyramidal Cu(II) to a tetrahedral Cu(I) coordination geometry.  
In order to obtain evidence in support of this theory, the Cu(I) complexes of NaHL8 and 
NaHL9 were synthesised. The crystal structure of both Cu(I) complexes indicate that 
PVAH ligands bind partially to the Cu(I) centre in a bidentate manner, thus allowing the 
Cu(I) complex to adopt a tetrahedral geometry. The other two coordination sites are 
occupied by the soft phosphorus donor atoms of PPh3 ligands which were introduced 
during the synthesis of the Cu(I) complex in order to stabilise the soft Cu(I) centre. The 
1H NMR spectra of the Cu(I) complexes confirm their diamagnetic nature, whereas 
broad phosphorus signals in 31P NMR spectra at room temperature indicate ligand-
exchange processes in solution. 
In the cyclic voltammograms, redox waves corresponding to the reduction of 
Cu1+ to Cu0 have also been observed, indicating that the investigated Cu(II) complexes 
are reduced to Cu(0), through a Cu(I) intermediate. The redissolution of the Cu(0) 
deposited on the electrode surface leads to a higher anodic peak current as compared 
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to its corresponding cathodic peak current. The peak potential values obtained for the 
Cu(II) complexes indicate that the type of PVAH ligand affects the metal-based redox 
potential, when compared with Cu(II) for example in CuCl2, irrespective of the 
subsituent on the aromatic ring. 
In order to investigate the stability of the Cu(II) complexes in the 
electrochemical solvent, DMSO, EPR spectra were recorded for selected complexes 
and these were compared with the spectra of ‘free’ Cu(II) ions (CuCl2, CuSO4). The 
EPR parameters, A║, g║ and g⊥ were found to be similar for the studied Cu(II) 
complexes of PVAHs, but distinct from ‘free’ Cu(II) ions (CuCl2, CuSO4). Hence, it can 
be concluded from the EPR studies that the ligands remain bound to the Cu(II) centre, 
even though there is large excess of DMSO present in solution.  
In addition, a series of cinnamaldehyde hydrazones; HCA1-HCA2 and their 
respective Cu(II) complexes was synthesised and characterised. ESI-MS and 
elemental analysis data indicate a 1:2, Cu(II):L ratio with a possible bidentate mode of 
binding allowing for a square planar geometry. The reduction of the azomethine bond 
of HCA1 was unsuccessful, as the olefinic bond was reduced instead, as indicated by 
ESI-MS and NMR spectroscopic analysis. The X-ray crystal structures of PVAHs reveal 
extensive intra and intermolecular hydrogen bonding, in contrast to CAHs. This may be 
accounted for by the higher number of hydrogen bond donor and acceptor atoms in 
PVAHs. Accordingly, higher CLogP values are obtained for CAHs. These higher 
CLogP values may lead to poor oral drug absorption but may prove to be 
advantageous in promoting permeation through the lipid bilayer of the mycobacterial 
cell wall. 
Positive ion ESI-MS of the Cu(II) complexes of PVAHs and CAHs indicated the 
presence of two positive charges, either due to Na+ and H+ or two protons. This can be 
rationalised by the reduction of Cu(II) to Cu(I) during the ionisation process. 
The pH-dependent stability studies of selected PVAHs and their respective Cu(II) 
and Zn(II) complexes indicate that these are unstable under acidic conditions, but 
reasonably stable at basic pH. The instability of the compounds is due to the hydrolysis 
of the azomethine bond under acidic conditions.  On the other hand, HCA1 and HCA5 
from the CAH series remain reasonably stable under both basic and acidic conditions 
over a certain period of time. HCA5, which possesses an electron withdrawing 
substituent, undergoes hydrolysis, as indicated from the spectrum recorded after 5 
hours, no change was observed for HCA1. In addition, the corresponding Cu(II) 
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complex [Cu(CA1)2]  undergoes dissociation in acidic pH, however it re-forms and 
remains stable at basic pH. 
Stability studies in PBS buffer at pH 7.4 indicate that NaHL11, NaHL14 and 
NaHL16 undergo slow hydrolysis with a t1/2 ranging from 36 – 57 hours. Similarly, 
[Zn(HL11)2)] proved to be unstable in PBS buffer with a t1/2 of 32 hours. In contrast, the 
corresponding Cu(II) complexes are stable over a period of up to 6 days. Hence, the 
coordination of Cu(II) to PVAHs, helps to stabilise the ligands by preventing them from 
undergoing hydrolysis. Although HCA1 appears to be stable in PBS buffer over the 
monitored period of time, its Cu(II) complex rapidly dissociates in the buffer solution. 
This indicates that the bidentate mode of binding of CAHs is not as strong as the 
tridentate mode of binding of the PVAH ligands. 
The reaction of 4-methyl benzoyl hydrazide and 3-bromopyruvate leads to the 
formation the di-hydrazide analogue (NaH3D1) via dehalogenation. The identity of the 
product was confirmed using ESI MS and NMR spectroscopy. NaH3D1 is fairly stable in 
PBS buffer, which can be attributed to the C-N single bond r and/or the two aromatic 
rings of the molecule.  
Antitubercular activity tests revealed that the hydrazone formation increases the 
inhibitory activity of the corresponding hydrazides by almost 3-7-fold when tested under 
high iron conditions. In addition, coordinating the hydrazones to Cu(II) increases the 
activity further to up to 270-fold in certain complexes. The activity of some of the Cu(II) 
complexes of PVAHs are similar to that of the present antitubercular drug isoniazid and 
may potentially prove useful in resistant bacterial strains. The Cu(II) complexes of 
PVAHs possessing nitro, fluoro, methyl and tert-butyl groups are active, whereas those 
with methoxy, bromo and chloro substituents were inactive. In addition, the redox 
active nature of Cu(II) may add to the activity of the compounds and the coordination of 
Cu(II) to di-anionic PVAHs provided stability and lipophilicity to the resulting copper 
complexes. This cannot be achieved in Zn(II) complexes of PVAHs, and these hence 
fail to show any promising activity.  
The clogP values indicate greater lipophilicity of CAHs than PVAHs, which can be 
useful as it can facilitate the uptake of hydrophobic molecules across the lipophilic cell 
membrane of mycobacteria. Unfortunately, CAHs could not be tested for their 
antimycobacterial activity using the assay used for PVAH series due to their limited 
solubility in aqueous buffer. 
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In summary, the aim of this project to synthesise a series of metal-based 
antitubercular compounds has been achieved. The Cu(II) complexes of PVAHs which 
exhibited potential activity against Mtb can be considered as potential prodrugs for TB. 
6.2 Future Work 
This project can be taken to various directions which are as follows: 
• The reduction of the azomethine bond could not be achieved using sodium 
borohydride and catalytic hydrogenation. Hence strong reducing agents, such 
as LiAlH4 could be tried. If this proves to be successful, then the complexation 
of the reduced hydrazones could also be tried. The reduced hydrazones and 
their respective metal complexes can be further investigated for their stability in 
various pH conditions and their half-life can be determined using PBS buffer. In 
addition, antitubercular activity testing can also be carried out. 
• It is evident from the antitubercular studies that adding Fe(II) salts improves the 
activity of the compounds drastically. Hence, the synthesis of Fe(II) complexes 
of PVAHs can also serve as a good strategy to improve the MIC values of 
hydrazones and antitubercular studies could help to achieve a comparative 
study with Cu(II) complexes of PVAHs.  
• According to literature studies metal complexes have proven to combat 
bacterial resistance.87 Therefore, Cu(II) complexes of PVAHs which exhibited 
promising MIC values against INH susceptible bacteria can be tested for their 
potential against INH resistant strains. 
• As compounds containing the pyruvate moiety have been shown to inhibit the 
ICL enzyme53, PVAHs can be explored for ICL inhibition. This could be 
achieved by either co-crystallising PVAHs with the ICL enzyme so as to study 
the binding mode of the ligand with the active of the enzyme. Earlier 
computational studies have shown that PVAHs can bind in the active site of 
ICL84, hence to prove this concept co-crystallising PVAH/s with ICL can be 
tried. ICL enzyme inhibitory assays as reported earlier for hydrazones83 can 
also be tried in order to study the behavior of direct inhibition of the enzyme by 
PVAHs and their metal complexes. 
• Due to low solubility of the CAH ligands and their corresponding Cu(II) 
complexes in aqueous solution, the compounds precipitated from the buffer 
solution that was used for the antitubercular testing. In order to overcome this 
problem, testing could also be done using the disc diffusion method.306 This 
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would limit the requirement of an aqueous solution and allow hydrophobic 
molecules like CAHs to be put in direct contact with the bacterial cells, hence 
would increase their cellular uptake.  
• ClogP values of PVAH and CAH ligands were calculated using OSIRIS 
software programme217, however this software does not allow calculating the 
values of metal complexes. Instead, the logP could be obtained using the 
octanol/water partition coefficient method. The logP obtained for the ligands 
can be used as a comparative study with clogP values calculated using 
computational methods.  
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7.0 Experimental 
7.1 Materials  
Chemicals were purchased from the following suppliers: Pyruvic acid 
(Fluka), all commercial hydrazides, cinnamaldehyde and metal salts (Sigma-
Aldrich), TLC plates F254 (Merck), solvents, NaOH pellets, conc. HCl (Fisher 
scientific), Dulbecco’s PBS buffer (Sigma). 
7.2 Instrumentation 
1H and 13C NMR spectra were recorded on a JEOL ECS, ECX 400 (1H NMR 
400 MHz, 13C 100.6 MHz). Chemical shifts (δ) are given in terms of parts per million 
(ppm) referenced to the residual solvent d6-DMSO: 1H NMR 2.50 ppm,13C NMR 
39.52 ppm, d4-MeOD: 1H NMR 3.30 ppm,13C NMR 49.50 ppm, D2O: 1H NMR 4.90 
ppm. All carbon-13 experiments were confirmed using carbon-DEPT experiments. 
VT experiments were recorded on a Bruker 500 MHz instrument (1H NMR 500 MHz) 
and carried out by Heather Fish. The spectra were processed using Bruker’s 
Topspin software. TLC was carried out on a Merck silica gel 60 F254 aluminium 
backed plates using a chloroform:methanol solvent system and visualised under a 
UV lamp (chromato-vue Model CC-10) and/or stained with iodine. Infrared spectra 
were recorded on an Avatar 370 FT-IR Thermo Nicolet instrument (400 – 4000 cm-1) 
using KBr discs. The data was processed using OMNIC software. The KBr 
purchased from Sigma-Aldrich was used as obtained. Electro spray ionisation mass 
spectrometry (ESI-MS) spectra were recorded on a Bruker microTOF electrospray 
mass spectrometer by Dr. T. Dransfield and Dr. K. Heaton. Elemental (CHN) 
analysis was performed by Dr. P. Helliwell and Dr. G. McAllister on an Exeter 
analytical CE-440 elemental analyser. Melting points were measured on a Stuart 
Scientific SMP3 apparatus. Electron paramagnetic resonance (EPR) was performed 
on JEOL JESRE-1 X-band machine in Dr. Victor Chechik’s laboratory by Kazim 
Naqvi. 
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7.3 X-ray Crystallography 
 Single crystal X-ray diffraction data was collected and processed with the 
help of  Dr. A. Whitwood, Dr. R. Thatcher and Dr. S. Hart. 
7.3.1 Bruker SMART Apex 
Diffraction data for NaHL9.2H2O, NaHL112H2O, [Cu(L7)(H2O)(MeOH)], 
[Cu(L8)(MeOH)2], [Cu(L9)(H2O)2], [Cu(L11)(H2O)2].H2O, [Cu(L17)(H2O)2], 
[Cu(HL9)2Cl2], [Cu(HL15)2Cu(HL15(L15] and [Zn(HL8)2].H2O were collected on a 
Bruker Smart Apex diffractometer with Mo-Kα radiation (λ = 0.71073 Å) using a 
SMART CCD camera. Absorption corrections were applied by SADABS (v2.10).307 
Structures were solved by either direct or Patterson methods using SHELXS-97 and 
refined by full-matrix least squares using SHELXL-97.308 All non-hydrogen atoms 
were refined anisotropically. Hydrogen atoms were placed using a riding model and 
included in the refinement at calculated positions. Acidic protons were placed using 
difference map method. 
7.3.2 Oxford Diffraction SuperNova 
Diffraction data for H2L20.H2O, [Cu(L13)(H2O)(MeOH)], 
[Zn(II)(HL7)2].H2O.DMSO, [Zn(HL9)2].H2O.CH3OH, [Zn(HL13)2], 
[Cu(I)2HL8(PPh3)5]PF6, [Cu(I)2HL9(PPh3)5]PF6,  [Cu(I)2HL9(PPh3)4]PF6.2Et2O.H2O , 
HCA2 and HCA5 were collected on an Oxford Diffraction SuperNova diffractometer 
with Mo-Kα radiation (λ = 0.71073 Å) using a EOS CCD camera. The crystals were 
cooled with an Oxford Instruments Cryojet. Face-indexed absorption corrections 
were applied using SCALE3 ABSPACK scaling. OLEX2309  was used for overall 
structure solution, refinement and preparation of computer graphics and publication 
data.  Within OLEX2, the algorithms used for structure solution were either direct or 
Patterson methods using SHELXS-97 and refinement by full-matrix least-squares 
used SHELXL-97 within OLEX2. All non-hydrogen atoms were refined 
anisotropically. Hydrogen atoms were placed using a riding model and included in 
the refinement at calculated positions. Acidic hydrogen atoms were placed using 
difference map method. 
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7.4 Stability Studies using UV/vis Spectroscopy 
7.4.1 pH titrations 
7.4.1.1 Preparation of solution 
 Accurate weight measurements were conducted on a Mettler AE 240 five 
figure balance. The stock solution for pH titrations of PVAH series including NaHL9, 
NaHL20, [Cu(L20)(H2O)2], [Zn(HL20)2]  each with a  concentration of 1mM was 
prepared in deionised water. 5 mL of 1mM respective stock solution accurately 
measured using Eppendorf pipette were made up to a final concentration of 0.05 
mM using deionised water with 100 mL volumetric flask. The stock solution for pH 
titrations of CAH series including HCA1, HCA5 and [Cu(CA1)2] each with a 
concentration of 1mM was prepared in methanol. 2 mL of a 1mM respective stock 
solution accurately measured using Eppendorf pipette were made up to a final 
concentration of 0.02 mM using methanol:deionised water(4:1) with 100 mL 
volumetric flask. pH were adjusted using 0.001 M HCl and 0.001 M NaOH for acid 
and base titrations respectively. 0.001 M NaOH was made by dissolving NaOH 
pellets in deionised water and 0.001 M HCl was made using conc. HCl (12 M) in 
deionised water. pH values were determined using a WTW Profilab pH 597 pH 
meter with a Mettler Toledo Inlab 422 electrode.  
7.4.1.2 UV/vis measurements 
 Acid and base titrations were performed individually in two sets of 
experiments. The UV/vis spectra were recorded on a HP 8453 Agilent Diode Array 
spectrophotometer using a 5Q quartz UV cell with path length 10 mm. Dropwise 
addition of either 0.001 M HCl or 0.001 M NaOH was added to the respective stock 
solution (approx 40 mL) at regular intervals. Once the pH was stabilised, the 
solution was transferred into the UV cell and the UV/vis spectra were recorded in 
the 1.0 – 13.0 pH range at room temperature. These spectra were recorded 
manually at an interval ranging from 0.2-1.0 pH units. The UV/vis spectra were 
recorded in the range 200-1100 nm. 
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7.4.2 PBS stability studies 
7.4.2.1 Preparation of solution 
The stock solution for PBS stability studies of PVAH series including 
NaHL11, NaHL14, NaHL16, NaH3D1, [Cu(L11)(H2O)2], [Cu(L14)(H2O)2], 
[Cu(L16)(H2O)],  [Zn(HL11)2]  each with a  concentration of 1mM was prepared in 
spectroscopic grade DMSO. 0.05 mL of 1mM respective stock solution accurately 
measured using Eppendorf pipette were made up to a final concentration of 0.05 
mM using PBS buffer:DMSO (9:1) with 10 mL volumetric flask. Dulbecco’s PBS 
buffer purchased from Sigma was used as obtained. For CAHs series, the 
compounds including HCA1 and [Cu(CA1)2] the final concentration of 0.02 mM with 
a ratio of 1:1; PBS buffer:DMSO  was used. 
7.4.1.2 UV/vis measurements 
10 mL of final stock solution was incubated at 37 °C in a closed container 
(carousel tube). The temperature was maintained using a water bath with the 
carousel tube immersed in it. Solution was transferred to the UV cells at regular 
intervals (at indicated hours in the study) and the UV/vis spectra were recorded 
ranging from 200-1100 nm. 
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7.5 Electrochemistry 
Cyclic voltammetric experiments were preformed on an Epsilon, 
bioanalytical system instrument (BASi). The studies were carried out at room 
temperature using a standard three electrode configuration, consisting of a platinum 
working electrode, 1.6 mm (MF-2013), platinum wire as auxiliary electrode, 7.5 cm 
(MW-1032) and Ag/AgCl reference electrode (MF-2013) with supporting electrolyte 
0.1 M tetra-butyl ammonium hexafluorophosphate (TBAHFP) in DMSO. The 
Ag/AgCl reference electrode was stored in 3M NaCl solution. The solution was 
purged with N2 gas prior to use and maintained under a layer of N2 throughout the 
experiment. The platinum working electrode was polished with alumina on textmet 
pads, washed with deionised water and DMSO which was further dried before 
using. The concentration of the ligand and the complexes was approximately 2 mM 
and the cyclic voltammogram was scanned in DMSO. After use of the electrodes 
were washed with DMSO, water and conc. HNO3. Electrochemical grade, TBAHFP 
(99% CHN) was purchased from Fluka and used as obtained, whereas 
spectrophotometric grade DMSO (99.9%) was purchased from Sigma and dried 
over molecular sieves (3 Å) before use. Ferrocene (98 %) was purchased from 
Sigma-Aldrich and recrystallised using ethanol and then sublimed under vacuum 
using Schlenk lines. The sublimed ferrocene was used as an internal standard. 
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7.6 General synthetic procedure and characterisation detail of PVAHs 
(NaHL1-NaHL20) 
The respective hydrazide (1.82 mmol) and sodium pyruvate (1.82 mmol) 
were dissolved in 25 ml of a water-methanol mixture (methanol-water; 7:3). The 
solution was heated under reflux for 2 hours. The product was precipitated with 
Et2O, isolated and recrystallised from ethanol. The purified product was dried in 
vacuo 
NaHL1 
N
H
N
O
CH3
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Sodium 2-[(benzoyl)-hydrazono]-propionate 
NaHL1 was synthesised using sodium pyruvate 0.20 g (1.82 mmol) and 
benzoyl hydrazide 0.25 g (1.82 mmol) to give NaHL1, 0.34 g (1.49 mmol, 82%); 
Melting point: 110-112 °C; ESI-MS: positive ion m/z = 229.0586, 100%, HR ESI-
MS: For C10H10N2O3Na ([M+H]+), observed mass 229.0586, calculated mass 
229.0584, difference -0.3 mDa; δ  1H NMR (400 MHz, d6-DMSO): Major isomer: 
2.01 (s, 3H, H-3), 7.45-7.90 (m, 5H, H-6-8), 16.17 (bs, 1H, H-N), Minor isomer: 2.15 
(s, H-3); δ 13C NMR (100.6 MHz, d6-DMSO): Major isomer: 166.3 (4°), 162.0 (4°), 
150.7 (4°), 133.7 (4°), 131.7 (CH), 128.8 (CH), 126.9 (CH), 21.2 (CH3), Minor 
isomer: 132.2 (CH), 128.4 (CH), 128.2 (CH), 13.9 (CH3); Significant IR bands : 
(KBr disc, cm-1): (ν C=O, νas ym  COO, ν C=N ) 1645br. 
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Sodium 2-[(2-hydroxy-benzoyl)-hydrazono]-propionate 
NaHL2  was synthesized using sodium pyruvate 0.20 g (1.82 mmol) and 3-
hydroxy benzoyl hydrazide 0.28 g (1.82 mmol) to give NaHL2, 0.40 g (1.63 mmol, 
89%); Melting point: >350 °C; ESI-MS: positive m/z = 245.0541, 100%, HR ESI-
MS: For C10H10N2O4Na ([M+H]+), observed mass 245.0541, calculated mass 
245.0533, difference -0.8 mDa; δ 1H NMR (400 MHz, d6-DMSO): Major isomer: 2.05 
(s, 3H, H-3), 6.89 (apparent t, 1H, JH-H= 7.4 Hz, H-8 or H-9), 7.14 (d, 1H, JH-H= 8.4 
Hz, H-7 or H-10), 7.39 (apparent t, 1H, JH-H= 7.4 Hz, 1.4 Hz, H-7 or H-10), 7.68 (d, 
1H, JH-H= 8.4 Hz, 1.2 Hz, H-7 or H-10), 13.04 (1H, br, H-O) 16.02 (1H, br, H-N), 
Minor isomer: 2.09 (s, H-3), 6.83 (apparent t, JH-H= 7.4 Hz, H-8 or H-9), 7.01 (d, JH-
H= 8.4 Hz, H-7 or H-10), 7.33 (apparent t, JH-H= 7.4 Hz, H-8 or H-9), 7.95 (d, JH-H= 
8.4 Hz, H-7 or H-10); δ 13C NMR (100 MHz, d6-DMSO): Major isomer: 165.9 (4°), 
164.6 (4°), 160.2 (4°), 151.5 (4°), 133.7 (CH), 130.5 (CH), 117.8 (CH), 118.7 (CH), 
115.5 (C-4), 21.3 (CH3), Minor isomer: 167.2 (4°), 133.6 (CH), 130.5 (CH), 117.9 
(CH), 117.3 (CH), 48.6 (CH3), 12.9 (CH3); Significant IR bands : (KBr disc, cm-1): 
(ν OH) 3499br ,  (ν C=O) 1661s, (νas ym  COO, ν C=N) 1606s. 
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Sodium 2-[(3-hydroxy-benzoyl)-hydrazono]-propionate 
NaHL3 was synthesised using sodium pyruvate 0.20 g (1.82 mmol) and 3-
hydroxy-benzoyl hydrazide 0.27 g (1.82 mmol) to give NaHL3, 0.39 g (1.59 mmol, 
87%); Melting point: 278-281 °C; ESI-MS: positive m/z = 245.0533, 100%; HR ESI-
MS: For C10H10N2O4Na ([M+H]+), observed mass 245.0533, calculated mass 
245.0533, difference 0.0 mDa; δ 1H NMR (400 MHz, d6-DMSO): Major isomer: 2.01 
(s, 3H, H-3), 6.97 (dd, 1H, JH-H= 7.8 Hz, 2.08 Hz, H-8 or H-10), 7.78 (m 3H, H-6, H-
9, H-8 or H-10), 10.20 (bs, 1H, H-O), 15.92 (bs, 1H, H-N), Minor isomer: 2.16 (s, H-
3), 7.02 (d, JH-H= 7.8 Hz, H-8 or H-10); δ 13C NMR (100.6 MHz, d6-DMSO): Major 
isomer: 166.4 (4°), 162.3 (4°), 157.9 (4°), 150.5 (4°), 135.1 (4°), 129.8 (CH), 118.9 
(CH), 117.3 (CH), 114.1 (CH), 21.2 (CH3), Minor isomer: 129.6 (CH), 118.7 (CH), 
115.0 (CH), 13.9 (CH3); Anal. Calcd. for C10H9N2O4Na1 x 1.6  H2O: C, 44.00; H, 
4.50; N, 10.26. Found: C, 44.16; H, 4.43; N, 10.10; Significant IR bands : (KBr 
disc, cm-1): (ν OH) 3426br ,  (ν C=O) 1663s, (νas ym  COO) 1633s, (ν C=N) 
1612s. 
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Sodium 2-[(4-hydroxy-benzoyl)-hydrazono]-propionate 
NaHL4 was synthesised using sodium pyruvate 0.20 g (1.82 mmol) and 3-
hydroxy-benzoyl hydrazide 0.28 g (1.82 mmol) to give NaHL4, 0.37 g (1.51 mmol, 
83%); Melting point: 310-312 °C; ESI-MS: positive m/z =245.05, 100%, HR ESI-
MS: For C10H9N2O4Na ([M+H]+), observed mass 245.0533, calculated mass 
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245.0533, difference -0.0 mDa; δ 1H NMR (400 MHz, d6-DMSO): Major isomer: 2.01 
(s, 3H, H-3), 6.88 (d, 2H, JH-H= 8.4 Hz, H-6 or H-7), 7.68 (d, 2H, JH-H= 8.4 Hz, H-6 or 
H-7), 10.82 (bs, 1H, O-H),  15.75 (bs, 1H, N-H), Minor: 2.16(s, H-3), 7.84 (d, JH-H= 
8.4 Hz, H-6 or H-7); δ 13C NMR (100.6 MHz, d6-DMSO): Major isomer: 166.5 (4°), 
162.0 (4°), 149.5 (4°), 135.1 (4°), 128.9 (CH), 123.8 (4°), 115.4 (CH), 21.0 (CH3), 
Minor: 130.4 (CH), 115.1 (CH), 12.9 (CH3); Significant IR bands : (KBr disc, cm-1): 
(ν OH) 3452br ,  (ν C=O) 1684m, (ν C=O) 1659s, (νas ym  COO) 1630s, (ν 
C=N) 1610s. 
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Sodium 2-[(2-chloro-benzoyl)-hydrazono]-propionate 
NaHL5 was synthesized using sodium pyruvate 0.20 g (1.82 mmol) and 3-
hydroxy benzoyl hydrazide 0.25 g (1.82 mmol) to give NaHL5, 0.40 g (1.52 mmol, 
83%); Melting point: 105-108 °C; ESI-MS: positive m/z = 263.02, 100%, HR ESI-
MS: For C10H9N3O3Cl1Na ([M+H]+), observed mass 263.0202, calculated mass 
263.0194, difference -0.8 mDa; δ 1H NMR (400 MHz, d6-DMSO): Major isomer: 2.04 
(s, 3H, H-3), 7.31-7.57 (m, 4H, H-7-10), 15.48 (bs, 1H, H-N), Minor: 1.96, 1.72 (s, H-
3), 11.33 (bs, H-N), 15.10 (bs, H-N); δ 13C NMR (100.6 MHz, d6-DMSO): 135.6-
165.6 (4°), (126.7-131.6 (CH), 21.1, 14.0 (CH3); Anal. Calcd for C10H8N2O3Cl1Na1 x 
0.95 CH3OH x 0.05 moles H2O: C, 44.74; H, 4.08; N, 9.53. Found: C, 44.77; H, 
3.85; N, 9.31: Significant IR bands: (KBr disc, cm-1): (ν C=O) 1660s, (ν C=N) 
1610s.  
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Sodium 2-[(4-chloro-benzoyl)-hydrazono]-propionate 
NaHL6 was synthesised using sodium pyruvate 0.2 g (1.82 mmol) and 4-
chloro-benzoyl hydrazide 0.31 g (1.82 mmol) to give NaHL6, 0.43 g (1.64 mmol, 
90%); Melting point: 279-281 °C; ESI-MS: positive m/z = 263.0202, 100%; HR ESI-
MS: For C10H9N2O3Cl1Na ([M+H]+), observed mass 263.0202, calculated mass 
263.0194, difference -0.8 mDa; δ 1H NMR (400 MHz, d6-DMSO): Major isomer: 2.01 
(s, 3H, H-3), 7.58 (d, 2H, JH-H= 8.8 Hz, H-6 or H-7), 7.81 (d, 2H, JH-H=  8.8 Hz, H-6 or 
H-7), 16.48 (bs, 1H, H-N), Minor: 2.15 (s, H-3), 7.98, 7.85 (d, JH-H = 8.8 Hz, H-6 or 
H-7); δ 13C NMR (100.6 MHz, d6-DMSO): Major isomer: 166.3 (4°),160.9 (4°), 151.1 
(4°), 136.5 (4°), 132.5 (4°), 128.8 (CH), 128.4 (CH), 21.2 (CH3), Minor isomer: 130.2 
(CH), 128.4 (CH); Significant IR bands : (KBr disc, cm-1): (ν C=O) 1684s, (νas ym  
COO) 1649s, (ν C=N) 1612s.  
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Sodium 2-[(3-methyl-4-nitro-benzoyl)-hydrazono]-propionate 
NaHL7 was synthesised using sodium pyruvate 0.20 g (1.82 mmol) and 3-
methyl-4-nitro-benzoyl hydrazide 0.35 g (1.82 mmol) to give NaHL7, 0.43 g (1.5 
mmol, 82%); Melting point: 243-245 °C; ESI-MS: positive m/z = 288.06, 100%, HR 
ESI-MS: For C11H11N3O5Na ([M+H]+), observed mass 288.0581, calculated mass 
288.0596, difference 1.5 mDa; δ 1H NMR (400 MHz, d6-DMSO): 2.01 (s, 3H, H-3), 
2.56 (s, 3H, H-11), 7.78 (dd, 1H, JH-H=  8.3 Hz, 1.1 Hz, H-9 or H-10), 7.87 (s, 1H, H-
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6), 8.09 (d, 1H, JH-H=  8.5 Hz, H-9 or H-10),  16.60 (bs, 1H H-N); δ 13C NMR (100.6 
MHz, d6-DMSO): 165.9 (4°), 160.1 (4°), 151.7(4°), 150.5 (4°), 137.9 (4°), 133.2 (4°), 
131.4 (CH), 125.5 (CH), 124.9 (CH), 21.1 (CH3), 19.4 (CH3); Anal. Calcd. for 
C11H10N3O5Na1 x 0.25 CH3OH x 1.8 H2O: C, 40.95; H, 4.13; N, 12.45. Found: C, 
41.24; H, 4.49; N, 12.82; Significant IR bands: (KBr disc, cm-1): (ν C=O) 1662s, 
(νas ym  COO) 1627s, (νas ym  (N=O)2) 1522s ,   (νs ym  (N=O)2) 1356s .   
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Sodium 2-[(4-nitro-benzoyl)-hydrazono]-propionate 
 NaHL8 was synthesised using sodium pyruvate 0.20 g (1.82 mmol) and 4-
nitro-benzoyl hydrazide 0.33 g (1.82 mmol) to give NaHL8, 0.47 g (1.72 mmol, 
95%); Melting point: 204-205 °C; ESI-MS: positive m/z = 274.0429, 100%, HR ESI-
MS: For C10H9N3O5Na ([M+H]+), observed mass 274.0429, calculated mass 
274.0434, difference 0.5 mDa; δ 1H NMR (400 MHz, d6-DMSO): Major isomer: 2.01 
(s, 3H, H-3), 8.03 (d, 2H, JH-H= 8.8 Hz, H-6 or H-7), 8.34 (d, 2H, JH-H=  8.8 Hz, H-6 or 
H-7), 16.70 (bs, 1H, H-N), Minor isomer: 2.17 (s, H-3), 7.88, 8.15 (d, H-6 or H-7); δ 
13C NMR (100.6 MHz, d6-DMSO): 166.1 (4°), 160.2 (4°), 151.9 (4°), 149.2 (4°), 
139.6 (4°), 128.4 (CH), 124.0, (CH), 21.2 (CH3); Anal. Calcd. for C10H8N3O5Na1 x 
2.2 H2O: C, 38.40; H, 4.00; N, 13.28. Found: C, 38.69; H, 3.87; N, 13.43; 
Significant IR bands : (KBr disc, cm-1): (ν C=O) 1665s, (νas ym  COO) 1633s, (ν 
C=N) 1600s, (νas ym  (N=O)2) 1521s, (νs ym  (N=O)2) 1352s. 
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Sodium 2-[(4-methyl-benzoyl)-hydrazono]-propionate 
NaHL9 was synthesised using sodium pyruvate 0.20 g (1.82 mmol) and 4-
methyl benzoyl hydrazide 0.27 g (1.82 mmol) to give NaHL9, 0.38 g (1.57 mmol, 
86%); Melting point: 242-244 °C; ESI-MS: positive m/z = 243.07, 100%, HR ESI-
MS: For C11H12N2O3Na ([M+H]+), observed mass: 243.0738, calculated mass: 
243.0740, difference: 0.2 mDa; δ 1H NMR (400 MHz, d6-DMSO): Major isomer: 1.98 
(s, 3H, H-3),  2.36 (s, 3H, H-9), 7.31 (d, 2H, JH-H=  8.0 Hz, H-6 or H-7), 7.71 (d, 2H, 
JH-H=  8.0 Hz, H-6 or H-7), 16.20 (bs, 1H, H-N), Minor isomer: 2.14 (s, H-3), 7.34, 
7.84 (d, JH-H= 8.1 Hz, H-6 or H-7),; δ 13C NMR (100.6 MHz, d6-DMSO): Major 
isomer: 166.3 (4°), 161.9 (4°), 150.5 (4°), 141.7 (4°), 130.9 (4°), 129.3 (CH), 127.0 
(CH), 21.24 (CH3), 21.0 (CH3), Minor isomer: 128.9 (CH), 128.3 (CH), 21.1 (CH3), 
13.9 (CH3); Anal. Calcd for C11H12N2O3Na x 2.2 H2O: C, 46.88; H, 5.51; N, 9.94. 
Found: C, 46.92; H, 5.41; N, 9.75; Significant IR bands : (KBr disc, cm-1): (ν C=O) 
1649s, (νas ym  COO) 1631s, (ν C=N) 1610s. 
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Sodium 2-[(4-bromo-benzoyl)-hydrazono]-propionate 
NaHL10 was synthesised using sodium pyruvate 0.20 g (1.82 mmol) and 4-
bromo-benzoyl hydrazide 0.39 g (1.82 mmol) to give NaHL10, 0.48 g (1.56 mmol, 
86%); Melting point: 276 - 278 °C; ESI-MS: positive m/z = 306.97, 100%, HR ESI-
MS: For C10H9N3O3Br1Na ([M+H]+), observed mass 306.9685, calculated mass 
306.9689, difference 0.4 mDa; δ 1H NMR (400 MHz, d6-DMSO): Major isomer: 2.01 
(s, 3H, H-3), 7.48 (apparent t, 1H, JH-H= 7.88 Hz, H-9), 7.78 (m 2H, H-6, H-8 or H-
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10), 7.92 (s,1H, H-6), 16.46 (bs, 1H, H-N), Minor isomer: 2.16 (s, H-3), 8.09 (bs, 1H, 
H-N); δ 13C NMR (100.6 MHz, d6-DMSO): 166.1 (4°),160.3 (4°), 151.3 (4°), 134.4 
(CH), 131.0 (CH), 129.7 (CH), 129.3 (4°), 125.7 (CH), 122.1 (4°), 21.1 (CH3); 
Significant IR bands : (KBr disc, cm-1): (ν C=O) 1666s, 1649s, (νas ym  COO) 
1627s, (ν C=N)1606s. 
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Sodium 2-[(3-bromo-benzoyl)-hydrazono]-propionate 
NaHL11 was synthesised using sodium pyruvate 0.20 g (1.82 mmol) and 4-
bromo-benzoyl hydrazide 0.39 g (1.82 mmol) to give NaHL11, 0.54 g (1.75 mmol, 
96%); Melting point:  279-281 °C; ESI-MS: positive m/z = 306.9678, 100%, HR 
ESI-MS: For C10H9N2O3Na ([M+H]+), observed mass 306.9678, calculated mass 
306.9689, difference 1.1 mDa; δ 1H NMR (400 MHz, d6-DMSO): Major isomer: 2.01 
(s, 3H, CH3), 7.73 (apparent d, 4H, JH-H= 1.6 Hz, H-6 and H-7), 16.36 (bs, 1H, H-N); 
δ 
13C NMR (100.6 MHz, d6-DMSO): 166.2 (4°),161.0 (4°), 151.1 (4°), 131.8 (CH), 
132.9 (4°), 129.0 (CH), 125.4 (4°),  21.2 (CH3); Significant IR bands : (KBr disc, 
cm-1): (ν C=O) 1687s,  (νas ym  COO) 1648s, (ν C=N) 1627s. 
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Sodium; 2-[(3-methoxy-benzoyl)-hydrazono]-propionate 
NaHL12 was synthesised using sodium pyruvate 0.20 g (1.82 mmol) and 3-
methoxy-benzoyl hydrazide 0.30 g (1.82 mmol) to give NaHL12, 0.38 g (1.47 mmol, 
81%); Melting point: 268-270 °C; ESI-MS: positive m/z = 259.07, 100%, HR ESI-
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MS: For C11H12N2O4Na ([M+H]+), observed mass 259.0692, calculated mass 
259.0689, difference -0.3 mDa; δ 1H NMR (400 MHz, d6-DMSO): Major isomer: 2.00 
(s, 3H, H-3), 3.80 (s, 3H, H-11), 7.13 (d, 1H, JH-H= 8.0 Hz, H-8 or H-10 ), 7.42 (m, 
3H, H-6 and/or H-8-10), 16.22 (bs, 1H, H-N), Minor isomer: 2.14 (s, H-3), 3.80 (s, H-
11), 11.05 (bs, 1H, NH); δ 13C NMR (100.6 MHz, d6-DMSO): Minor isomer: 166.3 
(4°), 161.7 (4°), 159.4 (4°), 150.7 (4°), 135.1 (4°), 129.9 (CH), 118.8 (CH), 117.3 
(CH), 112.4 (CH), 55.2 (CH3), 21.2 (CH3), Minor isomer; 164.7 (4°), 162.6 (4°), 
159.1 (4°), 149.0 (4°), 129.5 (CH), 120.4 (CH), 117.8 (CH), 113.6 (CH), 55.3 (CH3), 
12.7 (CH3); Significant IR bands : (KBr disc, cm-1): (ν C=O) 1644s,  (νasym  COO) 
1628s, (ν C=N) 1601s. 
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Sodium 2-[(4-methoxy-benzoyl)-hydrazono]-propionate 
NaHL13 was synthesised using sodium pyruvate 0.2 g (1.82 mmol) and 4-
bromo-benzoyl hydrazide 0.30 g (1.82 mmol) to give NaHL13, 0.39 g (1.51 mmol, 
83%); Melting point: 240 - 242 °C; ESI-MS: positive m/z = 259.0697, 100%, HR 
ESI-MS: For C11H12N2O4Na ([M+H]+), observed mass 259.0697, calculated mass 
259.0689, difference -0.7 mDa; δ 1H NMR (400 MHz, d6-DMSO): Major isomer: 1.99 
(s, 3H, H-3), 3.79 (s, 3H, H-9), 7.03 (d, 2H, JH-H= 8.8 Hz, H6 or H-7), 7.77 (d, 2H, JH-
H= 8.8 Hz, H6 or H-7), 16.09 (bs, 1H, H-N), Minor isomer: 2.13 (s, H-3), 3.78 (s, H-
9), 6.98, 7.85 (d, JH-H = 7.2 Hz, 8.8 Hz, H-6 or H-7), 10.89 (bs, 1H, H-N); δ 13C NMR 
(100.6 MHz, d6-DMSO): Major isomer: 166.3 (4°), 161.5 (4°), 161.9(4°), 150.1 (4°), 
141.7 (4°), 128.8 (CH), 114.0 (CH), 21.2 (CH3), 55.4 (CH3), Minor isomer: 162.4 
(4°), 130.3 (CH), 113.5 (CH), 55.4 (CH3), 13.8 (CH3); Significant IR bands  (KBr 
disc, cm-1): (ν C=O) 1642s,  (νas ym  COO) 1625s, (ν C=N) 1607s. 
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Sodium 2-[(4-tert-butyl-benzoyl)-hydrazono]-propionate 
NaHL16 was synthesised using sodium pyruvate 0.2 g (1.82 mmol) and 4-
tert-butyl-benzoyl hydrazide 0.35 g (1.82 mmol) to give NaHL16, 0.46 g (1.75 mmol, 
96 %); Melting point: 260-262 °C; ESI-MS: positive m/z = 263.14, 100%, HR ESI-
MS: For C14H19N2O3 ([M-Na+2H]+), observed mass 263.1391, calculated mass 
263.1390, difference -0.1 mDa; δ 1H NMR (400 MHz, d6-DMSO): Major isomer: 1.29 
(s, 9H, H-10), 1.99 (s, 3H, H-3), 7.74 (d, 2H, JH-H=  8.0 Hz, H-6 or H-7), 7.51 (d, 2H, 
JH-H=  8.0 Hz, H-6 or H-7), 16.17 (bs, 1H, H-N) Minor isomer: 7.84 (d, JH-H=  8.0 Hz, 
Ar-H), 2.15 (s, 8); δ 13C NMR (100.6 MHz, d6-DMSO): Major isomer: 166.1 (4°), 
161.7 (4°), 154.4 (4°), 150.4 (4°), 131.1 (4°), 126.7 (CH), 125.4 (CH), 34.6 (4°), 30.9 
((CH3)3), 21.2 (CH3), Minor isomer: 128.0 (CH), 125.1 (CH), 34.7 (4°), 30.8 ((CH3)3), 
13.8 (CH3); Anal. Calcd for C14H17N2O3Na x 1.75 H2O: C, 53.24; H, 6.54; N, 8.87. 
Found C, 53.45; H, 6.41; N, 8.64; Significant IR bands (KBr disc, cm-1): (ν C=O) 
1651s, (νas ym  COO) 1635s, ν (C=N) 1609s.  
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Sodium; 2-[(4-trifluoro-benzoyl)-hydrazono]-propionate 
NaHL15 was synthesised using sodium pyruvate 0.20 g (1.82 mmol) and 4-
triflouromethyl benzoyl hydrazide 0.37 g (1.82 mmol) to give NaHL15, 0.48 g (1.62 
mmol, 89%); Melting point: 126-128 °C ; ESI-MS: positive m/z = 297.04, 100%, HR 
ESI-MS: For C11H9N2O3F3Na ([M+H]+), observed mass 297.0465, calculated mass 
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297.0457, difference -0.7 mDa; δ 1H NMR (400 MHz, d6-DMSO): 2.01 (s, 3H, H-3), 
7.89 (d, 2H, JH-H= 8.3 Hz, H-6 or H-7), 7.99 (d 2H, JH-H= 8.3 Hz, H-6 or H-7) 16.60 
(bs, 1H, H-N) ; δ 13C NMR (100.6 MHz, d6-DMSO): 165.9 (4°), 151.6 (4°), 160.5 
(4°), 137.8 (CH), 127.8 (CH) 131.3 (4°), 123.8 (C-9, 1J, JC-F = 271), 21.1 (CH3); 
Anal. Calcd. for C11H7N2O3F3Na2 x 1.4 CH3OH x 1.7 H2O: C, 37.83; H, 4.10; N, 
7.12. Found: C, 37.46; H, 3.73; N, 6.74; Significant IR bands  (KBr disc, cm-1): (ν 
C=O) 1653s, (νas ym  COO, ν C=N) 1632s. 
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Sodium 2-[(3-fluoro-benzoyl)-hydrazono]-propionate 
NaHL16 was synthesised using sodium pyruvate 0.20 g (1.82 mmol) and 3-
fluoro-benzoyl hydrazide 0.27 g (1.82 mmol) to give NaHL16, 0.36 g (1.46 mmol, 
80%); Melting point: 255-256 °C; ESI-MS: positive m/z = 247.05, 100%, HR ESI-
MS: For C10H9N2O3Na ([M+H]+), observed mass 247.0496, calculated mass 
247.0489, difference -0.7 mDa; δ 1H NMR (400 MHz, d6-DMSO): Major isomer: 1.99 
(s, 3H, H-3), 7.40-7.80 (m, 4H, H-6, H-8-10), 16.42 (bs, 1H, H-N), Minor isomer: 
2.15 (s, H-3), 11.15 (bs, 1H, H-N); δ 13C NMR (100.6 MHz, d6-DMSO): Major 
isomer: 166.2 (4°), 162.0 (1J, JC-F = 247, C-7), 160.6 (4J, JC-F = 3, C-4), 151.2 (4°), 
136.0 (3J, JC-F= 7, C-9), 122.0 (4J, JC-F = 3, C-10), 131.0 (3J, JC-F = 7, C-9), 118.0 (2J, 
JC-F = 22, C-6 or C-8), 113.0 (2J, JC-F = 22, C-6 or C-8),  21.1 (CH3); Anal. Calcd. for 
C10H8N2O3FNa1 x 0.15 7H3OH x 1.1 H2O: C, 45.02; H, 4.02; N, 10.34. Found: C, 
45.03;  H, 3.92; N, 10.30; Significant IR bands : (KBr disc, cm-1): (ν C=O, νas ym  
COO, ν C=N) 1635br. 
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Sodium 2-[(2-hydroxy-4-methoxy-benzoyl)-hydrazono]-propionate 
NaHL17 was synthesised using sodium pyruvate 0.20 g (1.82 mmol) and 2-
hydroxy-4-methoxy-benzoyl hydrazide 0.33 g (1.82 mmol) to give NaHL17, 0.46 g 
(1.68 mmol, 92%); Melting point: 258-260 °C, ESI-MS: negative m/z = 251.07, 
100%, HR ESI-MS: For C11H11N2O5 ([M-Na]-), observed mass 251.0665, calculated 
mass 251.0673, difference 0.9 mDa; δ 1H NMR (400 MHz, d6-DMSO): Major 
isomer: 2.03 (s, 3H, H-3), 6.38 (d, 1H, JH-H= 6.8 Hz, H-9 or H-10), 6.54 (s, 1H, H-7), 
7.86 (d, 1H, JH-H= 8.0 Hz, H-9 or H-10), 15.81 (bs, 1H, H-N), Minor isomer: 2.05 (s, 
3H, H-3), 6.48 (d, 1H, JH-H= 8.8 Hz, H-9, H-10), 6.68 (s, 1H, H-7), 7.57 (d, 1H, JH-H= 
8.8 Hz, H-9 or H-10), 13.39 (bs, 1H, NH); δ 13C NMR (100.6 MHz, d6-DMSO): Major 
isomer: 166.1 (4°), 164.7 (4°), 163.7 (4°), 150.6 (4°), 128.8 (4°), 128.8 (CH), 101.5 
(CH), 106.5 (CH), 55.5 (CH3), 21.2 (CH3), Minor isomer: 167.6 (4°), 164.8 (4°), 
162.6 (4°), 148.7 (4°), 132.0 (CH), 128.8 (4°), 101.6 (CH), 105.1 (CH), 55.1 (CH3), 
48.6 (CH3), 18.6 (CH3), 12.7 (CH3); Significant IR bands : (KBr disc, cm-1): (ν 
C=O) 1652s, (νas ym  COO, ν C=N) 1610s. 
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Sodium 2-[(pyridine-4-carbonyl)-hydrazono]-propionate 
NaHL18 was synthesised using sodium pyruvate 0.20 g (1.82 mmol) and 
pyridine-4-carbonyl-benzoyl hydrazide 0.25 g (1.82 mmol) to give NaHL18, 0.37 g 
(1.62 mmol, 89%), Melting point: 281-282 °C; ESI-MS: positive m/z = 208.07, 
100%, HR ESI-MS: For C9H10N3O3Na ([M-Na+2H]+), observed mass 208.0719, 
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calculated mass 208.0717, difference -0.2 mDa; δ 1H NMR (400 MHz, d6-DMSO): 
2.03 (s, 3H, H-3), 8.75 (dd, 2H, JH-H=  4.4 Hz, 1.6 Hz, H-6 or H-7), 7.70 (dd 2H, JH-H=  
4.4 Hz, 1.6 Hz, H-6 or H-7), 16.46 (bs, 1H, H-N); δ 13C NMR (100.6 MHz, d6-
DMSO): 166.3 (4°), 160.5 (4°), 152.0 (4°), 150.7 (CH),  132.5 (4°), 121.0  (CH), 21.2 
(CH3); Significant IR bands : (KBr disc, cm-1): (ν C=O, νas ym  COO, ν C=N) 
1644br. 
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Sodium 2-[(pyridine-3-carbonyl)-hydrazono]-propionate 
NaHL19 was synthesised using sodium pyruvate 0.20 g (1.82 mmol) and 
pyridine-3-carbonyl-benzoyl hydrazide 0.25 g (1.82 mmol) to give NaHL19, 0.34 g 
(1.49 mmol, 82%); Melting point: 265-267 °C; ESI-MS: positive m/z = 208.0717, 
100%, HR ESI-MS: For C9H10N3O3Na ([M-Na+2H]+), observed mass 208.0717, 
calculated mass 208.0717, difference -0.0 mDa; δ 1H NMR (400 MHz, d6-DMSO): 
2.02 (s, 3H, H-3), 8.97 (d, 1H, JH-H= 1.8 Hz, H-9), 8.74 (dd, 1H, JH-H=  1.6 Hz, 4.8 
Hz, H-6 or H-8), 8.14 8.74 (d,d  1H, JH-H=  1.9 Hz, 8.0 Hz, H-7), 7.55 (q, 1H, JH-H=  
4.8 Hz, H-7), 16.46 (bs, 1H, H-N); δ 13C NMR (100.6 MHz, d6-DMSO): 166.3 (4°), 
160.5 (4°), 152.4 (CH), 151.4 (4°), 148.0 (CH), 134.8 (CH), 129.4 (4°),124.0 (CH), 
21.2 (CH3); Significant IR bands: (KBr disc, cm-1): (ν C=O, νas ym  COO, ν C=N) 
1640br. 
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NaHL20 
N
N
N
H
N
O
CH3
O ONa 1
2
3
4
87
6 5
 
Sodium 2-[(pyrazine-2-carbonyl)-hydrazono]-propionate 
NaHL20 was synthesised using sodium pyruvate 0.20 g (1.82 mmol) and 
pyrazinoyl hydrazide 0.27 g (1.82 mmol) to give NaHL20 0.36 g (1.46 mmol, 80%); 
Melting point: decomp. > 200 °C; ESI-MS: positive m/z = 209.07, 100%, HR ESI-
MS: For C8H9N4O3 ([M-Na+2H]+), observed mass 209.0670, calculated mass 
209.0669, difference -0.1 mDa; δ 1H NMR (400 MHz, d6-DMSO): 2.02 (s, 3H, H-3), 
8.72 (dd, 1H, JH-H=  2.5 Hz, 1.5 Hz, H-7), 8.85 (d, 1H, JH-H=  2.5 Hz, H-6), 9.21 (d, 
1H, JH-H= 1.4 Hz, H-8); δ 13C NMR (100.6 MHz, d6-DMSO): 165.7 (4°), 159.1 (4°), 
152.0 (4°), 147.6 (CH), 143.9 (CH), 143.6 (4°), 21.4 (CH3); Anal. Calcd. for 
C8H7N4O3Na1 x 0.15 CH3OH x 1.75 H2O: C, 36.73; H, 4.20; N, 21.02. Found: C, 
36.55; H, 3.90; N, 20.76; Significant IR bands: (KBr disc, cm-1): (ν C=O) 1670s ,  
(νas ym  COO, ν C=N) 1625br .  
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7.7 Synthetic procedure and characterisation detail of the di-
hydrazide analogue; NaH3D1 
O
N
H
N
Na OO
HN
NH
O
H3C
H3C
H
H
4
3
3
i
1
2
ii
7iii
14
12
12
13
13
5
10
9
8
64
15
11
 
             Z isomer       (1)             
4
3
3
i
12
ii
7
iii
14
12
12
13
13
5
10
98
6
4
15
11
O
N
H
N
Na
H3C
O
O
NHH
H
HN
O
CH3
 
  
                          E isomer    (2)                  
Sodium 3-[N'-(4-methyl-benzoyl)-hydrazino]-2-[(4-methyl-benzoyl)-hydrazono]-
propionate 
NaH3D1 was synthesized by dissolving 3-bromopyruvate (0.2 g, 1.10 mmol) 
and 4-methyl benzoic acid hydrazide (0.32 mg, 2.05 mmol) in methanol with an 
equimolar amount of NaHCO3 (95 mg, 1.13 mmol). The reaction mixture was heated 
under reflux for 2 hours. A white precipitate was obtained, which was washed with 
an excess of methanol and water, filtered and dried under vacuum to give NaH3D1, 
0.24 g (0.06 mmol, 55%); Melting point: 248-250 °C; ESI-MS: negative m/z = 
367.1428, 100%, HR ESI-MS: For C19H19N4O4 ([([M-H-Na]-), observed mass 
367.1428, calculated mass 367.1412, difference -1.6 mDa; δ 1H NMR (400 MHz, d6-
DMSO): Z isomer: 2.36, (bs, 6H, H-1 and H-15), 3.69 (d, 2H, CH2, H-7), 5.70 
(apparent q, 1H, N(ii)-H), 7.22-7.76 (m, 8H, H-3-4 & H-12-13), 10.11 (d, 1H, N(i)-H), 
16.38, (s, 1H, N(iii)-H): E isomer : 2.33/2.30 (s, H-1 and H-15), 3.88 (s, CH2, H-7), 
7.22-7.76 (m, H-3-4 & H-12-13) 9.83 (bs, N(iii)H), 16.38 (s, 1H, N(i/ii)-H); 13C NMR 
(100.6 MHz, d6-DMSO): Z and E isomers: 166.59(4°), 166.25(4°), 165.96(4°), 
165.34(4°), 163.53(4°), 162.80(4°), 149.47(4°), 148.73(4°), 142.89(4°), 142.44(4°), 
142.03(4°), 141.55(4°), 131.15(4°), 130.93(4°), 130.75(4°), 130.35(4°), 129.91(CH), 
129.81(CH), 129.30(CH), 129.28(CH), 127.84(CH), 127.53(CH), 127.49(CH), 
127.45(CH), 60.45(CH2), 54.68(CH2), 20.94(CH3), 20.91(CH3), 20.85(CH3), 
20.84(CH3); Anal. Calcd. for C19H19N4O4Na x 1.6 H2O: C, 54.44; H, 5.34; N, 13.37. 
Found C, 54.01; H, 4.86; N, 13.11; Significant IR bands : (KBr disc, cm-1): (ν 
C=O) 1639s, (νas ym  COO, ν C=N) 1620br. 
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7.8 General synthetic procedure and characterisation detail of Cu(II)          
complexes of PVAHs [Cu(L1)(H2O)2]- [Cu(L20)(H2O)2] 
To a methanolic solution of the respective pyruvate-based aroylhydrazone 
(0.58 mmol) was added CuCl2 x 2 H2O (0.58 mmol). The mixture was stirred for 2 
hours. The resultant clear green solution was allowed to evaporate slowly giving 
green coloured crystalline powders which were isolated, washed with water and 
then re-dissolved in methanol. The resultant solution was allowed to evaporate 
slowly at room temperature, giving rise to green coloured crystals, which were 
isolated and dried in vacuo. 
[Cu(L1)(H2O)2]  
O
N
N O
O
CH3
Cu
H2O OH2
2+
 
[(Bis-hydroxy)(2-[(benzoyl)-hydrazono]-propionate)]copper(II) 
[Cu(L1)(H2O)2] was synthesised using NaHL1, 0.13 g (0.58 mmol) and 
CuCl2.2H2O, 0.10 g (0.58 mmol), to give [Cu(L1)(H2O)2], 0.067 g (0.22 mmol, 37 
%); Melting point: 245-247 °C; ESI-MS: positive ion m/z = 309.01, 20 %, ESI-
MS: For 63Cu1(I)C10H11N2O4Na1 ([M-H2O+H+Na)]+), observed mass: 309.01, 
calculated mass: 308.99; Anal. Calcd. for Cu1C10H12N2O5 x 0.45 H2O: C, 38.51; 
H, 4.17; N, 8.98. Found C, 38.35; H, 4.00; N, 8.83; Significant IR bands (KBr 
disc, cm-1): (ν C=O, νasym  COO, ν C=N) 1629br. 
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[Cu(L2)(H2O)2]  
O
N
N O
O
CH3
Cu
H2O OH2
2+OH
 
[(Bis-hydroxy)(2-[(2-hydroxy-benzoyl)-hydrazono]-propionate)]copper(II) 
 [Cu(L2)(H2O)2] was synthesised using NaHL2, 0.14 g (0.58 mmol) and 
CuCl2.2H2O 0.1 g (0.58 mmol), to give [Cu(L2)(H2O)2] 0.065 g (0.20 mmol, 35%); 
Melting point: > 350 °C; ESI-MS: positive ion m/z = 309.01, 20%, ESI-MS: For 
63Cu1(I)C10H11N2O4Na1 [M-H2O+H+Na)]+, observed mass: 309.01, calculated mass: 
308.99; Significant IR bands (KBr disc, cm-1): (ν C=O, νas ym  COO, ν C=N) 
1618br. 
 
[Cu(L3)(H2O)2]  
O
N
N O
O
CH3
Cu
H2O OH2
2+
HO
  
[(Bis-hydroxy)(2-[(3-hydroxy-benzoyl)-hydrazono]-propionate)]copper(II) 
 [Cu(L3)(H2O)2] was synthesised using NaHL3, 0.14 g (0.58 mmol) and 
CuCl2.2H2O 0.1 g (0.58 mmol), to give [Cu(L3)(H2O)2] 0.064 g (0.20 mmol, 34 %) 
Melting point: 265-268 °C; ESI-MS: positive ion m/z = 325.01, 67 %, ESI-MS: For 
63Cu1(I)C10H11N2O5Na1 [M-H2O+H+Na)]+), observed mass: 325.01, calculated mass: 
324.99; Anal. Calcd. for Cu1C10H12N2O6: C, 37.56; H, 3.78; N, 8.76. Found: C, 
37.53; H, 3.85; N, 8.23; Significant IR bands (KBr disc, cm-1): (ν C=O, νas ym  
COO, ν C=N) 1645br. 
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[Cu(L4)(H2O)2] 
O
N
N O
O
CH3
Cu
H2O OH2
HO
2+
 
[(Bis-hydroxy)(2-[(4-hydroxy-benzoyl)-hydrazono]-propionate)]copper(II) 
 [Cu(L4)(H2O)2] was synthesised using NaHL4, 0.14 g (0.58 mmol) and 
CuCl2.2H2O 0.1 g (0.58 mmol), to give [Cu(L4)(H2O)2] 0.061 g (0.20 mmol, 34 
%); Melting point: 310-312 °C; ESI-MS: positive ion m/z = 325.01, 15 %, ESI-
MS: For 63Cu1(I)C10H11N2O5Na1 ([M-H2O+H+Na)]+), observed mass: 325.01, 
calculated mass: 324.99; Significant IR bands (KBr disc, cm-1): (ν C=O, νas ym  
COO, ν C=N) 1642br. 
[Cu(L5)(H2O)2]  
O
N
N O
O
CH3
Cu
H2O OH2
2+Cl
 
[(Bis-hydroxy)(2-[(2-chloro-benzoyl)-hydrazono]-propionate)]copper(II) 
 [Cu(L5)(H2O)2] was synthesized using NaHL5, 0.15 g (0.58 mmol) and 
CuCl2.2H2O, 0.10 g (0.58 mmol), to give(0.32 mg, 2.05 mmol)  [Cu(L5)(H2O)2], 
0.06 g (0.18 mmol, 31 %); Melting point: decomposes above 200 °C; ESI-MS: 
positive ion m/z = 360.32, 100 %, ESI-MS: For 63Cu1C10H11N2O5Cl1Na1 
([M+Na]+), observed mass: 360.32, calculated mass: 359.95; Significant IR 
bands (KBr disc, cm-1): (ν C=O, νas ym  COO, ν C=N) 1630br. 
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[Cu(L6)(H2O)2]  
O
N
N O
O
CH3
Cu
H2O OH2
Cl
2+
 
[(Bis-hydroxy)(2-[(4-chloro-benzoyl)-hydrazono]-propionate)]copper(II) 
[Cu(L6)(H2O)2] was synthesised using NaHL6, 0.15 g (0.58 mmol) and 
CuCl2.2H2O, 0.10 g (0.58 mmol), to give [Cu(L6)(H2O)2], 0.10 g (0.30 mmol, 52%); 
Melting point: 249-251 °C; ESI-MS: positive ion m/z = 325.01, 80 %, ESI-MS: For 
63Cu1(I)C10H11N2O5Na1 ([M-H2O+H+Na)]+), observed mass: 342.98, calculated mass: 
324.95; Anal. Calcd. for Cu1C10H11N2O5Cl (0.5 CH3OH, 0.15 x H2O): C, 35.33; H, 
3.76; N, 7.85. Found C, 34.95; H, 3.33; N, 7.43; Significant IR bands (KBr disc, 
cm-1): (ν C=O, νas ym  COO, ν C=N) 1633br. 
[Cu(L7)(H2O)2]  
O
N
N O
O
CH3
Cu
H2O OH2
2+
H3C
O2N
 
[(Bis-hydroxy)(2-[(3-methyl-4-nitro-benzoyl)-hydrazono]-propionate)]copper(II) 
[Cu(L7)(H2O)2] was synthesized using NaHL7, 0.17 g (0.58 mmol) and 
CuCl2.2H2O, 0.10 g (0.58 mmol), to give [Cu(L7)(H2O)2], 0.12 g (0.31 mmol, 54%); 
Melting point: 210-212 °C; ESI-MS: positive ion m/z = 368.02, 19 %, ESI-MS: For 
63Cu(I)1C11H12N3O6Na1 ([M-H2O+H+Na)]+), observed mass: 368.02, calculated 
mass: 368.00; Anal. Calcd. for Cu1C11H13N3O7 x 0.1 H2O: C, 36.06; H, 3.69; N, 
11.47. Found: C, 36.06; H, 3.55; N, 11.35; Significant IR bands: (KBr disc, cm-1): 
(ν C=O, νas ym  COO, ν C=N) 1642 br, (νas ym  (N=O)2) 1524s, (νs ym  (N=O)2) 
1360s. 
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[Cu(L8)(H2O)2] 
O
N
N O
O
CH3
Cu
H2O OH2
2+
O2N
 
[(Bis-hydroxy)(2-[(4-nitro-benzoyl)-hydrazono]-propionate)]copper(II) 
  [Cu(L8)(H2O)2] was synthesised using NaHL8, 0.16 g (0.58 mmol) and 
CuCl2.2H2O, 0.10 g (0.58 mmol), to give [Cu(L8)(H2O)2], 0.08 g (0.24 mmol, 41 %); 
Melting point: 250-252 °C; ESI-MS: positive ion m/z = 372.01, 100 %, ESI-MS: For 
63Cu(I)1C10H12N3O7Na1 ([M+H+Na]+), observed mass: 372.01, calculated mass: 
371.99; Anal. Calcd. for Cu1C10H11N3O7 x 1.15 H2O: C, 32.51; H, 3.63; N, 11.37. 
Found: C, 32.67; H, 3.31; N, 11.05; Significant IR bands (KBr disc, cm-1): (ν C=O, 
νas ym  COO, ν C=N) 1639br, (νas ym  (N=O)2) 1527s, (νs ym  (N=O)2) 1347s. 
[Cu(L9)(H2O)2] 
O
N
N O
O
CH3
Cu
H2O OH2
H3C
2+
 
[(Bis-hydroxy)(2-[(4-methyl-benzoyl)-hydrazono]-propionate)]copper(II) 
[Cu(L9)(H2O)2] was synthesised using NaHL9, 0.14 g (0.58 mmol) and 
CuCl2.2H2O, 0.10 g (0.58 mmol), to give [Cu(L9)(H2O)2] 0.13 g ( 0.38 mmol, 65 
%); Melting point: 223-225 °C; ESI-MS: positive ion m/z = 341.04, 100 %, ESI-
MS: For 63Cu(I)1C11H14N2O5 ([M+H+Na]+), observed mass: 341.04, calculated 
mass: 341.02; Anal. Calcd. for Cu1C11H14N2O5 x 0.3 H2O: C, 40.88; H, 4.55; N, 
8.67. Found C, 40.54; H, 4.23; N, 8.48; Significant IR bands: (KBr disc, cm-1): 
(ν C=O) 1653s ,  (νas ym  COO) 1637s ,  (ν C=N) 1609br. 
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[Cu(L10)(H2O)2] 
O
N
N O
O
CH3
Cu
H2O OH2
2+
Br
 
[(Bis-hydroxy)(2-[(3-bromo-benzoyl)-hydrazono]-propionate)]copper(II) 
 [Cu(L10)(H2O)2] was synthesised using NaHL10, 0.18 g (0.58 mmol) and 
CuCl2.2H2O, 0.10 g (0.58 mmol), to give [Cu(L10)(H2O)2], 0.092 g (0.24 mmol, 
42 %); Melting point: 247-249 °C; ESI-MS: positive ion m/z = 327.01, 100 %, 
ESI-MS: For 63Cu(I)1C10H10N2O4Br1Na1 ([M-H2O+H+Na]+), observed mass: 
388.93, calculated mass: 388.63; Significant IR bands: (KBr disc, cm-1): (ν 
C=O, νas ym  COO, ν C=N) 1643br 
[Cu(L11)(H2O)2] 
O
N
N O
O
CH3
Cu
H2O OH2
Br
2+
 
 
[(Bis-hydroxy)(2-[(4-bromo-benzoyl)-hydrazono]-propionate)]copper(II) 
[Cu(L11)(H2O)2] was synthesised using NaHL11, 0.18 g (0.58 mmol) and 
CuCl2.2H2O, 0.10 g (0.58 mmol), to give [Cu(L11)(H2O)2], 0.12 g (0.31 mmol, 
54%); Melting point: 239-241 °C; ESI-MS: positive ion m/z = 388.93, 100 %, 
ESI-MS: For 63Cu(I)1C10H10N2O4Br1Na1 ([M-H2O+H+Na]+), observed mass: 
388.93, calculated mass: 388.63; Anal. Calcd. for Cu1C11H13N2O5Br: C, 33.31; 
H, 3.30; N, 7.06. Found C, 33.41; H, 2.84; N, 7.11; Significant IR bands: (KBr 
disc, cm-1): (ν C=O, νasym  COO, ν C=N) 1635br. 
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[Cu(L12)(H2O)2] 
 
O
N
N O
O
CH3
Cu
H2O OH2
2+
H3CO
 
 
[(Bis-hydroxy)(2-[(3-methoxy-benzoyl)-hydrazono]-propionate)]copper(II) 
[Cu(L12)(H2O)2] was synthesised using NaHL12, 0.15 g (0.58 mmol) and 
CuCl2.2H2O, 0.10 g (0.58 mmol), to give [Cu(L12)(H2O)2], 0.088 g (0.23 mmol, 
39%); Melting point: 229-231 °C; ESI-MS: positive ion m/z = 339.03, 15 %, 
ESI-MS: For 63Cu1(I)C11H14N2O6 ([M-H2O+H+Na]+), observed mass: 339.03, 
calculated mass: 339.00; Significant IR bands: (KBr disc, cm-1): (ν C=O, 
νas ym  COO) 1642br ,  (ν C=N) 1609s. 
[Cu(L13)(H2O)2] 
O
N
N O
O
CH3
Cu
H2O OH2
H3CO
2+
 
[(Bis-hydroxy)(2-[(3-methoxy-benzoyl)-hydrazono]-propionate)]copper(II) 
 [Cu(L13)(H2O)2] was synthesized using NaHL13, 0.15 g (0.58 mmol) and 
CuCl2.2H2O, 0.10 g (0.58 mmol), to give [Cu(L13)(H2O)2], 0.11 g (0.30 mmol, 51%); 
Melting point: 229-231 °C; ESI-MS: positive ion m/z = 339.03, 15 %, ESI-MS: For 
63Cu1(I)C11H14N2O6 ([M-H2O+H+Na]+), observed mass: 339.03, calculated mass: 
339.00; Anal. Calcd for Cu1C11H14N2O6: C, 39.58;  H, 4.23; N, 8.39 C, Found 39.70; 
H, 4.01; N, 8.24; Significant IR bands: (KBr disc, cm-1): (ν C=O, νas ym  COO) 
1639br ,  (ν C=N) 1603s. 
                                                                                                      Chapter-7                                                                                    
 258 
[Cu(L14)(H2O)2] 
O
N
N O
O
CH3
Cu
OH2
2+
 
[(2-[(4-tert-butyl-benzoyl)-hydrazono]-propionate)(hydroxy)]copper(II) 
[Cu(L14)(H2O)] was synthesized using NaHL14, 0.16 g (0.58 mmol) and 
CuCl2.2H2O 0.1 g (0.58 mmol), to give [Cu(L14)(H2O)] 0.1 g (0.27 mmol, 47 %); 
Melting point: 244-247 °C; ESI-MS: positive ion m/z = 365.08, 100 %, ESI-MS: For 
63Cu(I)1C14H19N2O4Na1 ([M-H+Na]+), observed mass: 365.08, calculated mass: 
365.05; Anal. Calcd. for Cu1C14H18N2O4 x 0.25 CH3OH: C, 48.92; H, 5.47; N, 8.01. 
Found: C, 49.09;  H, 5.38; N, 7.87; Significant IR bands (KBr disc, cm-1): (ν C=O) 
1645s  (νas ym  COO) 1628s ,  (ν C=N) 1602s. 
[Cu(L15)(H2O)2] 
O
N
N O
O
CH3
Cu
H2O OH2
2+
F
 
[(Bis-hydroxy)(2-[(3-flouro-benzoyl)-hydrazono]-propionate)]copper(II) 
 [Cu(L15)(H2O)2] was synthesized using NaHL15, 0.14 g (0.58 mmol) and 
CuCl2.2H2O, 0.10 g (0.58 mmol), to give [Cu(L15)(H2O)2], 0.06 g (0.19 mmol, 32 %); 
Melting point: 232-235 °C; ESI-MS: positive ion m/z = 327.01, 4 %, ESI-MS: For 
63Cu(I)1C10H10N2O4F1Na1 ([M-H2O+H+Na]+), observed mass: 327.01, calculated 
mass: 326.98; Anal. Calcd. for Cu1C10H11N2O5F1 x 0.27 H2O: C, 45.02; H, 3.56; N, 
8.57. Found: C, 45.03;  H, 3.29; N, 8.25; Significant IR bands (KBr disc, cm-1): (ν 
C=O, νas ym  COO, ν C=N) 1630br .  
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[Cu(L16)(H2O)2] 
O
N
N O
O
CH3
Cu
H2O OH2
F3C
2+
 
[(Bis-hydroxy)(2-[(4-triflouromethyl -benzoyl)-hydrazono]-propionate)]copper(II) 
 [Cu(L16)(H2O)2] was synthesized using NaHL16, 0.17 g (0.58 mmol) and 
CuCl2.2H2O 0.1 g (0.58 mmol), to give [Cu(L16)(H2O)2], 0.08 g (0.21 mmol, 36 %); 
Melting point: 214-217°C; ESI-MS: positive ion m/z = 394.99, 100 %, ESI-MS: For 
63Cu(I)1C11H12N2O5F3Na1 ([M+H+Na]+), observed mass: 394.99, calculated mass: 
395.01; Anal. Calcd. for Cu1C11H11N2O5F3 x 0.27 H2O: C, 34.28; H, 3.27; N, 7.27. 
Found: C, 34.28; H, 3.07; N, 6.77; Significant IR bands (KBr disc, cm-1): (ν C=O, 
νas ym  COO, ν C=N) 1633br .  
[Cu(L17)(H2O)2] 
O
N
N O
O
CH3
Cu
H2O OH2
H3CO
2+OH
 
 
[(Bis-hydroxy)(2-[(2-hydroxy-4-methoxy-benzoyl)-hydrazono]-propionate)]copper(II) 
[Cu(L17)(H2O)2] was synthesized using NaHL17, 0.16 g (0.58 mmol) and 
CuCl2.2H2O, 0.10 g (0.58 mmol), to give [Cu(L17)(H2O)2], 0.07 g (0.19 mmol, 34 %); 
Melting point: 244-246 ° C; ESI-MS: positive ion m/z = 353.07, 60 %, ESI-MS: For 
63CuC11H12N2O6Na1 ([M-H2O+Na]+), observed mass: 353.07, calculated mass: 
353.98; Significant IR bands: (KBr disc, cm-1): (ν C=O) 1676s ,  (νas ym  COO) 
1614s ,  (ν C=N) 1600s .  
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[Cu(L18)(H2O)Cu(L18)] 
N
O
N
N
O
O
H3C
Cu
H2
O Cu
N
O
N
N
O
O
CH3
2+ 2+
 
[2-[( pyridine-4-carbonyl)-hydrazono]-propionate]µ-hydroxy copper(II) 
[Cu(L18)(H2O)Cu(L18)] synthesized using NaHL18, 0.13 g (0.58 mmol) and 
CuCl2.2H2O, 0.10 g (0.58 mmol), to give [Cu(L18)(H2O)Cu(L18)], 0.10 g (0.36 mmol, 
62 %); Melting point: decomposes above 300 °C; Anal. Calcd. for Cu2C18H16N6O7 
x 0.2 CH3OH, 0.1 H2O: C, 38.78; H, 3.04; N, 14.91. Found C, 38.71; H, 2.77; N, 
14.63; Significant IR bands: (KBr disc, cm-1): (ν C=O) 1670s ,  (νas ym  COO) 
1640s ,  ν C=N) 1619s .  
[Cu(L19)(H2O)Cu(L19)] 
N
O
N
N
O
O
H3C
Cu
H2
O Cu
N
O
N
N
O
O
CH3
2+ 2+
 
[2-[( pyridine-3-carbonyl)-hydrazono]-propionate]copper(II) 
[Cu(L19)(H2O)Cu(L19)] was synthesized using NaHL19, 0.13 g (0.58 mmol) and 
CuCl2.2H2O, 0.10 g (0.58 mmol), to give [Cu(L19)(H2O)Cu(L19)], 0.11 g (0.39 mmol, 
68 %); Melting point: decomposes above 300 °C; Significant IR bands: (KBr disc, 
cm-1): (ν C=O) 1661s ,  (νas ym  COO, ν C=N) 1614br .  
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[Cu(L20)(H2O)(Cl)] 
N
N
O
N
H
N O
O
CH3
Cu
2+
H2O Cl
 
[2-[(pyrazine-2-carbonyl)-hydrazono]-propionate]copper(II) 
[Cu(L20)(H2O)(Cl)] synthesized using NaHL20, 0.13 g (0.58 mmol) and 
CuCl2.2H2O, 0.10 g (0.58 mmol), to give [Cu(HL20)(H2O)(Cl)], 0.11 g (0.34 mmol, 
58 %). Melting point: 137-139 °C; ESI-MS: positive ion m/z = 311.02, 100 %, ESI-
MS: For 63Cu(I)1C8H9N4O4Na1 ([M-Cl+Na]+), observed mass: 311.02, calculated 
mass: 310.99; Anal. Calcd. for Cu1C8H9N4O4Cl x 1.0 H2O x 0.1  CH3OH: C, 28.00; 
H, 3.17; N, 16.03. Found C, 27.81; H, 2.88; N, 15.78; Significant IR bands: (KBr 
disc, cm-1): (ν C=O) 1645s ,  (νas ym  COO, ν C=N) 1614br .  
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7.9 Synthesis and characterisation detail of the Cu(I) complexes of 
HL8- and HL9- 
Synthesis of [Cu(I)(CH3CN)4]PF6   
 To a stirred suspension of Cu2O (1g, 7 mmol) in acetonitrile (20 ml) was 
added 60 % HPF6 (2.5 ml) in 0.5 ml portions. The heat released helps to dissolve 
the white solid formed. The hot solution was stirred for 3 minutes. The solution was 
then cooled to room temperature and left in the freezer for 3 hours. The resulting 
precipitate was isolated by filtration and dried in vacuo to afford the title compound 
as a white solid (2.6 g, 50 %). The solid was stored under N2.173  
δ 
1H NMR (400 MHz, CDCl3): δ 2.19 (s) 
Synthesis of [Cu(I)2HL9(PPh3)5]PF6  
N
O
N
CH3
O
O
Cu Cu
Ph3P
PPh3
PPh3
Ph3P
PPh3
H3C
1+ 1+
c
b
b
a
d c
Har
 
[Cu(I)(CH3CN)4]PF6- (0.6 g, 1.65 mmol) was dissolved in anhydrous and 
degassed THF (15 mL) and added to a methanolic solution (15 mL) of ligand L9 
(0.20 g, 0.82 mmol) under an atmosphere of N2 to yield a yellow-brown solution. 
After stirring the reaction mixture for 10 minutes at room temperature, 
triphenylphosphine (1.08 g, 4.13 mmol), dissolved in dry and degassed THF (10 
mL), was added to the reaction mixture. The resultant pale yellow solution was 
concentrated in vacuo to a volume of 5 mL, to which Et2O was added. The resulting 
precipitate obtained after addition of Et2O was filtered and dried under vacuo to 
yield the title compound as pale yellow solid. The solid was recrystallised from hot 
MeOH to yield a colourless crystalline powder. Crystals suitable for single crystal X-
ray diffraction were obtained from MeOH and Et2O. 
Yield: 90 mg (0.69 mmol, 84%); Melting point: 163-165 °C; 
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ESI-MS: The dinuclear copper complex gave the following ESI-MS peaks 
corresponding to the two different Cu(I) centres 
Positive ion, m/z reported for 63Cu: 
587.1111 (60 %) – [Cu(PPh3)2]+ 
807.1956 (60 %) – [L9Cu2(PPh3)2]+ 
849.2031 (100 %) – [Cu(PPh3)3]+ 
1) [L9Cu2(PPh3)2]+ 
HR ESI-MS for C47H42CuN2O3P2 [M+], observed mass 807.1956, calculated mass 
807.3380, difference -1.4 mDa 
2) [Cu(PPh3)3]+ 
HR ESI-MS for C54H45CuP3 [M+], observed mass 849.2043, calculated mass 
849.2025, difference -1.8 mDa 
δ 
1H NMR (400 MHz, d4- MeOH): 1.84 (s, 3H, H-a), 2.41 (s, 3H, H-d), 7.33 (d, 2H, 
JH-H = 8.1 Hz, H-b or H-c), 7.69 (d, 2H, JH-H=  8.1 Hz, H-b or H-c), 7.40 (m, 15 H, Har 
(PPh3)),  7.23 (m, 60 H, Har (PPh3)); Anal. Calcd. for Cu2C101H86N2O3P6F6 (3.75 x 
CH3OH): C, 65.43; H, 4.29; N, 1.46. Found C, 65.08; H, 4.94; N, 1.54; Significant 
IR bands: (KBr disc, cm-1): (νas ym  COO, ν C=O, ν C=N) 1622br .  
Synthesis of [Cu(I)2HL8(PPh3)5]PF6  
N
O
N
CH3
O
O
Cu Cu
Ph3P
PPh3
PPh3
Ph3P
PPh3
O2N
1+ 1+
c
b
b
a
c
Har
 
[Cu(I)(CH3CN)4]PF6 (0.3 g, 0.8 mmol) was dissolved in anhydrous and 
degassed methanol (15 ml) and added to a methanolic solution (15 ml) of ligand L8 
(0.22g, 0.4 mmol) under an atmosphere of N2 to yield a yellow-brown solution. After 
stirring the reaction mixture for 10 minutes at room temperature, triphenylphosphine 
(0.42g, 2.0 mmol) dissolved in dry and degassed MeOH was added to the reaction 
mixture. The resultant green solution was concentrated in vaccuo to yield a light 
green precipitate. The reaction mixture was filtered and the filtrate was left to stand 
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at room temperature for 24 hours. Bright yellow single crystals suitable for X-ray 
diffraction were obtained from the filtrate. The solution was filtered and the solid 
obtained was dried in vacuo to yield the title compound as yellow crystalline solid. 
Yield: 0.33 g (45 %, 0.18 mmol); Melting point: 210-212 °C; 
ESI-MS: The dinuclear complex yielded the follwing ESI-MS peaks corresponding to 
the two different Cu(I) centres 
Positive ion, m/z reported for 63Cu  
587.1120 (100 %) – [Cu(PPh3)2]+ 
838.1663 (10 %) – [L8Cu2(PPh3)2]+ 
849.2043 (40 %) – [Cu(PPh3)3]+ 
1) L8Cu2(PPh3)2 
HR ESI-MS for C46H39CuN3O5P2 [M+], observed mass 838.1663, calculated mass 
838.1655, difference -0.7 mDa 
2) Cu(PPh3)3 
HR ESI-MS for C54H45CuP3 [M+], observed mass 849.2043, calculated mass 
849.2025, difference -1.8 mDa 
δ 
1H NMR (400 MHz, d4- MeOH): 1.94 (s, 3H, H-a), 7.98 (d, 2H, JH-H= 8.8 Hz, H-a or 
H-b), 8.35 (d, 2H, JH-H=  8.8 Hz, H-a or H-b), 7.27-7.44 (m, 75H, Har (PPh3)) 
Significant IR bands: (KBr disc, cm-1): (νas ym  COO, ν C=O) 1632br ,  (ν C=N) 
1597s, (νas ym  (N=O)2) 1527s, (νs ym  (N=O)2) 1346s. 
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7.10 General synthetic procedure and characterisation detail of Zn(II) 
complexes of PVAHs [Zn(HL1)2]  - [Zn(HL20)2] 
To a methanolic solution of the respective pyruvate-based aroylhydrazone 
(0.35 mmol) was added ZnSO4.7H2O (0.17 mmol). The mixture was stirred for 2 
hours. The resultant white precipitate, which was isolated was washed with water 
and dried in vacuo. 
[Zn(HL1)2] 
O
N
H
N O
O
CH3
Zn
O
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N
H
O
O
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6
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6
7
6
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Bis[2-[(benzoyl)-hydrazono]-propionate] zinc(II) 
[Zn(HL1)2] was synthesised using ZnSO4.7H2O 0.05 g (0.17 mmol) and 
NaHL1 0.080 g (0.35 mmol) to give 0.040 g [Zn(HL1)2], (0.068 mmol, 40 %); Melting 
point: 266-268 °C; ESI-MS: positive ion m/z = 475.0564, 10 %, HR ESI-MS: For 
64ZnC20H19N4O6 [(M+H)+], observed mass: 475.0564, calculated mass: 475.0591, 
difference mDa: 2.7 mDa; δ 1H NMR (400 MHz, d6-DMSO): 2.36 (s, 6H, H-3), 7.54 
(m, 4H, H-6 or H-7), 7.65 (m, 2H, H-8), 7.97 (s, 4H, H-6 or H-7); Anal. Calcd. for 
Zn1C20H18N4O6 x 2.25 H2O: 46.53; H, 4.39; N, 10.85. Found: C, 46.17; H, 4.02; N, 
10.55; Significant IR bands: (KBr disc, cm-1): (ν C=O, νas ym  COO, ν C=N) 
1631br. 
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Bis[2-[(2-hydroxy- benzoyl)-hydrazono]-propionate] zinc(II) 
[Zn(HL2)2] was synthesised using ZnSO4.7H2O 0.05 g (0.17 mmol) and 
NaHL2 0.09 g (0.35 mmol) to give 0.050 g [Zn(HL)2] (0.10 mmol, 58%); Melting 
point: >350 °C; ESI-MS: positive ion m/z = 507.0491, 46 %, HR ESI-MS: For 
64ZnC20H18N4O8 [(M+H)+], observed mass: 507.0491, calculated mass: 507.0489, 
difference: -0.4 mDa; δ 1H NMR (400 MHz, d6-DMSO): 2.18 (s, 3H, H-3), 6.93 (m, 
2H, Ar-H), 7.39 (d,t, 2H, JH-H = 7.8 Hz, 1.6 Hz Ar-H), 7.87 (d, 1H, JH-H= 7.5 Hz, Ar-H); 
Anal. Calcd. for Zn1C22H23N4O6 x 0.45 H2O: 46.57; H, 3.69; N, 10.86. Found: C, 
46.49; H, 3.57; N, 10.74; Significant IR bands: (KBr disc, cm-1): (ν OH) 3406br ,  
(ν C=O) 1650s ,  (νas ym  COO, ν C=N) 1614br. 
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Bis[2-[(3-hydroxy- benzoyl)-hydrazono]-propionate] zinc(II) 
[Zn(HL3)2] was synthesised using ZnSO4.7H2O 0.05 g (0.17 mmol) and 
NaHL3 0.086 g (0.35 mmol) to give 0.035 g [Zn(HL3)2], (0.07 mmol, 40%); Melting 
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point: 312-314 °C; ESI-MS: positive ion m/z = 507.0501, 40 % HR ESI-MS: For 
64ZnC20H19N4O8 [(M+H)+], observed mass: 507.0501, calculated mass: 507.0489, 
difference: -1.3 mDa; δ 1H NMR (400 MHz, d6-DMSO): 2.37 (s, 6H, H-3), 7.05 (d, 
2H, JH-H= 7.4 Hz, H-8 or H-10), 7.34 (m, 4H, H-9 and/or H-8,10), 7.41 (s, 2H, JH-H= 
7.8 Hz, H-6), 9.93 (bs, 2H, H-O), 12.72 (bs, 2H, H-N); Anal. Calcd. for 
Zn1C20H19N4O6 x 2.1 H2O: 44.03; H, 4.10; N, 10.27. Found: C, 43.54; H, 3.52; N, 
10.04; Significant IR bands: (KBr disc, cm-1): (ν OH) 3341br ,  (ν C=O) 1640s ,  
(νas ym  COO, ν C=N) 1618br 
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Bis[2-[(4-hydroxy- benzoyl)-hydrazono]-propionate] zinc(II) 
[Zn(HL4)2] was synthesised using ZnSO4.7H2O 0.05 g (0.17 mmol) and 
NaHL4 0.09 g (0.35 mmol) to give [Zn(HL4)2], (0.01 mmol, 58%); Melting point: 
322-324 °C; ESI-MS: positive ion m/z = 507.0499, 50 %, HR ESI-MS: For 
64ZnC20H19N4O8 [(M+H)+], observed mass: 507.0499, calculated mass: 507.0489, 
difference: -1.0 mDa; δ 1H NMR (400 MHz, d6-DMSO): 2.20 (s, 6H, H-3), 7.49 (d, 
4H, JH-H = 8.3 Hz H-6 or H-7), 8.10 (d, 4H, JH-H= 8.3 Hz, H-6 or H-7). 
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Bis[2-[(2-chloro-benzoyl)-hydrazono]-propionate]zinc(II) 
[Zn(HL5)2] was synthesised using ZnSO4.7H2O 0.05 g (0.17 mmol) and 
NaHL5 0.09 g (0.35 mmol) to give [Zn(HL5)2], (0.01 mmol, 58%); Melting point: 
261-263 °C; ESI-MS: positive ion m/z = 542.9828, 5%, HR ESI-MS: For 
64ZnC20H17N4O6Cl2 [(M+H)+], observed mass: 542.9828, calculated mass: 541.9811, 
difference: -1.7 mDa, difference: -1.0 mDa; δ 1H NMR (400 MHz, d6-DMSO): 2.18 
(s, 6H, H-3), 6.47 (m, 4H, H-8,9), 7.80 (d, 4H, JH-H = 8.8 Hz, H-7,10); Significant IR 
bands: (KBr disc, cm-1): (ν C=O, νas ym  COO) 1625s ,  (ν C=N) 1609s. 
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Bis[2-[(4-chloro-benzoyl)-hydrazono]-propionate]zinc(II) 
[Zn(HL6)2] was synthesised using ZnSO4.7H2O 0.05 g (0.17 mmol) and 
NaHL6 0.09 g (0.35 mmol) to give [Zn(HL6)2], 0.060 g (0.11 mmol, 65 %); Melting 
point: 249-251°C; ESI-MS: positive ion m/z = 542.9811, 20 % HR ESI-MS: For 
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64ZnC20H17N4O6Cl2 [(M+H)+], observed mass: 542.9826, calculated mass: 541.9811, 
difference: -1.5 mDa; δ 1H NMR (400 MHz, d6-DMSO): 2.18 (s, 6H, H-3), 7.55 (d, 
4H, Ar-H, JH-H = 8.5 Hz H-6 or H-7), 8.04 (d, 4H, JH-H = 8.5 Hz, H-6 or H-7); Anal. 
Calcd for Zn1C20H16N4O6Cl2 x 2.50 H2O: 40.74; H, 2.96; N, 10.29. Found: C, 40.52; 
H, 3.35; N, 9.38. Significant IR bands: (KBr disc, cm-1): (ν C=O) 1650s ,  (νas ym  
COO, ν C=N) 1614br 
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Bis[2-[(3-methyl-4-nitro-benzoyl)-hydrazono]-propionate]zinc(II) 
[Zn(HL7)2] was synthesised using ZnSO4.7H2O 0.05 g (0.17 mmol) and 
NaHL7 0.10 g (0.35 mmol) to give [Zn(HL7)2], 0.051 g (0.085 mmol, 50 %); Melting 
point: 287-289 °C; ESI-MS: positive ion m/z = 593.0596, 10 %, HR ESI-MS: For 
64ZnC22H21N6O10 [(M+H)+], observed mass: 593.0596, calculated mass: 593.0605, 
difference: 0.9 mDa; δ 1H NMR (400 MHz, d6-DMSO): 2.27 (s, 6H, H-3), 2.55 (s, 6H, 
H-11), 8.04 (bs, 6H, H-6,9,10); Anal. Calcd. for Zn1C22H20N6O10 x 1.6 H2O: 42.44; 
H, 3.76; N, 13.50. Found: C, 42.08; H, 3.36; N, 13.16; Significant IR bands (KBr 
disc, cm-1): (ν C=O, νas ym  COO, ν C=N) 1631br, (νas ym  (N=O)2) 1526s, (νs ym  
(N=O)2) 1358s. 
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[Zn(HL8)2] was synthesised using ZnSO4.7H2O 0.05 g (0.17 mmol) and 
NaHL8 0.10 g (0.35 mmol) to give [Zn(HL8)2], 0.054 g (0.095 mmol, 56 %); Melting 
point: 282-284 °C; ESI-MS: positive ion m/z = 565.00, 5 %, ESI-MS: For 
64ZnC20H17N6O10 [(M+H)+], observed mass: 565.00, calculated mass: 565.00; Anal. 
Calcd for Zn1C20H16N6O10 x 0.75 CH3OH, 0.2 H2O: 42.00; H, 3.30; N, 14.16. Found: 
C, 42.80; H, 3.02; N, 13.91; Significant IR bands: (KBr disc, cm-1): (ν C=O) 
1638s ,  (νas ym  COO, ν C=N) 1621br, (νas ym  (N=O)2) 1530s, (νs ym  (N=O)2) 
1338br.. 
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Bis[2-[(4-methyl-benzoyl)-hydrazono]-propionate]zinc(II) 
[Zn(HL9)2] was synthesised using ZnSO4.7H2O 0.050 g (0.17 mmol) and 
NaHL9 0.85 g (0.35 mmol) to give 0.046 g [Zn(HL9)2], 0.046 g (0.09 mmol, 54%); 
Melting point: 244-246 °C; ESI-MS: positive ion m/z = 503.0911, 30 %, HR ESI-
MS: For 64ZnC22H23N4O6 [(M+H)+], observed mass: 503.0911, calculated mass: 
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503.0904, difference: -1.6 mDa; δ 1H NMR (400 MHz, d6-DMSO): 2.39 (s, 12H, H-
3,9), 7.35 (d, 4H, JH-H= 7.9 Hz, H-6 or H-7), 7.90 (d, 4H, JH-H= 7.9 Hz, H-6 or H-7), 
12.69 (bs, 1H, H-N); Anal. Calcd for Zn1C22H22N4O6 x 2.25 H2O: 48.54; H, 4.91; N, 
10.29. Found: C, 48.49; H, 4.79; N, 10.21; Significant IR bands: (KBr disc, cm-1): 
(ν C=O) 1649s ,  (νas ym  COO) 1623s,  (ν C=N) 1618s. 
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Bis[2-[(3-bromo-benzoyl)-hydrazono]-propionate] zinc(II) 
[Zn(HL10)2] was synthesised using ZnSO4.7H2O 0.05 g (0.17 mmol) and 
NaHL10 0.11 g (0.35 mmol) to give [Zn(HL10)2], 0.09 g (0.14 mmol, 84%); Melting 
point: 262-263 °C; ESI-MS: positive ion m/z =, HR ESI-MS: For 64ZnC20H17N4O6Br2 
[(M+H)+], observed mass:, calculated mass: 630.8801, difference: 0.3 mDa; δ 1H 
NMR (400 MHz, d6-DMSO): 2.29 (s, 6H, H-3), 7.76 (d, 2H, JH-H= 7.6 Hz, H-8 or H-
10), 7.44 (t, 2H, JH-H = 7.9 Hz, H-9), 8.17 (s, 2H, H-6), 8.00 (d, 2H, JH-H= 7.2 Hz, H-8 
or H-10); Anal. Calcd for Zn1C20H16N6O6Br2 x 1.15 H2O: 36.72; H, 2.82; N, 8.56. 
Found: C, 36.92; H, 2.65; N, 8.35. 
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Bis[2-[(4-bromo-benzoyl)-hydrazono]-propionate] zinc(II) 
[Zn(HL11)2] was synthesised using ZnSO4.7H2O 0.05 g (0.17 mmol) and 
sodium; 2-[(4-bromo-benzoyl)-hydrazono]-propionate 0.11 g (0.35 mmol) to give 
[Zn(HL11)2], 0.087 (0.136 mmol, 81 %) Melting point: 260-262 °C; ESI-MS: 
positive ion m/z = 630.8799, 6 %, HR ESI-MS: For 64ZnC20H17N4O6Br2 [(M+H)+], 
observed mass: 630.8799, calculated mass: 630.8801, difference: -1.6 mDa; δ 1H 
NMR (400 MHz, d6-DMSO): 2.30 (s, 6H, CH3), 7.70 (d, 4H, JH-H= 7.8 Hz Ar-H), 7.95 
(d, 4H, JH-H = 7.8 Hz Ar-H); Anal. Calcd. for Zn1C20H16N6O6Br2 x 2.15 H2O: 35.73; H, 
3.04; N, 8.33. Found: C, 35.98; H, 2.79; N, 8.08; Significant IR bands: (KBr disc, 
cm-1): (ν C=O, νas ym  COO, ν C=N 1627br. 
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Bis [2-[(3-methoxy-benzoyl)-hydrazono]-propionate] zinc(II) 
[Zn(HL12)2] was synthesised using ZnSO4.7H2O 0.05 g (0.17 mmol) and 
NaHL12 0.09 g (0.35 mmol) to give [Zn(HL12)2], (0.01 mmol, 58%); Melting point: 
269-271 °C; ESI-MS: positive ion m/z = 535.0810, 60 %, HR ESI-MS: For 
64ZnC22H23N4O6 [(M+H)+], observed mass: 535.0810, calculated mass: 535.0802, 
difference: -1.6 mDa; δ 1H NMR (400 MHz, d6-DMSO): 2.34 (s, 6H, H-3), 3.81 (s, 
6H, H-11), 7.19 (d, 2H, JH-H= 7.0 Hz, H-8 or H-10), 7.43 (t, 2H, JH-H = 8.0 Hz, H-9), 
7.51 (s, 2H, H-6), 7.59 (d, 2H, JH-H= 7.0 Hz, H-8 or H-10) 
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Bis[2-[(4-methoxy-benzoyl)-hydrazono]-propionate] zinc(II) 
[Zn(HL13)2] was synthesised using ZnSO4.7H2O 0.05 g (0.17 mmol) and 
NaHL13 0.09 g (0.35 mmol) to give [Zn(HL13)2], 0.055 g (0.10 mmol, 60 %); 
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Melting point: 287-289 °C; ESI-MS: positive ion m/z = 535.0805, 85 %, HR ESI-
MS: For 64ZnC22H23N4O6 [(M+H)+], observed mass: 535.0805, calculated mass: 
535.0802, difference: 0.3 mDa; δ 1H NMR (400 MHz, d6-DMSO): 2.22 (s, 6H, H-3), 
3.81 (s, 6H, H-9), 7.00 (d, 4H, JH-H=  8.4 Hz, H-6 or H-7),  8.05 (d, 4H, JH-H=  8.4 Hz, 
H-6 or H-7); Anal. Calcd. for Zn1C22H22N4O8 x 1.7 H2O: 46.65; H, 4.52; N, 9.89. 
Found: C, 46.11; H, 3.92; N, 9.51; Significant IR bands: (KBr disc, cm-1): (ν C=O, 
νas ym  COO) 1628s ,  (ν C=N) 1606s. 
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Bis[2-[(4-tert-butyl-benzoyl)-hydrazono]-propionate] zinc(II) 
[Zn(HL14)2] was synthesised using ZnSO4.7H2O 0.05 g (0.17 mmol) and 
NaHL14 0.10 g (0.35 mmol) to give [Zn(HL14)2], (0.01 mmol, 58%); Melting point: 
257-259 °C; ESI-MS: positive ion m/z = 587.1857, 10 %, HR ESI-MS: For 
64ZnC28H35N4O6 [(M+H)+], observed mass: 587.1857, calculated mass: 587.1843, 
difference: -2.5 mDa; δ 1H NMR (400 MHz, d6-DMSO): 2.27 (s, 6H, H-3), 1.29 (s, 
18H, H-10), 7.45 (d, 4H, JH-H=  8.0 Hz, H-6 or H-7),  7.97 (bs, 4H, H-6 or H-7); 
Significant IR bands (KBr disc, cm-1): (ν C=O, νas ym  COO, ν C=N ) 1624br. 
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Bis[2-[(4-tri-fluoro-methyl)-benzoyl-hydrazono]-propionate] zinc(II) 
[Zn(HL15)2] was synthesised using ZnSO4.7H2O 0.05 g (0.17 mmol) and  
NaHL15 0.10 g (0.35 mmol) to give [Zn(HL15)2] 0.070 g (0.11 mmol, 67%); Melting 
point: 262-264 °C; δ 1H NMR (400 MHz, d6-DMSO): 2.26 (s, 6H, H-3), 7.86 (d, 2H, 
JH-H= 6.9 Hz, H-6 or H-7), 8.20 (apparent bs, 4H, H-6 or H-7); Anal. Calcd. for 
Zn1C22H16N4O6F6 x 1.1 H2O x 0.45 CH3OH: C, 41.74; H, 3.12; N, 8.67. Found: C, 
41.45; H, 2.75; N, 8.30, Significant IR bands: (KBr disc, cm-1): (ν C=O, νas ym  
COO, ν C=N) 1617br. 
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Bis[2-[(3-fluoro-benzoyl)-hydrazono]-propionate] zinc(II) 
[Zn(HL16)2] was synthesised using ZnSO4.7H2O 0.05 g (0.17 mmol) and 
NaHL16 0.09 g (0.35 mmol) to give [Zn(HL16)2], 0.047 g (0.09 mmol, 54%); Melting 
point: 249-251 °C; ESI-MS: positive ion m/z = 511.0399, 100 %, HR ESI-MS: For 
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64ZnC20H17N4O6F2 [(M+H)+], observed mass: 511.0399, calculated mass: 511.0402, 
difference: 0.7 mDa; δ 1H NMR (400 MHz, d6-DMSO): 2.28 (s, 6H, CH3), 7.45 (m, 
2H, Har), 7.55 (d, 2H, JH-H = 6.3 Hz, Har), 7.79 (m, 4H, Har), 12.74 (bs, 2H, NH); δ 
Anal. Calcd. for Zn1C20H16N4O6F2 x 1.55 H2O: 44.51; H, 3.57; N, 10.38. Found: C, 
44.35; H, 3.30; N, 10.12; Significant IR bands (KBr disc, cm-1): (ν C=O, νas ym  
COO, ν C=N) 1634br. 
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Bis[2-[(2-hydroxy-4-methoxy-benzoyl)-hydrazono]-propionate] zinc(II) 
 [Zn(HL17)2] was synthesised using ZnSO4.7H2O 0.05 g (0.17 mmol) and 
NaHL17 0.09 g (0.35 mmol) to give [Zn(HL17)2], 0.047 g (0.09 mmol, 52%); 
Melting point: 249-251 °C; ESI-MS: positive ion m/z = 511.0399, 30 %, HR 
ESI-MS: For 64ZnC20H17N4O6F2 [(M+H)+], observed mass: 511.0399, calculated 
mass: 511.0402, difference: 0.7 mDa; δ 1H NMR (400 MHz, d6-DMSO): 2.16 (s, 
6H, H-3), 3.76 (s, 6H, H-11), 6.47 (m, 4H, H-7, H-9 or H-10), 7.80 (d, 2H, JH-H = 
8.7 Hz, H-9 or H-10); Significant IR bands: (KBr disc, cm-1): (ν OH) 3432br ,  
(ν C=O, νas ym  COO, ν C=N ) 1606br. 
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Bis[2-[( pyridine-4-carbonyl)-hydrazono]-propionate] zinc(II) 
[Zn(HL18)2] was synthesised using ZnSO4.7H2O 0.05 g (0.17 mmol) and 
NaHL18 0.09 g (0.35 mmol) to give [Zn(HL18)2], 0.065 g (0.14 mmol, 82%); 
Melting point: decomposes above 300 °C; Anal. Calcd. for Zn1C18H16N6O6 x 
4.4 H2O: 38.81; H, 4.49; N, 15.09. Found: C, 39.14; H, 4.12; N, 14.76. 
Significant IR bands: (KBr disc, cm-1): (ν C=O, νas ym  COO, ν C=N) 
1652br. 
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Bis[2-[( pyridine-4-carbonyl)-hydrazono]-propionate] zinc(II) 
[Zn(HL19)2] was synthesised using ZnSO4.7H2O 0.05 g (0.17 mmol) and 
NaHL19 0.09 g (0.35 mmol) to give [Zn(HL19)2], 0.047 g (0.09 mmol, 55%); 
Melting point: decomposes above 300 °C; Significant IR bands: (KBr Disc, 
cm-1): (ν C=O) 1661s ,  (νas ym  COO) 1634s ,  (ν C=N) 1610s. 
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Bis[2-[( pyrazine-2-carbonyl)-hydrazono]-propionate] zinc(II) 
[Zn(HL20)2] was synthesised using ZnSO4.7H2O 0.05 g (0.17 mmol) and 
NaHL16 0.09 g (0.35 mmol) to give [Zn(HL20)2], 0.057 g (0.12 mmol, 72%); 
Melting point: decomposes above 200 °C; δ 1H NMR (400 MHz, D2O): 2.03 (s, 
6H, H-3), 8.60 (dd, 2H, JH-H = 3.0 Hz, 1.2 Hz, H-6 or H-7), 9.14 (d, 2H, JH-H = 2.8 
Hz, H-6 or H-7), 9.67 (s, 2H, H-8); Significant IR bands: (KBr disc, cm-1): (ν 
C=O, νas ym  COO, ν C=N ) 1616br. 
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7.10 General synthetic procedure and characterisation detail of CAHs 
(HCA1-HCA14) 
 
Cinnamaldehyde (1.5 mmol) was added dropwise to an ethanolic solution of the 
respective hydrazide (1.25 mmol). The mixture was then refluxed for 5 hours and 
the precipitate that formed after slow cooling of the solution was isolated by 
filtration. The volume of the filtrate was reduced to approximately a quarter of the 
initial volume. The solid formed was isolated by filtration and the two solids were 
combined and dried under vacuo. 
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Benzoic acid (3-phenyl-allylidene)-hydrazide 
HCA1 was synthesised using cinnamaldehyde 0.24 g (1.85 mmol) and 
benzoyl hydrazide 0.18 g (1.32 mmol) to give HCA1, 0.23 g (0.92 mmol, 73%); 
Melting point: 193-194 °C; ESI-MS: positive ion m/z = 251.1181, 100%, HR ESI: 
For C16H15N2O2 ([M+H]+), observed mass 251.1181, calculated mass 251.1179, 
difference 0.2 mDa; δ 1H NMR (400 MHz, d6-DMSO): 11.75  (bs, 1H, H-N), 8.23 
(dd, 1H, JH-H = 6.8 Hz, 1.2 Hz, H-6), 7.89 (d, 2H, JH-H = 7.6 Hz, Har), 7.31-7.90 (m, 
8H, Har), 7.06 – 7.08 (m, 2H, H-4,5); δ 13C NMR (100.6 MHz, d6-DMSO): δ 163.0 
(4°), 149.7 (CH), 139.0 (CH), 135.9 (4°), 133.4 (4°), 131.7 (CH), 128.8 (CH), 128.4 
(CH), 127.6 (CH), 127.1 (CH), 125.6 (CH); Significant IR bands (KBr disc, cm-1): (ν 
NH) 3268m, (ν C=O) 1646s, (ν C=N) 1624s. 
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4-Chloro-benzoic acid (3-phenyl-allylidene)-hydrazide 
HCA2 was synthesised using cinnamaldehyde 0.2 g (1.50 mmol) and 4-
chloro-benzoyl hydrazide 0.21 g (1.25 mmol) to give HCA2, 0.28 g (0.98 mmol, 
78%); Melting point: 223-224 °C; ESI-MS: positive ion m/z = 285.0786, 100%, HR 
ESI-MS: For C16H14N2OCl ([M+H]+), observed mass 285.0786, calculated mass 
285.0789, difference 0.3 mDa; δ 1H NMR (400 MHz, d6-DMSO): 11.80  (bs, 1H, H-
N), 8.23 (t, 1H, 3JH-H = 4.0 Hz, H-6), 7.93 (d, 2H, JH-H = 8.4 Hz, Har), 7.31-7.64 (m, 
7H, Har) 7.06 – 7.08 (m, 2H, H-4,5); δ 13C NMR (100.6 MHz, d6-DMSO): δ 161.8 
(4°), 150.0 (CH), 139.1 (CH), 136.4 (4°), 135.8 (4°), 132.0 (4°), 129.4 (CH), 128.7 
(CH), 128.4 (CH), 127.0 (CH), 125.5 (CH); Anal. Calcd for C16H13N2OCl: C, 67.49; 
H, 4.60; N, 9.84. Found C, 67.44; H, 4.61; N, 9.74; Significant IR bands (KBr disc, 
cm-1): (ν NH) 3268m, (ν C=O) 1660s, (ν C=N) 1625s. 
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4-Methyl-benzoic acid (3-phenyl-allylidene)-hydrazide 
HCA3 was synthesised using cinnamaldehyde 0.2 g (1.50 mmol) and 4-
methyl-benzoyl hydrazide 0.19 g (1.25 mmol) to give HCA3, 0.27 g (1.00 mmol, 
80%); Melting point: 125-127 °C; ESI-MS: positive ion m/z = 265.1345 100%, HR 
ESI-MS: For C17H17N2O ([M+H]+), observed mass 265.1345, calculated mass 
265.1335, difference 1.0 mDa; δ 1H NMR (400 MHz, d6-DMSO): δ 11.67  (bs, 1H, 
H-N), 8.24 (d, 1H, 3JH-H = 7.4 Hz, H-6), 7.81 (d, 2H, JH-H = 8.1 Hz, Har), 7.31 (m, 7H, 
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Har) 7.10 – 7.01 (m, 2H, H-4,5), 2.38 (s, 3H, H-11); δ 13C NMR (100.6 MHz, d6-
DMSO): δ 162.8 (4°), 149.3 (CH), 141.6 (4°), 138.6 (CH), 135.8 (4°), 130.4 (4°), 
128.9 (CH), 128.7 (CH), 127.5 (CH), 126.9 (CH), 125.6 (CH), 21.5 (CH3); Anal. 
Calcd for C17H16N2O: C, 77.24; H, 6.10; N, 10.60. Found C, 77.07; H, 6.10; N, 
10.70; Significant IR bands (KBr disc, cm-1): ν (NH) 3200m, (ν C=O) 1637s, (ν 
C=N) 1525s. 
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4-Methoxy-benzoic acid (3-phenyl-allylidene)-hydrazide 
HCA4 was synthesised using cinnamaldehyde 0.20 g (1.5 mmol) and 4-
methoxy-benzoyl hydrazide 0.21 g (1.25 mmol) to give HCA4, 0.25 g (0.89 mmol, 
71%); Melting point:  217-219 °C; ESI-MS: positive ion m/z = 281.1290, 100%; HR 
ESI-MS: For C17H17N2O2 ([M+H]+), observed mass 281.1290, calculated mass 
281.1285, difference 0.6 mDa; δ 1H NMR (400 MHz, d6-DMSO): δ 11.62  (bs, 1H, 
H-N), 8.23 (d, 1H, 3JH-H = 7.3 Hz, H-6), 7.90 (d, 2H, JH-H = 8.4 Hz, Har), 7.62 (d, 2H, 
JH-H = 7.4 Hz, Har), 7.04-7.40 (m, 7H, Har, H-4,5) 3.83 (s, 3H, H-11); δ 13C NMR 
(100.6 MHz, d6-DMSO): δ 162.4 (4°), 162.0 (4°), 149.1 (CH), 138.6 (CH), 136.0 (4°), 
129.5 (CH), 128.8 (CH), 127.0 (CH), 125.8 (CH), 125.4 (4°), 113.7 (CH), 55.4 (CH3); 
Significant IR bands (KBr disc, cm-1): (ν NH) 3195m,  (ν C=O) 1634s, ν (C=N) 
1622s. 
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4-Nitro-benzoic acid (3-phenyl-allylidene)-hydrazide 
HCA5 was synthesised using cinnamaldehyde 0.20 g (1.5 mmol) and 4-
nitro-benzoyl hydrazide 0.23 g (1.25 mmol) to give HCA5, 0.31 g (1.06 mmol, 85%); 
Melting point: 243-245 °C; ESI-MS: positive ion m/z = 296.1023, 100%; HR ESI-
MS: For C16H14N3O3 ([M+H]+), observed mass 296.1023, calculated mass 296.1030, 
difference 0.6 mDa; δ 1H NMR (400 MHz, d6-DMSO): δ 12.01  (bs, 1H, H-N), 8.37 
(d, 2H, 3JH-H = 8.8 Hz, H-8 or H-9), 8.25 (dd, 1H, JH-H = 6.2 Hz, 2.5 Hz, H-6), 8.14 (d, 
2H, JH-H = 8.8 Hz, H-8 or H-9), 7.64 (d, 2H, JH-H = 7.2 Hz, H-2 or H-3), 7.32-7.42 (m, 
3H, H-1, H-2 or H-3) 7.09 – 7.10 (2H, m, H-4,5); δ 13C NMR (100.6 MHz, d6-DMSO): 
δ 161.3 (4°), 150.9 (CH), 149.2 (4°), 139.8 (4°), 139.1 (CH), 135.8 (4°), 129.2 (CH), 
129.0 (CH), 128.8 (CH), 127.2 (CH), 125.4 (CH), 123.6 (CH); Anal. Calcd for 
C16H13N3O3: C, 65.08; H, 4.43; N, 14.23. Found C, 64.70; H, 4.50; N, 13.96; 
Significant IR bands (KBr disc, cm-1): (ν NH) 3276m, (ν C=O) 1657s, ν C=N) 
1625s, (νas ym  (N=O)2) 1518s ,   (νs ym  (N=O)2)  1347s.  
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4-Trifluoromethyl-benzoic acid (3-phenyl-allylidene)-hydrazide 
HCA6 was synthesised using cinnamaldehyde 0.23 g (1.76 mmol) and 4-
trifluoromethyl- benzoyl hydrazide 0.35 g (1.26 mmol) to give HCA6, 0.33 g (1.04 
mmol, 83%); Melting point: 206-208 °C; ESI-MS: positive ion m/z = 319.1057 
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100%, HR ESI-MS: For C17H14N2OF3 ([M+H]+), observed mass 319.1057, calculated 
mass 319.1053, difference 0.4 mDa; δ 1H NMR (400 MHz, d6-DMSO): δ 11.94  (bs, 
1H, NH), 8.25 (t, 1H, 3JH-H = 4.4 Hz, H-6), 8.10 (d, 2H, 3JH-H = 8.1 Hz, H-9 or H-8), 
7.91 (d, 2H, 3JH-H = 8.2 Hz, H-9 or H-8), 7.64 (d, 2H, 3JH-H = 7.3 Hz, H-2 or H-3), 
7.31-7.42 (m, 3H, H-1, H-2 or H-3), 7.08 – 7.09 (m, 2H, m, H-4,5); δ 13C NMR 
(100.6 MHz, d6-DMSO): δ 161.9 (4°), 150.6 (CH), 139.6 (CH), 137.3 (4°), 135.8 (4°), 
131.6 (4°), 128.9 (CH), 128.8 (CH), 128.6 (CH), 127.2 (CH), 125.5 (CH); Anal. 
Calcd for C17H13N2OF3: C, 64.15; H, 4.12; N, 8.80. Found C, 64.01; H, 4.10; N, 
8.69; Significant IR bands (KBr disc, cm-1): (ν NH) 3257m, (ν C=O) 1659s, (ν C=N) 
1624s. 
HCA7  
N
H
N
O 1
2
4
9
8
7
6
5
10
3
3
2
8
911
12
12
12
 
4-tert-Butyl-benzoic acid (3-phenyl-allylidene)-hydrazide 
HCA7 was synthesised using cinnamaldehyde 0.21 (1.6 mmol) and 4-tert-butyl 
benzoyl hydrazide 0.19 g (1.14 mmol) to give HCA7, 0.28 g (0.91 mmol, 80%); 
Melting point: 240-242 °C; ESI-MS: positive ion m/z = 307.1801 100%; HR ESI-
MS: For C20H23N2O ([M+H]+), observed mass 307.1081, calculated mass 307.1085, 
difference 0.8 mDa; δ 1H NMR (400 MHz, d6-DMSO): δ 11.68  (bs, 1H, H-N), 8.23 
(d, 1H, JH-H = 7.2 Hz, H-6), 7.83 (d, 2H, JH-H = 8.3 Hz, H-8 or H-9), 7.63 (d, 2H, JH-H = 
7.4 Hz, H-2 or H-3), 7.53 (d, 2H, JH-H = 8.3 Hz, H-8 or H-9), 7.30-7.42 (m, 3H, H-1, 
H-2 or H-3), 7.05-7.07 (m, 2H, H-4, 5), 1.31 (s, 9H, H-12); δ 13C NMR (100.6 MHz, 
d6-DMSO): δ 163.0 (4°), 154.6 (4°), 149.5 (CH), 138.9 (CH), 135.9 (4°), 130.6 (4°), 
128.8 (CH), 127.5 (CH), 127.1 (CH), 125.7 (CH), 125.2 (CH), 34.7 (4°), 30.9 
((CH3)3); Significant IR bands (KBr disc, cm-1): (ν NH) 3204m,  (ν C=O) 1635s, (ν 
C=N) 1624s. 
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4-Hydroxy-benzoic acid (3-phenyl-allylidene)-hydrazide 
HCA8 was synthesised using cinnamaldehyde 0.21 g (1.5 mmol) and 4-hydroxy-
benzoyl hydrazide 0.22 g (1.25 mmol) to give HCA8, 0.23 g (1.23 mmol, 70%); 
Melting point: 232-234 °C; ESI-MS: positive ion m/z = 267.1124, 100%, HR ESI-
MS: For C16H15N2O2 ([M+H]+), observed mass 267.1124, calculated mass 267.1128, 
difference 0.4 mDa; δ 1H NMR (400 MHz, d6-DMSO): δ 11.53 (bs, 1H, H-N), 10.15 
(bs, 1H, H-O), 8.21 (d, 1H, JH-H = 7.4 Hz, 9), 7.78 (2H, d, JH-H = 8.7 Hz, H- 8 or H-9), 
7.62 (2H, d, JH-H = 7.4 Hz, H-2 or H-3), 7.30-7.41 (m, 3H, H-1, H-2 or H-3), 6.98-7.09 
(m, 2H, H-4,5), 6.85 (d, 2H, JH-H = 8.7 Hz, H-8 or H-9); δ 13C NMR (100.6 MHz, d6-
DMSO): δ 160.7 (4°), 148.7 (CH), 138.4 (CH), 136.0 (4°), 129.7 (CH), 128.8 (CH), 
128.7 (CH), 127.0 (CH), 125.8 (CH), 123.8 (4°), 115.0 (CH); Significant IR bands 
(KBr disc, cm-1): (ν NH) 3270m,  (ν C=O, C=N) 1621s. 
HCA9  
N
H
N
O 1
2
4
9
8 7
6
5
10
3
3
2
12
11
F
13
 
3-Fluoro-benzoic acid (3-phenyl-allylidene)-hydrazide 
HCA9 was synthesized using cinnamaldehyde 0.2 g (1.53 mmol) and 3-
fluoro-benzoyl hydrazide 0.19 g (1.26 mmol) to give HCA9, 0.27 g (1.00 mmol, 
80%); Melting point: 207– 209 °C; ESI-MS: positive ion m/z = 269.1084, 100%; HR 
ESI-MS: For C16H14N2OF ([M+H]+), observed mass 269.1092, calculated mass 
269.1085, difference 0.8 mDa; δ 1H NMR (400 MHz, d6-DMSO): 11.80 (1H, bs, H-
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N), 7.31 – 7.77 (m, 9H, Har) 7.07 - 7.08 (2H, m, H-4, 5); δ 13C NMR (100.6 MHz, d6-
DMSO): 161.9 (d , 1jC-F = 243.4 Hz, C-13), 161.7 (4°), 150.3 (CH), 139.4 (CH), 135.9 
(4°), 135.8 (d, 3jC-F = 6.9 Hz, C-8), 130.7 (d, 3jC-F = 5.5 Hz, C-10), 128.9 (CH), 128.8 
(CH), 127.2 (CH), 125.4 (CH), 123.8 (d, 4jC-F = 3.1 Hz, C-9), 118.6 (d, 2jC-F = 20.7 Hz, 
C14), 114.4 (d, 2jC-F = 22.9 Hz, C-13); Anal. Calcd. for C16H13N2OF: C, 71.63; H, 
4.89; N, 10.44. Found C, 71.63; H, 4.91; N, 10.48; Significant IR bands (KBr disc, 
cm-1): (ν NH) 3234m, (ν C=O) 1650s, (ν C=N) 1627s.  
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3-Hydroxy-benzoic acid (3-phenyl-allylidene)-hydrazide 
HCA10 was synthesised using cinnamaldehyde 0.24 g (1.84 mmol) and 3-
hydroxy-benzoyl hydrazide 0.20 g (1.31 mmol) to give HCA10, 0.28 g (1.05 mmol, 
80%); Melting point: 255 - 257 °C; ESI-MS: positive ion m/z = 267.1121, 100%, HR 
ESI-MS: For C16H15N2O2 ([M+H]+), observed mass 267.1121, calculated mass 
267.1128, difference 0.7 mDa; δ 1H NMR (400 MHz, d6-DMSO): δ 11.67  (bs, 1H, 
H-N), 9.77 (bs, 1H, H-O), 8.22 (d, 1H, JH-H = 7.4 Hz, H-6), 7.63 (d, 2H, JH-H = 7.3 Hz, 
Har), 7.26 – 7.42 (m, 6H, Har), 7.04 – 7.06 (2H, m, H-4, 5), 6.96 (1H, m, Har); δ 13C 
NMR (100.6 MHz, d6-DMSO): δ 163.0 (4°), 157.4 (4°), 149.6 (CH), 138.9 (CH), 
135.9 (4°), 134.8 (4°), 129.5 (CH), 128.8 (CH), 127.1 (CH), 125.7 (CH), 118.7 (CH), 
118.1 (CH), 114.5 (CH); Significant IR bands (KBr disc, cm-1): (ν NH) 3240m,  (ν 
C=O) 1638s, (ν C=N) 1624s. 
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HCA11  
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2-Hydroxy-benzoic acid (3-phenyl-allylidene)-hydrazide 
HCA11 was synthesised using cinnamaldehyde 0.24 g (1.84 mmol) and 2-
hydroxy-benzoyl hydrazide 0.20 g (1.31 mmol) to give HCA11, 0.30 g (1.13 mmol, 
87%);  Melting point: 259 - 261 °C; ESI-MS: positive ion m/z = 267.1122, 100%, 
HR ESI-MS: For C16H15N2O2 ([M+H]+), observed mass 267.1122, calculated mass 
267.1128, difference 0.6 mDa; δ 1H NMR (400 MHz, d6-DMSO): δ 11.78 (bs, 1H, H-
N), 8.24 (1H, dd, JH-H = 5.0 Hz, 3.6 Hz, H-6), 7.87 (1H, dd, 3JH-H = 7.7, 1.3 Hz, Har) 
7.63 (2H, d, 3JH-H = 7.4 Hz, Har), 7.32 - 7.45 (m, 4H, m, Har), 7.08 – 7.09 (2H, m, H-4, 
5), 6.92 – 6.98 (2H, m, Har); δ 13C NMR (100.6 MHz, d6-DMSO): δ 164.7 (4°), 159.2 
(4°), 150.7 (CH), 139.7 (CH), 135.8 (4°), 133.8 (CH), 129.0 (CH), 128.9 (CH), 128.5 
(CH), 127.2 (CH), 125.4 (CH), 118.9 (CH), 117.3 (CH), 115.8 (4°); Significant IR 
bands (KBr disc, cm-1):  (ν OH) 3457br ,  (ν NH) 3258m ,  (ν C=O) 1649s ,  (ν 
C=N) 1626s. 
HCA12  
N
H
N
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3-Methyl-4-nitro-benzoic acid (3-phenyl-allylidene)-hydrazide 
HCA12 was synthesised using cinnamaldehyde 0.19 g (1.43 mmol) and 3-
methyl-4-nitro-benzoyl hydrazide 0.20 g (1.03 mmol) to give HCA12, 0.26 g (0.83 
mmol, 81%); Melting point: 184-186 °C; ESI-MS: positive ion m/z = 310.1184 
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100%, HR ESI-MS: For C17H16N3O3 ([M+H]+), observed mass 310.1184, calculated 
mass 310.1186, difference 0.2 mDa; δ 1H NMR (400 MHz, d6-DMSO): δ 11.93  (bs, 
1H, H-N), 8.24 (dd, 1H, JH-H = 5.0, 3.8 Hz, H-6), 8.10 (d, 1H, JH-H = 8.4 Hz, H- 9 or 
H-10), 8.00 (s, 1H, H-13), 7.92 (1H, dd, JH-H = 8.4, 1.5 Hz, H-9 or H-10), 7.64 (2H, d, 
JH-H = 7.3 Hz, H-2 or H-3), 7.32-7.41 (m, 3H, H-1, H-2 or H-3), 7.08 – 7.10 (2H, m, 
H-4, 5), 2.58 (3H, s, H-14); δ 13C NMR (100.6 MHz, d6-DMSO): δ 161.4 (4°), 150.6 
(CH), 150.5 (4°), 139.7 (C7), 137.3 (4°), 135.8 (4°), 132.8 (4°), 132.0 (CH), 129.0 
(CH), 128.8 (CH), 127.2 (CH), 126.4 (CH), 125.4 (CH), 124.5 (CH), 19.3 (CH3); 
Anal. Calcd for C17H15N3O3: C, 66.01; H, 4.89; N, 13.58. Found C, 65.88; H, 4.90; 
N, 13.50; Significant IR bands (KBr disc, cm-1): (ν NH) 3234m, (ν C=O) 1655s, (ν 
C=N) 1625s, (νas ym  (N=O)2) 1518s, (νsym  (N=O)2) 1348s. 
HCA13 
N
N
H
N
O 1
2
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Nicotinic acid (3-phenyl-allylidene)-hydrazide 
HCA13 was synthesised using cinnamaldehyde 0.24 g (1.83 mmol) and 
nicotinic acid hydrazide 0.18 g (1.31 mmol) to give HCA13, 0.24 g (0.96 mmol, 
73%), Melting point :  176-177 °C; ESI-MS:  posit ive ion m/z = 
252.1128, 100%, HR ESI-MS: For C15H14N3O ([M+H]+), observed mass 
252.1128, calculated mass 252.1131, difference 0.3 mDa; δ 1H NMR (400 MHz, , 
d6-DMSO): δ 11.91 (bs, 1H, H-N), 9.05 (d, 1H, JH-H = 1.7 Hz, H-12), 8.76 (dd, 1H, JH-
H = 4.8 Hz, 1.5 Hz, H-6), 8.21-8.25 (m, 2H, Har), 7.64 (d, 2H, JH-H = 7.3 Hz, Har), 7.57 
(dd, 1H, JH-H = 7.7 Hz, 4.8 Hz, Har), 7.32-7.42 (m, 3H, Har) 7.08-7.10 (2H, m, H-4, 5); 
δ 
13C NMR (100.6 MHz, , d6-DMSO): δ 161.5 (4°), 152.3 (CH), 150.4 (CH), 148.6 
(CH), 139.6 (CH), 135.8 (4°), 135.5 (CH), 129.2 (4°), 129.0 (CH), 128.9 (CH), 127.2 
(CH), 125.5 (CH), 123.6 (CH); Significant IR bands (KBr disc, cm-1): (ν NH) 
3242m,  (ν C=O) 1646s, (ν C=N) 1625s. 
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Isonicotinic acid (3-phenyl-allylidene)-hydrazide 
 
HCA14 was synthesised using cinnamaldehyde 0.24 g (1.84 mmol) and 
isonicotinic acid hydrazide 0.18 g (1.31 mmol) to give HCA14, 0.23 g (0.90 mmol, 
69%); Melting point: 201-203 °C; ESI-MS: positive ion m/z = 252.1134, 100%, HR 
ESI-MS: For C15H14N3O ([M+H]+), observed mass 252.1134, calculated mass 
252.1131, difference 0.2 mDa; δ 1H NMR (400 MHz, d6-DMSO): 11.96 (bs, 1H, H-
N), 8.78 (d, 2H, JH-H = 6.2 Hz, H-9 or H-10), 8.24 (1H, dd, JH-H = 1.6 Hz, 4.4 Hz, H-6), 
7.81 (d, 2H, JH-H = 6.2 Hz, H-9 or H-10), 7.64 (2H, d, JH-H = 7.2 Hz, H-2 or H-3), 7.40 
(2H, t, 3JH-H = 7.2 Hz H-2, 4), 7.32 - 7.42 (m, 3H, H-1, H-2 or H-3), 7.09 – 7.10 (2H, 
m, H-4, 5); δ 13C NMR (100 MHz, d6-DMSO): 161.5 (4°), 151.0 (CH), 150.3 (CH), 
140.5 (4°), 139.9 (CH), 135.8 (4°), 129.0 (CH), 128.9 (CH), 127.2 (CH), 125.4 (CH), 
121.5 (CH); Significant IR bands (KBr disc, cm-1): (ν NH) 3244m,  (ν C=O) 1650s, 
(ν C=N) 1626s. 
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7.11 General synthetic procedure and characterisation detail 
copper(II) complexes  of  CAHs ([Cu(II)(CA1)2]- [Cu(II)(CA1)2]) 
Copper(II) acetate (0.30 mmol) was added to a methanolic solution of the 
respective cinnamaldehyde hydrazone. The mixture was refluxed for 2 hours and 
the green precipitate formed was isolated and dried under vaccuo. 
[Cu(II)(CA1)2] 
N
N
O
Cu
N
N
O
 
Bis[benzoic acid (3-phenyl-allylidene)-hydrazide]copper(II) 
 [Cu(II)(CA1)2] was synthesised using copper acetate 0.06 g (0.31 mmol) and 
HCA1 0.10 g (0.38 mmol) to give [Cu(II)(CA1)2], (1.23 mmol, 85%); Melting point: 
343-345 °C; ESI-MS: positive ion m/z = 563.1513, 65%, HR ESI-MS: For 
63Cu(I)C32H28N4O2 ([M+2H]+), observed mass 563.1513, calculated mass 563.1503, 
difference 1.1 mDa; Anal. Calcd. for C32H26N4O2Cu: C, 68.13; H, 4.98; N, 9.93. 
Found C, 68.03; H, 4.65; N, 9.95; Significant IR bands (KBr disc, cm-1): (ν C=O) 
1612s, (ν C=N) 1589s. 
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[Cu(II)(CA2)2] 
N
N
O
Cu
N
N
O
Cl
Cl
 
Bis[4-chloro-benzoic acid (3-phenyl-allylidene)-hydrazide]copper(II) 
[Cu(II)(CA2)2] was synthesised using copper(II) acetate 0.06 g (0.31 mmol) 
and HCA2 0.10 g (0.38 mmol) to give [Cu(II)(CA2)2], 0.10 g (0.32 mmol, 84%); 
Melting point: 263-264 °C; ESI-MS: negative ion m/z = 628.0560, HR ESI-MS: For 
63Cu(I)C32H24N4O2Cl2 ([M]-), observed mass 628.0560, calculated mass 629.0572, 
difference 1.0 mDa; Anal. Calcd for C32H26N4O2Cl2Cu1x 0.25 CH3OH x 0.55 H2O: C, 
59.51; H, 4.35; N, 8.61. Found C, 59.45; H, 4.46; N, 8.73; Significant IR Bands 
(KBr disc, cm-1): (ν C=O) 1616s, (ν C=N) 1593s. 
[Cu(II)(CA3)2] 
N
N
O
Cu
N
N
O
CH3
H3C
 
Bis[4-methyl-benzoic acid (3-phenyl-allylidene)-hydrazide]copper(II) 
[Cu(II)(CA3)2] was synthesised using copper(II) acetate 0.06 g (0.31 mmol) 
and HCA3 0.10 g (0.38 mmol) to give [Cu(II)(CA3)2], (0.32 mmol, 84%); Melting 
point: 257-259 °C; ESI-MS: positive ion m/z = 591.1808, 40% HR ESI-MS: For 
63Cu(I)C34H32N4O2 ([M+2H]+), observed mass 591.1808, calculated mass 591.1816, 
difference 0.8 mDa; Anal. Calcd for C34H30N4O2Cu1x 0.3 H2O: C, 68.57; H, 5.18; N, 
9.41. Found C, 68.57; H, 5.11; N, 9.33; Significant IR bands: (KBr disc, cm-1): (ν 
C=O) 1611s, (ν C=N) 1587s. 
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[Cu(II)(CA4)2] 
N
N
O
Cu
N
N
O
OCH3
H3CO
 
Bis[4-methoxy-benzoic acid (3-phenyl-allylidene)-hydrazide]copper(II) 
[Cu(II)(CA4)2] was synthesised using copper(II) acetate (0.3 mmol) and 
HCA4 0.35 g (1.25 mmol) to give [Cu(II)(CA4)2], 0.23 g (1.23 mmol, 70%); Melting 
point: 255-257 °C; ESI-MS: positive ion m/z = 623.1715, 100%; HR ESI-MS: For 
63Cu(I)C34H32N4O4 ([M+2H]+), observed mass 623.1715, calculated mass 623.1719, 
difference 0.5 mDa; Significant IR bands: (KBr disc, cm-1): (ν C=O) 1610s, (ν C=N) 
1590s. 
 [Cu(II)(CA5)2] 
N
N
O
Cu
N
N
O
NO2
O2N
 
Bis[4-nitro-benzoic acid (3-phenyl-allylidene)-hydrazide]copper(II) 
[Cu(II)(CA5)2] was synthesised using copper(II) acetate 0.06 g (0.31 mmol) 
and HCA5 0.11 g (0.37 mmol) to give [Cu(II)(CA5)2], 0.09 g (0.28 mmol, 76%); 
Melting point: 275 - 277 °C; ESI-MS: negative ion m/z = 651.108, 100%; HR ESI-
MS: For 63Cu(I)C32H24N6O6 ([M]-), observed mass 651.1081, calculated mass 
651.1059, difference 2.2 mD; Anal. Calcd. for C32H24N6O6Cu x 1.5 H2O: C, 56.59; 
H, 4.01; N, 12.37. Found C, 56.12; H, 3.62; N, 12.85; Significant IR bands: (KBr 
disc, cm-1): (ν C=O) 1607s, ν (C=N) 1582s, (νas ym  (N=O)2) 1534s, (νs ym  (N=O)2) 
1348br. 
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[Cu(II)(CA6)2] 
N
N
O
Cu
N
N
O
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CF3
 
Bis[4-triflouromethyl-benzoic acid (3-phenyl-allylidene)-hydrazide]copper(II) 
[Cu(II)(CA6)2] was synthesised using copper(II) acetate 0.045 g (0.25 mmol) 
and HCA6 0.10 g (0.31 mmol) to give [Cu(II)(CA6)2], 0.095 g (0.27 mmol, 87%); 
Melting point: 258-260 °C; ESI-MS: positive ion m/z = 699.1241, 10%, HR ESI-
MS: For 63Cu(I)C34H26N4O2F6 ([M+2H]+), observed mass 699.1241, calculated mass 
699.1250, difference 0.9 mDa; Anal. Calcd for C34H24N4O2F6Cu1 x 0.4 H2O: C, 
57.90; H, 3.54; N, 7.94. Found C, 57.81; H, 3.46; N, 8.02; Significant IR bands 
(KBr disc, cm-1): (ν C=O) 1610s, (ν C=N) 1590s. [Cu(II)(CA7)2] 
N
N
O
Cu
N
N
O
 
Bis[4-tert-butyl-benzoic acid (3-phenyl-allylidene)-hydrazide]copper(II) 
[Cu(II)(CA7)2] was synthesised using copper(II) acetate 0.05 g (0.27 mmol) 
and HCA7 0.10 g (0.32 mmol) to give [Cu(II)(CA7)2], 0.09 g (0.26 mmol, 81%); 
Melting point: 254-256 °C; ESI-MS: positive ion m/z = 675.2753, 7%, HR ESI-MS: 
For 63Cu(I)C40H44N4O2 ([M+2H]+), observed mass 675.2753, calculated mass 
675.2755, difference 0.2 mDa; Anal. Calcd. for C40H42N4O2Cu1: C, 71.24; H, 6.28; 
N, 8.31. Found C, 71.03; H, 6.28; N, 8.24; Significant IR bands (KBr disc, cm-1):  (ν 
C=O) 1612s, (ν C=N) 1584s. 
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 [Cu(II)(CA8)2] 
N
N
O
Cu
N
N
O
HO
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Bis[4-hydroxy-benzoic acid (3-phenyl-allylidene)-hydrazide]copper(II) 
[Cu(II)(CA8)2] was synthesised using copper(II) acetate 0.057 g (0.31 mmol) 
and HCA8 0.10 g (0.37 mmol) to give [Cu(II)(CA8)2], 0.077 g (0.26 mmol, 70%); 
Melting point: 256 - 258 °C; ESI-MS: positive ion m/z = 595.1401, 53%, HR ESI-
MS: For 63Cu(I)C32H28N4O4 ([M+2H]+), observed mass 595.1408, calculated mass 
595.1401, difference 0.7 mDa; Significant  IR bands (KBr disc, cm-1): (ν C=O) 
1610s, (ν C=N) 1595s. 
 
[Cu(II)(CA9)2] 
N
N
O
Cu
N
N
O
F
F
 
Bis[3-flouro-benzoic acid (3-phenyl-allylidene)-hydrazide]copper(II) 
[Cu(II)(CA9)2] was synthesised using copper(II) acetate 0.04 g (0.23 mmol) 
and HCA9 0.075 g (0.28 mmol) to give [Cu(II)(CA9)2], 0.07 g (0.23 mmol, 84%); 
Melting point: 248-250 °C; ESI-MS: positive ion m/z = 599.1333, 30%, HR ESI-MS: 
For 63Cu(I)C32H28N4O2 ([M+2H]+), observed mass 599.1333, calculated mass 
599.1314, difference 1.9 mDa; Significant IR bands (KBr disc, cm-1): (ν C=O) 
1609s, (ν C=N) 1583s. 
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[Cu(II)(CA10)2] 
N
N
O
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Bis[3-hydroxy-benzoic acid (3-phenyl-allylidene)-hydrazide]copper(II) 
[Cu(II)(CA10)2] was synthesised using copper(II) acetate 0.057 g (0.31 
mmol) and HCA10 0.10 g (0.37 mmol) to give [Cu(II)(CA10)2], 0.066 g (0.22 mmol, 
60%); Melting point: 254-256 °C; ESI-MS: positive ion m/z = 595.1399, 100%, HR 
ESI-MS: For 63Cu(I)C32H28N4O4 ([M+2H]+), observed mass 595.1399, calculated 
mass 595.1401, difference 0.2 mDa; Anal. Calcd for C32H26N4O4Cu1 x 0.25 CH3OH 
x 0.4 H2O: C, 63.76; H, 4.58; N, 9.22. Found C, 63.74; H, 4.48; N, 9.12; Significant 
IR bands (KBr disc, cm-1): (ν C=O) 1613s, (ν C=N) 1578s. 
 
[Cu(II)(CA11)2] 
N
N
O
Cu
N
N
O
OH
HO
 
Bis[2-hydroxy-benzoic acid (3-phenyl-allylidene)-hydrazide]copper(II) 
  [Cu(II)(CA11)2] was synthesised using copper(II) acetate 0.057 g (0.31 
mmol) and HCA11 0.11 g (0.37 mmol) to give [Cu(II)(CA11)2], 0.08 g (0.27 mmol, 73 
%); Melting point: 279-281 °C; ESI: negative ion m/z = 593.1272, 100 % HR ESI-
MS: For 63Cu(I)C32H26N4O4 ([M]-), observed mass 593.1272, calculated mass 
593.1256, difference 1.7 mDa; Significant IR bands (KBr disc, cm-1): (ν C=O) 
1617s, (ν C=N) 1593s. 
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[Cu(II)(CA12)2]  
N
N
O
Cu
N
N
O
NO2
O2N
CH3
H3C
 
Bis[3-methyl-4-nitro-benzoic acid (3-phenyl-allylidene)-hydrazide]copper(II) 
[Cu(II)(CA12)2] was synthesised using copper(II) acetate 0.057 g (0.31 
mmol) and HCA12 0.11 g (0.37 mmol) to give [Cu(II)(CA12)2], 0.10 g (0.30 mmol, 
82%); Melting point: 273-275°C; ESI-MS: negative ion m/z = 679.1402, 100%,  HR 
ESI-MS: For 63Cu(I)C34H28N6O6 ([M]-), observed mass 679.1402, calculated mass 
679.1372, difference 3.0 mDa; Anal. Calcd for C34H28N6O6Cu1 x 0.15 CH3OH x 
0.25 H2O: C, 59.49; H, 4.25; N, 12.19. Found C, 59.48; H, 4.15; N, 12.35; 
Significant IR bands (KBr disc, cm-1): (ν C=O) 1608s, (ν C=N) 1580s, (ν asym 
(N=O)2) 1536br, (ν sym (N=O)2) 1343br. 
[Cu(II)(CA13)2] 
N
N
N
O
Cu
N
N
N
O
 
Bis[nicotinic acid (3-phenyl-allylidene)-hydrazide]copper(II) 
[Cu(II)(CA13)2] was synthesised using copper(II) acetate 0.04 g (0.24 mmol) 
and HCA13 0.10 g (0.40 mmol) to give [Cu(II)(CA13)2], 0.09 g (0.32 mmol, 79%); 
Melting point :  252-254 °C; ESI-MS: negative ion m/z = = 563.1401, 81%, HR 
ESI-MS: For 63 Cu(I)C30H24N6O2 ([M]-), observed mass 563.1401, calculated mass 
563.1413, difference 1.1 mDa; Anal. Calcd. for C30H24N6O2Cu x 0.6 CH3OH: C, 
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63.01; H, 4.63; N, 14.41. Found C, 62.82; H, 4.56; N, 14.34; Significant IR bands 
(KBr disc, cm-1): (ν C=O) 1621s, (ν C=N) 1592s. 
[Cu(II)(CA14)2] 
N
N
N
O
Cu
N
N
N
O
 
Bis[isonicotinic acid (3-phenyl-allylidene)-hydrazide]copper(II) 
 [Cu(II)(CA14)2] was synthesised using copper(II) acetate 0.04 g (0.24 mmol) 
and HCA14 0.10 g (0.40 mmol) to give [Cu(II)(CA14)2], 0.09 g (0.31 mmol, 78 %); 
Melting point: 248-250 °C; ESI-MS: positive ion m/z = 565.1399, 37% HR ESI-MS: 
For 63CuC30H24N6O2 ([M+H]+), observed mass 565.1399, calculated mass 
565.1413, difference 1.3 mDa; Significant IR bands (KBr disc, cm-1): (ν C=O) 
1621s, (ν C=N) 1582s. 
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7.12.  Single crystal X-ray data  (Crystal data and structure refinement); 
All other crystallographic data can be found in appendices 3-22  
NaHL9.2H2O 
Empirical formula  C11 H15 N2 Na O5 
Formula weight  278.24 
Temperature  110(2) K 
Wavelength  0.71073 Å 
Crystal system  Rhombohedral 
Space group  R-3 
Unit cell dimensions a = 30.7555(9) Å α= 90°. 
 b = 30.7555(9) Å β= 90°. 
 c = 7.3013(4) Å γ = 120°. 
Volume 5981.0(4) Å3 
Z 18 
Density (calculated) 1.390 Mg/m3 
Absorption coefficient 0.136 mm-1 
F(000) 2628 
Theta range for data collection 1.32 to 28.30°. 
Index ranges -40<=h<=40, -40<=k<=40, -9<=l<=9 
Reflections collected 20886 
Independent reflections 3303 [R(int) = 0.0331] 
Completeness to theta = 28.30° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.987 and 0.836 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3303 / 0 / 194 
Goodness-of-fit on F2 1.091 
Final R indices [I>2sigma(I)] R1 = 0.0386, wR2 = 0.1026 
R indices (all data) R1 = 0.0513, wR2 = 0.1192 
Largest diff. peak and hole 0.470 and -0.282 e.Å-3 
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NaHL11.2H2O 
Empirical formula  C10H9BrN2NaO3  
Formula weight  308.09  
Temperature/K  566(2)  
Crystal system  trigonal  
Space group  R-3  
a/Å  30.9014(4)  
b/Å  30.9014(4)  
c/Å  7.2710(2)  
α/°  90.00  
β/°  90.00  
γ/°  120.00  
Volume/Å3  6012.9(2)  
Z  23  
ρcalcmg/mm3  1.957  
m/mm-1  5.777  
F(000)  3519  
2Θ range for data collection  9.92 to 141.74°  
Index ranges  -35 ≤ h ≤ 37, -32 ≤ k ≤ 37, -8 ≤ l ≤ 8 
Reflections collected  10998  
Independent reflections  2420[R(int) = 0.0305]  
Data/restraints/parameters  2420/0/195  
Goodness-of-fit on F2  1.053  
Final R indexes [I>=2σ (I)]  R1 = 0.0243, wR2 = 0.0592  
Final R indexes [all data]  R1 = 0.0307, wR2 = 0.0625  
Largest diff. peak/hole / e Å-3 0.313/-0.361  
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NaHL20 .H2O  
Empirical formula  C10H9BrN2NaO3  
Formula weight  308.09  
Temperature/K  566(2)  
Crystal system  trigonal  
Space group  R-3  
a/Å  30.9014(4)  
b/Å  30.9014(4)  
c/Å  7.2710(2)  
α/°  90.00  
β/°  90.00  
γ/°  120.00  
Volume/Å3  6012.9(2)  
Z  23  
ρcalcmg/mm3  1.957  
m/mm-1  5.777  
F(000)  3519  
2Θ range for data collection  9.92 to 141.74°  
Index ranges  -35 ≤ h ≤ 37, -32 ≤ k ≤ 37, -8 ≤ l ≤ 8 
Reflections collected  10998  
Independent reflections  2420[R(int) = 0.0305]  
Data/restraints/parameters  2420/0/195  
Goodness-of-fit on F2  1.053  
Final R indexes [I>=2σ (I)]  R1 = 0.0243, wR2 = 0.0592  
Final R indexes [all data]  R1 = 0.0307, wR2 = 0.0625  
Largest diff. peak/hole / e Å-3 0.313/-0.361  
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[Cu(L7)(H2O)(MeOH)] 
Empirical formula  C13H17CuN3O7  
Formula weight  390.84  
Temperature / K  110.0  
Crystal system  monoclinic  
Space group  P21/n  
a/Å, b/Å, c/Å  10.159(3), 14.1559(7), 11.895(2)  
α/°, β/°, γ/°  90.00, 114.11(3), 90.00  
Volume / Å3  1561.3(5)  
Z  4  
ρcalc/mg mm-3  1.663  
µ/mm-1  1.441  
F(000)  804  
Crystal size / mm3  0.1963 × 0.0833 × 0.042  
2Θ range for data collection 5.76 to 64.22°  
Index ranges  -15 ≤ h ≤ 15, -21 ≤ k ≤ 20, -16 ≤ l ≤ 17 
Reflections collected  13154  
Independent reflections  4881[R(int) = 0.0235]  
Data/restraints/parameters  4881/0/229  
Goodness-of-fit on F2  1.058  
Final R indexes [I>2σ (I)]  R1 = 0.0300, wR2 = 0.0682  
Final R indexes [all data]  R1 = 0.0377, wR2 = 0.0723  
Largest diff. peak/hole/e Å-3 0.466/-0.397  
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[Cu(L8)(MeOH)2] 
Empirical formula  C12 H15 Cu N3 O7 
Formula weight  376.81 
Temperature  110(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 7.8471(4) Å             α= 90° 
 b = 17.0584(8) Å           β= 93.9220(10)° 
 c = 11.0122(5) Å           γ = 90° 
Volume 1470.63(12) Å3 
Z 4 
Density (calculated) 1.702 Mg/m3 
Absorption coefficient 1.527 mm-1 
F(000) 772 
Theta range for data collection 2.20 to 28.30°. 
Index ranges -10<=h<=10, -22<=k<=22, -14<=l<=14 
Reflections collected 15054 
Independent reflections 3660 [R(int) = 0.0178] 
Completeness to theta = 28.30° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.941 and 0.823 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3660 / 0 / 219 
Goodness-of-fit on F2 1.072 
Final R indices [I>2sigma(I)] R1 = 0.0255, wR2 = 0.0695 
R indices (all data) R1 = 0.0276, wR2 = 0.0709 
Largest diff. peak and hole 0.454 and -0.338 e.Å-3 
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[Cu(L9)(H2O)2] 
Empirical formula  C11 H14 Cu N2 O5 
Formula weight  317.78 
Temperature  110(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 7.3879(9) Å              α = 93.602(2)° 
 b = 11.4695(13) Å          β = 102.437(2)° 
 c = 15.3898(18) Å           γ = 103.124(2)° 
Volume 1231.6(3) Å3 
Z 4 
Density (calculated) 1.714 Mg/m3 
Absorption coefficient 1.792 mm-1 
F(000) 652 
Theta range for data collection 1.84 to 28.33°. 
Index ranges -9<=h<=9, -15<=k<=15, -20<=l<=19 
Reflections collected 10913 
Independent reflections 5970 [R(int) = 0.0181] 
Completeness to theta = 28.33° 97.2 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.882 and 0.619 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5970 / 2 / 371 
Goodness-of-fit on F2 1.047 
Final R indices [I>2sigma(I)] R1 = 0.0379, wR2 = 0.0982 
R indices (all data) R1 = 0.0471, wR2 = 0.1048 
Largest diff. peak and hole 0.982 and -0.728 e.Å-3 
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[Cu(HL9)2Cl2] 
Empirical formula  C22 H22 Cl2 Cu2 N4 O6 
Formula weight  636.42 
Temperature  110(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 8.3637(8) Å                α = 90° 
 b = 15.0338(15) Å            β = 94.701(2)° 
 c = 9.4535(9) Å γ = 90° 
Volume 1184.7(2) Å3 
Z 2 
Density (calculated) 1.784 Mg/m3 
Absorption coefficient 2.069 mm-1 
F(000) 644 
Theta range for data collection 2.55 to 28.27°. 
Index ranges -11<=h<=11, -20<=k<=20, -12<=l<=12 
Reflections collected 12070 
Independent reflections 2927 [R(int) = 0.0257] 
Completeness to theta = 28.27° 99.7 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.940 and 0.857 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2927 / 0 / 168 
Goodness-of-fit on F2 1.058 
Final R indices [I>2sigma(I)] R1 = 0.0277, wR2 = 0.0697 
R indices (all data) R1 = 0.0352, wR2 = 0.0732 
Largest diff. peak and hole 0.482 and -0.239 e.Å-3 
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[Cu(L11)(H2O)2].H2O 
Empirical formula  C20 H24 Br2 Cu2 N4 O11 
Formula weight  783.33 
Temperature  110(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 7.3908(6) Å                α = 82.329(2)° 
 b = 11.0776(8) Å              β = 84.287(2)° 
 c = 16.9653(13) Å             γ = 75.676(2)° 
Volume 1330.56(18) Å3 
Z 2 
Density (calculated) 1.955 Mg/m3 
Absorption coefficient 4.666 mm-1 
F(000) 776 
Theta range for data collection 1.91 to 28.28°. 
Index ranges -9<=h<=9, -14<=k<=14, -22<=l<=22 
Reflections collected 13852 
Independent reflections 6557 [R(int) = 0.0212] 
Completeness to theta = 28.28° 99.2 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.756 and 0.565 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6557 / 3 / 388 
Goodness-of-fit on F2 1.069 
Final R indices [I>2sigma(I)] R1 = 0.0304, wR2 = 0.0765 
R indices (all data) R1 = 0.0383, wR2 = 0.0803 
Largest diff. peak and hole 1.193 and -0.774 e.Å-3 
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[Cu(L13)(H2O)(MeOH)] 
 
Empirical formula  C12H16CuN2O6  
Formula weight  347.81  
Temperature/K  110.0  
Crystal system  Monoclinic  
Space group  P21/n  
a/Å, b/Å, c/Å  10.2445(5), 13.1835(5), 10.7163(5)  
α/°, β/°, γ/°  90.00, 108.444(5), 90.00  
Volume/Å3  1372.97(11)  
Z  4  
ρcalc/mg mm-3  1.683  
µ/mm-1  1.620  
F(000)  716  
Theta range for data collection 3.33 to 25.05°  
Index ranges  -12 ≤ h ≤ 12, -15 ≤ k ≤ 15, -12 ≤ l ≤ 12 
Reflections collected  13705  
Independent reflections  2436[R(int) = 0.1120]  
Data/restraints/parameters  2436/59/212  
Goodness-of-fit on F2  1.064  
Final R indexes [I>2σ (I)]  R1 = 0.0387, wR2 = 0.0816  
Final R indexes [all data]  R1 = 0.0482, wR2 = 0.0879  
Largest diff. peak/hole/e Å-3  0.411/-0.375  
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[Cu(HL15)2Cu(HL15)(L15].Na.3H2O.CH3OH 
Empirical formula  C40.81 H41 Cu2 F4 N8 Na O16.19 
Formula weight  1128.67 
Temperature  110(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 9.9798(8) Å               α = 74.730(2)° 
 b = 11.8246(10) Å            β = 81.705(2)° 
 c = 20.4296(17) Å             γ = 82.246(2)° 
Volume 2289.5(3) Å3 
Z 2 
Density (calculated) 1.636 Mg/m3 
Absorption coefficient 1.036 mm-1 
F(000) 1152.8 
Theta range for data collection 1.79 to 28.34°. 
Index ranges -13<=h<=13, -15<=k<=15, -27<=l<=26 
Reflections collected 24057 
Independent reflections 11321 [R(int) = 0.0382] 
Completeness to theta = 28.34° 99.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.920 and 0.796 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 11321 / 13 / 751 
Goodness-of-fit on F2 1.019 
Final R indices [I>2sigma(I)] R1 = 0.0454, wR2 = 0.0974 
R indices (all data) R1 = 0.0726, wR2 = 0.1099 
Largest diff. peak and hole 0.623 and -0.377 e.Å-3 
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[Cu(L17)2(H2O)2] 
Empirical formula  C11 H16 Cu N2 O8 
Formula weight  367.80 
Temperature  110(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 7.2658(7) Å                 α = 81.01(2)° 
 b = 7.3165(7) Å                β = 87.867(2)° 
 c = 13.8816(13) Å             γ = 73.718(2)° 
Volume 699.64(12) Å3 
Z 2 
Density (calculated) 1.746 Mg/m3 
Absorption coefficient 1.605 mm-1 
F(000) 378 
Theta range for data collection 2.92 to 28.29°. 
Index ranges -9<=h<=9, -9<=k<=9, -18<=l<=18 
Reflections collected 7147 
Independent reflections 3444 [R(int) = 0.0152] 
Completeness to theta = 28.29° 98.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.968 and 0.648 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3444 / 0 / 229 
Goodness-of-fit on F2 1.089 
Final R indices [I>2sigma(I)] R1 = 0.0280, wR2 = 0.0729 
R indices (all data) R1 = 0.0321, wR2 = 0.0755 
Largest diff. peak and hole 0.530 and -0.480 e.Å-3 
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[Cu(I)2HL8(PPh3)5]PF6 
Empirical formula  C401H336Cu8F24N12O21P24  
Formula weight  7366.42  
Temperature/K  110.0  
Crystal system  monoclinic  
Space group  P21/a  
a/Å  25.9574(5)  
b/Å  18.2375(3)  
c/Å  37.8159(6)  
α/°  90.00  
β/°  100.0501(18)  
γ/°  90.00  
Volume/Å3  17627.3(5)  
Z  2  
ρcalcmg/mm3  1.388  
m/mm-1  0.661  
F(000)  7604.0  
2Θ range for data collection  5.7 to 57.84°  
Index ranges  -35 ≤ h ≤ 24, -22 ≤ k ≤ 23, -49 ≤ l ≤ 44 
Reflections collected  71520  
Independent reflections  38784[R(int) = 0.0311]  
Data/restraints/parameters  38784/114/2763  
Goodness-of-fit on F2  1.067  
Final R indexes [I>=2σ (I)]  R1 = 0.0614, wR2 = 0.1269  
Final R indexes [all data]  R1 = 0.0874, wR2 = 0.1401  
Largest diff. peak/hole / e Å-3 1.03/-1.15  
 
                                                                                                      Chapter-7                                                                                    
 309 
[Cu(I)2HL9(PPh3)5]PF6 
Empirical formula  C104H98Cu2F6N2O6P6  
Formula weight  1898.74  
Temperature/K  110.00(10)  
Crystal system  monoclinic  
Space group  P21/n  
a/Å  12.7572(3)  
b/Å  45.481(3)  
c/Å  16.3277(4)  
α/°  90.00  
β/°  99.241(2)  
γ/°  90.00  
Volume/Å3  9350.6(7)  
Z  4  
ρcalcmg/mm3  1.349  
m/mm-1  0.625  
F(000)  3944.0  
2Θ range for data collection  5.82 to 58.28°  
Index ranges  -11 ≤ h ≤ 16, -58 ≤ k ≤ 50, -21 ≤ l ≤ 21 
Reflections collected  36824  
Independent reflections  21014[R(int) = 0.0307]  
Data/restraints/parameters  21014/26/1150  
Goodness-of-fit on F2  1.134  
Final R indexes [I>=2σ (I)]  R1 = 0.0614, wR2 = 0.1129  
Final R indexes [all data]  R1 = 0.0770, wR2 = 0.1207  
Largest diff. peak/hole / e Å-3 0.91/-0.81  
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[Cu(I)2HL9(PPh3)4]PF6.2Et2O.2H2O 
Empirical formula  C89H86.36892Cu2F6N2O4.68446P5  
Formula weight  1654.85  
Temperature/K  110  
Crystal system  triclinic  
Space group  P-1  
a/Å  12.937(3)  
b/Å  13.150(4)  
c/Å  24.582(3) 
α/°  90.543(15)  
β/°  95.990(14)  
γ/°  100.77(2)  
Volume/Å3  4084.2(17)  
Z  2  
ρcalcmg/mm3  1.346  
m/mm-1  0.685  
F(000)  1718.0  
2Θ range for data collection  5.66 to 55.98°  
Index ranges  -17 ≤ h ≤ 11, -16 ≤ k ≤ 15, -29 ≤ l ≤ 30 
Reflections collected  25830  
Independent reflections  16093[R(int) = 0.0315]  
Data/restraints/parameters  16093/19/1032  
Goodness-of-fit on F2  1.060  
Final R indexes [I>=2σ (I)]  R1 = 0.0499, wR2 = 0.1137  
Final R indexes [all data]  R1 = 0.0716, wR2 = 0.1260  
Largest diff. peak/hole / e Å-3 0.62/-0.62  
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[Zn(HL7)2].H2O.DMSO 
Empirical formula  C23H28N4O8Zn  
Formula weight  553.86  
Temperature/K  110.4  
Crystal system  triclinic  
Space group  P-1  
a/Å, b/Å, c/Å  9.5115(6), 10.4966(6), 13.7572(9)  
α/°, β/°, γ/°  70.049(6), 79.268(5), 74.847(5)  
Volume/Å3  1239.03(13)  
Z  2  
ρcalc/mg mm-3  1.485  
µ/mm-1  1.046  
F(000)  576  
Theta range for data collection 3.0009 to 49.9474°  
Index ranges  -5 ≤ h ≤ 11, -10 ≤ k ≤ 12, -15 ≤ l ≤ 16 
Reflections collected  6342  
Independent reflections  4340[R(int) = 0.0211]  
Data/restraints/parameters  4340/0/339  
Goodness-of-fit on F2  1.057  
Final R indexes [I>2σ (I)]  R1 = 0.0398, wR2 = 0.0881  
Final R indexes [all data]  R1 = 0.0484, wR2 = 0.0937  
Largest diff. peak/hole/e Å-3  1.202/-0.375  
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[Zn(HL8)2].H2O 
Empirical formula  C21 H22 N6 O12 Zn 
Formula weight  615.82 
Temperature  110(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 9.1998(8) Å          α = 98.2510(10)° 
 b = 12.1658(10) Å      β = 110.4530(10)° 
 c = 12.4475(10) Å       γ = 93.257(2)° 
Volume 1283.20(18) Å3 
Z 2 
Density (calculated) 1.594 Mg/m3 
Absorption coefficient 1.032 mm-1 
F(000) 632 
Theta range for data collection 1.70 to 28.33°. 
Index ranges -12<=h<=12, -16<=k<=16, -16<=l<=16 
Reflections collected 17406 
Independent reflections 6364 [R(int) = 0.0178] 
Completeness to theta = 28.33° 99.4 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.765 and 0.627 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6364 / 0 / 383 
Goodness-of-fit on F2 1.046 
Final R indices [I>2sigma(I)] R1 = 0.0335, wR2 = 0.0888 
R indices (all data) R1 = 0.0365, wR2 = 0.0905 
Largest diff. peak and hole 0.971 and -0.579 e.Å-3 
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[Zn(HL9)2].H2O.CH3OH 
Empirical formula  C22H24Cl2N4O8SZn  
Formula weight  640.78  
Temperature/K  110K  
Crystal system  Triclinic  
Space group  P-1  
a/Å, b/Å, c/Å  8.5985(7), 10.5440(7), 15.5551(10)  
α/°, β/°, γ/°  104.251(6), 95.218(6), 109.582(7)  
Volume/Å3  1264.36(15)  
Z  2  
ρcalc/mg mm-3  1.683  
µ/mm-1  1.322  
F(000)  656  
Theta range for data collection 2.95 to 30.08°  
Index ranges  -12 ≤ h ≤ 12, -11 ≤ k ≤ 14, -21 ≤ l ≤ 14 
Reflections collected  11277  
Independent reflections  7335[R(int) = 0.0270]  
Data/restraints/parameters  7335/0/363  
Goodness-of-fit on F2  1.040  
Final R indexes [I>2σ (I)]  R1 = 0.0371, wR2 = 0.0847  
Final R indexes [all data]  R1 = 0.0467, wR2 = 0.0913  
Largest diff. peak/hole/e Å-3  0.642/-0.655  
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[Zn(HL13)2] 
Empirical formula  C22H24.5N4O9.25Zn  
Formula weight  1116.66  
Temperature/K  110.0  
Crystal system  tetragonal  
Space group  P43212  
a/Å, b/Å, c/Å  21.1918(3), 21.1918(3), 21.6652(4)  
α/°, β/°, γ/°  90.00, 90.00, 90.00  
Volume/Å3  9729.7(3)  
Z  8  
ρcalc/mg mm-3  1.525  
µ/mm-1  1.070  
F(000)  4616  
2Θ range for data collection  5.76 to 55.86°  
Index ranges  -25 ≤ h ≤ 24, -26 ≤ k ≤ 13, -28 ≤ l ≤ 25 
Reflections collected  32001  
Independent reflections  10157[R(int) = 0.0233]  
Data/restraints/parameters  10157/15/722  
Goodness-of-fit on F2  1.025  
Final R indexes [I>2σ (I)]  R1 = 0.0482, wR2 = 0.1155  
Final R indexes [all data]  R1 = 0.0726, wR2 = 0.1329  
Largest diff. peak/hole/e Å-3 0.788/-1.624  
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HCA2 
Empirical formula  C16H13N2OCl  
Formula weight  284.73  
Temperature/K  110.0  
Crystal system  triclinic  
Space group  P-1  
a/Å, b/Å, c/Å  5.2471(3), 8.3279(6), 15.3824(7)  
α/°, β/°, γ/°  92.175(5), 91.516(4), 91.150(5)  
Volume/Å3  671.31(7)  
Z  2  
ρcalc/mg mm-3  1.409  
µ/mm-1  0.281  
F(000)  296  
Theta range for data collection 3.5322 to 59.9346°  
Index ranges  -7 ≤ h ≤ 7, -11 ≤ k ≤ 11, -20 ≤ l ≤ 21 
Reflections collected  5933  
Independent reflections  3842[R(int) = 0.0224]  
Data/restraints/parameters  3842/0/185  
Goodness-of-fit on F2  1.044  
Final R indexes [I>2σ (I)]  R1 = 0.0442, wR2 = 0.1010  
Final R indexes [all data]  R1 = 0.0577, wR2 = 0.1100  
Largest diff. peak/hole/e Å-3  0.493/-0.284  
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HCA5 
Empirical formula  C16H13N3O3  
Formula weight  295.29  
Temperature/K  110.0  
Crystal system  monoclinic  
Space group  P21/c  
a/Å, b/Å, c/Å  16.429(4), 5.3321(8), 17.054(3)  
α/°, β/°, γ/°  90.00, 114.74(2), 90.00  
Volume/Å3  1356.8(5)  
Z  4  
ρcalc/mg mm-3  1.446  
µ/mm-1  0.103  
F(000)  616  
Theta range for data collection 2.8858 to 51.9984°  
Index ranges  -19 ≤ h ≤ 20, -6 ≤ k ≤ 4, -19 ≤ l ≤ 21 
Reflections collected  5760  
Independent reflections  2686[R(int) = 0.0226]  
Data/restraints/parameters  2686/0/203  
Goodness-of-fit on F2  0.985  
Final R indexes [I>2σ (I)]  R1 = 0.0428, wR2 = 0.0939  
Final R indexes [all data]  R1 = 0.0608, wR2 = 0.1039  
Largest diff. peak/hole/e Å-3  0.204/-0.276  
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7.13 Screening of the compounds for anti-mycobacterial activity 
The compounds were screened in the Department of Animal Sciences, School 
of Life Sciences, University of Hyderabad by Dr. Manjula Sritharan’s research group 
Mycobacterial strain and growth conditions: 
Mycobacterium tuberculosis ATCC 27294 was grown in Middlebrook 7H9 
broth medium (pH 7.0, Difco, Detroit, Mich., USA) containing 10% (v/v) albumin-
dextrose-catalase (ADC; Difco) enrichment and 0.2% glycerol and maintained with 
shaking at 150 rpm at 37 °C.  
Iron-regulated growth was performed in Proskauer and Beck medium (pH 
6.8) with iron added at 0.02 µg Fe/mL (low iron) and 8 µg Fe/mL (high iron), 
respectively. Ferrous sulphate was used as the iron source. The iron-regulated 
cultures were harvested in the mid-log phase after 10 days of growth. The iron 
status of the organisms was confirmed by assaying the siderophores mycobactin 
and carboxymycobactin using established protocols.310 Care was taken to ensure 
that the cells were harvested before the onset of iron limitation in high iron 
organisms. The cells were washed and re-suspended in the respective medium to 
get a cell density equivalent to McFarland 1 (3 x 108 cfu/mL) and further adjusted to 
get an OD600nm of 0.15 (Biophotometer, Eppendorf, USA). This cell suspension was 
used for the screening of the compounds. 
Preparation of the compounds for screening: 
Stock solutions of the compounds were prepared in HPLC grade dimethyl 
sulfoxide (Sigma Chemical Co., St. Louis, Mo., USA) at a concentration of 10 
mg/mL. These were filter-sterilized (0.22 µm filters, Sartorius) and stored at -80°C.  
Screening of the compounds: 
The compounds were first  screened  in the MB/BacT™ 240 Mycobacteria 
Detection System (BioMerieux / Organon Teknika, France) followed by the 
determination of the MIC values by Microplate Alamar Blue assay (MABA). Finally, 
the MIC values were confirmed in the MB/BacT™ 240 system by growth at MIC and 
sub-MIC concentrations of the compounds. 
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Compounds were screened for anti-mycobacterial activity in the 
MB/BacT™240 Mycobacteria Detection System (BioMerieux / Organon Teknika, 
France). The detection system employs standard bottles of 10 ml of culture media to 
which 0.5 mL of the mycobacterial cell suspension (prepared as detailed above) 
was added. The system also included the ‘proportion control’ that was inoculated 
with 0.5 mL of the cell suspension diluted 1:100. The system was standardised for 
the screening by adding INH at 0.1- 0.5 µg/mL final concentration. All the 
compounds were added at 256 µg/mL and checked for their effectiveness on M. 
tuberculosis. 
This was carried out essentially as described earlier.310 Briefly, it included 
testing of the compounds in 96 clear bottomed, sterile, microtitre plates (Corning, 
New York, USA). The outer perimeter wells were filled with 200 µL of sterile, distilled 
water to prevent evaporation from the experimental wells during incubation.  100 µL 
of 7H9 medium was added to all wells except those of column 2. 100 µL of the 
compound(s) to be tested was added to column 2. This represented the highest 
concentration of the compound(s). 100 µL of the compound(s) was added to column 
3 followed by serial dilutions of the compounds from columns 3 – 10. Column 11 
served as the control with no added drug. 100 µL of the cell suspension (1:50 
dilution of the cell suspension prepared above) was added to all wells and the plate 
was incubated at 37 °C for 5 days. 50 µL of Alamar Blu e [Invitrogen Corporation, 
Carlsbad, Ca., USA; prepared as a 1:1 (v/v) mixture with 10% Tween-80 (Sigma)] 
was added to the first control well and observed after 12 h. If the colour changed 
from blue to pink, Alamar Blue was added to all the wells and visual grading of the 
colour change was made 6 h after the dye addition. The MIC of the specific 
compound was taken as the lowest concentration in which there was no change of 
the blue colour of Alamar Blue indicating lack of any viable bacilli. 
Once the MIC value was established by MABA, the MICs of the compounds 
were confirmed by adding them at MIC and sub-MIC concentrations in the 
MB/BacT™240 system. 
Influence of iron levels on the anti-bacterial activity   
The organisms were grown in high and low iron conditions as described 
above. The cells were harvested and re-suspended in the respective medium and 
tested by MABA, essentially as described above except that the 7H9 medium was 
replaced by high and low iron Proskauer and Beck medium.  
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Abbreviations:  
4°  quaternary carbon (NMR) 
σ  Hammett parameter 
β  Bohr magneton (EPR) 
δ  chemical shift 
ε  molar absorption coefficient 
λmax  wavelenght of maximum absorption 
τ  tau 
°C  degrees Celcsius 
µ  micro 
ν  microwave frequency 
νas ym   asymmetric stretching (IR) 
νas ym   symmetric stretching (IR) 
Å  Angstroms (10-10 m) 
Arg  Argenine 
Asn  Arsenin 
br  broad (NMR) 
bs  broad singlet (NMR) 
CAH/s  cinnamaldehyde hydrazone/s 
clogP  calculated log P (lipohilicity) 
cm-1  wavenumber (IR) 
CoA  coenzyme A 
COSY  Correlation Spectroscopy 
CV  Cyclic voltamometry 
Cys  Cysteine 
dx  deuterated (NMR)  
d  doublet (NMR) 
dd  (double doublet) 
DEPT  Distortion Enhancement by Polarisation Transfer 
DFT  Density Functional Theory 
DMF  Dimethyl formamide 
DMSO  Dimethyl sulfoxide 
DNA  Deoxyribonucleic acid 
DPPH  Diphenylpicrylhydrazyl 
EC99  Lowest concentrations, effecting 99% reductions in colony forming  units 
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Et2O Diethyl ether 
ESI-MS  Electronic spray ionisation-Mass Spectrometry 
EPR  Electron Paramagnetic Resonance 
FTIR  Fourier Transform Infrared spectroscopy 
Glu  Glutamic acid 
GSP  Glyoxylate shunt pathway 
H  magnetic feild (EPR) 
h  Planck’s constant 
hr  hour/s 
Har  aromatic proton/s 
His  Histidine 
HPLC  High Pressure Liquid Chormatography 
HRMS  High Resolution Mass Spectrometry 
Hz  Hertz 
INA  isonicotinic acid 
INH  Isoniazid/ Isonicotinic acid hydrazide 
ICL  Isocitrate lyase enzyme 
INH  Isoniazid/ Isonicotinic acid hydrazide 
IR  Infrared 
J  coupling constant 
KatG  Catalase-peroxidase 
L  ligand 
M  Metal 
m  multpiplet (NMR) 
m  medium (IR) 
MABA  Microplate Alamar Blue assay 
MB/BacT™ Mycobacteria Detection System  
MeOH  Methanol 
mDa  milli Dalton  
MDR  Multiple drug resistance 
MIC  Minimum inhibitory concentration 
mM  millimolar 
Mtb  Mycobacterium tuberculosis 
m/z  mass/charge 
MHz  megahertz 
min  minutes 
mol  moles 
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nm  nanometer 
NMR  Nuclear magnetic resonance 
NaBH4  sodium borohydride 
NADH  Nicotinamide Adenine Dinucleotide 
LMCT  Ligand to metal charger transfer 
PBS  Phosphate Buffered Saline 
ppm  parts per million 
PVAH/s pyruvate hydrazone/s 
q  quartet (NMR) 
s  singlet (s) 
s  sharp (IR) 
SAR  Structure Activity Relationship  
SOD  superoxide dismutase 
Ser  Serine 
Subsp  subspecies 
t  triplet (NMR) 
t1/2  half-life 
TB  Tuberculosis 
THF  Tetrahedronfuran 
TLC  Thin-Layer Chromatography 
Thr  Threonine 
TBAHFP tetra-butyl ammonium hexafluorophosphate 
UV-Vis  Ultraviolet-visible spectroscopy 
VT  variable temperature (NMR) 
W.H.O  World health organisation 
XRD  X-ray Diffraction 
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